<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002894.pub2" GROUP_ID="EPOC" ID="086100010811432101" MERGED_FROM="" MODIFIED="2013-11-07 08:47:49 +0000" MODIFIED_BY="Elizabeth Paulsen" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-11-07 08:47:49 +0000" MODIFIED_BY="Elizabeth Paulsen">
<TITLE MODIFIED="2013-09-26 18:16:18 +0200" MODIFIED_BY="[Empty name]">Computerized advice on drug dosage to improve prescribing practice</TITLE>
<CONTACT MODIFIED="2013-11-07 08:47:49 +0000" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="8850" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pierre</FIRST_NAME><LAST_NAME>Durieux</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>pierre.durieux@egp.aphp.fr</EMAIL_1><EMAIL_2>pierdurieux@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Public Health and Medical Informatics</DEPARTMENT><ORGANISATION>Georges Pompidou European Hospital, Paris Descartes University, INSERM U872 eq 22</ORGANISATION><ADDRESS_1>20 rue Leblanc</ADDRESS_1><CITY>Paris</CITY><ZIP>75015</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>33 1 56 09 20 43</PHONE_1><FAX_1>33 1 56 09 20 52</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-11-07 08:47:49 +0000" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="67580075777139363708101222110552" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Florence</FIRST_NAME><LAST_NAME>Gillaizeau</LAST_NAME><EMAIL_1>gillaizeauflorence-hegp@yahoo.fr</EMAIL_1><ADDRESS><DEPARTMENT>French Cochrane Center</DEPARTMENT><ORGANISATION>Hôpital Hôtel-Dieu</ORGANISATION><ADDRESS_1>1 place du Parvis Notre-Dame</ADDRESS_1><CITY>Paris</CITY><ZIP>75004</ZIP><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="40594786589506816117100610162421" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ellis</FIRST_NAME><LAST_NAME>Chan</LAST_NAME><EMAIL_1>ellis.chan@htd.aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>Centre d'Epidémiologie Clinique</DEPARTMENT><ORGANISATION>Hôpital Hôtel-Dieu</ORGANISATION><ADDRESS_1>1, place du Parvis Notre-Dame</ADDRESS_1><CITY>Paris</CITY><ZIP>75004</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 42 34 78 24</PHONE_1><FAX_1>+33 1 40 25 67 73</FAX_1></ADDRESS></PERSON><PERSON ID="386815A782E26AA2010715372E7AD77C" ROLE="AUTHOR"><FIRST_NAME>Ludovic</FIRST_NAME><LAST_NAME>Trinquart</LAST_NAME><POSITION>Biostatician</POSITION><EMAIL_1>ludovic.trinquart@htd.aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>French Cochrane Center</DEPARTMENT><ORGANISATION>Hôpital Hôtel-Dieu</ORGANISATION><ADDRESS_1>1 place du Parvis Notre-Dame</ADDRESS_1><CITY>Paris</CITY><ZIP>75004</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+331 42 34 78 19</PHONE_1><FAX_1>+331 42 34 87 90</FAX_1></ADDRESS></PERSON><PERSON ID="3868131682E26AA201071537AF1A360C" ROLE="AUTHOR"><FIRST_NAME>Isabelle</FIRST_NAME><LAST_NAME>Colombet</LAST_NAME><EMAIL_1>isabelle.colombet@egp.aphp.fr</EMAIL_1><EMAIL_2>isabelle.colombet@spim.jussieu.fr</EMAIL_2><ADDRESS><DEPARTMENT>Medical Informatics Department</DEPARTMENT><ORGANISATION>Georges Pompidou European Hospital, Paris Descartes University, INSERM U872 eq20</ORGANISATION><CITY>Paris</CITY><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="386818D382E26AA20107153764EC7CE9" ROLE="AUTHOR"><FIRST_NAME>RT</FIRST_NAME><LAST_NAME>Walton</LAST_NAME><POSITION>Professor of Primary Medical Care</POSITION><EMAIL_1>rtwalton123@gmail.com</EMAIL_1><EMAIL_2>rtwalton123@googlemail.com</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Health Sciences</DEPARTMENT><ORGANISATION>Barts and the London Medical School</ORGANISATION><ADDRESS_1>Abernethy Building</ADDRESS_1><CITY>London</CITY><ZIP>E1 2AT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)20 7882 2503</PHONE_1><FAX_1>+44 (0)20 7882 2552</FAX_1></ADDRESS></PERSON><PERSON ID="8DD1A45B82E26AA20022B7F82C13ABE8" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Myriam</FIRST_NAME><LAST_NAME>Rège-Walther</LAST_NAME><EMAIL_1>myriam.rege@chuv.ch</EMAIL_1><EMAIL_2>swiss.cochrane@chuv.ch</EMAIL_2><URL>www.swiss.cochrane.org</URL><ADDRESS><DEPARTMENT>Cochrane Switzerland, Institute of Social and Preventive Medicine</DEPARTMENT><ORGANISATION>Lausanne University Hospital</ORGANISATION><ADDRESS_1>Biopôle 2</ADDRESS_1><ADDRESS_2>Route de la Corniche 10</ADDRESS_2><CITY>Lausanne</CITY><ZIP>1010</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 21 314 73 15</PHONE_1></ADDRESS></PERSON><PERSON ID="17166" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernard</FIRST_NAME><LAST_NAME>Burnand</LAST_NAME><POSITION>Chief Physician, Professor</POSITION><EMAIL_1>Bernard.Burnand@chuv.ch</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Switzerland, Institute of Social and Preventive Medicine</DEPARTMENT><ORGANISATION>Lausanne University Hospital</ORGANISATION><ADDRESS_1>Biopôle 2</ADDRESS_1><ADDRESS_2>Route de la Corniche 10</ADDRESS_2><CITY>Lausanne</CITY><ZIP>CH-1010</ZIP><REGION>Vaud</REGION><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 21 314 72 55</PHONE_1><FAX_1>+41 21 314 49 54</FAX_1></ADDRESS></PERSON><PERSON ID="8850" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pierre</FIRST_NAME><LAST_NAME>Durieux</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>pierre.durieux@egp.aphp.fr</EMAIL_1><EMAIL_2>pierdurieux@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Public Health and Medical Informatics</DEPARTMENT><ORGANISATION>Georges Pompidou European Hospital, Paris Descartes University, INSERM U872 eq 22</ORGANISATION><ADDRESS_1>20 rue Leblanc</ADDRESS_1><CITY>Paris</CITY><ZIP>75015</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>33 1 56 09 20 43</PHONE_1><FAX_1>33 1 56 09 20 52</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-11-04 13:33:22 +0100" MODIFIED_BY="Alain Mayhew">
<UP_TO_DATE>
<DATE DAY="12" MONTH="12" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-11-06 10:52:44 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-11-06 10:52:44 +0100" MODIFIED_BY="Elizabeth Paulsen">
<DATE DAY="6" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>A new search for studies was conducted January 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-04 12:47:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>Search strategies were significantly revised and databases searched from 1996 to January 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-07 09:32:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">Computerized advice on drug dosage to improve prescribing practice</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;'can bleed to death'&lt;/p&gt;&lt;p&gt;&lt;b&gt;Is this too alarming? Would it be better to say 'people may experience excessive bleeding and even death'&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-09-24 14:19:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;deleted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:32:28 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Physicians and other healthcare professionals often prescribe drugs that will only work at certain concentrations. These drugs are said to have a narrow therapeutic window. This means that if the concentration of the drug is too high or too low, they may cause serious side effects or not provide the benefits they should. For example, blood thinners (anticoagulants) are prescribed to thin the blood to prevent clots. If the concentration is too high, people may experience excessive bleeding and even death. In contrast, if the concentration is too low, a clot could form and cause a stroke. For these types of drugs, it is important that the correct amount of the drug be prescribed.</P>
<P>Calculating and prescribing the correct amount can be complicated and time-consuming for healthcare professionals. Sometimes determining the correct dose can take a long time since healthcare professionals may not want to prescribe high doses of the drugs initially because they make mistakes in calculations. Several computer systems have been designed to do these calculations and assist healthcare professionals in prescribing these types of drugs.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We sought clinical trial evidence from scientific databases to evaluate the effectiveness of these computer systems. The evidence is current to January 2012. We found data from 42 trials (40 randomized controlled trials (trials that allocate people at random to receive one of a number of drugs or procedures) and two non-randomized controlled trials).</P>
<P>
<B>Key results</B>
</P>
<P>Computerized advice for drug dosage can benefit people taking certain drugs compared with empiric dosing (where a dose is chosen based on a doctor's observations and experience) without computer assistance. When using the computer system, healthcare professionals prescribed appropriately higher doses of the drugs initially for aminoglycoside antibiotics and the correct drug dose was reached more quickly for oral anticoagulants. It significantly decreased thromboembolism (blood clotting) events for anticoagulants and tended to reduce unwanted effects for aminoglycoside antibiotics and anti-rejection drugs (although not an important difference). It tended to reduce the length of hospital stay compared with routine care with comparable or better cost-effectiveness. There was no evidence of effects on death or clinical side events for insulin (low blood sugar (hypoglycaemia)), anaesthetic agents, anti-rejection drugs (drugs taken to prevent rejection of a transplanted organ) and antidepressants.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>The quality of the studies was low so these results must be interpreted with caution.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-07 09:32:16 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Maintaining therapeutic concentrations of drugs with a narrow therapeutic window is a complex task. Several computer systems have been designed to help doctors determine optimum drug dosage. Signi&#64257;cant improvements in health care could be achieved if computer advice improved health outcomes and could be implemented in routine practice in a cost-effective fashion. This is an updated version of an earlier Cochrane systematic review, first published in 2001 and updated in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>To assess whether computerized advice on drug dosage has beneficial effects on patient outcomes compared with routine care (empiric dosing without computer assistance).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-07 09:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>The following databases were searched from 1996 to January 2012: EPOC Group Specialized Register, Reference Manager; Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Ovid; EMBASE, Ovid; and CINAHL, EbscoHost. A "top up" search was conducted for the period January 2012 to January 2013; these results were screened by the authors and potentially relevant studies are listed in Studies Awaiting Classification. The review authors also searched reference lists of relevant studies and related reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-11-04 13:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials, non-randomized controlled trials, controlled before-and-after studies and interrupted time series analyses of computerized advice on drug dosage. The participants were healthcare professionals responsible for patient care. The outcomes were any objectively measured change in the health of patients resulting from computerized advice (such as therapeutic drug control, clinical improvement, adverse reactions).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed study quality. We grouped the results from the included studies by drug used and the effect aimed at for aminoglycoside antibiotics, amitriptyline, anaesthetics, insulin, anticoagulants, ovarian stimulation, anti-rejection drugs and theophylline. We combined the effect sizes to give an overall effect for each subgroup of studies, using a random-effects model. We further grouped studies by type of outcome when appropriate (i.e. no evidence of heterogeneity).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Forty-six comparisons (from 42 trials) were included (as compared with 26 comparisons in the last update) including a wide range of drugs in inpatient and outpatient settings. All were randomized controlled trials except two studies. Interventions usually targeted doctors, although some studies attempted to influence prescriptions by pharmacists and nurses. Drugs evaluated were anticoagulants, insulin, aminoglycoside antibiotics, theophylline, anti-rejection drugs, anaesthetic agents, antidepressants and gonadotropins. Although all studies used reliable outcome measures, their quality was generally low.</P>
<P>This update found similar results to the previous update and managed to identify specific therapeutic areas where the computerized advice on drug dosage was beneficial compared with routine care:</P>
<P>1. it increased target peak serum concentrations (standardized mean difference (SMD) 0.79, 95% CI 0.46 to 1.13) and the proportion of people with plasma drug concentrations within the therapeutic range after two days (pooled risk ratio (RR) 4.44, 95% CI 1.94 to 10.13) for aminoglycoside antibiotics;</P>
<P>2. it led to a physiological parameter more often within the desired range for oral anticoagulants (SMD for percentage of time spent in target international normalized ratio +0.19, 95% CI 0.06 to 0.33) and insulin (SMD for percentage of time in target glucose range: +1.27, 95% CI 0.56 to 1.98);</P>
<P>3. it decreased the time to achieve stabilization for oral anticoagulants (SMD -0.56, 95% CI -1.07 to -0.04);</P>
<P>4. it decreased the thromboembolism events (rate ratio 0.68, 95% CI 0.49 to 0.94) and tended to decrease bleeding events for anticoagulants although the difference was not significant (rate ratio 0.81, 95% CI 0.60 to 1.08). It tended to decrease unwanted effects for aminoglycoside antibiotics (nephrotoxicity: RR 0.67, 95% CI 0.42 to 1.06) and anti-rejection drugs (cytomegalovirus infections: RR 0.90, 95% CI 0.58 to 1.40);</P>
<P>5. it tended to reduce the length of time spent in the hospital although the difference was not significant (SMD -0.15, 95% CI -0.33 to 0.02) and to achieve comparable or better cost-effectiveness ratios than usual care;</P>
<P>6. there was no evidence of differences in mortality or other clinical adverse events for insulin (hypoglycaemia), anaesthetic agents, anti-rejection drugs and antidepressants.</P>
<P>For all outcomes, statistical heterogeneity quantified by I<SUP>2</SUP> statistics was moderate to high.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>This review update suggests that computerized advice for drug dosage has some benefits: it increases the serum concentrations for aminoglycoside antibiotics and improves the proportion of people for which the plasma drug is within the therapeutic range for aminoglycoside antibiotics.</P>
<P>It leads to a physiological parameter more often within the desired range for oral anticoagulants and insulin. It decreases the time to achieve stabilization for oral anticoagulants. It tends to decrease unwanted effects for aminoglycoside antibiotics and anti-rejection drugs, and it significantly decreases thromboembolism events for anticoagulants. It tends to reduce the length of hospital stay compared with routine care while comparable or better cost-effectiveness ratios were achieved.</P>
<P>However, there was no evidence that decision support had an effect on mortality or other clinical adverse events for insulin (hypoglycaemia), anaesthetic agents, anti-rejection drugs and antidepressants. In addition, there was no evidence to suggest that some decision support technical features (such as its integration into a computer physician order entry system) or aspects of organization of care (such as the setting) could optimize the effect of computerized advice.</P>
<P>Taking into account the high risk of bias of, and high heterogeneity between, studies, these results must be interpreted with caution.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-07 09:30:34 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Medication mistakes still represent 20% of all medical errors although many efforts have focused in recent years on reducing the risk of drug errors (<LINK REF="REF-Brennan-1991" TYPE="REFERENCE">Brennan 1991</LINK>). Maintaining therapeutic concentrations of drugs is a complex task requiring knowledge of evidence-based clinical guidelines, clinical pharmacology and skills in dose calculation. The potential for error is great since many of the drugs commonly used have a narrow 'window' within which therapeutic benefits can be obtained with a low risk of unwanted effects.<BR/>
</P>
<CONDITION MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Monitoring drug therapy to optimize effects and minimize dangers can be very time consuming. Practitioners may need access to a large amount of information to make an appropriate dose adjustment in situations such as prevention of deep vein thrombosis or management of people with renal insufficiency (<LINK REF="REF-Durieux-2005" TYPE="REFERENCE">Durieux 2005</LINK>). Under these conditions, healthcare professionals make errors of judgement because their ability to process information is finite (<LINK REF="REF-McDonald-1976a" TYPE="REFERENCE">McDonald 1976a</LINK>).</P>
<P>For example, in ambulatory settings, general practitioners (GP) reported difficulties with drug dosing, especially for children, elderly people and people with renal impairment (<LINK REF="REF-Franke-2000" TYPE="REFERENCE">Franke 2000</LINK>). Moreover, physicians' computational abilities are often insufficient to perform calculations for drug dosage (<LINK REF="REF-Baldwin-1995" TYPE="REFERENCE">Baldwin 1995</LINK>). For example, 82 out of 150 hospital doctors were unable to calculate how many milligrams of lidocaine were in a 10 mL ampoule of 1% solution (<LINK REF="REF-Rolfe-1995" TYPE="REFERENCE">Rolfe 1995</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Clinical decision support systems (CDSS), either computerized or not, have been proposed to improve clinical practice (<LINK REF="REF-Kawamoto-2005" TYPE="REFERENCE">Kawamoto 2005</LINK>). Ideally, decision support, integrated in the electronic medical record as the platform, can provide physicians with tools making it possible to improve practice and patient safety (<LINK REF="REF-Bates-2003" TYPE="REFERENCE">Bates 2003</LINK>). An effective decision support system would anticipate needs and deliver information quickly in real time, adapted to the user's workflow (<LINK REF="REF-Bates-2003" TYPE="REFERENCE">Bates 2003</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>Computers are very good at collecting information and performing repetitive calculations. Moreover, the drugs that cause the most problems have often been in use for many years. The pharmacology of the drugs is, therefore, well understood and thus computer models can be used to generate advice on dosage. Several types of computer systems have been designed to help doctors in the task of determining the optimum dosage of drugs. Significant improvements in health could be achieved if computer advice was shown to be beneficial and was provided by the computers that clinicians now use for their everyday work.</P>
<P>In addition, the logistics by which the advice on drug dosage is delivered to the healthcare professional is critical to its effectiveness and to the transferability of this effectiveness in other settings. Computer physician order entry (CPOE) systems, which allow physicians to enter orders directly into a computer rather than hand writing them, have the potential to incorporate CDSS into daily practice (<LINK REF="REF-Kuperman-2003" TYPE="REFERENCE">Kuperman 2003</LINK>). According to three systematic reviews (<LINK REF="REF-Garg-2005" TYPE="REFERENCE">Garg 2005</LINK>; <LINK REF="REF-Kawamoto-2005" TYPE="REFERENCE">Kawamoto 2005</LINK>; <LINK REF="REF-Nieuwlaat-2011a" TYPE="REFERENCE">Nieuwlaat 2011a</LINK>), CDSSs are more often associated with improvement of practice when the decision aid is automatically prompted, integrated in clinicians' workflow, and provided at time and location of decision making.</P>
<P>This review focuses on advice with a personalized dosage for a specific participant. Two other Cochrane systematic reviews were interested in computer-generated reminders: one evaluated the effects of on-screen computer reminders delivered to clinicians at the point of care (<LINK REF="REF-Shojania-2009" TYPE="REFERENCE">Shojania 2009</LINK>), and one considered reminders delivered on paper to healthcare professionals (<LINK REF="REF-Arditi-2012" TYPE="REFERENCE">Arditi 2012</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>This is an updated version of two earlier Cochrane systematic reviews (<LINK REF="REF-Walton-2001" TYPE="REFERENCE">Walton 2001</LINK>; <LINK REF="REF-Durieux-2008" TYPE="REFERENCE">Durieux 2008</LINK>).Those earlier reviews provided some evidence to support the use of computer assistance in determining drug dosage but concluded that further clinical trials were necessary to confirm those results.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-04 12:48:04 +0100" MODIFIED_BY="[Empty name]">
<P>The primary objective of this systematic review was to examine whether computerized advice on drug dosage given to healthcare professionals is beneficial when compared with routine care (empiric dosing without computer assistance). The secondary objective was to determine whether any technical features of computerized systems or organizational aspects concerning their implementation influence their effectiveness.</P>
<SUBSECTION>
<HEADING LEVEL="2">Hypothesis tested</HEADING>
<P>In previous versions of this review, we tested the benefit in terms of effects on process of care (healthcare professional oriented) and on outcome of care (patient oriented). The effect on process of care was any change in drug dose as a process measure. However, there are problems with this approach since a higher dose may, in some circumstances, be beneficial and, in others, be disadvantageous. Thus, in this review we have removed this outcome and only reported effects on dosage where we judged the changes to be meaningful. We examined six hypotheses on patient-oriented outcomes (most of them measuring surrogate outcomes).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Effect on outcome of care (patient-oriented outcomes)</HEADING>
<OL>
<LI>Decisions on drug dosage based on computer advice lead more often to drug levels within the therapeutic range.</LI>
<LI>Decisions on drug dosage based on computer advice lead more often to a physiological parameter being maintained within the desired range (e.g. blood pressure or prothrombin (PT) time).</LI>
<LI>Decisions on drug dosage based on computer advice lead to more rapid therapeutic control, assessed by a physiological parameter.</LI>
<LI>Decisions on drug dosage based on computer advice lead to greater clinical effectiveness, assessed by clinical improvement.</LI>
<LI>Decisions on drug dosage based on computer advice lead to fewer unwanted effects than conventional dose adjustment.</LI>
<LI>Computer advice reduces the cost of health care or the use of resources (e.g. length of hospital stay).</LI>
</OL>
<P>Unlike the previous update of this review, we decided to analyze the results individually for each drug because of a high clinical and statistical heterogeneity between drugs (each drug has its specific outcomes).</P>
<P>Other hypotheses address our secondary objectives and reflect a series of subgroup analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Effect of decision support logistics and organization of care</HEADING>
<OL>
<LI>Computer advice given in real time is more effective than that given by delayed feedback.</LI>
<LI>Computer advice integrated in CPOE system is more effective than other systems.</LI>
<LI>System-initiated computer advice is more effective than user-initiated computer advice.</LI>
<LI>Direct intervention (system delivers advice directly to the provider) is more effective than indirect intervention (advice is made available to the provider by the intermediate of a third party actor, i.e. system is not directly used by the provider).</LI>
<LI>The impact of computer advice depends on the setting where it is implemented (inpatient versus outpatient care).</LI>
<LI>Computer advice given as a recommendation is more effective than a calculated dose proposed without possibility of change and which does not take into account the healthcare professional's experience).</LI>
</OL>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-07 09:30:34 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-11-04 12:48:22 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>We considered for inclusion all types of study designs that met Effective Practice and Organization of Care Group (EPOC) inclusion criteria:</P>
<UL>
<LI>Randomized controlled trials (RCTs) where the unit of randomization was:</LI>
</UL>
<OL>
<LI>the participant or</LI>
<LI>the cluster: healthcare professionals (doctors, nurses or pharmacists) or groups of professionals (practices or hospitals);</LI>
</OL>
<UL>
<LI>Non-randomized controlled trials (NRCTs);</LI>
<LI>Controlled before-and-after (CBA) studies with:</LI>
</UL>
<OL>
<LI>the same pre- and postintervention periods for study and control sites;</LI>
<LI>comparable study and control sites with respect to level of care, setting of care and baseline characteristics;</LI>
<LI>two intervention sites and two control sites;</LI>
</OL>
<UL>
<LI>Interrupted time series (ITS) studies with:</LI>
</UL>
<OL>
<LI>a clearly defined point in time when the intervention occurred;</LI>
<LI>at least three data points before and three after the intervention.</LI>
</OL>
<P>See the EPOC checklist for definition of designs (<LINK REF="REF-EPOC-2012" TYPE="REFERENCE">EPOC 2012</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>The participants were healthcare professionals with responsibility for patient care.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-10-08 17:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>We sought to identify all comparative studies comparing computerized advice on drug dosage given to routine care (empiric dosing without computer assistance). We defined computerized advice on drug dosage as a recommendation provided to the healthcare professional on the drug dosage needed for a specific participant and a specific drug and calculated by a computer.</P>
<SUBSECTION>
<HEADING LEVEL="4">Computer program</HEADING>
<P>The computer program was a software model or an application integrated into a laptop, a smartphone, a tablet computer, the CPOE, or a website (online calculator). We did not consider interventions where the recommended drug dose was not calculated by a computer, for example an equation or a nomogram not implemented in a computer device.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nature of advice</HEADING>
<P>The advice included a dosage personalized for a specific participant. We did not include studies reporting a popup with general advice on the dosage required for a specific condition (most frequently dose of medication, dose interval, maximum total daily dose).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Content of recommendation and calculation of drug dose</HEADING>
<P>The recommendation could be evidence-based, a clinical practice guideline developed by expert bodies (government, professional) or local clinicians, or population pharmacokinetic/pharmacodynamic models. The participant's drug dose was computed using an equation including participant's characteristics (participant's age, weight, previous drug levels&#8230;). Alternatively, a more complex mathematical model was used, which was generally a pharmacokinetic model of the relationship between administered doses of the drug and observed concentrations in the participant's body.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Advice delivery and timing</HEADING>
<P>The computerized advice could be delivered to clinicians when they are writing their prescription (point of care delivery) or it could be delivered at a later time. In addition, the computerized advice could be delivered to another healthcare professional (e.g. a pharmacist or a pharmacokinetic unit) and passed to the clinician. Unlike the review on the effect of point-of-care computer reminders on physician behaviour (<LINK REF="REF-Shojania-2009" TYPE="REFERENCE">Shojania 2009</LINK>), we included systems that were not encountered during routine performance of the activities of interest, for example a dedicated computer used only for performing dose calculation for anticoagulants. These systems require clinicians to depart from their usual workflow in order to avail themselves of the reminder or decision support.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control of the healthcare professional</HEADING>
<P>We included studies where advice was given as a recommendation so that the healthcare professional was able to accept or refuse it. We did not include studies reporting non-specific advice given to a healthcare professional to adjust drug dosage or when the healthcare professional was not in charge of every adjustment of the drug, for example studies reporting the direct administration of a drug to the participant by means of a computer supervised device (closed-loop system) or through self dosing devices (one Cochrane review addresses the evaluation of anticoagulant self management (<LINK REF="REF-Garcia_x002d_Alamino-2010" TYPE="REFERENCE">Garcia-Alamino 2010</LINK>)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Starter</HEADING>
<P>The advice could be system-initiated (advice appears without user intervention) or user-initiated (the computer program must be started by the user to obtain an advice).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control group</HEADING>
<P>The control group included empiric dosing without computer assistance, in general routine care.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-04 12:48:22 +0100" MODIFIED_BY="[Empty name]">
<P>All outcome measures included were patient-oriented outcomes.</P>
<OL>
<LI>Proportion of participants or time for which the plasma drug concentrations was within the therapeutic range.</LI>
<LI>Proportion of participants or time for which the studied physiological parameter was maintained within the target range.</LI>
<LI>Time to achieve therapeutic control.</LI>
<LI>Proportion of participants with toxic drug levels.</LI>
<LI>Proportion of participants with clinical improvement.</LI>
<LI>Proportion of participants with adverse effects of drug therapy.</LI>
<LI>Proportion of deaths.</LI>
<LI>Length of hospital stay.</LI>
<LI>Total cost per participant.</LI>
</OL>
<P>We excluded the outcomes for which reporting was incomplete (e.g. no numerical values reported, no measure of dispersion) and excluded studies whose only relevant outcomes were death or adverse effects requiring monitoring and which did not explicitly report such outcomes as primary.</P>
<P>For serum concentrations, we also considered peak, trough and steady-state concentrations. The measurement of drug levels in the blood, called therapeutic drug monitoring (TDM), is required for some drugs to ensure that the participants maintain the concentration of drug within the established therapeutic range (drug effective without toxicity). Blood for peak level is collected at the drug's highest concentration within the dosing period. Trough levels (occasionally called residual levels) are measured just prior to administration of the next dose, and are the lowest concentration in the dosing interval. Most therapeutic drugs have a narrow trough to peak difference (therapeutic range), and, therefore, only trough levels are needed to detect blood levels that are too low or too high. Peak levels are needed for some drugs, especially aminoglycoside antibiotics: a concentration below the therapeutic range will not resolve the bacterial infection so high peak concentrations are necessary for optimal efficacy; however, too high a level can cause damage such as nephrotoxicity so it is important that the trough concentration be allowed to fall in order to avoid accumulation. The steady-state concentration is defined as the point at which the amount of drug administered (drug intake) and the amount of drug excreted (drug elimination) reach an equilibrium. The goal of TDM is to optimize the drug dose so that the participant's drug concentrations remain within the therapeutic range.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-07 09:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Updates to Cochrane systematic reviews usually entail executing previously used search strategies for the update period or, in other words, from the date of the last search, to present. In some cases, however, search strategies must be assessed and revised in order to optimize the identification of evidence. When this occurs, it is advisable to search retrospectively--that is, to re-search previously searched time periods, in order to discover whether or not studies have been missed. This update represents a review where search strategies have been revised significantly (by M. Fiander, Information Scientist, and Trials Search Co-ordinator for the EPOC Group) and where, consequently, searching has been conducted not only from the date of last search in 2006, but retrospectively from 1996 to January 2012, where 1996 to 2006 represents a previously searched time period.</P>
<P>The revised search strategies had an impact on the review since the strategies identified a number of studies which should have been found during previous searches: <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>, <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>, <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>, <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>, <LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>, <LINK REF="STD-Poller-2002" TYPE="STUDY">Poller 2002</LINK>, <LINK REF="STD-Poller-2003" TYPE="STUDY">Poller 2003</LINK>.</P>
<P>For the initial review, the databases listed below were searched from database start date to 1996; for the first update, the search period was 1996 to 2006; for this, the second, update, searches were run from 1996 to January 2012. Two methodological search filters were used to limit retrieval to appropriate study designs: the Cochrane Highly Sensitive Search Strategy (sensitivity- and precision-maximizing version, 2008 revision) to identify randomized trials; and an EPOC methodology filter (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) to identify non-RCT designs. Related reviews were identified by searching the Database of Abstracts of Reviews (DARE). All databases were searched from their start date forward; start date represents the date the database began to index journals. Note that database start dates vary by database (Medline, EMBASE, etc.) and provider (OVID, Ebsco, etc.). Start dates are provided in the list of databases, below.</P>
<P>A top-up search was conducted for the period January 2012 to January 2013; the authors screened the titles and abstracts of these results and added potentially relevant studies to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>The original MEDLINE search strategies used until 2006 are in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. The revised search strategies used for this update are in Appendices 2 to 6 as follows: MEDLINE, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; EMBASE, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; CINAHL, <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; Cochrane Central Register of Controlled Trials, <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; EPOC Specialised Register, <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases searched</HEADING>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), Issue 12, 2012, OvidSP EBM Reviews</LI>
<LI>MEDLINE, including In-Process &amp; Other Non-Indexed Citations, OvidSP, 1946-January 2013</LI>
<LI>EMBASE, 1947 to January 2013, OvidSP</LI>
<LI>CINAHL (Cumulative Index to Nursing and Allied Health Literature), 1980-January 2013, EbscoHost</LI>
<LI>EPOC Group, Specialised Register</LI>
</UL>
</SUBSECTION>
<OTHER_SEARCHES MODIFIED="2013-11-07 09:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors handsearched reference lists from primary articles and relevant reviews identified, and conference proceedings. We contacted experts in the field.</P>
<P>We also:</P>
<UL>
<LI>Screened (hand searched) the following journals:</LI>
<UL>
<LI>
<I>Therapeutic Drug Monitoring</I> journal (1979 to December 2006).</LI>
<LI>
<I>Journal of the American Medical Informatics Association</I> (January 1996 to March 2007).</LI>
</UL>
<LI>Reviewed reference lists of all included studies, relevant systematic reviews and primary studies.</LI>
<LI>Contacted authors of relevant studies/ reviews to clarify reported published information and to seek unpublished results/data.</LI>
<LI>Contacted researchers with expertise relevant to the review topic/ EPOC interventions.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-05 13:55:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We merged the search results using Reference Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>), and removed duplicate records. We examined all titles and abstracts.</P>
<P>Two review authors (FG, PD) examined independently each title and abstract to exclude obviously irrelevant reports (mainly therapeutic trials and genetic research). We retrieved full texts, which were independently screened. We then randomly allocated each selected study to two pairs of review authors (IC and FG, MR and PD) who reviewed it and extracted data independently. We resolved disagreements by group discussion with the four review authors. We reported reasons for excluding full papers.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We reviewed the data abstraction form for the previous update of the review. We adapted a checklist to the specific subject to extract the decision support technical features by which the advice on drug dosage was delivered to the healthcare professional.</P>
<UL>
<LI>Was the computerized advice delivered in real time (at the moment of the practitioners decision making) or by delayed feedback?</LI>
<LI>Was the computerized advice integrated in a CPOE?</LI>
<LI>Was the computerized advice user-initiated or system-initiated?</LI>
<LI>Was the intervention direct or indirect (a third party brought advice from computer and transfers it to user)?</LI>
</UL>
<P>An additional feature was added:</P>
<UL>
<LI>Was the information of the calculated dose given as a recommendation to the healthcare professional who prescribed through the computer or through another healthcare professional (the healthcare professional had the possibility to accept or refuse the advice)?</LI>
</UL>
<P>The review authors abstracted the data independently and resolved disagreements by discussion. A statistician (FG) reviewed all data and contacted authors of included studies for additional information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of the studies using the 'Risk of bias' criteria described by the EPOC group and extracted data using the EPOC checklist (<LINK REF="REF-EPOC--2009" TYPE="REFERENCE">EPOC 2009</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used nine standard criteria for RCTs, NRCTs and CBAs: allocation sequence adequately generated; allocation adequately concealed; baseline outcome measurements similar; baseline characteristics similar; incomplete outcome data adequately addressed; knowledge of the allocated interventions adequately prevented during the study; study adequately protected against contamination; study free from selective outcome reporting; study free from other risks of bias. We scored studies using cluster randomization to be adequate on concealment of allocation (if the sequence generation was adequate) and on protection against contamination. Baseline characteristics were considered for similarity at the unit of analysis level. Risk of bias on baseline outcome measurements was only evaluated for insulin. For the other drugs, the baseline measurement was not relevant since there was no drug intake before the intervention. Therefore, we considered risk of bias on baseline outcome measurements to be 'low risk' for these drugs.</P>
<P>The risk of bias for ITS studies can be evaluated using seven standard criteria but we found no ITS studies.</P>
<P>We included all the 'Risk of bias' criteria in the data abstraction form and independently scored criteria as 'yes' (adequate), 'no' (inadequate) or 'unclear'. We resolved disagreements by discussion and, where necessary, with a third review author. The risk of bias of included studies is summarized in the text and presented in the 'Risk of bias' section within the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Two review authors (EC, PD) assessed the quality of evidence for each main outcome - that is the extent of confidence in the estimate of effect across studies (high, moderate, low or very low) - using the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>For dichotomous variables, we used the risk ratio (RR).</P>
<P>When the outcomes were continuous variables, we calculated standardized mean differences (SMD) with 95% confidence intervals (CI). The SMD is a statistical measure of the impact of the intervention, which is independent of the units used to measure study outcomes. This measure allows studies of the same intervention using different outcomes to be compared. For example, measurement of drug concentrations in blood in different studies may use different assays in several laboratories and results may be reported in different units. The SMD compares differences between experimental and control groups to the standard deviation of the outcome for each study. Hence, a quantitative approximation can be made of the overall effect of decision support on plasma levels. Because SMD can be difficult to interpret (as it is reported in units of standard deviation), we also presented mean difference (MD), that is the absolute difference between the mean value in two groups, in relevant cases (when measurements were made on the same scale).</P>
<P>Clinical adverse events were expressed as RRs or rate ratios. In a randomized trial, rate ratios may often be very similar to RRs obtained after dichotomizing the participants, since the mean period of follow-up should be similar in all intervention groups. Rate ratios and RRs will differ, however, if an intervention affects the likelihood of some participants experiencing multiple events.</P>
<P>The effect sizes were combined to give an overall effect for each subgroup of studies, using a random-effects model. The random-effects model was chosen because it does not assume that all interventions have the same underlying effect.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>Analyses of studies using cluster randomization that do not account for the design effect risk inflating the type 1 error-rate resulting in artificially narrow CIs (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>). We have reported potential errors and did not attempt to reanalyze data unless standard errors were correctly stated with number of clusters allowing the calculation of appropriate CIs.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>When the mean and standard deviation were missing, we estimated the mean from the median and standard deviation from the interquartile range or range (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>). Missing data on outcomes or estimated data are explicitly indicated in the tables and text. We did not attempt to impute or model other missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity using tests of heterogeneity and examinations of direction, magnitude and variability of effects. The statistical test for heterogeneity (Chi<SUP>2</SUP> test) tests the null hypothesis that all studies in a meta-analysis have the same underlying magnitude of effects. The I<SUP>2</SUP> statistic quantifies the proportion of the variation in point estimates due to among-study differences but is influenced by sample size. An I<SUP>2 </SUP>statistic greater than 50% may be considered as substantial heterogeneity and I<SUP>2 </SUP>statistic greater than 75% as considerable heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). High P value for the test of heterogeneity (P value &gt; 0.1) and low I<SUP>2</SUP> values do not necessarily indicate low heterogeneity (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>). Thus, we also manually examined the variability in point estimates across studies and the overlap of CIs.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-11-05 13:55:53 +0100" MODIFIED_BY="[Empty name]">
<P>To be meaningful and appropriate, funnel-plot asymmetry tests must be performed when four criteria are met: no significant heterogeneity (P value for the Chi<SUP>2</SUP> test of heterogeneity &gt; 0.10), low I<SUP>2 </SUP>statistic (&lt; 50%), 10 or more studies with at least one with significant results, and a ratio of the maximal to minimal variance across studies greater than four (<LINK REF="REF-Ioannidis-2007" TYPE="REFERENCE">Ioannidis 2007</LINK>). We could not assess publication bias because these conditions were not met.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-28 22:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped the results from the included studies by drug used and the effect aimed at for aminoglycoside antibiotics, amitriptyline, anaesthetics, insulin, anticoagulants, ovarian stimulation, anti-rejection drugs and theophylline. We further grouped studies by type of outcome when appropriate (i.e. no evidence of heterogeneity).</P>
<P>We constructed Forest plots for the main outcomes without potential unit of analysis error for which data were available for more than one comparison.</P>
<P>The doses of drugs administered to participants and the number of dose changes per participant were described but not compared.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We considered the following potential sources of heterogeneity to explain variation in the results of the included studies:</P>
<UL>
<LI>time of delivery of advice (real time/delayed feedback);</LI>
<LI>location of advice (integrated in CPOE systems/other);</LI>
<LI>initiation of the computer advice (system-initiated/user-initiated);</LI>
<LI>advice given directly to the provider (direct intervention) versus the intermediate of a third party actor (indirect intervention);</LI>
<LI>type of hospital (outpatient/inpatient);</LI>
<LI>type of advice (recommendation/calculated dose proposed without possibility of change).</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We had planned to perform a sensitivity analysis, excluding high risk of bias studies, but, since most of the identified studies had high risk of bias, we were unable to perform this analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>The initial review identified 15 comparisons (14 articles) (<LINK REF="REF-Walton-2001" TYPE="REFERENCE">Walton 2001</LINK>), whereas the previous update of this review identified 26 comparisons (23 articles) that met inclusion criteria (<LINK REF="REF-Durieux-2008" TYPE="REFERENCE">Durieux 2008</LINK>).</P>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the study PRISMA flow chart (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>). We screened 5328 non-duplicate records, of which 64 were identified through other sources than database searches (references from previous versions of this review and published before 1996, references from bibliography or website of screened articles or systematic reviews). We assessed 199 articles for potential inclusion: 136 articles identified from the new updated search strategy (from January 1996) (including eight from the previous version of the review) and 48 additional relevant articles from handsearches and reference lists of trials and systematic reviews, leading to 176 potential 'new' inclusions as compared with the previous version of the review; and 15 articles from the previous review and published before 1996.</P>
<P>Since the search strategy missed studies we will search pre-1996 for the next update of this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-11-04 12:51:40 +0100" MODIFIED_BY="[Empty name]">
<P>This update identified 20 new trials with 21 comparisons, for a total of 42 trials and 46 comparisons and are included as follows: 25 comparisons (22 trials) from the previous update of this review (<LINK REF="REF-Durieux-2008" TYPE="REFERENCE">Durieux 2008</LINK>), and 21 comparisons (20 trials) from this update.</P>
<P>These 42 trials were reported in 53 references (many reports for some trials). Three articles were separate cost-effectiveness analyses: <LINK REF="STD-Jowett-2009" TYPE="STUDY">Jowett 2009</LINK> (main results in <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>), <LINK REF="STD-Rousseau-2010" TYPE="STUDY">Rousseau 2010</LINK> (main results in <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>), and <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK> (main results in <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>). One article was a separate safety analysis: <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK> (main results in <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>).</P>
<P>In four trials, two different comparisons were analyzed in one article, midazolam and fentanyl continuous infusion anaesthesia for cardiac surgery were independently titrated to maintain haemodynamic stability infusions but analyzed in the same population (<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>). Therefore, these two drugs were reviewed separately. In one article, <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK> considered people starting warfarin with a targeted international normalized ratio (INR) between 2 and 3; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK> considered people on long-term treatment with a targeted INR between 3 and 4.5. <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK> considered inpatients needing anticoagulant therapy (stabilized patients); <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK> considered outpatients needing anticoagulant therapy (in the stabilization period). The results from two computer-assisted dosage programs (DAWN AC and PARMA 5) were first published in one clinical endpoint report from the European Action on Anticoagulation (EAA), which gave the combined results (<LINK REF="STD-Poller-2008" TYPE="STUDY">Poller 2008</LINK>) and secondly published in two separate reports (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>), because the computer-assistance differed considerably between the participant centres in the study using the two alternative programs. We decided to include the two computer-assisted dosage programs as two subgroup analyses.</P>
<P>All studies were RCTs, except two (<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>; <LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>), which we classified as NRCTs.</P>
<P>In one publication concerning warfarin dosage adjustment (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>), three groups were studied: we reviewed only the comparison between the group using an analogue-computer method and the group using empiric dosing (control). The third group, using a linear regression model, was excluded because it did not involve any computer assistance.</P>
<P>In one publication (<LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>), two different groups of people were studied: one group starting oral anticoagulants (induction) and one group on long-term treatment (maintenance). The maintenance study was not reviewed because of the absence of relevant data for the primary outcome.</P>
<P>In one publication, two different studies were reported: the first study considered people starting warfarin with a targeted INR between 2 and 3 (<LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>); the second study considered people on long-term treatment with a targeted INR between 3 and 4.5 (<LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>).</P>
<P>In one publication (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>), there were two levels of randomization. Practices were randomized to intervention or control. The study used two control populations: people individually randomly allocated to control in the intervention practices (intrapractice controls) and all participants in the control practices (interpractice controls). We did not analyze interpractice controls to avoid a possible unit of analysis error.</P>
<P>In one publication concerning oral anticoagulation therapy at steady state where randomization was at the GP practice level (reported in <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>), four groups were studied: we reviewed only the comparison between group A (Grol's multifaceted education: summary of the guidelines printed on the cover of a folder containing the anticoagulation files; information booklets on anticoagulation for their patients; website with guidelines, study design, and general information; newsletter sent every two months to inform the GPs on the study progress and requested them to send the anticoagulation files for checking) and group D (Grol's multifaceted education + DAWN AC computer-assisted advice that generated a recommended dosing scheme and the time to next visit). Group A did not correspond to standard practice but it was considered as a control group because GPs in group D also received the multifaceted education. Groups B and C were excluded because the interventions were not computerized advice on drug dosage.</P>
<P>In one publication concerning insulin in cardiac surgery patients (<LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>), three groups were studied: we reviewed only the comparison between the group using the Matias protocol based on the absolute glucose value and the group using computer-based model predictive control algorithm with variable sampling rate (Enhanced software Model Predictive Control (eMPC)). The third group, using the Bath protocol based on the relative glucose change was excluded since most standard protocols in blood glucose management use the absolute glucose value and the Bath protocol had not been used in the hospital before the study.</P>
<P>Four comparisons/three trials included (<LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>) had duplicate publications (<LINK REF="STD-Poller-2002" TYPE="STUDY">Poller 2002</LINK>; <LINK REF="STD-Anderson-2008" TYPE="STUDY">Anderson 2008</LINK>; <LINK REF="STD-Poller-2008" TYPE="STUDY">Poller 2008</LINK>), and three comparisons/two trials included (<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>) were mentioned earlier in abstracts (<LINK REF="STD-Poller-2003" TYPE="STUDY">Poller 2003</LINK>; <LINK REF="STD-Le-Meur-2007-extract" TYPE="STUDY">Le Meur 2007 extract</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 143 of the 199 full-text articles assessed for eligibility: 72 because the intervention was not a computerized drug dosage, 38 for an inappropriate design, 12 for absence of relevant data for primary outcome, seven because the patient aid was not under physician control, five because the dose advice was not individualized, three discussions, two conferences publications where contact to author failed (<LINK REF="STD-Ghazal_x002d_Aswad-1997" TYPE="STUDY">Ghazal-Aswad 1997</LINK>; <LINK REF="STD-Tomek-2011" TYPE="STUDY">Tomek 2011</LINK>), one abstract published elsewhere (<LINK REF="STD-van-Leeuwen-2005" TYPE="STUDY">van Leeuwen 2005</LINK>), one because some participants were already included in another publication (<LINK REF="STD-Jankovic-1999" TYPE="STUDY">Jankovic 1999</LINK>) and one comment (<LINK REF="STD-Ligtenberg-2006" TYPE="STUDY">Ligtenberg 2006</LINK>).</P>
<P>One study included in the previous update of the review was excluded because the intervention corresponded to a closed-loop system (automatic optimization of the infusion rate of sodium nitroprusside achieved by an integrated hardware-software closed-loop controller implemented as a small bedside device) (<LINK REF="STD-Ruiz-1993" TYPE="STUDY">Ruiz 1993</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>A total of 17 studies are awaiting classification (possibly relevant ongoing studies published between January 2012 and January 2013). Three references corresponding to conference publications not published at the time of the search for this update (<LINK REF="STD-Overgaard-2010" TYPE="STUDY">Overgaard 2010</LINK>; <LINK REF="STD-Anderson-2011" TYPE="STUDY">Anderson 2011</LINK>; <LINK REF="STD-Nieuwlaat-2011" TYPE="STUDY">Nieuwlaat 2011</LINK>), have been published since then (<LINK REF="STD-Anderson-2012" TYPE="STUDY">Anderson 2012</LINK>; <LINK REF="STD-Nieuwlaat-2012" TYPE="STUDY">Nieuwlaat 2012</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the providers</HEADING>
<P>The providers were primarily doctors, although 14 studies (33.3%) targeted several categories of healthcare professionals including pharmacists (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>; <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>), nurses (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>), or other healthcare professionals (<LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>). Three studies addressed only nurses' behaviour (<LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>).</P>
<P>Twenty studies (47.6%) were conducted in North America (17 in the US, three in Canada) and 15 (35.7%) in Europe (three studies with numerous countries <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>). Two studies took place in New Zealand (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>), one in Australia (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>), one in Israel (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>), one in Norway (<LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>), and one in Serbia (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>; <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>). One study was conducted in 13 countries from Europe, Israel and Australia (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>).</P>
<P>Thirty-one studies (73.8%) were conducted in one centre, and seven studies (16.7%) in two to five centres. One study took place in 11 centres (<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>); one study included 12 practices (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>); one study was conducted in 32 centres from Europe (29 centres), Israel (two centres), and Australia (one centre) (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>); one study included 96 GPs regrouped in 66 GP practices (<LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>).</P>
<P>Twenty-seven comparisons (58.7%) included fewer than 100 participants in the analyses (median: 80 participants, mean: 779 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Target behaviour</HEADING>
<P>The target behaviour of the healthcare provider was the prescription and the dosing of drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the interventions</HEADING>
<P>Most of the studies provided advice about appropriate drug dosages to healthcare professionals who then decided whether to follow this or not. Fifteen studies (35.7%) (18 comparisons) evaluated anticoagulants, 10 studies (23.8%) evaluated the administration of insulin, five studies (11.9%) evaluated the administration of aminoglycoside antibiotics, four studies (9.5%) evaluated theophylline, four studies (9.5%) evaluated anti-rejection drugs requiring adjustments for renal impairment, two studies (4.8%) (three comparisons) evaluated computer-controlled infusions of anaesthetic agents, one study (2.4%) evaluated amitriptyline in the treatment of major depressive episodes and one study (2.4%) evaluated ovarian stimulation by gonadotropins.</P>
<P>Most of the computer support systems used a mathematical model of the pharmacokinetics of the drug to predict the required dose. These models represent the compartments in the body in which the drug is distributed, with rate constants determining the movement of the drug between different compartments. These systems allowed the operator to specify a target serum drug level, which the computer attempted to achieve using Bayesian forecasting methods. Where the effect of the drug was more important than the serum level, pharmacodynamic parameters based on population data could be added to the model (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>Fourteen studies evaluated oral anticoagulant and one study evaluated heparin (<LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>). Five studies analyzed initiation of warfarin (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>), with varying target INR ranges (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Four studies (five comparisons) analyzed long-term warfarin therapy (<LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>), with varying target INR ranges (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). One study analyzed heparin therapy (<LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>). Six studies (five comparisons) analyzed both initiation and long-term warfarin therapy with at least three months of follow-up (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>).</P>
<P>The setting was outpatient care for six studies (<LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>; <LINK REF="STD-Poller-2008" TYPE="STUDY">Poller 2008</LINK>), community-based care in two studies (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>), and inpatient care for six studies (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>: <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>); it was mixed in one study (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>).</P>
<P>The computer support systems were programs that were not integrated into a CPOE. The computer-generated program DAWN AC (4S Information Systems Ltd.) was used in five studies (<LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>). Two modules existed in the DAWN AC program (induction and maintenance). Four studies used a (Bayesian) computer pharmacokinetic or a pharmacodynamic model (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>), or both, whereas one used a pharmacogenetics model (<LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>). One study used the PARMA (Program for Archive, Refertation, and Monitoring of Anticoagulated patients) software program developed in Italy (<LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>), and one comparison used PARMA 5, a new version of the program (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>). Other studies used dosage algorithms or prediction rules.</P>
<P>The advice was given in real time to the healthcare professional in all studies except three, where it was unclear (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>). The computerized advice was user-initiated in seven studies (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>), system-initiated in two studies (<LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>), and it was unclear in six studies (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>). The intervention was direct in seven studies (<LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>), indirect in three studies (dosage determined by pharmacy in <LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK> and <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>, and the pathologist reviewed the computer-generated advice in <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>) and it was unclear in five studies (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Poller-2008" TYPE="STUDY">Poller 2008</LINK>).</P>
<P>Three comparisons provided the warfarin maintenance doses per participant (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>), and there was no significant difference between groups (MD -0.33 mg/day, 95% CI -1.18 to 0.53). One study reported significantly larger amounts of drug prescribed for people with high INR target both of warfarin (computer group = 33.3 mg/week versus manual = 31.3 mg/week; P value &lt; 0.001), and acenocoumarol (computer group = 19.2 mg/week versus manual = 17.8 mg/week; P value &lt; 0.01), whereas there was no significant difference between the doses prescribed for people with low INR target (<LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>). One study analyzed the number of dose adjustments (<LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>): pharmacogenetic guidance significantly decreased the number of required dose adjustments (by 0.62 dose adjustments per participant; 95% CI 0.04 to 1.19; P value = 0.035).</P>
<P>There were two eligible comparisons with potential unit of analysis error that analyzed the proportion of dose adjustments. In one comparison (<LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>), the percentage of dose adjustments performed by the healthcare professionals was 47.4%, whereas the computer needed 31.3% dose adjustments, a statistically significant 34.0% relative reduction (95% CI -41.9% to -24.7%). In the other comparison (<LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>), the proportion of dose adjustments was 48% in the computer group and 45% in the manual group, a non-significant relative increase of 7% (95% CI -10% to 27%).</P>
<P>In <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>, there was no significant difference among the groups in number of tests per participant per month and per cent of participants with treatment changes.</P>
<P>For heparin (<LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>), the mean dose was not significantly different between the computer and the standard groups (MD 100 units/hour, 95% CI -96 to 296).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Insulin (ten studies)</HEADING>
<P>Eight studies (80%) evaluated insulin in people admitted into the intensive care unit with hyperglycaemia: six studies in cardiac surgery patients (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>) and two studies in critically ill patients (<LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>). One study was conducted in general medical inpatients with type 2 diabetes (<LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>) and one study in diabetic outpatients (<LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>).</P>
<P>The computer support system was integrated into a CPOE in one study (<LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), whereas other systems were software developed by companies. The software Model Predictive Control (MPC) was used in two studies (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>). The laptop-based algorithm MPC is a model representing the glucoregulatory system. Glucose concentration, insulin dosage and carbohydrate intake are the input variables for the MPC. The insulin infusion rate is the output parameter based on hourly glucose sampling. eMPC was used in four studies (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>). The eMPC is an enhanced version of the model predictive control algorithm (MPC), which additionally generates the time of the next glucose measurement with an interval between samples varying from 0.5 to 4 hours. All six studies were part of the <LINK REF="REF-CLINICIP" TYPE="REFERENCE">CLINICIP</LINK> (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community working towards the development of a closed-loop system to achieve safe tight glucose control in intensive care patients. Three studies used other software that take account of the characteristics of glucose dynamics (KArlsburg Diabetes Management System (KADIS): <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>, EndoTool Glucose Management System (MD Scienti&#64257;c): <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>, GIN Computer Software (GINCS): <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>), and one study used a weight-based insulin dose calculator (<LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>).</P>
<P>The advice was given in real time to the healthcare professional in all studies except one, where it was unclear (<LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>). The computerized advice was user-initiated in six studies (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>), system-initiated in two studies (<LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), and it was unclear in two studies (<LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>). The intervention was direct in seven studies (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>), indirect in one study (eMPC algorithm was run by study personnel (input glucose and change of Insulin infusion rate) under the supervision of the healthcare professional in <LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>) and it was unclear in two studies (<LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>).</P>
<P>Seven comparisons provided the insulin doses. The statistical heterogeneity was moderate. In one study (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>), the mean insulin infusion rate was significantly higher in the computerized glucose management group than standard management protocol group (MD +2.10 insulin units/hour, 95% CI 0.77 to 3.43), whereas there were no significant differences in the others (four comparisons with higher doses in the computer group, two comparisons with higher doses in the standard group). Overall, the insulin doses were higher in the computer groups, but this was not significantly different (pooled SMD 0.23, 95% CI -0.04 to 0.50).</P>
<P>One study reported no differences in the amount of glucose administered between the computer group (79.4 ± 24 g) and the manual group (81.6 ± 28 g) during the study period (before, during and after cardiopulmonary bypass) (MD -2.2 g, 95% CI -19.2 to 14.8) (<LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>).</P>
<P>One study analyzed the number of times the insulin rate was changed in 72 hours: the insulin infusion rate was altered a mean of 23.5 times more (95% CI 19.0 to 28.0) in the computer group than in the control group (35.5, 95% CI 31.1 to 39.9 versus 12.0, 95% CI 10.3 to 13.7) (<LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aminoglycoside antibiotics (five studies)</HEADING>
<P>Five studies (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>) evaluated the administration of aminoglycoside in inpatient care. All computer support systems used a (Bayesian) pharmacokinetic model with the advice given in real time to the healthcare professional, not integrated into a CPOE, and it was not clear if the computerized advice was user-initiated. The intervention was indirect in two studies (<LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>: a clinical pharmacokinetic service reviewed the initial aminoglycoside dose and dosing interval and made an oral recommendation to the attending physician or resident; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>: the orders for aminoglycoside dosing were written by a pharmacist with countersignature by a physician and the duration of antibiotic therapy as well as other aspects of clinical care were determined by the primary physicians).</P>
<P>One comparison provided outcomes for the analysis on initial and maintenance doses (<LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>). There was no statistical difference between groups for initial doses (MD +8 mg/day, 95% CI -11 to 27) or for maintenance doses (MD +11 mg/day, 95% CI -16 to 38).</P>
<P>Two studies reported data on total administered dose with different magnitude of effects. In one study (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>), the aminoglycoside dose per day was significantly higher in the pharmacokinetic group than in the standard group (+109 g, 95% CI 67 to 151). In the other study (<LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>), the milligrams per dose were higher and number of doses per day was lower in the pharmacist-directed dosing group compared with the standard group (milligrams/dose: 107 ± 21 versus 91 ± 26; doses/day: 2.0 ± 0.6 versus 2.3 ± 0.5) but the mean total doses of aminoglycoside were not significantly different between groups (pooled MD 141 mg, 95% CI -342 to 624).</P>
<P>One study analyzed the number of dosage changes and indicated higher dosage changes in the group with pharmacokinetic service recommendation than in the control group (MD +0.50 dosage change, 95% CI 0.21 to 0.79) (<LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Theophylline (four studies)</HEADING>
<P>Four studies evaluated theophylline (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>), a drug that is not considered as the first choice of treatment of asthma at present. However, monitoring serum concentrations of theophylline is essential to ensure that non-toxic doses are achieved (<LINK REF="REF-National-Asthma-2002" TYPE="REFERENCE">National Asthma 2002</LINK>). There were no studies on recently introduced drugs where it is considered important to monitor drug levels such as for glycopeptides, antifungal (fluconazole) and antiretroviral drugs.</P>
<P>The setting was inpatient care for all four studies.</P>
<P>All computer support systems used a Bayesian compartmental pharmacokinetic model. The advice was given in real time to the healthcare professional in three studies, whereas it was unclear in one study (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>). The computer support system was integrated into a CPOE with a direct intervention in one study (<LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>), whereas it was unclear for the others. The computerized advice was user-initiated in two studies and it was unclear in two studies.</P>
<P>Three comparisons provided data on initial dose with substantial heterogeneity (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>). The theophylline initial dose was significantly higher in the computer group (SMD 1.7, 95% CI 0.7 to 2.6), whereas the difference did not reach significance in the two other studies (SMD 0.2, 95% CI -0.1 to 0.6). Two comparisons provided data on maintenance dose and indicated higher doses in the computer group (SMD 0.8, 95% CI 0.5 to 1.1) (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anti-rejection drugs (four studies)</HEADING>
<P>Four studies evaluated anti-rejection drugs requiring adjustments for renal impairment (<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>; <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>; <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>). Two studies evaluated high-use medications that required adjustments for renal impairment (<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>), one study evaluated cyclosporine A (CsA) in the early post-transplant phase (<LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>), and one study evaluated mycophenolate mofetil (MMF) dosing in renal transplant patients (<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>).</P>
<P>The studies evaluating medications that required adjustments for renal impairment took place in inpatient care, with the computer support system integrated into a CPOE, and the advice system initiated and given in real time. In the study evaluating CsA in early post-transplant phase (<LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>), the individual computer dosing of CsA doses were calculated by a population pharmacokinetic model and suggested to the physician (patients were admitted in nephrology and had a standard clinical follow-up). In the study evaluating MMF dosing in renal transplant patients (<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>), the MMF dose adjustments in the concentration-controlled regimen were calculated by a computer program to reach a mycophenolic acid (MPA) area under the curve (AUC) target of 40 mg.h/L and were proposed to the physician.</P>
<P>No study reported data on drug dosages. One eligible study with potential unit of analysis error showed that a computerized decision support system for prescribing drugs in people with renal insufficiency improved the proportion of appropriate orders (RR 1.71, 95% CI 1.64 to 1.78) (<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>Two studies (three comparisons) evaluated computer-controlled infusions of anaesthetic agents (<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>; <LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>). One study evaluated the lidocaine therapy (<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>), whereas one study evaluated fentanyl and midazolam infusions (<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>).</P>
<P>The setting was inpatient care for the two studies. The computer support system for initial therapy of lidocaine was an individualized linear two-compartment pharmacokinetic model not integrated into a CPOE, and the advice was user-initiated and given at real time. The computer-controlled pump for fentanyl and midazolam infusions used a pharmacokinetic model integrated into a CPOE, and the advice was system-initiated.</P>
<P>
<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK> provided outcomes for the initial, maintenance and total doses. Computerized advice had no significant effect on lidocaine dosage (SMD 2.5, 95% CI 1.3 to 3.8 for initial dose; -0.2, 95% CI -1.0 to 0.7 for maintenance dose; 0.2, 95% CI -0.7 to 1.1 for total dose).</P>
<P>
<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK> and <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK> provided outcomes for the initial, maintenance and total doses for both fentanyl and midazolam infusions. Computerized advice had no significant effect on fentanyl drug dosage (SMD 0.5, 95% CI -0.3 to 1.3 for initial dose; 0.0, 95% CI -0.8 to 0.8 for maintenance dose; 0.5, 95% CI -0.3 to 1.3 for total dose), but reduced significantly midazolam initial, maintenance and total drug doses (SMD -1.9, 95% CI -2.9 to -0.9 for initial dose; -1.2, 95% CI -2.1 to -0.3 for maintenance dose; -1.1, 95% CI -1.9 to -0.2 for total dose). There was no significant difference in the number of infusion changes during the cardio-pulmonary bypass (MD -0.2, 95% CI -1.0 to 0.6 for fentanyl; 0.5, 95% CI -0.3 to 1.3 for midazolam).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antidepressants (one study)</HEADING>
<P>One study evaluated amitriptyline in the treatment of major depressive episodes (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>; <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>). The study took place in one psychiatric clinic of a clinical hospital centre. The computer-aided dose of amitriptyline was calculated using the modified Bayesian method. It was not clear if the computer support system was integrated into a CPOE, if the intervention was direct or if the advice was user-initiated and given at real time.</P>
<P>The drug daily doses of amitriptyline plus nortriptyline at day 14 were significantly lower when they were individualized compared with empiric doses (133.3 mg, 95% CI 126.7 to 140.0 versus 148.3 mg, 95% CI 140.2 to 156.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gonadotropins (one study)</HEADING>
<P>One study evaluated ovarian stimulation by gonadotropins (<LINK REF="STD-Lesourd-2002" TYPE="STUDY">Lesourd 2002</LINK>). The study included women from three centres who were undergoing ovarian stimulation to treat infertility. The software (GonaSoft) was created by the author to help clinicians to monitor ovarian stimulation and to provide a tool for evaluation of efficiency and complications. The software was not integrated into a CPOE. The intervention was direct with the advice given at real time.</P>
<P>There was no significant difference between groups in the number of follicle-stimulating hormone units administered (860 units, 95% CI 776 to 944 in the intervention group versus 938 units, 95% CI 825 to 1051 in the control group).</P>
</SUBSECTION>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-04 12:55:08 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>Four studies were not assessed for the risk of bias, since they were cost-effectiveness or safety analyses conducted as a part of previous included studies (same trial): <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK> (see <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>); <LINK REF="STD-Jowett-2009" TYPE="STUDY">Jowett 2009</LINK> (see <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>); <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK> (see <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>); and <LINK REF="STD-Rousseau-2010" TYPE="STUDY">Rousseau 2010</LINK> (see <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Random sequence generation (selection bias)</HEADING>
<P>The sequence generation process used a random component in 21 studies (50%). A non-random method was used in two studies (5%): in one study the study periods were four alternating eight-week blocks of intervention and control subperiods<I> </I>(<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>); and in one study, the randomization was based on the final digit in the patient's identification card number (odds versus even) (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>). The sequence generation process was not specified in 19 studies (45%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment (selection bias)</HEADING>
<P>The allocation was adequately concealed in 16 studies (38%). The unit of allocation was institution, team or provider in five studies (<LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), but cluster effect was not taken into account in statistical analysis for <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK> and <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>. The unit of allocation was by participant or episode of care and there was some form of centralized randomization scheme in 11 studies (on-site computer system: eight studies, sealed opaque envelopes: three studies). The allocation was not considered adequately concealed in the two studies (5%) where a non-random method was used (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>; <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>). The allocation concealment was not specified in 24 studies (57%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline outcome measurements similar</HEADING>
<P>The mean blood glucose was measured prior to the intervention and no important differences were present across study groups in eight (80%) of the 10 studies on insulin drug administration. One study reported the blood glucose at entry for each centre but not across study group (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>), and in one study there were many data reported on blood glucose but it was unclear if results given were baseline measurements (<LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>).</P>
<P>Other studies were considered at 'low risk' because baseline outcome measurements were not relevant (baseline data realized before medication intake).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline characteristics similar</HEADING>
<P>Of the five studies where the unit of allocation was by institution, team or professional, only one reported the characteristics of providers (<LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>). Baseline characteristics of participants were reported and similar in 26 studies (62%). Seven studies (17%) reported differences between participants in control and intervention groups, one study reported the participants' characteristics only in a subgroup of participants (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>), one study reported the participants' characteristics by centres (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>), and three studies did not report participants' characteristics (<LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>). Four studies mentioned participants' characteristics in text but no data were presented (<LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>; <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data (attrition bias)</HEADING>
<P>In 18 studies (43%), the missing outcome measures were unlikely to bias the results (e.g. the proportions of missing data were similar in the intervention and control groups or the proportions of missing data were unlikely to overturn the study result). In 13 studies (31%), missing outcome measures were not specified in the paper or it was unclear if missing data could overturn the study result. In 11 studies, the missing outcome data were likely to bias the results<I> </I>(<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of outcome assessment (detection bias)</HEADING>
<P>In 36 studies (86%), the assessment of primary outcome was objective or blinded. In six studies (14%), there was a risk of detection bias: five studies used clinical events as main outcomes and they were not clearly defined (<LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>); and one study used a hetero-questionnaire as main outcome (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of participants and personnel (performance bias)</HEADING>
<P>When studies were randomized by participant, the same healthcare professional may have given treatment both to intervention and control groups: it is possible that computerized advice influenced the treatment of the control groups. Protection against contamination was considered to be done only in three studies (<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>), and it was unclear for three studies were it was possible that communication between intervention and control professionals could have occurred (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>).</P>
<P>Thirty-seven studies (88%) randomized the participants, but in two of them the participants were blinded (<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>). Two studies randomized the GP practices (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>), one study randomized 42 emergency medicine faculty and resident physicians from one urban public hospital (<LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>), and one study randomized seven teams of providers (42 internal medicine residents) in general medical acute care units of one medical centre (<LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>). There was a risk of performance bias in one study where the house staff teams were randomized (17 house staff teams in one Veterans Administration medical centre) and at the end of each four months during the study, intervention groups were changed to control and vice versa (<LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective reporting (reporting bias)</HEADING>
<P>The relevant outcomes were reported in the results section in 39 studies (93%). In three studies, the outcomes were not presented in the methods section (<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>; <LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other bias</HEADING>
<P>There was no evidence of other risk of biases in 34 studies (81%), an evidence of other risk of bias in three studies (7%) and it was unclear in five studies (12%).</P>
<P>In one study, an erratum had been published because there were some inconsistencies in the text and tables; we found other inconsistencies in tables, full text, and abstract; the author was contacted but had not replied (<LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>, by January 2012). There is a risk of selection bias for one study (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>; <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>): there was a first publication in 1999 including 15 participants during 1997 (<LINK REF="STD-Jankovic-1999" TYPE="STUDY">Jankovic 1999</LINK>, study excluded because the author confirmed that the participants were included in the Mihajlovic study), a second publication in 2003 on main outcomes including 60 participants during 1997 (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>), and a third publication in 2010 on clinical adverse events (<LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>). In one study, there was a risk of contamination due to logistical problems ("it was difficult to shield the clinicians from the CDSS suggestions") and the nurse practitioners used the computer-decision support system and were compared with the clinician group of three junior doctors undergoing general professional training in general medicine (<LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>).</P>
<P>There was potential other risk of bias in five studies: in one study, the Cockcroft-Gault formula might overestimate renal function when the serum creatinine was increasing, and underestimate renal function when the serum creatinine was decreasing (<LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>); one study was described as a pilot study (10 participants in each group), the article was in Czech language so it was difficult to understand all details (authors were contacted in February 2012 but queries remained unanswered) (<LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>); in one study, few results were reported (one sentence in the results) so there was not enough information to evaluate the bias of the study (<LINK REF="STD-Lesourd-2002" TYPE="STUDY">Lesourd 2002</LINK>); in one study, only 20 participants were included (<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>); and in one study, 46% participant visits were excluded (only prescription that required dosage adjustment were analyzed), there was no adjustment for within-patient correlation, and providers in the intervention group initially prescribed targeted medications more often than control physicians did and consequently had substantially more opportunities to adjust dosing (<LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Protection against bias</HEADING>
<P>No study met the nine previous criteria for protection against bias. Two studies met eight criteria (<LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>), nine studies met seven criteria (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>; <LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), 16 studies met six criteria (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>; <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>; <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>), nine studies met five criteria (<LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>; <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>), seven studies met four criteria (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>; <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>; <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>), and three studies met three criteria (<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>; <LINK REF="STD-Lesourd-2002" TYPE="STUDY">Lesourd 2002</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Power calculation</HEADING>
<P>Fifteen studies (36%) reported a sample size calculation, among them, one study was presented as a non-inferiority trial but no margin was addressed (<LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>). The power calculation was not reported in 22 studies (53%) and in five studies (12%) the authors specifically reported that the study might be underpowered (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-04 12:55:49 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>, <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 1. Decisions on drug dosage based on computer advice lead more often to drug levels within the therapeutic range</HEADING>
<P>For this comparison, the outcomes analyzed were: the serum concentrations (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), the proportion of time for which the plasma drug concentrations was within the therapeutic range (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), the proportion of participants with plasma drug concentrations within the therapeutic range (at fixed time) and the proportion of participants with toxic drug levels (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Serum concentrations</HEADING>
<P>There was a high clinical and statistical heterogeneity between drugs so we did not pool the results. Since the interpretation of the direction of change in serum concentration varied according to the drug, we grouped the drugs in two Forest plots (part A and part B). Part A (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) includes the drugs for which an SMD greater than 0 corresponds to a difference in favour of the intervention; Part B (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) includes the drugs for which an SMD less than 0 corresponds to a difference in favour of the intervention.</P>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<P>Four comparisons (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>) analyzed the aminoglycoside target peak concentration and the objective was to obtain a higher target peak concentration since target peak concentrations are often not met. Heterogeneity was moderate (inconsistency I<SUP>2</SUP> = 51%, P value from the Chi<SUP>2</SUP> = 0.11) but the CIs for the results of individual studies overlapped and all studies resulted in a significant higher aminoglycoside peak concentration in the computer group (pooled SMD 0.79, 95% CI 0.46 to 1.13), which was in favour of the intervention.</P>
<P>In <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>, the proportion of participants with maximum peak serum aminoglycoside concentrations greater than 4 mg/L was greater in the Bayesian pharmacokinetic dosing group (RR 1.37, 95% CI 1.11 to 1.70; odds ratio (OR) 3.19, 95% CI 1.46 to 6.94).</P>
<P>One study analyzed the aminoglycoside trough concentration (residual) and the objective was to obtain a lower trough concentration (<LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>): the mean serum trough drug concentration was lower in the pharmacist-directed dosing group compared with the control group (SMD -0.42, 95% CI -0.74 to -0.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>Four comparisons analyzed the theophylline concentration: <LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK> compared the mean serum concentration at day two, <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK> compared the concentration four hours post load, <LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK> compared the serum concentration 20 minutes after completion of loading dose infusion and <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK> compared the serum level just before discontinuation of the infusion. The Forest plot and heterogeneity statistics showed high statistical heterogeneity (inconsistency I<SUP>2</SUP> = 76%, P value from the Chi<SUP>2</SUP> = 0.005). The theophylline concentration was significantly higher in the computer group in one comparison (<LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>), which was in favour of the intervention; tended to be higher in the computer group (although it did not reach statistical significance) in two comparisons (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>); and tended to be lower in one comparison (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>). The pooled difference was not significant (SMD 0.41, 95% CI -0.20 to 1.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>
<LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK> showed that computer-assisted initial lidocaine therapy significantly increased the lidocaine concentration (SMD 1.32, 95% CI 0.33 to 2.32), which is in favour of the intervention (Analysis part A).</P>
<P>In two comparisons dealing with anaesthesiology (<LINK REF="STD-Theil-1993-fentanyl" TYPE="STUDY">Theil 1993 fentanyl</LINK>; <LINK REF="STD-Theil-1993-midazolam" TYPE="STUDY">Theil 1993 midazolam</LINK>), the objective was to obtain a lower administered drug dose in order to provide a reduction in time for extubation. Computerized advice had no effect on fentanyl serum concentrations but significantly reduced midazolam serum concentrations (SMD -1.43, 95% CI -2.34 to -0.51), which was in favour of the intervention (Analysis part B).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>The steady-state plasma concentrations of amitriptyline plus nortriptyline during the treatment course (day 14) was significantly lower in the individualized regimen compared with the empiric dose regimen (SMD -0.68, 95% CI -41.20 to -0.16), which was in favour of the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of time for which the plasma drug concentrations were within the therapeutic range/proportion of participants with plasma drug concentrations within the therapeutic range (at a fixed time) (Analysis 1.3)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<P>Several studies have suggested that the mortality in people with severe infections treated with aminoglycosides may be substantially reduced if adequate peak plasma concentrations are achieved early in the course of treatment (<LINK REF="REF-Moore-1984a" TYPE="REFERENCE">Moore 1984a</LINK>, <LINK REF="REF-Moore-1984b" TYPE="REFERENCE">Moore 1984b</LINK>, <LINK REF="REF-Moore-1987" TYPE="REFERENCE">Moore 1987</LINK>). Thus, accurate dose prescription is important, not only to avoid toxicity associated with overdosage, but more important to avoid the higher mortality associated with underdosage during the first one or two days of treatment.</P>
<P>Three studies analyzed the proportion of participants with aminoglycoside peak concentration adequate: one study (<LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>) considered the first peak aminoglycoside serum 'adequate' 30 minutes after infusion whereas two studies (<LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK>; <LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>) considered the peak plasma concentrations within 6 to 10 mg/L after two days, so we pooled only the results of these two last studies. There was no evidence of difference in <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK> (RR 1.02, 95% CI 0.63 to 1.64), whereas there were significantly more participants within the therapeutic range after two days in the computer group for the two other studies (pooled RR 4.44, 95% CI 1.94 to 10.13).</P>
<P>
<LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK> and <LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK> also analyzed the proportion of participants with aminoglycoside peak and trough concentrations adequate: <LINK REF="STD-Hickling-1989" TYPE="STUDY">Hickling 1989</LINK> considered the peak trough concentrations lower than 2 mg/L after two days whereas <LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK> considered the peak trough concentrations within 1 to 2 mg/L after two days. Both comparisons tended to have more participants with aminoglycoside peak and trough concentrations adequate in the computer group and the pooled effect showed a significant difference between groups (pooled RR 3.88, 95% CI 1.04 to 14.44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>
<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK> reported that during oral therapy more monitored than control participants had trough concentrations in the therapeutic range (RR 1.60, 95% CI 1.00 to 2.55).</P>
<P>One study reported that serum theophylline concentrations during maintenance therapy in the computer group were maintained within the therapeutic range (10 to 20 µg/mL) longer than in the control group (77% versus 51%, P versus &lt; 0.05), but the study included a small number of participants (n = 25) (<LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>In <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>, there was no significant difference between concentration-controlled doses and &#64257;xed-dose MMF on the proportion of participants within therapeutic range at day 14 (MPA AUC &gt; 30 mg.h/L). The AUC is a model for determining MPA exposure. MPA is the active metabolite of the inactive prodrug MMF. However, by day 14, median MPA exposure was significantly higher in the concentration-controlled group than in the fixed-dose group (with a majority of participants in the concentration-controlled group, but not in the fixed-dose group, having met targeted levels), and at one month, the concentration-controlled group again had significantly higher median MPA AUC, with more than 90% of participants achieving target levels.</P>
<P>In <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>, the overall percentage of whole-blood concentrations of cyclosporine within the therapeutic window was not different between groups (SMD 0.23, 95% CI -0.39 to 0.85; MD 3.80%, 95% CI -6.25% to 13.85%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with toxic drug levels (Analysis 1.4)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycosides (five studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>Two studies analyzed the proportion of participants with toxic drug levels. In <LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>, fewer monitored participants in whom infusion rates were based on pharmacokinetic analysis had serum concentrations in the toxic range but the difference was not significant (RR 0.50, 95% CI 0.23 to 1.10; OR 0.38, 95% CI 0.13 to 1.09). <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK> found no statistical difference between the empiric and kinetic groups in the number of toxic (&gt; 20 mg/L) levels (one in each group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>In <LINK REF="STD-Terrell-2010" TYPE="STUDY">Terrell 2010</LINK>, where the physicians were randomized to decision support intervention group or control group, usual care physicians were more likely to dose medications excessively than intervention physicians were (OR 3.9, 95% CI 1.7 to 9.0, according to a mixed-effects logistic regression to adjust for within-physician correlation). After adjusting for participant age, sex, race and physician status, this difference remains significant in favour of intervention (OR usual care versus intervention 4.3, 95% CI 1.4 to 12.8).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>The results differed according to drugs. In summary, in spite of high heterogeneity and small number of studies, comparisons on serum concentrations were in favour of the computer group for aminoglycoside antibiotics (higher target peak and lower trough concentrations) and antidepressants (one study). Results were contrasted for theophylline and anaesthetic agents.</P>
<P>Computerized advice improved the proportion of participants for aminoglycoside antibiotics and theophylline (one study), and the proportion of time for theophylline (one study) for which the plasma drug concentrations were within the therapeutic range, but not for anti-rejection drugs before day 14.</P>
<P>There were three comparisons on toxic drug levels: there was no evidence of difference for theophylline (two studies) whereas the CPOE with decision support significantly reduced excessive dosing of targeted medications in one study on people with renal impairment where physicians were randomized.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 2. Decisions on drug dosage based on computer advice lead more often to a physiological parameter being maintained within the desired range (e.g. blood pressure or prothrombin time)</HEADING>
<P>For this comparison, the outcomes analyzed was the proportion of time for which the studied physiological parameter was maintained within the target range (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Oral anticoagulants (fifteen studies, eighteen comparisons): proportion of time in target international normalized ratio range</HEADING>
<P>The main outcome reported was the percentage of time spent in target INR range calculated for each participant as a mean time in range using interpolation methods between INR values. Six comparisons analyzed the mean % of TIR using various INR ranges (see <LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK>) (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>; <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>). The magnitude of effects differed between studies and the statistical heterogeneity was high (I<SUP>2</SUP> = 79%) but all studies were in favour of the computer groups: the difference was significant in four studies (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>), and did not reach significance in two studies (<LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK> considering outpatients in the stabilization period; and <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK> considering people starting oral anticoagulation). The pooled SMD favoured the computer group (SMD 0.19, 95% CI 0.06 to 0.33; MD 3.68%, 95% CI 0.90% to 6.45%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
<P>In one study where GP practices were randomized, there was a significant increase in percentage of time within 0.5 INR from target, from 49.5% at baseline to 60% after implementing the different interventions, but there was no evidence that the increases from baseline were different between the four intervention groups (P value = 0.8) (<LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>). The increase was +8% (95% CI 2.0% to 13.5%) in the group with multifaceted education and +11% (95% CI 5.5% to 16.5%) in the group with multifaceted education plus DAWN AC computer-assisted advice.</P>
<P>Another comparison on people within target final PT time showed no evidence of difference in anticoagulant control in people whose dose was determined by computer, compared with those who were treated by a nurse specialist (RR 0.87, 95% CI 0.47 to 1.61) (<LINK REF="STD-White-1991" TYPE="STUDY">White 1991</LINK>). Finally, one comparison analyzed the proportion of participants reaching a stable state of anticoagulation (three INR measurements within therapeutic range) and was in favour of the computer group compared with the control group (RR 1.46, 95% CI 1.07 to 2.00) (<LINK REF="STD-Manotti-2001" TYPE="STUDY">Manotti 2001</LINK>).</P>
<P>Five comparisons reported the number of days per 100 patient-days of treatment spent in the INR therapeutic range but the inconsistency across studies was very high (combined incidence rate ratio 1.10, 95% CI 1.00 to 1.20, inconsistency I<SUP>2</SUP> = 91%) (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>): in two studies, participants in the intervention group spent significantly more time in the therapeutic range (<LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>), whereas there was no evidence of difference in three studies.</P>
<P>Two comparisons analyzed the proportion of INRs measurements within therapeutic range and were in favour of computerized advice of drug dosage (RR 1.10, 95% CI 1.02 to 1.19) (<LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>; <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>). <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK> and <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK> compared the proportions of INRs above 5: there was no evidence of difference between the computer and standard groups. In <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>, during the intervention period there was a significant difference in per cent of participants with a least one INR above 5 between the four intervention groups (P value = 0.009), but there was no evidence that the decreases from baseline were different between the four intervention groups (P = 0.28) and group A (multifaceted education) and group D (multifaceted education plus DAWN AC computer-assisted advice) had the closest results. In <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK>, the INRs below 2 (underanticoagulated patients) were more in the computer-controlled group than in the manual group (RR 1.55, 95% CI 1.11 to 2.16) whereas in <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK> there was no statistically significant difference from baseline in the decrease of per cent of participants with at least one INR less than 2 (P = 0.67).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies): percentage of time in target glucose range (four studies), hyperglycaemia index (nine studies)</HEADING>
<P>Four studies of the CLINICIP project analyzed the percentage of time in target glucose range (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>). The magnitude of effects differed between studies and the statistical heterogeneity was high (I<SUP>2</SUP> = 83%) but all studies were in favour of the computer groups: the difference was significant in three studies (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>), and did not reach significance in one study (<LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>). The pooled SMD was in favour of the computer group (SMD 1.27, 95% CI 0.56 to 1.98; MD 22.18%, 95% CI 9.94% to 34.43%) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
<P>In one study with a potential unit of analysis error, the percentage of time in target range was significantly higher with the computer software program (SMD 1.91, 95% CI 1.70 to 2.11; MD 21.70%, 95% CI 20.02% to 23.38%) (<LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>). In the same study, participants in the computer group were significantly more likely to have all measurements within the target glycaemic range than participants in the manual group (RR 9.00, 95% CI 1.27 to 63.89).</P>
<P>In a CBA study, the change in A1C (primary outcome) was -0.34% ± 0.49% in the group with the diabetes management system-based decision support compared with +0.27% ± 0.67% in the group without the system (MD -0.60%, 95% CI -0.96% to -0.25%) (<LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>).</P>
<P>Two studies analyzed the hyperglycaemic index (HGI) for the assessment of glucose control (<LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>). In <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>, the HGI was defined as the AUC above the upper limit of normal (glucose level 6.1 mmol/L, modified from the original 6.0 mmol/L) divided by the total length of stay (time in study). The advantage of this measure of glucose control is the independence of the number of measurements, and it is not falsely lowered by hypoglycaemic values. In theory, the best HGI of 0.0 mM indicates that all glucose values were below the upper target limit. An HGI around 2.0 mM shows that the person was exposed on average to glucose values of 8.1 mM (exceeding the upper target limit of 6.1 mM) during the observed period. In general, a low HGI and a low number of hypoglycaemic events indicate tight and safe blood glucose control. In <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>, there were some inconsistencies in the text and tables so conclusions should be made with caution: in one centre (n = 20) the HGI was not significantly different between groups whereas in the other (n = 14) the HGI was significantly greater in the standard care group. In <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>, the HGI was significantly lower in the computer group (MD -1.20 mmol/L, 95% CI -1.63 to -0.77).</P>
<P>The time in blood glucose range was higher in the computer-guided glucose management during surgery (<LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>: MD 57.00 minutes, 95% CI 9.57 to 104.43), and after surgery in the intensive care unit (<LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>: pooled MD 257.92 minutes, 95% CI 60.96 to 454.87).</P>
<P>Nine studies reported the mean blood glucose with high heterogeneity (I<SUP>2</SUP> = 86%, one study with opposite direction): the mean blood glucose was significantly lower with the computer advice (pooled SMD -0.72, 95% CI -1.03 to -0.42; pooled MD -14.81 mg/dL, 95% CI -22.06 to -7.56) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>; <LINK REF="STD-Augstein-2007" TYPE="STUDY">Augstein 2007</LINK>; <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>). Excluding two studies with potential unit of analysis error did not change the conclusions (pooled SMD -0.55, 95% CI -0.83 to -0.27; pooled MD -10.48 mg/dL, 95% CI -17.10 to -3.86) (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>In summary, in spite of difference in magnitude effects, computerized advice led more often to a physiological parameter within the desired range for oral anticoagulants (significantly higher percentages of time in target INR range) and for insulin (significantly higher percentages of time in target glucose, lower levels of mean blood glucose).</P>
<P>This result may be explained by the fact that computer advice improved the sampling time and intervals for warfarin or insulin. These two drugs have a narrow therapeutic window. They have variable effects depending on the plasma concentration: a lower dose is ineffective and a higher dose is hazardous. For these drugs, sampling time is critical, since the drug concentration varies over the entire dosing interval and with the duration of dosing in relation to achieving a steady state. Sampling interval, the number of sampling, is also important. For insulin, in three studies, this interval was significantly lower in the computer groups (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>), in one study, there was no significant difference between groups (<LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>), whereas in one study, mean sampling intervals were significantly longer in the computer-assisted group compared with the manual group (<LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 3. Decisions on drug dosage based on computer advice led to more rapid therapeutic control, assessed by a physiological parameter</HEADING>
<P>For this comparison, the outcomes analyzed were the time to achieve therapeutic range and the time to stabilization (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>; <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Oral anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>Two comparisons analyzed the "time to achieve" therapeutic PT ratio (<LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>). There was no evidence of difference between groups (SMD -0.22, 95% CI -0.69 to 0.26; MD -0.58 days, 95% CI -1.84 to 0.6).</P>
<P>Three comparisons analyzed the "time to stabilization" (<LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>). In <LINK REF="STD-Carter-1987" TYPE="STUDY">Carter 1987</LINK>, the outcome was reported for participants who achieved stable PT ratios before discharge. The pooled effect showed a significant reduction in time to achieve stabilization (SMD -0.56, 95% CI -1.07 to -0.04; MD -2.49 days, 95% CI -3.93 to -1.05) even if there was an high inconsistency (I<SUP>2</SUP> = 71%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<P>The "time to target" (time to establish blood glucose control) for insulin was reported in three studies. In one study, the computer advice led to less rapid control of glycaemia (<LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>), whereas there was no significant difference in <LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK> and <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>. There was no evidence of difference between groups (SMD 0.22, 95% CI -0.52 to 0.95; MD 0.53 hour, 95% CI -1.22 to 2.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>The pooled effect showed a significant reduction in time to achieve stabilization for oral anticoagulants (three comparisons) whereas there was no evidence of difference for insulin.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 4. Decisions on drug dosage based on computer advice lead to more effectiveness, assessed by clinical improvement</HEADING>
<P>For this comparison, the outcomes analyzed was the proportion of participants with clinical improvement (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>; <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>). Forest plots are only presented for aminoglycoside antibiotics and anti-rejection drugs (no study or only one for other drugs).</P>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<P>Two studies reported efficacy outcomes. In <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>, there were no statistical differences in the number of participants cured (RR 0.95, 95% CI 0.55 to 1.64), whereas in <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>, there was more success to respond to treatment in the pharmacist-direct dosing based on a Bayesian pharmacokinetic dosing program (RR 1.12, 95% CI to 1.03 to 1.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<P>Two studies reported efficacy outcomes on biopsy-confirmed acute rejections. In <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>, there were no statistical differences in the number of participants without acute rejections (RR 0.94, 95% CI 0.71 to 1.25), whereas in <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>, there were more participants with clinical improvement (no acute rejections) in the individualized MMF dosing group (RR 1.22, 95% CI 1.05 to 1.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<P>In <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>, the participants from individualized or empiric doses of amitriptyline were evaluated clinically using the Hamilton Depression Rating Scale (HAM-D; 21 items) and Clinical Global Impression Scale (CGI). Total HAM-D scores were significantly lower in the experimental group after day 28 (MD -2.80, 95% CI -4.93 to -0.67). CGI scores had a statistically significant difference between the groups after day 28 for the three items (in favour of the intervention for Severity of illness and Therapeutic effect, and in favour of the control for Global improvement).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>In the study on the effectiveness of a computerized decision support system for ovarian stimulation with gonadotropins (<LINK REF="STD-Lesourd-2002" TYPE="STUDY">Lesourd 2002</LINK>), there were no statistical differences in the number of participants with clinical pregnancies (RR 1.15, 95% CI 0.59 to 2.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>For each drug, there were, at most, two comparisons. Some comparisons showed significant improvement with computer advice whereas there was no evidence of differences in others.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 5. Decisions on drug dosage based on computer advice lead to fewer unwanted effects</HEADING>
<P>For this comparison, we considered two outcomes: death and adverse reactions.</P>
<SUBSECTION>
<HEADING LEVEL="5">Death</HEADING>
<P>Ten comparisons analyzed death rates (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>). Globally, there was no significant difference observed between the computer and control groups (RR 1.08, 95% CI 0.80 to 1.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clinical adverse events</HEADING>
<P>Nineteen comparisons assessed the proportion of participants with clinical adverse events. Since there was a great diversity of drugs and of type of clinical adverse events, we did not pool the results that were presented by drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulants (fifteen studies, eighteen comparisons)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Bleeding events</HEADING>
<P>The proportion of participants with bleeding events was available in five comparisons (nine events in computer group, 15 events in control group). In <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>, the minor bleeding events were observed until discharge or until the seventh day of treatment, in <LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>; <LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>, haemorrhagic events were collected during the follow-up (maximum length of follow-up: 3 to 13 months) and in <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>, the bleeding complications were collected during hospitalization. There was a trend towards fewer people with bleeding events although it did not reach statistical significance (pooled RR 0.65, 95% CI 0.30 to 1.41) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>).</P>
<P>The participant exposure time was reported in four comparisons but the bleeding incidence rate could be calculated only in three comparisons (in <LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>, there was no serious bleeding in the control group). In two studies, there was significantly less bleeding events in the computer group (<LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>; <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>), whereas the difference was not statistically significant in one study (<LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>). The pooled effect showed a non-significant reduction in bleeding events with an estimated rate ratio of 0.81 (95% CI 0.60 to 1.08) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>).</P>
<P>For heparin, there was no statistical difference in bleeding events between the computer-assisted and the nomogram-directed therapy (<LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Thromboembolism</HEADING>
<P>In two studies, there was no thromboembolism due to undertreatment in both computer and standard dosing groups (<LINK REF="STD-Vadher-1997-pop2" TYPE="STUDY">Vadher 1997 pop2</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>). In two studies, the number of participants with thromboembolism tended to be higher in the computer group but the pooled effect showed no statistical difference between groups (pooled RR 3.25, 95% CI 0.66 to 16.03) (<LINK REF="STD-Vadher-1997" TYPE="STUDY">Vadher 1997</LINK>; <LINK REF="STD-Vadher-1997-pop1" TYPE="STUDY">Vadher 1997 pop1</LINK>) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>).</P>
<P>For the incidence rate, in two studies, there was significantly less thromboembolism events in the computer group (<LINK REF="STD-Fitzmaurice-2000" TYPE="STUDY">Fitzmaurice 2000</LINK>; <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>), whereas the difference was not significant in two studies (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>). The pooled effect showed a significant reduction in thromboembolism events with an estimated rate ratio of 0.68 (95% CI 0.49 to 0.94) but the inconsistency was high (I<SUP>2</SUP> = 65%) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Total clinical adverse events</HEADING>
<P>In <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>, total clinical adverse events (clinical events plus INR 4 or greater) were numerically fewer in the pharmacogenetic than standard arm (34 versus 42), although the difference was not significant (P value = 0.26) and the serious clinical events were infrequent (pharmacogenetic 4, standard 5) and were unrelated to out-of-range INRs.</P>
<P>In <LINK REF="STD-Mungall-1994" TYPE="STUDY">Mungall 1994</LINK> (heparin), there was a trend towards less clinical adverse events in the computer-assisted heparin therapy compared with nomogram-directed therapy (RR 0.08, 95% CI 0.00 to 1.35).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin (ten studies)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Hypoglycaemia</HEADING>
<P>The proportion of participants with hypoglycaemia was available in seven comparisons (11 events in computer group, 17 events in control group). Hypoglycaemia was defined as blood glucose less than 60 mg/dL (&lt; 3.3 mmol/L) in three studies (<LINK REF="STD-Saager-2008" TYPE="STUDY">Saager 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), less than less 54 mg/dL (&lt; 3.0 mmol/L) in one study (<LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>), and less than 52 mg/dL (&lt; 2.9 mmol/L) in three studies (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>). No significant difference was observed between the computer and control groups (pooled RR 0.71, 95% CI 0.35 to 1.48) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Severe hypoglycaemia</HEADING>
<P>The proportion of participants with severe hypoglycaemia was available in four comparisons (one event in computer group, two events in control group). Severe hypoglycaemia was defined as blood glucose less than 40 mg/dL (&lt; 2.2 mmol/L) in three studies (<LINK REF="STD-Pachler-2008" TYPE="STUDY">Pachler 2008</LINK>; <LINK REF="STD-Cordingley-2009" TYPE="STUDY">Cordingley 2009</LINK>; <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>), and less than less 41 mg/dL (&lt; 2.3 mmol/L) in one study (<LINK REF="STD-Blaha-2009" TYPE="STUDY">Blaha 2009</LINK>), and less than 42 mg/dL (&lt;2.9 mmol/L) in three studies (<LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>; <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK>; <LINK REF="STD-Sato-2011" TYPE="STUDY">Sato 2011</LINK>). No significant difference was observed between the computer and control groups (pooled RR 0.69, 95% CI 0.11 to 4.31).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aminoglycoside antibiotics (five studies)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Nephrotoxicity</HEADING>
<P>Four studies reported outcomes on nephrotoxicity (<LINK REF="STD-Begg-1989" TYPE="STUDY">Begg 1989</LINK>; <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK>). There was a trend towards lower nephrotoxicity in computer group although the difference was not significant (pooled RR 0.67, 95% CI 0.42 to 1.06) (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>; <LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Need for dialysis</HEADING>
<P>
<LINK REF="STD-Leehey-1993" TYPE="STUDY">Leehey 1993</LINK> compared people who needed dialysis. No difference was observed between the pharmacist-directed dosing using a Bayesian pharmacokinetic dosing program and the control group (RR 0.30, 95% CI 0.03 to 2.86).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Theophylline (four studies)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">
<I>Tachycardia</I>
</HEADING>
<P>
<LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK> analyzed the theophylline toxicity (including nausea, vomiting, tremor, tachycardia and seizures): one participant had a tachycardia in the kinetic group whereas there was no episode of toxicity in the empiric group (RR 3.17, 95% CI 0.14 to 72.80).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">
<I>Total clinical adverse events</I>
</HEADING>
<P>In <LINK REF="STD-Gonzalez-1989" TYPE="STUDY">Gonzalez 1989</LINK>, adverse reactions occurred in 7% of participants with population-based emergency department guidelines dosing, and 10% of participants with Bayesian-derived pharmacokinetic dosing (RR 1.62, 95% CI 0.32 to 8.26).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anti-rejection drugs (four studies)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Cytomegalovirus infections</HEADING>
<P>Two comparisons reported outcomes on cytomegalovirus infections (<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>; <LINK REF="STD-Asberg-2010" TYPE="STUDY">Asberg 2010</LINK>). No significant difference was observed between the computer and control groups (pooled RR 0.90, 95% CI 0.58 to 1.40) (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>; <LINK REF="FIG-20" TYPE="FIGURE">Figure 20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Total clinical adverse events</HEADING>
<P>
<LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK> analyzed clinical adverse events including anaemia, leukopenia, gastrointestinal adverse events and infections. There was no statistical difference between individualized doses based on therapeutic monitoring of MPA and fixed-dose MMF (RR 1.07, 95% CI 0.98 to 1.17).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaesthetic agents (two studies, three comparisons)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Total clinical adverse events</HEADING>
<P>In <LINK REF="STD-Rodman-1984" TYPE="STUDY">Rodman 1984</LINK>, there was no clinical adverse event in the people monitored clinically (monitoring of rhythm, intermittent hard-copy rhythm strips, serial ECGs, daily measurements of electrolyte and cardiac enzyme levels, liver function tests).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antidepressants (one study)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Total clinical adverse events</HEADING>
<P>The comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode (<LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>) was studied in <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>. The CGI scale and originally designed questionnaire were used for clinical adverse events assessment. In the experimental group, 69 complaints on nine different types of adverse effects were recorded during the eight-week treatment period and in control group, 111 complaints on 12 different types of adverse effects were recorded. <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK> indicated that "significantly higher number of patients complaining on adverse effects were in the control group". Nevertheless, none of the comparisons during the eight-week treatment period was significant (RR: day 14 0.63, 95% CI 0.34 to 1.15; day 28 0.71, 95% CI 0.41 to 1.21; day 42 0.75, 95% CI 0.30 to 1.90; day 56 0.75, 95% CI 0.30 to 1.90).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gonadotropins (one study)</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>No significant difference on death was observed between the computer and control groups. For clinical adverse events, we did not pool the results because of the diversity of outcomes. There was a trend for less nephrotoxicity for aminoglycoside antibiotics, for less bleeding and thromboembolism events for anticoagulants with the computer group. When considering the incidence rates for anticoagulants, which is a more precise outcome measure taking into account the exposure time, this difference was significant in favour of the computer group for thromboembolism despite a high heterogeneity. There was no evidence of difference for insulin, theophylline, anaesthetic agents, anti-rejection drugs and antidepressants.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypothesis 6. Computer advice reduces the cost of health care or the use of resources (length of stay)</HEADING>
<P>For this comparison, the outcomes analyzed were the length of stay (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="FIG-21" TYPE="FIGURE">Figure 21</LINK>) and the cost per participant.</P>
<SUBSECTION>
<HEADING LEVEL="6">Length of stay</HEADING>
<P>Nine comparisons analyzed the length of stay (oral anticoagulants: <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Mitra-2005" TYPE="STUDY">Mitra 2005</LINK>; insulin: <LINK REF="STD-Wexler-2010" TYPE="STUDY">Wexler 2010</LINK>; aminoglycoside: <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; theophylline: <LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-Verner-1992" TYPE="STUDY">Verner 1992</LINK>; <LINK REF="STD-Casner-1993" TYPE="STUDY">Casner 1993</LINK>; cyclosporine: <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>). There was a significant reduction of the length of stay in the computer group in four comparisons (<LINK REF="STD-Hurley-1986" TYPE="STUDY">Hurley 1986</LINK>; <LINK REF="STD-White-1987" TYPE="STUDY">White 1987</LINK>; <LINK REF="STD-Burton-1991" TYPE="STUDY">Burton 1991</LINK>; <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>), whereas the difference was not significant in five comparisons. The pooled effect tended to be in favour of the computer group (SMD -0.15, 95% CI -0.33 to 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Costs per participant and incremental cost-effectiveness ratio</HEADING>
<P>Five studies analyzed the costs of interventions using computer advice on drug dosage.</P>
<P>In <LINK REF="STD-Destache-1990" TYPE="STUDY">Destache 1990</LINK>, clinical pharmacokinetic service direct costs were significantly lower than usual care (without clinical pharmacokinetic service monitoring) for aminoglycoside antibiotics: USD7102.56 ± 8898.18 compared with USD13,758.64 ± 22,874.31 (P value &lt; 0.02).</P>
<P>In <LINK REF="STD-Chertow-2001" TYPE="STUDY">Chertow 2001</LINK>, there were no significant differences between intervention and control periods in estimated hospital and pharmacy costs for cyclosporine.</P>
<P>In <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK> (main results in <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>), the total cost per participant per month was EUR53.79 for usual care, EUR50.62 for intervention A (multifaceted intervention) and EUR53.20 for intervention D (multifaceted intervention plus DAWN AC computer advice) for anticoagulants.</P>
<P>
<LINK REF="STD-Jowett-2009" TYPE="STUDY">Jowett 2009</LINK> reported the cost-effectiveness for anticoagulants of the randomized multicentre study of two computer-assisted dosage programs (DAWN AC or PARMA 5) versus manual dosing conducted by Poller et al. (<LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>; <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>). Dosing time and costs were available in 28 of the 32 clinics participating. Total overall costs per participant were significantly lower in the computer-dosing arm (EUR -50.5, bootstrapped 95% CI -76.8 to -24.1), mainly driven by the difference in dosing costs. The authors concluded that computer-assisted dosage with the two programs (DAWN AC and PARMA 5) was not less effective clinically but was lower in cost than manual dosage.</P>
<P>In <LINK REF="STD-Rousseau-2010" TYPE="STUDY">Rousseau 2010</LINK> (main results in <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>), the mean total yearly cost per participant was EUR47,477 (95% CI 43,933 to 51,020) in the concentration-controlled group and EUR46,783 (95% CI 44,152 to 49,414) in the fixed-dose group (P value = 0.7) for mycophenolate.</P>
<P>In three studies (<LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>; <LINK REF="STD-Jowett-2009" TYPE="STUDY">Jowett 2009</LINK>; <LINK REF="STD-Rousseau-2010" TYPE="STUDY">Rousseau 2010</LINK>), the incremental cost-effectiveness ratio (ICER) was reported. The ICER represents the additional cost required to provide one unit of additional effect. In <LINK REF="STD-Jowett-2009" TYPE="STUDY">Jowett 2009</LINK>, as the costs were lower and the intervention more favourable, calculation of an ICER in this case was not appropriate. In <LINK REF="STD-Rousseau-2010" TYPE="STUDY">Rousseau 2010</LINK>, the incremental 12-month cost was <U>EUR</U>3757 per treatment failure (Purchasing Power Parities United States/France: USD4129). In <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>, the ICER for intervention A (multifaceted intervention) was EUR5.2 per day within range (DWR) and for intervention D (multifaceted intervention plus DAWN AC computer advice) EUR4.9 per DWR. Intervention A was less effective but also slightly less costly compared with D resulting in comparable cost-effectiveness ratios.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>There was a trend to a reduction of the length of stay in the computer groups. In most of trials, the computer-assisted dosage was not less effective but was lower in cost than manual dosage resulting in a comparable or better cost-effectiveness ratio than usual care.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>No study compared the effect of decision support logistics or organizations of care. We found no studies where the computerized advice was delivered by delayed feedback.</P>
<P>Since fewer than 10 studies were available for each characteristic to model, we did not investigate heterogeneity.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>This update found similar results to the previous review (<LINK REF="REF-Durieux-2008" TYPE="REFERENCE">Durieux 2008</LINK>), and, in addition, specific therapeutic areas where the intervention is beneficial (the level of evidence was based upon the 'Summary of findings' tables):</P>
<P>1. For oral anticoagulants, CDSS led more often to an INR within the desired range and reduced the time to achieve stabilization of PT and the incidence rates of thromboembolism, in a statistical significant manner.</P>
<P>2. For insulin, it significantly improved the percentage of time in target glucose and reduced the mean blood glucose. For clinical outcomes, there was no efficacy outcome assessed and the difference for safety outcomes was not statistically significant.</P>
<P>3. For aminoglycoside antibiotics, it was significantly more efficient for reaching appropriate drug serum concentrations. For clinical outcomes, positive treatment response was inconsistent in the two studies.</P>
<P>For all these drugs, the quality of evidence was very low due to the high heterogeneity, the low quality and small sample size in most of studies.</P>
<P>4. For the other drugs (theophylline, anti-rejection drugs, anaesthetic agents, antidepressants and gonadotropins), the level of evidence was too low (small number and sample size of studies) to conclude.</P>
<P>5. Overall, CDSS tended to reduce the length of stay but the difference did not reach statistical significance. Quality of evidence by drugs was low or moderate since there were generally only one or two trials studying this outcome. In most trials, the computer-assisted dosage had lower or equivalent costs than manual dosage.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-11-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>This review included 46 comparisons, of which 18 (39%) concerned anticoagulants and 10 (22%) insulin dosage, providing more consistent results for these drugs than for others (fewer than five comparisons). Five comparisons (10%) concerned aminoglycoside antibiotics but all studies were published before 1993. Three comparisons concerned theophylline, a drug that is not considered as the first-choice treatment of asthma at present. However, monitoring serum concentrations of theophylline is essential to ensure that non-toxic doses are achieved (<LINK REF="REF-National-Asthma-2002" TYPE="REFERENCE">National Asthma 2002</LINK>). Compared with the last version of this review, our update included new drugs such as insulin and anti-rejection drugs. We found no studies concerning some new drugs for which it is considered important to monitor drug levels such as glycopeptides, antifungal (fluconazole) and antiretroviral drugs. CDSS may be more efficient in sampling time and intervals for drugs with a narrow therapeutic window such as insulin or oral anticoagulants. However, we found no studies for other drugs with narrow therapeutic indexes (such as lithium, vancomycin, levothyroxine, digoxin, carbamazepine and phenytoin).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>However, the findings need to be read with caution.</P>
<P>First, the quality of studies was generally low (see 'Summary of findings' tables). There was no blinding of participants and personnel in all studies. The random sequence generation or the allocation concealment, or both were unclear in half of the studies. In most comparisons, sample size was small.</P>
<P>Second, even when grouping the studies by drug, heterogeneity remained high because of the widely different outcome definitions, clinical contexts or organizations of care. This issue limits the comparability between studies and the interpretation of the clinical significance of the results presented with the SMDs. Besides, the intervention type varied between studies. For example, <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK> used a pharmacogenetic guidance program for warfarin initiation. This differs totally with all the other studies on oral anticoagulants.</P>
<P>Third, for some indicators (length of stay, mortality), crude results can be affected by unknown confounding factors.</P>
<P>Last, the results are significant for relevant physiological outcomes (assessed for oral anticoagulants and insulin). However, efficacy clinical outcomes were assessed only for four drugs (aminoglycoside antibiotics, anti-rejection drugs, antidepressants and gonadotropins) and there were at most two comparisons for each drug. For aminoglycoside antibiotics and anti-rejection drugs (two comparisons), the studies showed contradictory results.</P>
<P>For safety clinical events, no significant difference on death was observed between the computer and control groups. For clinical adverse events, there was a trend for less nephrotoxicity for aminoglycoside antibiotics, for fewer bleeding and thromboembolism events for anticoagulants with the computer group. When considering the incidence rates for thromboembolism, this difference was significantly in favour of the computer group for anticoagulants despite a high heterogeneity. There was no significant difference in clinical adverse events for the other drugs.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>We identified no potential biases. We considered congress reports and other sources of unpublished studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>Nine reviews assessed the effect of computer advice on drug dosage. All found a low methodological quality and a high heterogeneity of studies included. Most presented a publication bias or no evaluation of the methodological quality of the studies included. We could not compare our results with seven reviews that reported their quantitative results as the percentage of studies that showed a significant improvement with computer advice (<LINK REF="REF-Garg-2005" TYPE="REFERENCE">Garg 2005</LINK> updated by <LINK REF="REF-Nieuwlaat-2011a" TYPE="REFERENCE">Nieuwlaat 2011a</LINK>; <LINK REF="REF-Yourman-2008" TYPE="REFERENCE">Yourman 2008</LINK>; <LINK REF="REF-Eslami-2009" TYPE="REFERENCE">Eslami 2009</LINK>; <LINK REF="REF-Mollon-2009" TYPE="REFERENCE">Mollon 2009</LINK>; <LINK REF="REF-Pearson-2009" TYPE="REFERENCE">Pearson 2009</LINK>; <LINK REF="REF-Robertson-2010" TYPE="REFERENCE">Robertson 2010</LINK>).</P>
<P>Two old reviews (<LINK REF="REF-Chatellier-1998" TYPE="REFERENCE">Chatellier 1998</LINK>; <LINK REF="REF-Fitzmaurice-1998a" TYPE="REFERENCE">Fitzmaurice 1998a</LINK>) suggested that computer advice may improve therapeutic INR control for oral anticoagulants, but no meta-analysis was performed and the evaluation of the quality of studies included was not clear or adequate.</P>
<P>
<LINK REF="REF-Eslami-2009" TYPE="REFERENCE">Eslami 2009</LINK> performed a systematic review on tight glycaemic control with insulin in intensive care units, but performed no meta-analysis because of the high heterogeneity. The results were expressed as the percentage of studies that showed a significant improvement with computer advice on the blood glucose regulatory process. Although most studies reported a positive effect, the evidence was very low: the review only searched for published studies in MEDLINE, there was no evaluation of the methodological quality of studies, which were mostly before-after designs. Causality was difficult to determine because of the simultaneous implementation of a new tight glycaemic control protocol with computer advice.</P>
<P>Three other reviews assessed the effect of computer advice more generally on all drugs, focusing on drug dosage, but their results were expressed as the percentage of studies that showed a significant improvement with computer advice (<LINK REF="REF-Mollon-2009" TYPE="REFERENCE">Mollon 2009</LINK>; <LINK REF="REF-Pearson-2009" TYPE="REFERENCE">Pearson 2009</LINK>; <LINK REF="REF-Robertson-2010" TYPE="REFERENCE">Robertson 2010</LINK>). <LINK REF="REF-Mollon-2009" TYPE="REFERENCE">Mollon 2009</LINK> excluded all RCTs that focused only on dose adjustment.</P>
<P>Two reviews assessed the general benefits of computer advice: <LINK REF="REF-Yourman-2008" TYPE="REFERENCE">Yourman 2008</LINK> for improving medication prescribing in older adults and <LINK REF="REF-Garg-2005" TYPE="REFERENCE">Garg 2005</LINK>, updated by <LINK REF="REF-Nieuwlaat-2011a" TYPE="REFERENCE">Nieuwlaat 2011a</LINK>, for drug monitoring and dosing. Unlike us, their results were the percentage of studies that showed a significant improvement with computer advice. A study was considered to have a positive effect (i.e. CDSS showed improvement) if at least 50% of the relevant study outcomes were statistically significantly positive. This approach does not give insight in the magnitude of effects and may have underestimated the overall efficacy. In contrast, there is a risk for publication bias of positive RCTs, which could cause overestimation of CDSS efficacy. <LINK REF="REF-Yourman-2008" TYPE="REFERENCE">Yourman 2008</LINK> found that computer advice was effective in improving medication prescribing in older adults, and <LINK REF="REF-Nieuwlaat-2011a" TYPE="REFERENCE">Nieuwlaat 2011a</LINK> in improving the process of care. In <LINK REF="REF-Yourman-2008" TYPE="REFERENCE">Yourman 2008</LINK>, there was no evaluation of the methodological quality of included studies, a likely publication bias and a high heterogeneity. In <LINK REF="REF-Nieuwlaat-2011a" TYPE="REFERENCE">Nieuwlaat 2011a</LINK>, the studies were small and of low quality when using a 10-point-scale extended from the Jadad scale.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>1. Analysis of trials suggests that computerized advice for drug dosage has some benefits over routine care. It increases the serum concentrations for aminoglycoside antibiotics. It improves the proportion of time for which the plasma drug is within the therapeutic range for aminoglycoside antibiotics and theophylline. It leads to a physiological parameter more often within the desired range for oral anticoagulants and insulin. It decreases the time to achieve stabilization for oral anticoagulants. It also reduces the length of hospital stay, and tends to decrease unwanted effects of anti-rejection drugs and aminoglycoside antibiotics. It significantly decreases unwanted effects for anticoagulants.</P>
<P>2. The results are based on studies mainly of low quality, concerning a small number of drugs. Even when analyzing by drugs, the heterogeneity was important for half of the outcomes.<BR/>3. No conclusion could be drawn concerning the logistics of the computerized support and organization of care aspects. It is not certain that these benefits could be achieved with different computer systems in different clinical situations.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-10-08 17:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>1. More studies are needed to demonstrate that the use of computers improves the quality of care. Well-designed trials randomized by clusters are mandatory for assessment of the effect of computerized support systems on drug dosage.</P>
<P>2. These studies should address the identification of the factors that predict a successful and acceptable system: the decision support logistics, the organizations of care and the healthcare professionals' characteristics.</P>
<P>3. Studies evaluating other drugs with a narrow therapeutic window or complicated pharmacokinetics (e.g. antibiotics) are needed. These studies should address the identification of the factors that predict a successful and acceptable system: the decision support logistics, the organizations of care and the healthcare professionals' characteristics.</P>
<P>4. Since the last update in 2008, we have found 22 additional trials, which indicate that this field is in rapid extension, especially with the advent of computer physician order entry (CPOE) systems. Future research should look at other directions than only drug dosage.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-04 12:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>The authors thank: Michelle Fiander, Effective Practice and Organisation of Care (EPOC) Trials Search Co-ordinator for redesigning and optimizing search strategies for this review and for writing the search methods for us; her revisions to the search strategies identified previously unidentified studies; Elske Ammenwerth for her review of an article in German; and Lucienne Boujon who provided English corrections. We would also like to thank Jessie McGowan and Doug Salzwedel for their assistance with searching for previous versions of this review; and Alan Forster and Jim Wright for their helpful comments on earlier versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-11-13 13:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-26 11:36:11 +0200" MODIFIED_BY="[Empty name]">
<P>PD, IC, LT and FG prepared the protocol. All authors applied the inclusion criteria, assessed the quality and extracted the data for the included studies. FG and LT conducted the quantitative analyses and qualitative analyses. FG and EC drafted the manuscript with input from all authors. RW conducted the initial review and provided comments on the revised manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-07 09:47:53 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-11-07 09:47:53 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-11-04 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ageno-1998" MODIFIED="2011-12-21 17:57:54 +0100" MODIFIED_BY="[Empty name]" NAME="Ageno 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ageno W, Turpie AG</AU>
<TI>A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy</TI>
<SO>Thrombosis Research</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>5</NO>
<PG>237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ageno-2000" MODIFIED="2013-09-25 20:21:36 +0200" MODIFIED_BY="[Empty name]" NAME="Ageno 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-25 20:21:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Thromb Haemost Ageno W Johnson J Nowacki B Turpie AG&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:21:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ageno W, Johnson J, Nowacki B, Turpie AG</AU>
<TI>A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>6</NO>
<PG>849-52</PG>
<IDENTIFIERS MODIFIED="2011-11-08 16:49:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0340-6245"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2007" MODIFIED="2013-11-04 12:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-04 12:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL., Horne BD, Stevens SM, Grove AS, Barton S, et al</AU>
<TI>Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation</TI>
<SO>Circulation</SO>
<YR>2007</YR>
<VL>116</VL>
<NO>22</NO>
<PG>2563-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-20 16:58:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2008" MODIFIED="2013-11-04 12:58:37 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-04 12:58:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AN - CN-00636115 Cochrane Peripheral Vascular Diseases Group Cochrane Heart Group&lt;br&gt;Coch-Jan 2012-searched all years; these results are from 2 lines added to version 1.5 of strategy&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:58:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL</AU>
<TI>A double blind randomised trial of genotype guided versus standard warfarin dosing in patients initiated on oral anticoagulation: the COUMAGEN study</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2008</YR>
<VL>97</VL>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asberg-2010" MODIFIED="2013-09-25 20:22:54 +0200" MODIFIED_BY="[Empty name]" NAME="Asberg 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 20:22:54 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ther Drug Monit Asberg A Falck P Undset LH Dorje C Holdaas H Hartmann A Midtvedt K&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:22:54 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asberg A, Falck P, Undset LH, Dorje C, Holdaas H, Hartmann A, et al</AU>
<TI>Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>2</NO>
<PG>152-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Augstein-2007" MODIFIED="2013-09-25 20:22:46 +0200" MODIFIED_BY="[Empty name]" NAME="Augstein 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 20:22:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PUBMED 17468357 Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/409/CN-00588409/frame.html Coch1.5 Cochrane ID: CN-00588409&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:22:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Augstein P, Vogt L, Kohnert KD, Freyse EJ, Heinke P, Salzsieder E</AU>
<TI>Outpatient assessment of Karlsburg Diabetes Management System-based decision support</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>7</NO>
<PG>1704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Begg-1989" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Begg EJ, Atkinson HC, Jeffery GM, Taylor NW</AU>
<TI>Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>2</NO>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blaha-2009" MODIFIED="2012-12-12 16:43:33 +0100" MODIFIED_BY="[Empty name]" NAME="Blaha 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-12-12 16:43:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Blaha, Jan&lt;br&gt;Kopecky, Petr&lt;br&gt;Matias, Michal&lt;br&gt;Hovorka, Roman&lt;br&gt;Kunstyr, Jan&lt;br&gt;Kotulak, Tomas&lt;br&gt;Lips, Michal&lt;br&gt;Rubes, David&lt;br&gt;Stritesky, Martin&lt;br&gt;Lindner, Jaroslav&lt;br&gt;Semrad, Michal&lt;br&gt;Haluzik, Martin&lt;br&gt;Comparative Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, N.I.H., Extramural&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;United States&lt;br&gt;Diabetes care&lt;br&gt;Diabetes Care. 2009 May;32(5):757-61. Epub 2009 Feb 5.&lt;/p&gt;" NOTES_MODIFIED="2012-12-12 16:43:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blaha J, Kopecky P, Matias M, Hovorka R, Kunstyr J, Kotulak T, et al</AU>
<TI>Comparison of three protocols for tight glycemic control in cardiac surgery patients</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<PG>757-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burton-1991" MODIFIED="2013-11-04 12:58:46 +0100" MODIFIED_BY="[Empty name]" NAME="Burton 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-11-04 12:58:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Burton ME, Ash CL, Hill DP, Jr., Handy T, Shepherd MD, Vasko MR. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991;49(6):685-94.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:58:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burton ME, Ash CL, Hill DPJ, Handy T, Shepherd MD, Vasko MR</AU>
<TI>A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1991</YR>
<VL>49</VL>
<NO>6</NO>
<PG>685-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1987" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Carter 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter BL, Taylor JW, Becker A</AU>
<TI>Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy</TI>
<SO>Clinical Pharmacy</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>1</NO>
<PG>37-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casner-1993" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Casner 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casner PR, Reilly R, Ho H</AU>
<TI>A randomized controlled trial of computerized pharmacokinetic theophylline dosing versus empiric physician dosing</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>6</NO>
<PG>684-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chertow-2001" MODIFIED="2011-12-21 17:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Chertow 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al</AU>
<TI>Guided medication dosing for inpatients with renal insufficiency</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>22</NO>
<PG>2839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claes-2005" MODIFIED="2013-09-25 20:24:24 +0200" MODIFIED_BY="[Empty name]" NAME="Claes 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 20:24:24 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Claes, Neree&lt;br&gt;Buntinx, Frank&lt;br&gt;Vijgen, Johan&lt;br&gt;Arnout, Jef&lt;br&gt;Vermylen, Jos&lt;br&gt;Fieuws, Steffen&lt;br&gt;Van Loon, Herman&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;England&lt;br&gt;European heart journal&lt;br&gt;Eur Heart J. 2005 Oct;26(20):2159-65. Epub 2005 May 25.&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:24:24 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claes N, Buntinx F, Vijgen J, Arnout J, Vermylen J, Fieuws S, et al</AU>
<TI>The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial</TI>
<SO>European H
eart 
Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>2159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claes-2006" MODIFIED="2013-11-04 12:58:57 +0100" MODIFIED_BY="[Empty name]" NAME="Claes 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-04 12:58:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Claes, Neree&lt;br&gt;Moeremans, Karen&lt;br&gt;Frank, Buntinx&lt;br&gt;Jef, Arnout&lt;br&gt;Jos, Vermylen&lt;br&gt;Herman, Van Loon&lt;br&gt;Lieven, Annemans&lt;br&gt;Randomized Controlled Trial&lt;br&gt;United States&lt;br&gt;Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research&lt;br&gt;Value Health. 2006 Nov-Dec;9(6):369-76.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:58:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claes N, Moeremans K, Frank B, Jef A, Jos V, Herman VL, et al</AU>
<TI>Estimating the cost-effectiveness of quality-improving interventions in oral anticoagulation management within general practice</TI>
<SO>Value in Health</SO>
<YR>2006</YR>
<VL>9</VL>
<PG>369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordingley-2009" MODIFIED="2013-09-25 20:25:15 +0200" MODIFIED_BY="[Empty name]" NAME="Cordingley 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 20:25:15 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Intensive Care Med Cordingley JJ Vlasselaers D Dormand NC Wouters PJ Squire SD Chassin LJ Wilinska ME Morgan CJ Hovorka R Van den Berghe G&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:25:15 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordingley JJ, Vlasselaers D, Dormand NC, Wouters PJ, Squire SD, Chassin LJ, et al</AU>
<TI>Intensive insulin therapy: enhanced Model Predictive Control algorithm versus standard care</TI>
<SO>Intensive Care Medicine</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>1</NO>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Destache-1990" MODIFIED="2013-09-26 17:41:45 +0200" MODIFIED_BY="[Empty name]" NAME="Destache 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-09-26 17:41:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Destache CJ, Meyer SK, Bittner MJ, Hermann KG</AU>
<TI>Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>5</NO>
<PG>419-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzmaurice-2000" MODIFIED="2011-12-21 17:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="Fitzmaurice 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE</AU>
<TI>Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>15</NO>
<PG>2343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-1989" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez ER, Vanderheyden BA, Ornato JP, Comstock TG</AU>
<TI>Computer-assisted optimization of aminophylline therapy in the emergency department</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1989</YR>
<VL>7</VL>
<NO>4</NO>
<PG>395-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hickling-1989" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hickling 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hickling K, Begg E, Moore ML</AU>
<TI>A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1989</YR>
<VL>15</VL>
<NO>4</NO>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hovorka-2007" MODIFIED="2013-11-04 12:59:08 +0100" MODIFIED_BY="[Empty name]" NAME="Hovorka 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-04 12:59:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hovorka, Roman&lt;br&gt;Kremen, Jaromir&lt;br&gt;Blaha, Jan&lt;br&gt;Matias, Michal&lt;br&gt;Anderlova, Katerina&lt;br&gt;Bosanska, Lenka&lt;br&gt;Roubicek, Tomas&lt;br&gt;Wilinska, Malgorzata E&lt;br&gt;Chassin, Ludovic J&lt;br&gt;Svacina, Stepan&lt;br&gt;Haluzik, Martin&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;United States&lt;br&gt;The Journal of clinical endocrinology and metabolism&lt;br&gt;J Clin Endocrinol Metab. 2007 Aug;92(8):2960-4. Epub 2007 Jun 5.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:59:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovorka R, Kremen J, Blaha J, Matias M, Anderlova K, Bosanska L, et al</AU>
<TI>Blood glucose control by a model predictive control algorithm with variable sampling rate versus a routine glucose management protocol in cardiac surgery patients: a randomized controlled trial</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2007</YR>
<VL>92</VL>
<PG>2960-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurley-1986" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hurley 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurley SF, Dziukas LJ, McNeil JJ, Brignell MJ</AU>
<TI>A randomized controlled clinical trial of pharmacokinetic theophylline dosing</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1986</YR>
<VL>134</VL>
<NO>6</NO>
<PG>1219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jowett-2009" MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Jowett 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Thromb Haemost Jowett S Bryan S Poller L VAN DEN Besselaar AM VAN DER Meer FJ Palareti G Shiach C Tripodi A Keown M Ibrahim S Lowe G Moia M Turpie AG Jespersen J&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 16:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jowett S, Bryan S, Poller L, Van Den Besselaar AMHP, Van Der Meer FJM, Palareti G, et al</AU>
<TI>The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1482-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kremen-2007" MODIFIED="2013-09-25 20:27:53 +0200" MODIFIED_BY="[Empty name]" NAME="Kremen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 20:27:53 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;L&amp;#8218;cba hyperglykemie u kriticky nemocnych pacient&amp;amp;#367;: srovn&amp;#160;n&amp;#161; standardn&amp;#161;ho protokolu a poc&amp;#161;tacov&amp;#8218;ho algoritmu PUBMED 18357861 Comparative Study English Abstract Journal Article Randomized Controlled Trial Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/930/CN-00630930/frame.html Cochrane ID: CN-00630930&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:27:53 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kremen J, Blaha J, Kopecky P, Bosansk  L, Kotrlikova  E, Roubicek T, et al</AU>
<TI>The treatment of hyperglycaemia in critically ill patients: comparison of standard protocol and computer algorithm [In Czech]
</TI>
<SO>Vnitrni Lekarstvi
</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>12</NO>
<PG>1269-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leehey-1993" MODIFIED="2013-09-25 20:57:44 +0200" MODIFIED_BY="[Empty name]" NAME="Leehey 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-25 20:57:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Leehey, D J&lt;br&gt;Braun, B I&lt;br&gt;Tholl, D A&lt;br&gt;Chung, L S&lt;br&gt;Gross, C A&lt;br&gt;Roback, J A&lt;br&gt;Lentino, J R&lt;br&gt;Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, U.S. Gov't, Non-P.H.S.&lt;br&gt;United states&lt;br&gt;Journal of the American Society of Nephrology : JASN&lt;br&gt;J Am Soc Nephrol. 1993 Jul;4(1):81-90.&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:57:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA, Roback JA, et al</AU>
<TI>Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Meur-2007" MODIFIED="2013-09-25 20:58:00 +0200" MODIFIED_BY="[Empty name]" NAME="Le Meur 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 20:58:00 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Am J Transplant Le Meur Y Buchler M Thierry A Caillard S Villemain F Lavaud S Etienne I Westeel PF Hurault de Ligny B Rostaing L Thervet E Szelag JC Rerolle JP Rousseau A Touchard G Marquet P&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:58:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al</AU>
<TI>Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation</TI>
<SO>American Journal of Transplantation</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>11</NO>
<PG>2496-503</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:04:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1600-6135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Meur-2007-extract" MODIFIED="2013-09-25 20:58:30 +0200" MODIFIED_BY="[Empty name]" NAME="Le Meur 2007 extract" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 20:58:30 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United Kingdom EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 20:58:30 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Individualized dosing of MMF is superior to fixed dosing in renal transplant patients</TI>
<SO>Nature Clinical Practice Nephrology</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>1</NO>
<PG>9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1745-8323"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lesourd-2002" MODIFIED="2011-12-21 17:58:56 +0100" MODIFIED_BY="[Empty name]" NAME="Lesourd 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lesourd F, Avril C, Boujennah A, Parinaud J</AU>
<TI>A computerized decision support system for ovarian stimulation by gonadotropins</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>3</NO>
<PG>456-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manotti-2001" MODIFIED="2013-09-25 21:00:32 +0200" MODIFIED_BY="[Empty name]" NAME="Manotti 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-25 21:00:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG</AU>
<TI>Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment)</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>10</NO>
<PG>1060-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mihajlovic-2003" MODIFIED="2013-09-25 21:00:52 +0200" MODIFIED_BY="[Empty name]" NAME="Mihajlovic 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 21:00:52 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Psychiatry Clin Neurosci Mihajlovic GS Milovanovic DR Jankovic SM&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:00:52 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mihajlovic GS, Milovanovic DR, Jankovic SM</AU>
<TI>Comparison of efficacy and safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode</TI>
<SO>Psychiatry &amp; Clinical Neurosciences</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>6</NO>
<PG>580-5</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:04:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1323-1316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mihajlovic-2010" MODIFIED="2013-07-28 18:02:09 +0200" MODIFIED_BY="[Empty name]" NAME="Mihajlovic 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-08 17:04:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Psychiatr Mihajlovic G Djukic-Dejanovic S Jovanovic-Mihajlovic N Jankovic S Janjic V Jovanovic M Petrovic D Borovcanin M Radmanovic B&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 17:04:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mihajlovic G, Djukic-Dejanovic S, Jovanovic-Mihajlovic N, Jankovic S, Janjic V, Jovanovic M, et al</AU>
<TI>Comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode</TI>
<SO>Psychiatria Danubina</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>2</NO>
<PG>354-7</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:04:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0353-5053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitra-2005" MODIFIED="2013-09-25 21:01:26 +0200" MODIFIED_BY="[Empty name]" NAME="Mitra 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 21:01:26 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Am J Phys Med Rehabil Mitra R Marciello MA Brain C Ahangar B Burke DT&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:01:26 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitra R, Marciello MA, Brain C, Ahangar B, Burke DT</AU>
<TI>Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>6</NO>
<PG>423-7</PG>
<IDENTIFIERS MODIFIED="2011-11-08 16:49:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0894-9115"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mungall-1994" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mungall 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mungall DR, Anbe D, Forrester PL, Luoma T, Genovese R, Mahan J, et al</AU>
<TI>A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram--directed heparin therapy</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>5</NO>
<PG>591-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pachler-2008" MODIFIED="2013-09-25 21:02:07 +0200" MODIFIED_BY="[Empty name]" NAME="Pachler 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:02:07 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Intensive Care Med Pachler C Plank J Weinhandl H Chassin LJ Wilinska ME Kulnik R Kaufmann P Smolle KH Pilger E Pieber TR Ellmerer M Hovorka R&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:02:07 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pachler C, Plank J, Weinhandl H, Chassin LJ, Wilinska ME, Kulnik R, et al</AU>
<TI>Tight glycaemic control by an automated algorithm with time-variant sampling in medical ICU patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>7</NO>
<PG>1224-30</PG>
<IDENTIFIERS MODIFIED="2011-11-08 16:49:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0342-4642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plank-2006" MODIFIED="2013-09-25 21:02:17 +0200" MODIFIED_BY="[Empty name]" NAME="Plank 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 21:02:17 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Accession Number: 2009290302. Language: English. Entry Date: 20061117. Revision Date: 20101231. Publication Type: journal article; randomized controlled trial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: European community, Sixth Framework Programme, Action Line eHealth, Project Reference 506965; Engineering and Physical Sciences Research Council project GR/S14344/01. No. of Refs: 23 ref. NLM UID: 7805975.&lt;br&gt;PMID: 16443872&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:02:17 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plank J, Blaha J, Cordingley J, Wilinska ME, Chassin LJ, Morgan C, et al</AU>
<TI>Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>271-6</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:02:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0149-5992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-1998-pop1" MODIFIED="2013-07-28 19:13:56 +0200" MODIFIED_BY="[Empty name]" NAME="Poller 1998 pop1" YEAR="1998">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, et al</AU>
<TI>Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9139</NO>
<PG>1505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-1998-pop2" MODIFIED="2013-07-28 19:15:26 +0200" MODIFIED_BY="[Empty name]" NAME="Poller 1998 pop2" YEAR="1998">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, et al</AU>
<TI>Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9139</NO>
<PG>1505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2002" MODIFIED="2013-11-04 12:59:18 +0100" MODIFIED_BY="[Empty name]" NAME="Poller 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-04 12:59:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - Turkey EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:59:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L</AU>
<TI>European Concerted Action on Anticoagulation (ECAA): studies on computer-assisted anticoagulant dosage</TI>
<SO>Turkish Journal of Haematology</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>2</NO>
<PG>179-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1300-7777"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2003" MODIFIED="2013-11-04 12:59:25 +0100" MODIFIED_BY="[Empty name]" NAME="Poller 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-04 12:59:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;RCT Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/298/CN-00550298/frame.html Coch1.5 Cochrane ID: CN-00550298&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:59:25 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Jespersen J, Tripodi A, Van Den Besselaar AMHP, Van der Mer FJM, Shiac C, et al</AU>
<TI>European Action on Anti-coagulation - cost effectiveness of computer assisted anti-coagulant dosage</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2008" MODIFIED="2013-08-01 02:10:44 +0200" MODIFIED_BY="[Empty name]" NAME="Poller 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-07-28 19:23:53 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Thromb Haemost Poller L Keown M Ibrahim S Lowe G Moia M Turpie AG Roberts C van den Besselaar AM van der Meer FJ Tripodi A Palareti G Shiach C Bryan S Samama M Burgess-Wilson M Heagerty A Maccallum P Wright D Jespersen J&lt;/p&gt;" NOTES_MODIFIED="2013-07-28 19:23:53 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, et al</AU>
<TI>An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>6</NO>
<PG>935-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2008-PARMA-5" MODIFIED="2011-11-09 16:10:50 +0100" MODIFIED_BY="[Empty name]" NAME="Poller 2008 PARMA 5" YEAR="2008">
<REFERENCE MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Br J Haematol Poller L Keown M Ibrahim S Lowe G Moia M Turpie AG Roberts C van den Besselaar AM van der Meer FJ Tripodi A Palareti G Jespersen J&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 16:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, et al</AU>
<TI>A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage</TI>
<SO>British Journal of Haematology</SO>
<YR>2008</YR>
<VL>143</VL>
<NO>2</NO>
<PG>274-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2009-DAWN-AC" MODIFIED="2013-11-04 12:59:33 +0100" MODIFIED_BY="[Empty name]" NAME="Poller 2009 DAWN AC" YEAR="2009">
<REFERENCE MODIFIED="2013-11-04 12:59:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Thromb Haemost Poller L Keown M Ibrahim S Lowe G Moia M Turpie AG Roberts C van den Besselaar AM van der Meer FJ Tripodi A Palareti G Shiach C Bryan S Samama M Burgess-Wilson M Heagerty A Maccallum P Wright D Jespersen J European Action on Anticoagulation (EAA) (Eaa) Munster AM Leed B Bowyer C Chillou C Defard M Halkin H Loebstein R Naparstek E Kirgner I Peternel P Krevel B Stegnar M Marques-Dias D Ageno W Dentali F Watzke H Weisser B Angeles Fernandez M Chatelain B Cornet I Gallus AS Osmond J Luckit J Charles F Comment in: Thromb Haemost. 2009 Mar;101(3):413-4; PMID: 19277397&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:59:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, et al</AU>
<TI>A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>2009</YR>
<VL>101</VL>
<NO>3</NO>
<PG>487-94</PG>
<IDENTIFIERS MODIFIED="2011-11-08 16:49:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0340-6245"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-2009-erratum" MODIFIED="2013-09-25 21:04:35 +0200" MODIFIED_BY="[Empty name]" NAME="Poller 2009 erratum" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:04:35 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - Germany EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:04:35 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller</AU>
<TI>Erratum: A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program (Thrombosis and Haemostasis (2009) 101 (487-494))</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>101</VL>
<NO>4</NO>
<PG>794</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0340-6245"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodman-1984" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Rodman 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodman JH, Jelliffe RW, Kolb E, Tuey DB, de Guzman MF, Wagers PW, et al</AU>
<TI>Clinical studies with computer-assisted initial lidocaine therapy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1984</YR>
<VL>144</VL>
<NO>4</NO>
<PG>703-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rousseau-2010" MODIFIED="2011-11-08 17:04:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rousseau 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-08 17:04:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Transplantation Rousseau A Laroche ML Venisse N Loichot-Roselmac C Turcant A Hoizey G Compagnon P Hary L Debruyne D Saivin S Jacqz-Aigrain E Buchler M Villeneuve C Vergnenegre A Le Meur Y Marquet P&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 17:04:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rousseau A, Laroche M-L, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, et al</AU>
<TI>Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial</TI>
<SO>Transplantation</SO>
<YR>2010</YR>
<VL>89</VL>
<NO>10</NO>
<PG>1255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saager-2008" MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Saager 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Saager L Collins GL Burnside B Tymkew H Zhang L Jacobsohn E Avidan M&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 16:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Saager L, Collins GL, Burnside B, Tymkew H, Zhang L, Jacobsohn E, et al</AU>
<TI>A randomized study in diabetic patients undergoing cardiac surgery comparing computer-guided glucose management with a standard sliding scale protocol</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>3</NO>
<PG>377-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2011" MODIFIED="2013-11-04 12:59:42 +0100" MODIFIED_BY="[Empty name]" NAME="Sato 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-04 12:59:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NLM full journal name - Diabetes technology &amp;amp; therapeutics&lt;br&gt;ML1.5-Jan2012&lt;br&gt;PM: 21175276&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 12:59:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato T, Carvalho G, Sato H, Lattermann R, Schricker T</AU>
<TI>Glucose and insulin administration while maintaining normoglycemia during cardiac surgery using a computer-assisted algorithm</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>13</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terrell-2010" MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Terrell 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Terrell KM Perkins AJ Hui SL Callahan CM Dexter PR Miller DK&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 16:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Terrell KM, Perkins AJ, Hui SL, Callahan CM, Dexter PR, Miller DK</AU>
<TI>Computerized decision support for medication dosing in renal insufficiency: a randomized, controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theil-1993-fentanyl" MODIFIED="2013-08-06 13:35:03 +0200" MODIFIED_BY="[Empty name]" NAME="Theil 1993 fentanyl" YEAR="1993">
<REFERENCE MODIFIED="2013-08-06 13:35:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theil DR, Stanley TE 3rd, White WD, Goodman DK, Glass PS, Bai SA, et al</AU>
<TI>Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>3</NO>
<PG>300-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theil-1993-midazolam" MODIFIED="2013-08-06 13:35:10 +0200" MODIFIED_BY="[Empty name]" NAME="Theil 1993 midazolam" YEAR="1993">
<REFERENCE MODIFIED="2013-08-06 13:35:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theil DR, Stanley TE 3rd, White WD, Goodman DK, Glass PS, Bai SA, et al</AU>
<TI>Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>3</NO>
<PG>300-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadher-1997" MODIFIED="2011-12-21 18:00:11 +0100" MODIFIED_BY="[Empty name]" NAME="Vadher 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadher B, Patterson DL, Leaning M</AU>
<TI>Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7089</NO>
<PG>1252-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadher-1997-pop1" MODIFIED="2013-09-26 16:11:55 +0200" MODIFIED_BY="[Empty name]" NAME="Vadher 1997 pop1" YEAR="1997">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadher BD, Patterson DL, Leaning M</AU>
<TI>Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians</TI>
<SO>Clinical and Laboratory Haematology</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>3</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadher-1997-pop2" MODIFIED="2013-09-26 16:13:07 +0200" MODIFIED_BY="[Empty name]" NAME="Vadher 1997 pop2" YEAR="1997">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadher BD, Patterson DL, Leaning M</AU>
<TI>Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians</TI>
<SO>Clinical and Laboratory Haematology</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>3</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verner-1992" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Verner 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verner D, Seligmann H, Platt S, Dany S, Almog S, Zulty L, et al</AU>
<TI>Computer assisted design of a theophylline dosing regimen in acute bronchospasm: serum concentrations and clinical outcome</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wexler-2010" MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Wexler 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-08 16:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wexler DJ Shrader P Burns SM Cagliero E&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 16:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wexler DJ, Shrader P, Burns SM, Cagliero E</AU>
<TI>Effectiveness of a computerized insulin order template in general medical inpatients with type 2 diabetes: a cluster randomized trial</TI>
<SO>Diabetes Care</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>10</NO>
<PG>2181-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1987" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="White 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RH, Hong R, Venook AP, Daschbach MM, Murray W, Mungall DR, et al</AU>
<TI>Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>3</NO>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1991" MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="White 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-11-08 17:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RH, Mungall D</AU>
<TI>Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>1</NO>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-07 09:47:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbrecht-1982" MODIFIED="2013-11-04 13:00:01 +0100" MODIFIED_BY="[Empty name]" NAME="Abbrecht 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-11-04 13:00:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbrecht PH, O'Leary TJ, Behrendt DM</AU>
<TI>Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1982</YR>
<VL>32</VL>
<NO>1</NO>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Absalom-2003" MODIFIED="2013-09-25 21:07:26 +0200" MODIFIED_BY="[Empty name]" NAME="Absalom 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 21:07:26 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Br J Anaesth Absalom AR Kenny GN&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:07:26 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Absalom AR, Kenny GNC</AU>
<TI>Closed-loop control of propofol anaesthesia using bispectral index: performance assessment in patients receiving computer-controlled propofol and manually controlled remifentanil infusions for minor surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>6</NO>
<PG>737-41</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0007-0912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albisser-2007" MODIFIED="2013-09-25 21:07:37 +0200" MODIFIED_BY="[Empty name]" NAME="Albisser 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 21:07:37 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Albisser, A M&lt;br&gt;Wright, C E&lt;br&gt;Sakkal, S&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Ireland&lt;br&gt;Diabetes research and clinical practice&lt;br&gt;Diabetes Res Clin Pract. 2007 May;76(2):207-14. Epub 2006 Oct 4.&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:07:37 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albisser AM, Wright CE, Sakkal S</AU>
<TI>Averting iatrogenic hypoglycemia through glucose prediction in clinical practice: progress towards a new procedure in diabetes</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2007</YR>
<VL>76</VL>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvis-1985" MODIFIED="2013-11-04 13:00:07 +0100" MODIFIED_BY="[Empty name]" NAME="Alvis 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-04 13:00:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvis JM, Reves JG, Govier AV, Menkhaus PG, Henling CE, Spain JA, et al</AU>
<TI>Computer-assisted continuous infusions of fentanyl during cardiac anesthesia: comparison with a manual method</TI>
<SO>Anesthesiology</SO>
<YR>1985</YR>
<VL>63</VL>
<NO>1</NO>
<PG>41&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barletta-2009" MODIFIED="2013-11-04 13:00:13 +0100" MODIFIED_BY="[Empty name]" NAME="Barletta 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-04 13:00:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;OT - The effect of a computer-assisted insulin infusion protocol on glucose control and variability in a surgical intensive care unit EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:00:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Barletta J, McAllen K, Eriksson E, Thayer S, Deines G, Blau S, et al</AU>
<TI>The effect of a computer-assisted insulin infusion protocol on glucose control and variability in a surgical intensive care unit</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<PG>A25</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0090-3493"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barras-2008" MODIFIED="2013-09-25 21:10:21 +0200" MODIFIED_BY="[Empty name]" NAME="Barras 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:10:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clin Pharmacol Ther Barras MA Duffull SB Atherton JJ Green B&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:10:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barras MA, Duffull SB, Atherton JJ, Green B</AU>
<TI>Individualized compared with conventional dosing of enoxaparin</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>83</VL>
<NO>6</NO>
<PG>882-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barras-2010" MODIFIED="2013-09-25 21:10:29 +0200" MODIFIED_BY="[Empty name]" NAME="Barras 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 21:10:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ther Drug Monit Barras MA Duffull SB Atherton JJ Green B&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:10:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barras MA, Duffull SB, Atherton JJ, Green B</AU>
<TI>Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>4</NO>
<PG>482-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartal-2003" MODIFIED="2013-11-04 13:00:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bartal 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-04 13:00:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bartal, Carmi&lt;br&gt;Danon, Abraham&lt;br&gt;Schlaeffer, Francisc&lt;br&gt;Reisenberg, Klaris&lt;br&gt;Alkan, Michael&lt;br&gt;Smoliakov, Rosa&lt;br&gt;Sidi, Aviel&lt;br&gt;Almog, Yaniv&lt;br&gt;Clinical Trial&lt;br&gt;Comment&lt;br&gt;Controlled Clinical Trial&lt;br&gt;United States&lt;br&gt;The American journal of medicine&lt;br&gt;Am J Med. 2003 Feb 15;114(3):194-8.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:00:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, et al</AU>
<TI>Pharmacokinetic dosing of aminoglycosides: a controlled trial</TI>
<SO>American Journal of Medicine</SO>
<YR>2003</YR>
<VL>114</VL>
<PG>194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berg-2009" MODIFIED="2013-09-25 21:11:09 +0200" MODIFIED_BY="[Empty name]" NAME="Berg 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:11:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hepatology Berg T Weich V Teuber G Klinker H Moller B Rasenack J Hinrichsen H Gerlach T Spengler U Buggisch P Balk H Zankel M Neumann K Sarrazin C Zeuzem S&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:11:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, et al</AU>
<TI>Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burger-2003" MODIFIED="2013-09-25 21:11:17 +0200" MODIFIED_BY="[Empty name]" NAME="Burger 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 21:11:17 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Aids Burger D Hugen P Reiss P Gyssens I Schneider M Kroon F Schreij G Brinkman K Richter C Prins J Aarnoutse R Lange J ATHENA Cohort Study Group&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:11:17 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, et al</AU>
<TI>Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1157-65</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0269-9370"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bury-2005" MODIFIED="2013-11-04 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Bury 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-04 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bury J, Hurt C, Roy A, Cheesman L, Bradburn M, Cross S, et al</AU>
<TI>LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>6</NO>
<PG>746-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-21 17:14:53 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caraballo-2008" MODIFIED="2013-09-25 21:11:51 +0200" MODIFIED_BY="[Empty name]" NAME="Caraballo 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:11:51 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AMIA Annu Symp Proc Caraballo PJ North F Peters S Puffer M Nyman M Epps S Peterson J Bleimeyer R Elkin P&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:11:51 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Caraballo PJ, North F, Peters S, Puffer M, Nyman M, Epps S, et al</AU>
<TI>Use of decision support to prevent errors when documenting height and weight in the hospital electronic medical record</TI>
<SO>AMIA</SO>
<YR>2008</YR>
<VL>Annual Symposium Proceedings/AMIA Symposium
</VL>
<PG>890</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1987a" MODIFIED="2013-09-25 21:12:12 +0200" MODIFIED_BY="[Empty name]" NAME="Carter 1987a" YEAR="1987">
<REFERENCE MODIFIED="2013-09-25 21:12:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter BL, Taylor JW, Becker A</AU>
<TI>Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy</TI>
<SO>Clinical Pharmacy</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>1</NO>
<PG>37-
45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavalcanti-2009" MODIFIED="2013-08-06 13:35:48 +0200" MODIFIED_BY="[Empty name]" NAME="Cavalcanti 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-06 13:35:48 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cavalcanti, Alexandre B&lt;br&gt;Silva, Eliezer&lt;br&gt;Pereira, Adriano J&lt;br&gt;Caldeira-Filho, Milton&lt;br&gt;Almeida, Francisca P&lt;br&gt;Westphal, Glauco A&lt;br&gt;Beims, Renate&lt;br&gt;Fernandes, Caio C&lt;br&gt;Correa, Thiago D&lt;br&gt;Gouvea, Marcos R&lt;br&gt;Eluf-Neto, Jose&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;United States&lt;br&gt;Journal of critical care&lt;br&gt;J Crit Care. 2009 Sep;24(3):371-8. Epub 2009 Jul 9.&lt;/p&gt;" NOTES_MODIFIED="2013-08-06 13:35:48 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavalcanti AB, Silva E, Pereira AJ, Caldeira-Filho M, Almeida FP, Westphal GA, et al</AU>
<TI>A randomized controlled trial comparing a computer-assisted insulin infusion protocol with a strict and a conventional protocol for glucose control in critically ill patients</TI>
<SO>Journal of Critical Care</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>371-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2006" MODIFIED="2013-09-25 21:12:36 +0200" MODIFIED_BY="[Empty name]" NAME="Chan 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 21:12:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chan AL Wang HY Leung HW&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:12:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan ALF, Wang H-Y, Leung HWC</AU>
<TI>Incorporation of a gentamicin dosage calculator into a computerized prescriber-order-entry system</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>14</NO>
<PG>1344-5</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1079-2082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiarelli-1990" MODIFIED="2013-09-25 21:12:54 +0200" MODIFIED_BY="[Empty name]" NAME="Chiarelli 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-09-25 21:12:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiarelli F, Tumini S, Morgese G, Albisser AM</AU>
<TI>Controlled study in diabetic children comparing insulin-dosage adjustment by manual and computer algorithms</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>10</NO>
<PG>1080-
4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2007" MODIFIED="2013-09-25 21:13:13 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 21:13:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Clin Endocrinol Metab Cohen P Rogol AD Howard CP Bright GM Kappelgaard AM Rosenfeld RG American Norditropin Study Group Comment in: Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):682-3; PMID: 17667897, Comment in: J Clin Endocrinol Metab. 2007 Jul;92(7):2436-8; PMID: 17616638&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:13:13 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard A-M, Rosenfeld RG, et al</AU>
<TI>Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2007</YR>
<VL>92</VL>
<NO>7</NO>
<PG>2480-6</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0021-972X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2004" MODIFIED="2013-09-25 21:13:28 +0200" MODIFIED_BY="[Empty name]" NAME="Collins 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-25 21:13:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:13:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins CD, Pedersen CA, Schneider PJ, Miller AS, Sierawski SJ, Roux RK</AU>
<TI>Effect on amphotericin B lipid complex use of a clinical decision support system for computerized prescriber order entry</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>13</NO>
<PG>1395-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1079-2082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cupissol-1996" MODIFIED="2013-11-04 13:00:41 +0100" MODIFIED_BY="[Empty name]" NAME="Cupissol 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-04 13:00:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Validation d'un nouveau logiciel interactif int&amp;#8218;gr&amp;#8218; &amp;#8230; une pompe &amp;#8230; d&amp;#8218;bit contrl&amp;#8218; et permettant l'adjustement de posologie du cisplatine en temps r&amp;#8218;el PUBMED 8869047 Clinical Trial Comparative Study Controlled Clinical Trial English Abstract Journal Article Research Support, Non-U.S. Gov't Review Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/883/CN-00131883/frame.html Coch1.5 Cochrane ID: CN-00131883&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:00:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cupissol D, Br&#352;S J, Gestin-Boyer C, Nouguier-Soul&#8218; J, Vian L, Tep A, et al</AU>
<TI>Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment</TI>
<SO>Bulletin du Cancer</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>8</NO>
<PG>664-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demakis-2000" MODIFIED="2013-11-04 13:00:46 +0100" MODIFIED_BY="[Empty name]" NAME="Demakis 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-04 13:00:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demakis JG, Beauchamp C, Cull WL, Denwood R, Eisen SA, Lofgren R, et al</AU>
<TI>Improving residents' compliance with standards of ambulatory care. Results from the VA Cooperative Study on Computerized Reminders</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>284</VL>
<PG>1411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dillon-1989" MODIFIED="2013-08-06 13:36:16 +0200" MODIFIED_BY="[Empty name]" NAME="Dillon 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-08-06 13:36:16 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NLM full journal name - The Journal of antimicrobial chemotherapy&lt;br&gt;ML1.5-1947-2012 (extra lines which will be added to ML1.6 for subsequent searches)&lt;br&gt;PM: 2693431&lt;/p&gt;" NOTES_MODIFIED="2013-08-06 13:36:16 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dillon KR, Dougherty SH, Casner P, Polly S</AU>
<TI>Individualized pharmacokinetic versus standard dosing of amikacin: a comparison of therapeutic outcomes</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1989</YR>
<VL>24</VL>
<PG>581-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donovan-2010" MODIFIED="2013-09-25 21:14:45 +0200" MODIFIED_BY="[Empty name]" NAME="Donovan 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 21:14:45 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:14:45 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donovan JL, Kanaan AO, Thomson MS, Rochon P, Lee M, Gavendo L, et al</AU>
<TI>Effect of clinical decision support on psychotropic medication prescribing in the long-term care setting</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2010</YR>
<VL>58</VL>
<NO>5</NO>
<PG>1005-7</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0002-8614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doran-2004" MODIFIED="2013-07-28 18:24:47 +0200" MODIFIED_BY="[Empty name]" NAME="Doran 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Med Eng Phys Doran CV Hudson NH Moorhead KT Chase JG Shaw GM Hann CE&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Doran CV, Hudson NH, Moorhead KT, Chase JG, Shaw GM, Hann CE</AU>
<TI>Derivative weighted active insulin control modelling and clinical trials for ICU patients</TI>
<SO>Medical Engineering &amp; Physics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>10</NO>
<PG>855-66</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1350-4533"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dortch-2008" MODIFIED="2013-09-25 21:28:11 +0200" MODIFIED_BY="[Empty name]" NAME="Dortch 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:28:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:28:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dortch MJ, Mowery NT, Ozdas A, Dossett L, Cao H, Collier B, et al</AU>
<TI>A computerized insulin infusion titration protocol improves glucose control with less hypoglycemia compared to a manual titration protocol in a trauma intensive care unit</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>1</NO>
<PG>18-27</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0148-6071"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1998" MODIFIED="2013-09-25 21:28:42 +0200" MODIFIED_BY="[Empty name]" NAME="Evans 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-25 21:28:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;N Engl J Med Evans RS Pestotnik SL Classen DC Clemmer TP Weaver LK Orme JF Jr Lloyd JF Burke JP Comment in: N Engl J Med. 1998 Jun 11;338(24):1775; author reply 1776; PMID: 9625641, Comment in: N Engl J Med. 1998 Jun 11;338(24):1775; author reply 1776; PMID: 9625642, Comment in: N Engl J Med. 1998 Jun 11;338(24):1775; author reply 1776; PMID: 9625643, Comment in: N Engl J Med. 1998 Jun 11;338(24):1775-6; PMID: 9625644, Comment in: N Engl J Med. 1998 Jan 22;338(4):259-60; PMID: 9435335&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:28:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF, et al</AU>
<TI>A computer-assisted management program for antibiotics and other antiinfective agents</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>4</NO>
<PG>232-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1998a" MODIFIED="2013-09-25 21:28:33 +0200" MODIFIED_BY="[Empty name]" NAME="Evans 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-09-25 21:28:33 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;N Engl J Med Evans WE Relling MV Rodman JH Crom WR Boyett JM Pui CH&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:28:33 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH</AU>
<TI>Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>8</NO>
<PG>499-505</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:34:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1999" MODIFIED="2013-09-25 21:28:51 +0200" MODIFIED_BY="[Empty name]" NAME="Evans 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-25 21:28:51 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:28:51 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans RS, Pestotnik SL, Classen DC, Burke JP</AU>
<TI>Evaluation of a computer-assisted antibiotic-dose monitor</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>10</NO>
<PG>1026-31</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1060-0280"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faber-2006" MODIFIED="2013-09-25 21:29:06 +0200" MODIFIED_BY="[Empty name]" NAME="Faber 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 21:29:06 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eur J Haematol Faber E Pytlik R Slaby J Zapletalova J Kozak T Raida L Papajik T Zikesova E Maresova I Hamouzova M Indrak K Trneny M&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:29:06 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida L, et al</AU>
<TI>Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma - 
results of a prospective multicentre controlled trial</TI>
<SO>European Journal of Haematology</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>6</NO>
<PG>493-500</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0902-4441"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldstein-2006" MODIFIED="2013-11-04 13:00:55 +0100" MODIFIED_BY="[Empty name]" NAME="Feldstein 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-04 13:00:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, et al</AU>
<TI>Improved therapeutic monitoring with several interventions. A randomized trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>1848-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fety-1998" MODIFIED="2013-09-25 21:35:02 +0200" MODIFIED_BY="[Empty name]" NAME="Fety 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-25 21:35:02 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clin Cancer Res Fety R Rolland F Barberi-Heyob M Hardouin A Campion L Conroy T Merlin JL Riviere A Perrocheau G Etienne MC Milano G&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:35:02 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, et al</AU>
<TI>Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas</TI>
<SO>Clinical Cancer Research</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>9</NO>
<PG>2039-45</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:34:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1078-0432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Field-2009" MODIFIED="2013-11-04 13:01:02 +0100" MODIFIED_BY="[Empty name]" NAME="Field 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-04 13:01:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;OT - Computerized clinical decision support during medication ordering for long-term care residents with renal insufficiency EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:01:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Field TS, Rochon P, Lee M, Baril JL, Gurwitz JH</AU>
<TI>Computerized clinical decision support during medication ordering for long-term care residents with renal insuf&#64257;ciency</TI>
<SO>Pharmacoepidemiology and Drug Safety (PDS)</SO>
<YR>2009</YR>
<PG>S121-2</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1053-8569"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Field-2009a" MODIFIED="2013-09-25 21:36:28 +0200" MODIFIED_BY="[Empty name]" NAME="Field 2009a" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:36:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Am Med Inform Assoc Field TS Rochon P Lee M Gavendo L Baril JL Gurwitz JH&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:36:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Field TS, Rochon P, Lee M, Gavendo L, Baril JL, Gurwitz JH</AU>
<TI>Computerized clinical decision support during medication ordering for long-term care residents with renal insufficiency</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>4</NO>
<PG>480-5</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1067-5027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fihn-1994" MODIFIED="2013-11-04 13:01:08 +0100" MODIFIED_BY="[Empty name]" NAME="Fihn 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-04 13:01:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fihn SD, McDonell MB, Vermes D, Henikoff JG, Martin DC, Callahan CM, et al</AU>
<TI>A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>3</NO>
<PG>131-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzmaurice-1996" MODIFIED="2013-09-25 21:37:02 +0200" MODIFIED_BY="[Empty name]" NAME="Fitzmaurice 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-25 21:37:02 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Br J Gen Pract Fitzmaurice DA Hobbs FD Murray ET Bradley CP Holder R&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:37:02 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Hobbs FD, Murray ET, Bradley CP, Holder R</AU>
<TI>Evaluation of computerized decision support for oral anticoagulation management based in primary care</TI>
<SO>British Journal of General Practice</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>410</NO>
<PG>533-5</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0960-1643"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzmaurice-1998" MODIFIED="2013-11-04 13:01:15 +0100" MODIFIED_BY="[Empty name]" NAME="Fitzmaurice 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-04 13:01:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Hobbs FD, Murray ET</AU>
<TI>Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic</TI>
<SO>Family Practice</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>2</NO>
<PG>144-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flanders-2009" MODIFIED="2011-10-04 16:50:15 +0200" MODIFIED_BY="[Empty name]" NAME="Flanders 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Flanders SJ Juneja R Roudebush CP Carroll J Golas A Elias BL&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Flanders SJ, Juneja R, Roudebush CP, Carroll J, Golas A, Elias BL</AU>
<TI>Glycemic control and insulin safety: the impact of computerized intravenous insulin dosing</TI>
<SO>American Journal of Medical Quality</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>6</NO>
<PG>489-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fritsch-2009" MODIFIED="2013-09-25 21:38:12 +0200" MODIFIED_BY="[Empty name]" NAME="Fritsch 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:38:12 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Paediatr Anaesth Fritsch N Nouette-Gaulain K Bordes M Semjen F Meymat Y Cros AM&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:38:12 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritsch N, Nouette-Gaulain K, Bordes M, Semjen F, Meymat Y, Cros A-M</AU>
<TI>Target-controlled inhalation induction with sevoflurane in children: a prospective pilot study</TI>
<SO>Paediatric Anaesthesia</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>2</NO>
<PG>126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukudo-2009" MODIFIED="2013-11-04 13:01:22 +0100" MODIFIED_BY="[Empty name]" NAME="Fukudo 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-04 13:01:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Clin Pharmacol Fukudo M Yano I Shinsako K Katsura T Takada Y Uemoto S Inui K&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:01:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukudo M, Yano I, Shinsako K, Katsura T, Takada Y, Uemoto S, et al</AU>
<TI>Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>7</NO>
<PG>789-97</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0091-2700"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamelin-2008" MODIFIED="2013-09-25 21:38:56 +0200" MODIFIED_BY="[Empty name]" NAME="Gamelin 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:38:56 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Clin Oncol Gamelin E Delva R Jacob J Merrouche Y Raoul JL Pezet D Dorval E Piot G Morel A Boisdron-Celle M Comment in: J Clin Oncol. 2008 May 1;26(13):2078-9; PMID: 18445837&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:38:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al</AU>
<TI>Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>13</NO>
<PG>2099-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghazal_x002d_Aswad-1997" MODIFIED="2013-11-04 13:01:30 +0100" MODIFIED_BY="[Empty name]" NAME="Ghazal-Aswad 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-04 13:01:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AN - CN-00218410 Cochrane Cancer Network (This is a Cochrane field not group) Cochrane Gynaecological Cancer Group&lt;br&gt;Coch-Jan 2012-searched all years; these results are from 2 lines added to version 1.5 of strategy&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:01:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghazal-Aswad S, Highley M, Bailey N, Lind M, Siddiqui N, Sinha DP, et al</AU>
<TI>A randomised phase III study to compare the toxicity and efficacy of carboplatin given by pharmacokinetically guided formula compared to conventional dosing in epithelial ovarian cancer</TI>
<SO>Acta Obstetrica et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gopakumaran-2004" MODIFIED="2013-11-04 13:01:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gopakumaran 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-11-04 13:01:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:01:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gopakumaran B</AU>
<TI>"Intelligent dosing system": a useful computer program for diabetes management?</TI>
<SO>Diabetes Technology and Therapeutics</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>3</NO>
<PG>336-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1520-9156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffey-2012" MODIFIED="2012-12-12 16:51:57 +0100" MODIFIED_BY="[Empty name]" NAME="Griffey 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-12-12 16:51:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NLM full journal name - Journal of the American Medical Informatics Association : JAMIA&lt;br&gt;ML1.5-Jan2012&lt;br&gt;PM: 22052899&lt;/p&gt;" NOTES_MODIFIED="2012-12-12 16:51:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffey R T, Lo H G, Burdick E, Keohane C, Bates D W</AU>
<TI>Guided medication dosing for elderly emergency patients using real-time, computerized decision support</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2012</YR>
<VL>19</VL>
<PG>86-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guarracino-2001" MODIFIED="2013-09-25 21:39:41 +0200" MODIFIED_BY="[Empty name]" NAME="Guarracino 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-25 21:39:41 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minerva Anestesiol Guarracino F De Cosmo D Penzo D Tedesco M Bossi A Zussa C Polesel E De Stefani R&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:39:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guarracino F, De Cosmo D, Penzo D, Tedesco M, Bossi A, Zussa C, et al</AU>
<TI>Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass</TI>
<SO>Minerva Anestesiologica</SO>
<YR>2001</YR>
<VL>67</VL>
<NO>4</NO>
<PG>165-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0375-9393"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guarracino-2003" MODIFIED="2013-09-25 21:39:50 +0200" MODIFIED_BY="[Empty name]" NAME="Guarracino 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 21:39:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eur J Anaesthesiol Guarracino F Penzo D De Cosmo D Vardanega A De Stefani R&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:39:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guarracino F, Penzo D, De Cosmo D, Vardanega A, De Stefani R</AU>
<TI>Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>5</NO>
<PG>385-90</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0265-0215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermayer-2007" MODIFIED="2013-09-25 21:40:05 +0200" MODIFIED_BY="[Empty name]" NAME="Hermayer 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 21:40:05 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Diabetes Technol Ther Hermayer KL Neal DE Hushion TV Irving MG Arnold PC Kozlowski L Stroud MR Kerr FB Kratz JM&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:40:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermayer KL, Neal DE, Hushion TV, Irving MG, Arnold PC, Kozlowski L, et al</AU>
<TI>Outcomes of a cardiothoracic intensive care web-based online intravenous insulin infusion calculator study at a Medical University Hospital</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>6</NO>
<PG>523-34</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1520-9156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hobbs-1996" MODIFIED="2013-09-25 21:40:19 +0200" MODIFIED_BY="[Empty name]" NAME="Hobbs 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-25 21:40:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hobbs FD, Delaney BC, Carson A, Kenkre JE</AU>
<TI>A prospective controlled trial of computerized decision support for lipid management in primary care</TI>
<SO>Family Practice</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>2</NO>
<PG>133-
7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-2004" MODIFIED="2013-09-25 21:40:35 +0200" MODIFIED_BY="[Empty name]" NAME="Hoffman 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-25 21:40:35 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Clin Endocrinol Metab Hoffman AR Strasburger CJ Zagar A Blum WF Kehely A Hartman ML T002 Study Group&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:40:35 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML, et al</AU>
<TI>Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>7</NO>
<PG>3224-33</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0021-972X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horn-2002" MODIFIED="2013-11-04 13:01:45 +0100" MODIFIED_BY="[Empty name]" NAME="Horn 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-04 13:01:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horn W, Popow C, Miksch S, Kirchner L, Seyfang A</AU>
<TI>Development and evaluation of VIE-PNN, a knowledge-based system for calculating the parenteral nutrition of newborn infants</TI>
<SO>Artificial Intelligence in Medicine</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>217-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-2004" MODIFIED="2013-09-25 21:41:05 +0200" MODIFIED_BY="[Empty name]" NAME="Hwang 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-25 21:41:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang HG, Chang IC, Hung WF, Sung ML, Yen D</AU>
<TI>The design and evaluation of clinical decision support systems in the area of pharmacokinetics</TI>
<SO>Medical Informatics and the Internet in Medicine</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3-4</NO>
<PG>239
-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jankovic-1999" MODIFIED="2013-09-25 21:41:18 +0200" MODIFIED_BY="[Empty name]" NAME="Jankovic 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-25 21:41:18 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eur J Drug Metab Pharmacokinet Jankovic SM Timotijevic I Mihajlovic GS Dukic-Dejanovic S&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:41:18 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic SM, Timotijevic I, Mihajlovic GS, Dukic-Dejanovic S</AU>
<TI>Comparison of two approaches to amitriptyline dose individualisation</TI>
<SO>European Journal of Drug Metabolism &amp; Pharmacokinetics</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0398-7639"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jannuzzi-2000" MODIFIED="2013-09-25 21:42:50 +0200" MODIFIED_BY="[Empty name]" NAME="Jannuzzi 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-25 21:42:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Epilepsia Jannuzzi G Cian P Fattore C Gatti G Bartoli A Monaco F Perucca E Comment in: Epilepsia. 2000 Jul;41(7):919-20; PMID: 10897170&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:42:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, et al</AU>
<TI>A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy</TI>
<SO>Epilepsia</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>2</NO>
<PG>222-30</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0013-9580"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jellinek-2005" MODIFIED="2013-09-25 21:43:01 +0200" MODIFIED_BY="[Empty name]" NAME="Jellinek 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 21:43:01 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:43:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jellinek SP, Cohen V, Likourezos A, Goldman WM, Lashley EL</AU>
<TI>Analyzing a health-system's use of unfractionated heparin to ensure optimal anticoagulation</TI>
<SO>Journal of Pharmacy Technology</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>2</NO>
<PG>69-78</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="8755-1225"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judge-2006" MODIFIED="2012-12-12 16:59:52 +0100" MODIFIED_BY="[Empty name]" NAME="Judge 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-12-12 16:59:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Judge, James&lt;br&gt;Field, Terry S&lt;br&gt;DeFlorio, Martin&lt;br&gt;Laprino, Jane&lt;br&gt;Auger, Jill&lt;br&gt;Rochon, Paula&lt;br&gt;Bates, David W&lt;br&gt;Gurwitz, Jerry H&lt;br&gt;HS010481/HS/AHRQ HHS/United States&lt;br&gt;HS15430/HS/AHRQ HHS/United States&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United States&lt;br&gt;Journal of the American Medical Informatics Association : JAMIA&lt;br&gt;J Am Med Inform Assoc. 2006 Jul-Aug;13(4):385-90. Epub 2006 Apr 18.&lt;/p&gt;" NOTES_MODIFIED="2012-12-12 16:59:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Judge J, Field T S, DeFlorio M, Laprino J, Auger J, Rochon P, et al</AU>
<TI>Prescribers' responses to alerts during medication ordering in the long term care setting</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2009" MODIFIED="2011-11-08 17:34:05 +0100" MODIFIED_BY="[Empty name]" NAME="Jung 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-08 17:34:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eur Jung H Land C Nicolay C De Schepper J Blum WF Schonau E&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 17:34:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schonau E</AU>
<TI>Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study</TI>
<SO>European Journal of Endocrinology</SO>
<YR>2009</YR>
<VL>160</VL>
<NO>2</NO>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazemi-2011" MODIFIED="2013-09-25 21:43:36 +0200" MODIFIED_BY="[Empty name]" NAME="Kazemi 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-25 21:43:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:43:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazemi A, Ellenius J, Pourasghar F, Tofighi S, Salehi A, Amanati A, et al</AU>
<TI>The effect of computerized physician order entry and decision support system on medication errors in the neonatal ward: e
xperiences from an Iranian teaching hospital</TI>
<SO>Journal of Medical Systems</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>1</NO>
<PG>25-37</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0148-5598"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirk-2005" MODIFIED="2013-09-25 21:43:49 +0200" MODIFIED_BY="[Empty name]" NAME="Kirk 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 21:43:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Drug Saf Kirk RC Li-Meng Goh D Packia J Min Kam H Ong BK&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:43:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirk RC, Li-Meng Goh D, Packia J, Min Kam H, Ong BKC</AU>
<TI>Computer calculated dose in paediatric prescribing</TI>
<SO>Drug Safety</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>9</NO>
<PG>817-24</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0114-5916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koide-2000" MODIFIED="2013-11-07 09:47:53 +0100" MODIFIED_BY="[Empty name]" NAME="Koide 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-07 09:47:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koide D, Ohe K, Ross-Degnan D, Kaihara S</AU>
<TI>Computerized reminders to monitor liver function to improve the use of etretinate</TI>
<SO>International Journal of Medical Informatics</SO>
<YR>2000</YR>
<VL>57</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristrom-2009" MODIFIED="2013-09-25 21:45:49 +0200" MODIFIED_BY="[Empty name]" NAME="Kristrom 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:45:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Clin Endocrinol Metab Kristrom B Aronson AS Dahlgren J Gustafsson J Halldin M Ivarsson SA Nilsson NO Svensson J Tuvemo T Albertsson-Wikland K&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:45:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristrom B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, et al</AU>
<TI>Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2009</YR>
<VL>94</VL>
<NO>2</NO>
<PG>483-90</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0021-972X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kroese-2005" MODIFIED="2013-09-25 21:46:07 +0200" MODIFIED_BY="[Empty name]" NAME="Kroese 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 21:46:07 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kroese WL Avery AJ Savelyich BS Brown NS Schers H Howard R Hippisley-Cox J Horsfield P&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:46:07 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kroese WLG, Avery AJ, Savelyich BSP, Brown NS, Schers H, Howard R, et al</AU>
<TI>Assessing the accuracy of a computerized decision support system for digoxin dosing in primary care: an observational study</TI>
<SO>Journal of Clinical Pharmacy &amp; Therapeutics</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>3</NO>
<PG>279-83</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0269-4727"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-la-Cour-Freiesleben-2009" MODIFIED="2013-09-25 21:46:21 +0200" MODIFIED_BY="[Empty name]" NAME="la Cour Freiesleben 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:46:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hum Reprod la Cour Freiesleben N Lossl K Bogstad J Bredkjaer HE Toft B Rosendahl M Loft A Bangsboll S Pinborg A Nyboe Andersen A&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:46:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Rosendahl M, et al</AU>
<TI>Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study</TI>
<SO>Human Reproduction</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>10</NO>
<PG>2523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lester-2006" MODIFIED="2013-11-04 13:02:01 +0100" MODIFIED_BY="[Empty name]" NAME="Lester 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-04 13:02:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lester WT, Grant RW, Barnett GO, Chueh HC</AU>
<TI>Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>22-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ligtenberg-2006" MODIFIED="2013-11-04 13:02:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ligtenberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-04 13:02:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ligtenberg JJ, Meertens JH, Monteban-Kooistra WE, Tulleken JE, Zijlstra JG</AU>
<TI>Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients: response to Plank et al</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>8</NO>
<PG>1987-8</PG>
<IDENTIFIERS MODIFIED="2011-12-21 17:37:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-21 17:35:24 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lillis-2003" MODIFIED="2013-09-25 21:48:44 +0200" MODIFIED_BY="[Empty name]" NAME="Lillis 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 21:48:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lillis K&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:48:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lillis K</AU>
<TI>Automated dosing. Computerized physician order entry reduces risk of medication and dosing errors in neonatal ICU</TI>
<SO>Health Management Technology</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>11</NO>
<PG>36-7</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1074-4770"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2013-11-04 13:02:15 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-04 13:02:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:02:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, et al</AU>
<TI>Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control. A prospective, randomized, multicenter study</TI>
<SO>Anesthesiology</SO>
<YR>2006</YR>
<VL>104</VL>
<NO>4</NO>
<PG>686-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0003-3022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manotti-2001--maintenance" MODIFIED="2013-09-26 17:57:39 +0200" MODIFIED_BY="[Empty name]" NAME="Manotti 2001  maintenance" YEAR="2001">
<REFERENCE MODIFIED="2013-09-26 17:57:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG</AU>
<TI>Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment)</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>10</NO>
<PG>1060-
70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mar-Fernandez-1996" MODIFIED="2013-09-25 21:49:36 +0200" MODIFIED_BY="[Empty name]" NAME="Mar Fernandez 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-25 21:49:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clin Pharmacol Ther Fernandez de Gatta MD Calvo MV Hernandez JM Caballero D San Miguel JF Dominguez-Gil A&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:49:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A</AU>
<TI>Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1996</YR>
<VL>60</VL>
<NO>3</NO>
<PG>332-40</PG>
<IDENTIFIERS MODIFIED="2011-11-08 17:34:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0009-9236"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mar-Fernandez-2009" MODIFIED="2013-09-25 21:49:48 +0200" MODIFIED_BY="[Empty name]" NAME="Mar Fernandez 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 21:49:48 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Pharm Pharmacol Mar Fernandez de Gatta MD Victoria Calvo M Ardanuy R Dominguez-Gil A Lanao JM Moreno SR&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:49:48 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mar Fernandez de Gatta MD, Victoria Calvo M, Ardanuy R, Dominguez-Gil A, Lanao JM, Moreno SR</AU>
<TI>Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients</TI>
<SO>Journal of Pharmacy &amp; Pharmacology</SO>
<YR>2009</YR>
<VL>61</VL>
<NO>6</NO>
<PG>759-66</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0022-3573"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matheny-2008" MODIFIED="2013-09-25 21:50:04 +0200" MODIFIED_BY="[Empty name]" NAME="Matheny 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 21:50:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Matheny, Michael E&lt;br&gt;Sequist, Thomas D&lt;br&gt;Seger, Andrew C&lt;br&gt;Fiskio, Julie M&lt;br&gt;Sperling, Michael&lt;br&gt;Bugbee, Don&lt;br&gt;Bates, David W&lt;br&gt;Gandhi, Tejal K&lt;br&gt;1-T15-LM-07092/LM/NLM NIH HHS/United States&lt;br&gt;5-U18-HS-011046/HS/AHRQ HHS/United States&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, N.I.H., Extramural&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United States&lt;br&gt;Journal of the American Medical Informatics Association : JAMIA&lt;br&gt;J Am Med Inform Assoc. 2008 Jul-Aug;15(4):424-9. Epub 2008 Apr 24.&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:50:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matheny ME, Sequist TD, Seger AC, Fiskio JM, Sperling M, Bugbee D, et al</AU>
<TI>A randomized trial of electronic clinical reminders to improve medication laboratory monitoring</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>424-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurizi-2011" MODIFIED="2013-11-04 13:02:39 +0100" MODIFIED_BY="[Empty name]" NAME="Maurizi 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-04 13:02:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NLM full journal name - Diabetes technology &amp;amp; therapeutics&lt;br&gt;ML1.5-Jan2012&lt;br&gt;PM: 21355727&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:02:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurizi AR, Lauria A, Maggi D, Palermo A, Fioriti E, Manfrini S, et al</AU>
<TI>A novel insulin unit calculator for the management of type 1 diabetes</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>13</VL>
<PG>425-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCluggage-2010" MODIFIED="2013-09-25 21:50:38 +0200" MODIFIED_BY="[Empty name]" NAME="McCluggage 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 21:50:38 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;McCluggage L Lee K Potter T Dugger R Pakyz A&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:50:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCluggage L, Lee K, Potter T, Dugger R, Pakyz A</AU>
<TI>Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2010</YR>
<VL>67</VL>
<NO>1</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCowan-2001" MODIFIED="2013-11-04 13:02:26 +0100" MODIFIED_BY="[Empty name]" NAME="McCowan 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-11-04 13:02:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCowan C, Neville RG, Ricketts IW, Warner FC, Hoskins G, Thomas GE</AU>
<TI>Lessons from a randomized controlled trial designed to evaluate computer decision support software to improve the management of asthma</TI>
<SO>Medical Informatics and the Internet in Medicine</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>191-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCoy-2008" MODIFIED="2013-11-04 13:02:33 +0100" MODIFIED_BY="[Empty name]" NAME="McCoy 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-04 13:02:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AMIA Annu Symp Proc McCoy AB Peterson JF Gadd CS Danciu I Waitman LR&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:02:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McCoy AB, Peterson JF, Gadd CS, Danciu I, Waitman LR</AU>
<TI>A system to improve medication safety in the setting of acute kidney injury: initial provider response</TI>
<SO>Annual Symposium Proceedings/AMIA Symposium</SO>
<YR>2008</YR>
<PG>1051</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCoy-2010" MODIFIED="2013-09-25 21:52:46 +0200" MODIFIED_BY="[Empty name]" NAME="McCoy 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 21:52:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Am J Kidney Dis McCoy AB Waitman LR Gadd CS Danciu I Smith JP Lewis JB Schildcrout JS Peterson JF Comment in: Am J Kidney Dis. 2010 Nov;56(5):809-12; PMID: 20970021&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:52:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCoy AB, Waitman LR, Gadd CS, Danciu I, Smith JP, Lewis JB, et al</AU>
<TI>A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>5</NO>
<PG>832-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDonald-1976" MODIFIED="2013-09-26 17:58:14 +0200" MODIFIED_BY="[Empty name]" NAME="McDonald 1976" YEAR="1976">
<REFERENCE MODIFIED="2013-09-26 17:58:14 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mc Donald, C J&lt;br&gt;United states&lt;br&gt;Annals of internal medicine&lt;br&gt;Ann Intern Med. 1976 Feb;84(2):162-7.&lt;/p&gt;" NOTES_MODIFIED="2013-09-26 17:58:14 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDonald CJ</AU>
<TI>Use of a computer to detect and respond to clinical events: its effect on clinician behavior</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1976</YR>
<VL>84</VL>
<NO>2</NO>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDonald-1980" MODIFIED="2013-11-04 13:02:48 +0100" MODIFIED_BY="[Empty name]" NAME="McDonald 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-11-04 13:02:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDonald CJ, Wilson GA, McCabe GP, Jr</AU>
<TI>Physician response to computer reminders</TI>
<SO>JAMA</SO>
<YR>1980</YR>
<VL>244</VL>
<NO>14</NO>
<PG>1579-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMichael-1993" MODIFIED="2013-11-04 13:02:55 +0100" MODIFIED_BY="[Empty name]" NAME="McMichael 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-04 13:02:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMichael J, Lieberman R, Doyle H, McCauley J, Fung J, Starzl TE</AU>
<TI>An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>7</NO>
<PG>599-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMullin-1997" MODIFIED="2013-09-25 21:58:29 +0200" MODIFIED_BY="[Empty name]" NAME="McMullin 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-25 21:58:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Am J Health-Syst Pharm McMullin ST Reichley RM Kahn MG Dunagan WC Bailey TC&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:58:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMullin ST, Reichley RM, Kahn MG, Dunagan WC, Bailey TC</AU>
<TI>Automated system for identifying potential dosage problems at a large university hospital</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>5</NO>
<PG>545-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1079-2082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMullin-2004" MODIFIED="2011-10-04 16:53:54 +0200" MODIFIED_BY="[Empty name]" NAME="McMullin 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ann Fam Med McMullin ST Lonergan TP Rynearson CS Doerr TD Veregge PA Scanlan ES&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McMullin ST, Lonergan TP, Rynearson CS, Doerr TD, Veregge PA, Scanlan ES</AU>
<TI>Impact of an evidence-based computerized decision support system on primary care prescription costs</TI>
<SO>Annals of Family Medicine</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>5</NO>
<PG>494-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1544-1709"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMullin-2005" MODIFIED="2013-09-25 21:58:38 +0200" MODIFIED_BY="[Empty name]" NAME="McMullin 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 21:58:38 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Manage Care Pharm McMullin ST Lonergan TP Rynearson CS Comment in: J Manag Care Pharm. 2005 May;11(4):353-5, 356-7; PMID: 15871649&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:58:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMullin ST, Lonergan TP, Rynearson CS</AU>
<TI>Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>322-32</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1083-4087"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motykie-1999" MODIFIED="2013-09-25 21:59:09 +0200" MODIFIED_BY="[Empty name]" NAME="Motykie 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-25 21:59:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Arthroplasty Motykie GD Mokhtee D Zebala LP Caprini JA Kudrna JC Mungall DR&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:59:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motykie GD, Mokhtee D, Zebala LP, Caprini JA, Kudrna JC, Mungall DR</AU>
<TI>The use of a Bayesian forecasting model in the management of warfarin therapy after total hip arthroplasty</TI>
<SO>Journal of Arthroplasty</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>8</NO>
<PG>988-93</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0883-5403"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullett-2001" MODIFIED="2013-09-25 21:59:22 +0200" MODIFIED_BY="[Empty name]" NAME="Mullett 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-25 21:59:22 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pediatrics Mullett CJ Evans RS Christenson JC Dean JM&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 21:59:22 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mullett CJ, Evans RS, Christenson JC, Dean JM</AU>
<TI>Development and impact of a computerized pediatric antiinfective decision support program</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>4</NO>
<PG>E75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murchie-1989" MODIFIED="2013-09-25 21:59:39 +0200" MODIFIED_BY="[Empty name]" NAME="Murchie 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-09-25 21:59:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murchie CJ, Kenny GN</AU>
<TI>Comparison among manual, computer-assisted, and closed-loop control of blood pressure after cardiac surgery</TI>
<SO>Journal of Cardiothoracic Anesthesia</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>1</NO>
<PG>16-
19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nash-2005" MODIFIED="2013-09-25 22:00:04 +0200" MODIFIED_BY="[Empty name]" NAME="Nash 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 22:00:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nash IS Rojas M Hebert P Marrone SR Colgan C Fisher LA Caliendo G Chassin MR&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:00:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nash IS, Rojas M, Hebert P, Marrone SR, Colgan C, Fisher LA, et al</AU>
<TI>Reducing excessive medication administration in hospitalized adults with renal dysfunction</TI>
<SO>American Journal of Medical Quality</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>64-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1062-8606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newby-2002" MODIFIED="2013-09-25 22:00:25 +0200" MODIFIED_BY="[Empty name]" NAME="Newby 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-25 22:00:25 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Thromb Thrombolysis Newby LK Harrington RA Bhapkar MV Van de Werf F Hochman JS Granger CB Simes RJ Davis CG Topol EJ Califf RM Moliterno DJ PARAGON A Investigators&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:00:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, et al</AU>
<TI>An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A</TI>
<SO>Journal of Thrombosis &amp; Thrombolysis</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>1</NO>
<PG>33-42</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0929-5305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nieuwenhuyze-1995" MODIFIED="2013-11-05 11:30:46 +0100" MODIFIED_BY="[Empty name]" NAME="Nieuwenhuyze 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-11-05 11:30:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Nieuwenhuyzen MC, Engbers FH, Burm AG, Vletter AA, van Kleef JW, Bovill JG</AU>
<TI>Computer-controlled infusion of alfentanil versus patient-controlled administration of morphine for postoperative analgesia: a double-blind randomized trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1995</YR>
<VL>81</VL>
<NO>4</NO>
<PG>671-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nightingale-2000" MODIFIED="2013-11-07 09:38:56 +0100" MODIFIED_BY="[Empty name]" NAME="Nightingale 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-07 09:38:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nightingale PG, Adu D, Richards NT, Peters M</AU>
<TI>Implementation of rules based computerised bedside prescribing and administration: intervention study</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>320</VL>
<NO>7237</NO>
<PG>750-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oppenheim-2002" MODIFIED="2013-11-04 13:03:06 +0100" MODIFIED_BY="[Empty name]" NAME="Oppenheim 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-04 13:03:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Oppenheim MI Vidal C Velasco FT Boyer AG Cooper MR Hayes JG Frayer WW&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:03:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oppenheim MI, Vidal C, Velasco FT, Boyer AG, Cooper MR, Hayes JG, et al</AU>
<TI>Impact of a computerized alert during physician order entry on medication dosing in patients with renal impairment</TI>
<SO>Proceedings/AMIA Annual Symposium</SO>
<YR>2002</YR>
<PG>577-81</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1531-605X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overhage-1997" MODIFIED="2013-09-25 22:01:41 +0200" MODIFIED_BY="[Empty name]" NAME="Overhage 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-25 22:01:41 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Overhage, J M&lt;br&gt;Tierney, W M&lt;br&gt;Zhou, X H&lt;br&gt;McDonald, C J&lt;br&gt;HS 05626/HS/AHRQ HHS/United States&lt;br&gt;HS 07719/HS/AHRQ HHS/United States&lt;br&gt;N01-LM-3-3410/LM/NLM NIH HHS/United States&lt;br&gt;Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United states&lt;br&gt;Journal of the American Medical Informatics Association : JAMIA&lt;br&gt;J Am Med Inform Assoc. 1997 Sep-Oct;4(5):364-75.&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:01:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overhage JM, Tierney WM, Zhou XH, McDonald CJ</AU>
<TI>A randomized trial of "corollary orders" to prevent errors of omission</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>364-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palen-2006" MODIFIED="2013-11-07 09:39:04 +0100" MODIFIED_BY="[Empty name]" NAME="Palen 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-07 09:39:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palen TE, Raebel M, Lyons E, Magid DM</AU>
<TI>Evaluation of laboratory monitoring alerts within a computerized physician order entry system for medication orders</TI>
<SO>American Journal of Managed Care</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pea-2002" MODIFIED="2013-09-25 22:04:09 +0200" MODIFIED_BY="[Empty name]" NAME="Pea 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-25 22:04:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Int J Antimicrob Agents Pea F Bertolissi M Di Silvestre A Poz D Giordano F Furlanut M&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:04:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M</AU>
<TI>TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5</NO>
<PG>326-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0924-8579"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peck-1973" MODIFIED="2013-11-07 09:39:09 +0100" MODIFIED_BY="[Empty name]" NAME="Peck 1973" YEAR="1973">
<REFERENCE MODIFIED="2013-11-07 09:39:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peck CC, Sheiner LB, Martin CM, Combs DT, Melmon KL</AU>
<TI>Computer-assisted digoxin therapy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1973</YR>
<VL>289</VL>
<NO>9</NO>
<PG>441-6</PG>
<IDENTIFIERS MODIFIED="2013-07-21 18:28:05 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-21 18:28:20 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1996" MODIFIED="2013-11-04 13:03:11 +0100" MODIFIED_BY="[Empty name]" NAME="Peters 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-04 13:03:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters A, Kerner W</AU>
<TI>Analytical design and clinical application of an intelligent control system for insulin treatment</TI>
<TO>Analytisches Design und klinische Anwendung eineslernfähigen Regelsystems für die Pharmakotherapie mit Insulin</TO>
<SO>Biomedizinische Technik</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>1-2</NO>
<PG>2-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-1986" MODIFIED="2013-09-25 22:05:17 +0200" MODIFIED_BY="[Empty name]" NAME="Peterson 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-25 22:05:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peterson CM, Jovanovic L, Chanoch LH</AU>
<TI>Randomized trial of computer-assisted insulin delivery in patients with type I diabetes beginning pump therapy</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>81</VL>
<NO>1</NO>
<PG>69
-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2005" MODIFIED="2013-09-25 22:05:31 +0200" MODIFIED_BY="[Empty name]" NAME="Peterson 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 22:05:31 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Arch Intern Med Peterson JF Kuperman GJ Shek C Patel M Avorn J Bates DW&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:05:31 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peterson JF, Kuperman GJ, Shek C, Patel M, Avorn J, Bates DW</AU>
<TI>Guided prescription of psychotropic medications for geriatric inpatients</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>7</NO>
<PG>802-7</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2007" MODIFIED="2013-09-25 22:05:49 +0200" MODIFIED_BY="[Empty name]" NAME="Peterson 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:05:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Stud Health Technol Inform Peterson JF Rosenbaum BP Waitman LR Habermann R Powers J Harrell D Miller RA&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:05:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peterson JF, Rosenbaum BP, Waitman LR, Habermann R, Powers J, Harrell D, et al</AU>
<TI>Physicians' response to guided geriatric dosing: initial results from a randomized trial</TI>
<SO>Studies in Health Technology &amp; Informatics</SO>
<YR>2007</YR>
<VL>129</VL>
<NO>Pt 2</NO>
<PG>1037-40</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0926-9630"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-2008" MODIFIED="2011-10-04 16:54:20 +0200" MODIFIED_BY="[Empty name]" NAME="Phillips 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Phillips IE Nelsen C Peterson J Sullivan TM Waitman LR&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Phillips IE, Nelsen C, Peterson J, Sullivan TM, Waitman LR</AU>
<TI>Improving aminoglycoside dosing through computerized clinical decision support and pharmacy therapeutic monitoring systems</TI>
<SO>AMIA</SO>
<YR>2008</YR>
<VL>Annual Symposium Proceedings/AMIA Symposium.</VL>
<PG>1093</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piazza-2009" MODIFIED="2013-11-04 13:03:19 +0100" MODIFIED_BY="[Empty name]" NAME="Piazza 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-04 13:03:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:03:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Piazza G, Goldhaber SZ</AU>
<TI>Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>120</VL>
<NO>12</NO>
<PG>1133-7</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poller-1993" MODIFIED="2013-08-06 13:38:00 +0200" MODIFIED_BY="[Empty name]" NAME="Poller 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-08-06 13:38:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Wright D, Rowlands M</AU>
<TI>Prospective comparative study of computer programs used for management of warfarin</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>4</NO>
<PG>299&#8211;303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popovic_x002d_Todorovic-2003" MODIFIED="2013-09-25 22:06:20 +0200" MODIFIED_BY="[Empty name]" NAME="Popovic-Todorovic 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 22:06:20 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hum Reprod Popovic-Todorovic B Loft A Bredkjaeer HE Bangsboll S Nielsen IK Andersen AN&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:06:20 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN</AU>
<TI>A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>11</NO>
<PG>2275-82</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0268-1161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Proost-2003" MODIFIED="2013-09-25 22:06:32 +0200" MODIFIED_BY="[Empty name]" NAME="Proost 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 22:06:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - Germany EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:06:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Proost JH, Punt NC</AU>
<TI>Dose individualization in PharmDIS-e+</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>10</NO>
<PG>451-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0946-1965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-2010" MODIFIED="2011-10-04 16:54:41 +0200" MODIFIED_BY="[Empty name]" NAME="Roberts 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Am Med Inform Assoc Roberts GW Farmer CJ Cheney PC Govis SM Belcher TW Walsh SA Adams RJ&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Roberts GW, Farmer CJ, Cheney PC, Govis SM, Belcher TW, Walsh SA, et al</AU>
<TI>Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>3</NO>
<PG>308-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rochon-2006" MODIFIED="2013-09-25 22:06:57 +0200" MODIFIED_BY="[Empty name]" NAME="Rochon 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 22:06:57 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - Canada EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:06:57 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rochon PA, Field TS, Bates DW, Lee M, Gavendo L, Erramuspe-Mainard J, et al</AU>
<TI>Clinical application of a computerized system for physician order entry with clinical decision support to prevent adverse drug events in long-term care</TI>
<SO>CMAJ</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>1</NO>
<PG>52-4</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0820-3946"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rood-2005" MODIFIED="2013-09-25 22:07:11 +0200" MODIFIED_BY="[Empty name]" NAME="Rood 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 22:07:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Am Med Inform Assoc Rood E Bosman RJ van der Spoel JI Taylor P Zandstra DF&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:07:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rood E, Bosman RJ, van der Spoel JI, Taylor P, Zandstra DF</AU>
<TI>Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>2</NO>
<PG>172-80</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1067-5027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothschild-2002" MODIFIED="2011-10-04 16:54:52 +0200" MODIFIED_BY="[Empty name]" NAME="Rothschild 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J Am Med Inform Assoc Rothschild JM Lee TH Bae T Bates DW&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rothschild JM, Lee TH, Bae T, Bates DW</AU>
<TI>Clinician use of a palmtop drug reference guide</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>3</NO>
<PG>223-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1067-5027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothschild-2003" MODIFIED="2013-11-04 13:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Rothschild 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-04 13:03:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AMIA Annu Symp Proc Rothschild JM Keohane CA Thompson S Bates DW&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:03:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rothschild JM, Keohane CA, Thompson S, Bates DW</AU>
<TI>Intelligent intravenous infusion pumps to improve medication administration safety</TI>
<SO>Annual Symposium Proceedings/AMIA Symposium</SO>
<YR>2003</YR>
<PG>992</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothschild-2005" MODIFIED="2011-10-04 16:53:34 +0200" MODIFIED_BY="[Empty name]" NAME="Rothschild 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Crit Care Med Rothschild JM Keohane CA Cook EF Orav EJ Burdick E Thompson S Hayes J Bates DW Comment in: Crit Care Med. 2005 Mar;33(3):679-80; PMID: 15753769&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rothschild JM, Keohane CA, Cook EF, Orav EJ, Burdick E, Thompson S, et al</AU>
<TI>A controlled trial of smart infusion pumps to improve medication safety in critically ill patients</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>3</NO>
<PG>533-40</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0090-3493"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotman-1996" MODIFIED="2013-11-04 13:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Rotman 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-04 13:03:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rotman BL, Sullivan AN, McDonald TW, Brown BW, DeSmedt P, Goodnature D, et al</AU>
<TI>A randomized controlled trial of a computer based physician workstation in an outpatient setting: implementation barriers to outcome evaluation</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>5</NO>
<PG>340-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roumie-2005" MODIFIED="2013-11-04 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Roumie 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-04 13:03:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, et al</AU>
<TI>Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>145</VL>
<PG>165-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz-1993" MODIFIED="2011-11-08 18:17:05 +0100" MODIFIED_BY="[Empty name]" NAME="Ruiz 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-11-08 18:17:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz R, Borches D, Gonzalez A, Corral J</AU>
<TI>A new sodium-nitroprusside-infusion controller for the regulation of arterial blood pressure</TI>
<SO>Biomedical Instrumentation &amp; Technology</SO>
<YR>1993</YR>
<VL>27</VL>
<NO>3</NO>
<PG>244-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryff_x002d_de-Leche-1992" MODIFIED="2013-11-07 09:39:21 +0100" MODIFIED_BY="[Empty name]" NAME="Ryff-de Leche 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-11-07 09:39:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryff-de Leche A, Engler H, Nutzi E, Berger M, Berger W</AU>
<TI>Clinical application of two computerized diabetes management systems: comparison with the log-book method</TI>
<SO>Diabetes Research</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>3</NO>
<PG>97-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana-2003" MODIFIED="2013-09-25 22:10:12 +0200" MODIFIED_BY="[Empty name]" NAME="Santana 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-25 22:10:12 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Santana VM Zamboni WC Kirstein MN Tan M Liu T Gajjar A Houghton PJ Stewart CF&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:10:12 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, et al</AU>
<TI>A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors</TI>
<SO>Clinical Cancer Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>2</NO>
<PG>633-40</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1078-0432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana-2005" MODIFIED="2011-10-04 16:53:40 +0200" MODIFIED_BY="[Empty name]" NAME="Santana 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-10-04 16:36:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Santana VM Furman WL Billups CA Hoffer F Davidoff AM Houghton PJ Stewart CF Comment in: J Clin Oncol. 2005 Jun 20;23(18):4003-5; PMID: 15767649&lt;/p&gt;" NOTES_MODIFIED="2011-10-04 16:36:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, et al</AU>
<TI>Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4039-47</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0732-183X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-2005" MODIFIED="2013-09-25 22:10:39 +0200" MODIFIED_BY="[Empty name]" NAME="Schneider 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 22:10:39 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Schneider BL Gulseth MP Cusick MA Sisson DC Tomsche JJ&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:10:39 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider BL, Gulseth MP, Cusick MA, Sisson DC, Tomsche JJ</AU>
<TI>Computer program to assist pharmacy management of an inpatient warfarin dosing service</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>22</NO>
<PG>2393-6</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1079-2082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schrezenmeir-2002" MODIFIED="2013-09-25 22:10:52 +0200" MODIFIED_BY="[Empty name]" NAME="Schrezenmeir 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-25 22:10:52 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Schrezenmeir J Dirting K Papazov P&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:10:52 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schrezenmeir J, Dirting K, Papazov P</AU>
<TI>Controlled multicenter study on the effect of computer assistance in intensive insulin therapy of type 1 diabetics</TI>
<SO>Computer Methods &amp; Programs in Biomedicine</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>2</NO>
<PG>97-114</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0169-2607"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiach-2002" MODIFIED="2013-11-04 13:03:50 +0100" MODIFIED_BY="[Empty name]" NAME="Shiach 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-04 13:03:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;RCT Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/725/CN-00461725/frame.html Coch1.5 Cochrane ID: CN-00461725&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:03:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiach CR, Campbell B, Poller L, Keown M, Chauhan N</AU>
<TI>Randomised cross-over study of near patient testing versus hospital laboratory testing with computer assisted dosing in a community anticoagulant clinic</TI>
<SO>British Journal of Haematology</SO>
<YR>2002</YR>
<VL>117</VL>
<NO>Suppl 1</NO>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shieh-2006" MODIFIED="2013-09-25 22:11:49 +0200" MODIFIED_BY="[Empty name]" NAME="Shieh 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 22:11:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Shieh JS Fu M Huang SJ Kao MC&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:11:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shieh J-S, Fu M, Huang S-J, Kao M-C</AU>
<TI>Comparison of the applicability of rule-based and self-organizing fuzzy logic controllers for sedation control of intracranial pressure pattern in a neurosurgical intensive care unit</TI>
<SO>IEEE Transactions on Biomedical Engineering</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1700-5</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0018-9294"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soper-2006" MODIFIED="2013-09-25 22:12:08 +0200" MODIFIED_BY="[Empty name]" NAME="Soper 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 22:12:08 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Soper J Chan GT Skinner JR Spinetto HD Gentles TL&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:12:08 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soper J, Chan GTC, Skinner JR, Spinetto HD, Gentles TL</AU>
<TI>Management of oral anticoagulation in a population of children with cardiac disease using a computerised system to support decision-making</TI>
<SO>Cardiology in the Young</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>3</NO>
<PG>256-60</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1047-9511"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparano-2006" MODIFIED="2013-09-25 22:12:30 +0200" MODIFIED_BY="[Empty name]" NAME="Sparano 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-25 22:12:30 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sparano JA&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:12:30 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparano JA</AU>
<TI>TAILORx: trial assigning individualized options for treatment (Rx)</TI>
<SO>Clinical Breast Cancer</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>4</NO>
<PG>347-50</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1526-8209"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strack-1985" MODIFIED="2013-11-07 09:39:28 +0100" MODIFIED_BY="[Empty name]" NAME="Strack 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-07 09:39:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strack T, Bergeler J, Beyer J, Hutten H</AU>
<TI>Computer assisted conventional insulin therapy</TI>
<SO>Life Support Systems</SO>
<YR>1985</YR>
<VL>3 Suppl 1</VL>
<PG>568-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamblyn-2003" MODIFIED="2013-11-04 13:03:57 +0100" MODIFIED_BY="[Empty name]" NAME="Tamblyn 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-04 13:03:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, et al</AU>
<TI>The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care</TI>
<SO>CMAJ</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>6</NO>
<PG>549-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamblyn-2008" MODIFIED="2013-09-25 22:14:16 +0200" MODIFIED_BY="[Empty name]" NAME="Tamblyn 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-25 22:14:16 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tamblyn R Huang A Taylor L Kawasumi Y Bartlett G Grad R Jacques A Dawes M Abrahamowicz M Perreault R Winslade N Poissant L Pinsonneault A&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:14:16 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G, Grad R, et al</AU>
<TI>A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>4</NO>
<PG>430-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1067-5027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamblyn-2010" MODIFIED="2013-09-25 22:14:26 +0200" MODIFIED_BY="[Empty name]" NAME="Tamblyn 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 22:14:26 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tamblyn R Reidel K Huang A Taylor L Winslade N Bartlett G Grad R Jacques A Dawes M Larochelle P Pinsonneault A&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:14:26 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamblyn R, Reidel K, Huang A, Taylor L, Winslade N, Bartlett G, et al</AU>
<TI>Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial</TI>
<SO>Medical Decision Making</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>2</NO>
<PG>176-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terrell-2009" MODIFIED="2013-09-25 22:14:41 +0200" MODIFIED_BY="[Empty name]" NAME="Terrell 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-25 22:14:41 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Terrell KM Perkins AJ Dexter PR Hui SL Callahan CM Miller DK Comment in: J Am Geriatr Soc. 2010 Feb;58(2):416-7; author reply 417; PMID: 20370886&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:14:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terrell KM, Perkins AJ, Dexter PR, Hui SL, Callahan CM, Miller DK</AU>
<TI>Computerized decision support to reduce potentially inappropriate prescribing to older emergency department patients: a randomized, controlled trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2009</YR>
<VL>57</VL>
<NO>8</NO>
<PG>1388-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomson-2011" MODIFIED="2013-11-07 09:39:37 +0100" MODIFIED_BY="[Empty name]" NAME="Thomson 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-07 09:39:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United Kingdom&lt;br&gt;EM-Jan2012&lt;br&gt;EM 2011563685&lt;/p&gt;" NOTES_MODIFIED="2013-11-07 09:39:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomson BKA, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA, et al</AU>
<TI>Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients</TI>
<SO>BMC Nephrology</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tierney-2005" MODIFIED="2013-11-04 13:04:04 +0100" MODIFIED_BY="[Empty name]" NAME="Tierney 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-04 13:04:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tierney, William M&lt;br&gt;Overhage, J Marc&lt;br&gt;Murray, Michael D&lt;br&gt;Harris, Lisa E&lt;br&gt;Zhou, Xiao-Hua&lt;br&gt;Eckert, George J&lt;br&gt;Smith, Faye E&lt;br&gt;Nienaber, Nancy&lt;br&gt;McDonald, Clement J&lt;br&gt;Wolinsky, Fredric D&lt;br&gt;HS07763/HS/AHRQ HHS/United States&lt;br&gt;Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United States&lt;br&gt;Health services research&lt;br&gt;Health Serv Res. 2005 Apr;40(2):477-97.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:04:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tierney WM, Overhage JM, Murray MD, Harris LE, Zhou XH, Eckert GJ, et al</AU>
<TI>Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial</TI>
<SO>Health Services Research</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>477-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomek-2011" MODIFIED="2013-11-04 13:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Tomek 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-04 13:04:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;LG - English&lt;br&gt;EM-Jan2012&lt;br&gt;EM 70432194&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:04:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tomek A, Mat'oka V, Kumstov T, Rmek M, Arbochov I, T'ovkov K, et al</AU>
<SO>Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients. Proceedings of the 20th European Stroke Conference; 2011 May 24-27; Hamburg, Germany</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Traugott-2011" MODIFIED="2013-09-25 22:20:19 +0200" MODIFIED_BY="[Empty name]" NAME="Traugott 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-25 22:20:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Traugott KA Maxwell PR Green K Frei C Lewis JS 2nd&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:20:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS, 2nd</AU>
<TI>Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2011</YR>
<VL>68</VL>
<NO>4</NO>
<PG>347-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trivedi-2007" MODIFIED="2013-09-25 22:20:31 +0200" MODIFIED_BY="[Empty name]" NAME="Trivedi 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:20:31 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trivedi MH Daly EJ&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:20:31 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trivedi MH, Daly EJ</AU>
<TI>Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2007</YR>
<VL>88 Suppl 2</VL>
<PG>S61-71</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0376-8716"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trivedi-2007a" MODIFIED="2013-09-25 22:21:00 +0200" MODIFIED_BY="[Empty name]" NAME="Trivedi 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:21:00 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trivedi MH Rush AJ Gaynes BN Stewart JW Wisniewski SR Warden D Ritz L Luther JF Stegman D Deveaugh-Geiss J Howland R&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:21:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trivedi MH, Rush AJ, Gaynes BN, Stewart JW, Wisniewski SR, Warden D, et al</AU>
<TI>Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>32</VL>
<NO>12</NO>
<PG>2479-89</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0893-133X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Bol-2010" MODIFIED="2013-09-25 22:21:18 +0200" MODIFIED_BY="[Empty name]" NAME="van der Bol 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 22:21:18 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;van der Bol JM Mathijssen RH Creemers GJ Planting AS Loos WJ Wiemer EA Friberg LE Verweij J Sparreboom A de Jong FA Comment in: Clin Cancer Res. 2010 Jan 15;16(2):371-2; PMID: 20068075&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:21:18 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Bol JM, Mathijssen RHJ, Creemers G-JM, Planting AST, Loos WJ, Wiemer EAC, et al</AU>
<TI>A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan</TI>
<SO>Clinical Cancer Research</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>2</NO>
<PG>736-42</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="1078-0432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Leeuwen-2005" MODIFIED="2013-11-04 13:04:31 +0100" MODIFIED_BY="[Empty name]" NAME="van Leeuwen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-04 13:04:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;RCT Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/499/CN-00601499/frame.html Coch1.5 Cochrane ID: CN-00601499&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:04:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>van Leeuwen Y, Rombouts EK, Kruithof CJ, Van Der Meer FJM, Rosendaal FR</AU>
<TI>Comparison between two computer algorithms in oral anticoagulant dosage: a double blind randomised controlled trial</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Leeuwen-2007" MODIFIED="2013-09-25 22:23:19 +0200" MODIFIED_BY="[Empty name]" NAME="van Leeuwen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:23:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;van Leeuwen Y Rombouts EK Kruithof CJ van der Meer FJ Rosendaal FR&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:23:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer FJM, Rosendaal FR</AU>
<TI>Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>8</NO>
<PG>1644-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1538-7933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Lent_x002d_Evers-1999" MODIFIED="2013-09-25 22:23:34 +0200" MODIFIED_BY="[Empty name]" NAME="van Lent-Evers 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-25 22:23:34 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;van Lent-Evers NA Mathot RA Geus WP van Hout BA Vinks AA&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:23:34 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA</AU>
<TI>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>1</NO>
<PG>63-73</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0163-4356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Wyk-2008" MODIFIED="2013-11-04 13:08:29 +0100" MODIFIED_BY="[Empty name]" NAME="Van Wyk 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-04 13:08:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CP - United States EM1.5&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:08:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Van Wyk JT, Van Wijk MAM, Sturkenboom MCJM, Mosseveld M, Moorman PW, van der Lei J</AU>
<TI>Electronic alerts versus on-demand decision support to improve dyslipidemia treatment: a cluster randomized controlled trial</TI>
<SO>Circulation</SO>
<YR>2008</YR>
<VL>117</VL>
<NO>3</NO>
<PG>371-8</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verstappen-2007" MODIFIED="2013-09-25 22:24:13 +0200" MODIFIED_BY="[Empty name]" NAME="Verstappen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:24:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Verstappen SM Jacobs JW van der Veen MJ Heurkens AH Schenk Y ter Borg EJ Blaauw AA Bijlsma JW Utrecht Rheumatoid Arthritis Cohort study group Comment in: Ann Rheum Dis. 2007 Nov;66(11):1409-10; PMID: 17934080, Comment in: Nat Clin Pract Rheumatol. 2008 Jul;4(7):338-9; PMID: 18493270&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:24:13 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, et al</AU>
<TI>Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1443-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0003-4967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verstappen-2010" MODIFIED="2011-11-08 17:00:00 +0100" MODIFIED_BY="[Empty name]" NAME="Verstappen 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-08 17:00:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ann Rheum Dis Verstappen SM Bakker MF Heurkens AH van der Veen MJ Kruize AA Geurts MA Bijlsma JW Jacobs JW Utrecht Rheumatoid Arthritis Cohort Study Group&lt;/p&gt;" NOTES_MODIFIED="2011-11-08 17:00:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Verstappen SMM, Bakker MF, Heurkens AHM, van der Veen MJ, Kruize AA, Geurts MAW, et al</AU>
<TI>Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>6</NO>
<PG>1044-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasmuth-2007" MODIFIED="2013-09-25 22:24:53 +0200" MODIFIED_BY="[Empty name]" NAME="Wasmuth 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:24:53 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wasmuth JC Lambertz I Voigt E Vogel M Hoffmann C Burger D Rockstroh JK&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:24:53 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, et al</AU>
<TI>Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2007</YR>
<VL>63</VL>
<NO>10</NO>
<PG>901-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasmuth-2007a" MODIFIED="2013-09-25 22:25:05 +0200" MODIFIED_BY="[Empty name]" NAME="Wasmuth 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-09-25 22:25:05 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wasmuth JC Rodermann E Voigt E Vogel M Lauenroth-Mai E Jessen A Burger D Rockstroh JK&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:25:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth-Mai E, Jessen A, et al</AU>
<TI>Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring</TI>
<SO>European Journal of Medical Research</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>7</NO>
<PG>289-94</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0949-2321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whipple-1991" MODIFIED="2013-11-04 13:08:39 +0100" MODIFIED_BY="[Empty name]" NAME="Whipple 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-11-04 13:08:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Whipple, J K&lt;br&gt;Ausman, R K&lt;br&gt;Franson, T&lt;br&gt;Quebbeman, E J&lt;br&gt;Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;United states&lt;br&gt;Critical care medicine&lt;br&gt;Crit Care Med. 1991 Dec;19(12):1480-5.&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:08:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whipple JK, Ausman RK, Franson T, Quebbeman EJ</AU>
<TI>Effect of individualized pharmacokinetic dosing on patient outcome</TI>
<SO>Critical Care Medicine</SO>
<YR>1991</YR>
<VL>19</VL>
<PG>1480-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1984" MODIFIED="2013-11-04 13:08:44 +0100" MODIFIED_BY="[Empty name]" NAME="White 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-11-04 13:08:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White KS, Lindsay A, Pryor TA, Brown WF, Walsh K</AU>
<TI>Application of a computerized medical decision-making process to the problem of digoxin intoxication</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>3</NO>
<PG>571-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willcourt-1994" MODIFIED="2013-09-25 22:26:01 +0200" MODIFIED_BY="[Empty name]" NAME="Willcourt 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-25 22:26:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willcourt RJ, Pager D, Wendel J, Hale RW</AU>
<TI>Induction of labor with pulsatile oxytocin by a computer-controlled pump</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>2</NO>
<PG>603-
8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-2002" MODIFIED="2013-09-25 22:26:28 +0200" MODIFIED_BY="[Empty name]" NAME="Wilson 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-25 22:26:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wilson WH Grossbard ML Pittaluga S Cole D Pearson D Drbohlav N Steinberg SM Little RF Janik J Gutierrez M Raffeld M Staudt L Cheson BD Longo DL Harris N Jaffe ES Chabner BA Wittes R Balis F&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:26:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al</AU>
<TI>Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>8</NO>
<PG>2685-93</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0006-4971"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-2005" MODIFIED="2013-09-25 22:26:43 +0200" MODIFIED_BY="[Empty name]" NAME="Yamamoto 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-25 22:26:43 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Yamamoto N Tamura T Murakami H Shimoyama T Nokihara H Ueda Y Sekine I Kunitoh H Ohe Y Kodama T Shimizu M Nishio K Ishizuka N Saijo N Comment in: J Clin Oncol. 2005 Feb 20;23(6):1053-5; PMID: 15657406&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 22:26:43 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, et al</AU>
<TI>Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1061-9</PG>
<IDENTIFIERS MODIFIED="2011-10-04 16:36:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="0732-183X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-11-04 13:11:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2011" MODIFIED="2013-11-04 13:08:52 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-04 13:08:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;LG - English&lt;br&gt;EM-Jan2012&lt;br&gt;EM 70618788&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:08:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al</AU>
<SO>A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing: CoumaGen-II. Proceedings of the American Heart Association; 2011 Nov 12-16; Orlando, FL</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2012" MODIFIED="2013-07-28 21:44:55 +0200" MODIFIED_BY="[Empty name]" NAME="Anderson 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-07-28 21:44:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al</AU>
<TI>A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)</TI>
<SO>Circulation</SO>
<YR>2012</YR>
<VL>125</VL>
<NO>16</NO>
<PG>1997-2005</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22431865"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caduff-2013" MODIFIED="2013-11-04 13:09:00 +0100" MODIFIED_BY="[Empty name]" NAME="Caduff 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-11-04 13:09:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caduff Good A, Nobel D, Krahenbuhl S, Geisen C, Henz S</AU>
<TI>Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2013</YR>
<VL>143</VL>
<PG>w13709</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23299853"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dumont-2012" MODIFIED="2013-11-04 13:09:07 +0100" MODIFIED_BY="[Empty name]" NAME="Dumont 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:09:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dumont C, Bourguignon C</AU>
<TI>Effect of a computerized insulin dose calculator on the process of glycemic control</TI>
<SO>American Journal of Critical Care</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>2</NO>
<PG>106-15</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22381987"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horibe-2012" MODIFIED="2013-11-04 13:09:14 +0100" MODIFIED_BY="[Empty name]" NAME="Horibe 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:09:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horibe M, Nair BG, Yurina G, Neradilek MB, Rozet I</AU>
<TI>A novel computerized fading memory algorithm for glycemic control in postoperative surgical patients</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2012</YR>
<VL>115</VL>
<NO>3</NO>
<PG>580-7</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22669346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeanne-2012" MODIFIED="2013-11-04 13:09:43 +0100" MODIFIED_BY="[Empty name]" NAME="Jeanne 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:09:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeanne M, Clement C, De Jonckheere J, Logier R, Tavernier B</AU>
<TI>Variations of the analgesia nociception index during general anaesthesia for laparoscopic abdominal surgery</TI>
<SO>Journal of Clinical Monitoring and Computing</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>4</NO>
<PG>289-94</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22454275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joerger-2012" MODIFIED="2013-11-04 13:09:48 +0100" MODIFIED_BY="[Empty name]" NAME="Joerger 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:09:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, et al</AU>
<TI>Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2012</YR>
<VL>51</VL>
<NO>9</NO>
<PG>607-17</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22804749"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2012" MODIFIED="2013-11-04 13:09:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:09:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly PJ, Kay-Lambkin FJ, Baker AL, Deane FP, Brooks AC, Mitchell A, et al</AU>
<TI>Study protocol: a randomized controlled trial of a computer-based depression and substance abuse intervention for people attending residential substance abuse treatment</TI>
<SO>BMC Public Health</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>113</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22325594"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2012" MODIFIED="2013-11-04 13:10:03 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim S, Lee HW, Lee W, Um TH, Cho CR, Chun S, et al</AU>
<TI>New allele-specific real-time PCR system for warfarin dose genotyping equipped with an automatic interpretative function that allows rapid, accurate, and user-friendly reporting in clinical laboratories</TI>
<SO>Thrombosis Research</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>1</NO>
<PG>104-9</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21911247"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magee-2012" MODIFIED="2013-11-04 13:10:09 +0100" MODIFIED_BY="[Empty name]" NAME="Magee 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee MC</AU>
<TI>Improving IV insulin administration in a community hospital</TI>
<SO>Journal of Visualized Experiments</SO>
<YR>2012</YR>
<VL>64</VL>
<PG>e3705</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22710978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nieuwlaat-2011" MODIFIED="2013-11-04 13:10:21 +0100" MODIFIED_BY="[Empty name]" NAME="Nieuwlaat 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-28 21:52:01 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;LG - EnglishEM-Jan2012EM 70613297&lt;/p&gt;" NOTES_MODIFIED="2013-07-28 21:52:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nieuwlaat R, Spyropoulos AC, Hubers L, Stehouwer A, Van Spall HG, Eikelboom JW, et al</AU>
<TI>Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing</TI>
<SO>23rd Congress of the International Society on Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>Proceedings of the 57th Annual SSC Meeting; 2011 Jul 23-28; Kyoto Japan;</VL>
<PG>302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nieuwlaat-2012" MODIFIED="2013-11-04 13:10:14 +0100" MODIFIED_BY="[Empty name]" NAME="Nieuwlaat 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nieuwlaat R, Hubers LM, Spyropoulos AC, Eikelboom JW, Connolly BJ, Van Spall HG, et al</AU>
<TI>Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2012</YR>
<VL>108</VL>
<NO>6</NO>
<PG>1228-35</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23015161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overgaard-2010" MODIFIED="2013-11-04 13:10:30 +0100" MODIFIED_BY="[Empty name]" NAME="Overgaard 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-11-04 13:10:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Overgaard K, Corell P, Madsen P, Rasmussen RS</AU>
<SO>Computer-aid improves oral anticoagulant therapy. Proceedings of the 19th European Stroke Conference; 2010 May 25-28; Barcelona, Spain</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pielmeier-2012" MODIFIED="2013-11-04 13:10:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pielmeier 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pielmeier U, Rousing ML, Andreassen S, Nielsen BS, Haure P</AU>
<TI>Decision support for optimized blood glucose control and nutrition in a neurotrauma intensive care unit: preliminary results of clinical advice and prediction accuracy of the Glucosafe system</TI>
<SO>Journal of Clinical Monitoring and Computing</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>4</NO>
<PG>319-28</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22581038"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radhakrishnan-2012" MODIFIED="2013-11-04 13:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Radhakrishnan 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radhakrishnan A, Vido D, Tayur S, Akan M, Murali S</AU>
<TI>Genotype guided therapeutic dosing of warfarin in geriatric patients</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2012</YR>
<VL>59</VL>
<NO>13 Suppl 1</NO>
<PG>E1696</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-2012" MODIFIED="2013-11-04 13:11:02 +0100" MODIFIED_BY="[Empty name]" NAME="Rasmussen 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:11:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen RS, Corell P, Madsen P, Overgaard K</AU>
<TI>Effects of computer-assisted oral anticoagulant therapy</TI>
<SO>Thrombosis Journal</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>1</NO>
<PG>17</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22935243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spaniel-2012" MODIFIED="2013-11-04 13:10:50 +0100" MODIFIED_BY="[Empty name]" NAME="Spaniel 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spaniel F, Hrdlicka J, Novak T, Kozeny J, Hoschl C, Mohr P, et al</AU>
<TI>Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>4</NO>
<PG>269-80</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22805901"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamblyn-2012" MODIFIED="2013-11-04 13:10:55 +0100" MODIFIED_BY="[Empty name]" NAME="Tamblyn 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:10:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamblyn R, Eguale T, Buckeridge DL, Huang A, Hanley J, Reidel K, et al</AU>
<TI>The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>4</NO>
<PG>635-43</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22246963"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitehead-2012" MODIFIED="2013-11-04 13:11:09 +0100" MODIFIED_BY="[Empty name]" NAME="Whitehead 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:11:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead J, Thygesen H, Jaki T, Davies S, Halford S, Turner H, et al</AU>
<TI>A novel phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer</TI>
<SO>Statistics in Medicine</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>18</NO>
<PG>1931-43</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22495759"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiltshire-2012" MODIFIED="2013-11-04 13:11:15 +0100" MODIFIED_BY="[Empty name]" NAME="Wiltshire 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-04 13:11:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM</AU>
<TI>A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2012</YR>
<VL>115</VL>
<NO>2</NO>
<PG>284-96</PG>
<IDENTIFIERS MODIFIED="2013-07-28 21:44:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22253270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-07-28 21:46:06 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-05 11:27:08 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-05 11:27:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arditi-2012" MODIFIED="2013-11-05 11:26:51 +0100" MODIFIED_BY="[Empty name]" NAME="Arditi 2012" TYPE="COCHRANE_REVIEW">
<AU>Arditi C, Rège-Walther M, Wyatt JC, Durieux P, Burnand B</AU>
<TI>Computer-generated reminders delivered on paper to healthcare professionals; effects on professional practice and health care outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<PG>CD001175</PG>
<IDENTIFIERS MODIFIED="2013-09-25 22:56:55 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-25 22:56:55 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001175.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldwin-1995" MODIFIED="2012-11-12 16:33:12 +0100" MODIFIED_BY="[Empty name]" NAME="Baldwin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Baldwin L</AU>
<TI>Calculating drug doses</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6988</NO>
<PG>1154</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bates-2003" MODIFIED="2013-11-04 13:11:25 +0100" MODIFIED_BY="[Empty name]" NAME="Bates 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, et al</AU>
<TI>Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>6</NO>
<PG>523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brennan-1991" MODIFIED="2013-11-04 13:11:30 +0100" MODIFIED_BY="[Empty name]" NAME="Brennan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al</AU>
<TI>Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>6</NO>
<PG>370-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chatellier-1998" MODIFIED="2013-11-04 13:11:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chatellier 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chatellier G, Colombet I, Degoulet P</AU>
<TI>Computer-adjusted dosage of anticoagulant therapy improves the quality of anticoagulation</TI>
<SO>Studies in Health Technology and Informatics</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>Pt 2</NO>
<PG>819-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CLINICIP" MODIFIED="2013-11-04 13:11:41 +0100" MODIFIED_BY="[Empty name]" NAME="CLINICIP" TYPE="OTHER">
<AU>CLINICIP Project</AU>
<TI>CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients)</TI>
<SO>www.clinicip.org</SO>
<YR>(accessed 25 September 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2013-11-04 13:11:49 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durieux-2005" MODIFIED="2013-11-04 13:11:55 +0100" MODIFIED_BY="[Empty name]" NAME="Durieux 2005" TYPE="JOURNAL_ARTICLE">
<AU>Durieux P</AU>
<TI>Electronic medical alerts - so simple, so complex</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>10</NO>
<PG>1034-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC--2009" MODIFIED="2013-11-04 13:12:02 +0100" MODIFIED_BY="[Empty name]" NAME="EPOC  2009" TYPE="OTHER">
<AU>EPOC</AU>
<TI>Risk of bias - EPOC specific</TI>
<SO>epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/Risk%20of%20Bias%2005-01-2009.doc</SO>
<YR>(accessed 25 September 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2012" MODIFIED="2013-11-04 13:12:08 +0100" MODIFIED_BY="[Empty name]" NAME="EPOC 2012" TYPE="OTHER">
<AU>EPOC</AU>
<TI>What study designs should be included in an EPOC review and what should they be called?</TI>
<SO>epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/What%20study%20designs%20should%20be%20included%20in%20an%20EPOC%20reviews%20and%20what%20should%20they%20be%20called.pdf</SO>
<YR>(accessed 25 September 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eslami-2009" MODIFIED="2013-11-04 13:12:16 +0100" MODIFIED_BY="[Empty name]" NAME="Eslami 2009" TYPE="JOURNAL_ARTICLE">
<AU>Eslami S, Abu-Hanna A, de Jonge E, de Keizer NF</AU>
<TI>Tight glycemic control and computerized decision-support systems: a systematic review</TI>
<SO>Intensive Care Medicine</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1505-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzmaurice-1998a" MODIFIED="2013-09-26 20:59:20 +0200" MODIFIED_BY="[Empty name]" NAME="Fitzmaurice 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Hobbs FD, Delaney BC, Wilson S, McManus R</AU>
<TI>Review of computerized decision support systems for oral anticoagulation management</TI>
<SO>British Journal of Haematology
</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>4</NO>
<PG>907-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franke-2000" MODIFIED="2013-11-04 13:12:21 +0100" MODIFIED_BY="[Empty name]" NAME="Franke 2000" TYPE="JOURNAL_ARTICLE">
<AU>Franke L, Avery AJ, Groom L, Horsfield P</AU>
<TI>Is there a role for computerized decision support for drug dosing in general practice? A questionnaire survey</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>5</NO>
<PG>373-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Alamino-2010" MODIFIED="2013-09-25 23:10:34 +0200" MODIFIED_BY="[Empty name]" NAME="Garcia-Alamino 2010" TYPE="COCHRANE_REVIEW">
<AU>Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al</AU>
<TI>Self-monitoring and self-management of oral anticoagulation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<VL>

</VL>
<NO>4</NO>
<PG>

</PG>
<IDENTIFIERS MODIFIED="2013-09-25 23:10:34 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-25 23:10:34 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003839.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garg-2005" MODIFIED="2013-11-04 13:12:27 +0100" MODIFIED_BY="[Empty name]" NAME="Garg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Garg AX, Adhikari NK, McDonald H, Rosas-Arellano M, Devereaux PJ, Beyene J, et al</AU>
<TI>Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>10</NO>
<PG>1223-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2013-11-04 13:12:36 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>British Medical Journal</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2013-11-04 13:12:50 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<PG>1294-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-11-04 13:12:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2012-03-26 15:08:37 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005" MODIFIED="2013-11-04 13:12:59 +0100" MODIFIED_BY="[Empty name]" NAME="Hozo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hozo SP, Djulbegovic B, Hozo I</AU>
<TI>Estimating the mean and variance from the median, range, and the size of a sample</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2007" MODIFIED="2013-11-04 13:13:06 +0100" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Trikalinos TA</AU>
<TI>The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2007</YR>
<VL>176</VL>
<PG>1091-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kawamoto-2005" MODIFIED="2013-09-25 23:24:13 +0200" MODIFIED_BY="[Empty name]" NAME="Kawamoto 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kawamoto K, Houlihan CA, Balas EA, Lobach DF</AU>
<TI>Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success</TI>
<SO>British M
edical 
Journal</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7494</NO>
<PG>765</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuperman-2003" MODIFIED="2013-11-04 13:13:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kuperman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kuperman GJ, Gibson RF</AU>
<TI>Computer physician order entry: bene&#64257;ts, costs, and issues</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>1</NO>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-1976a" MODIFIED="2013-11-04 13:13:22 +0100" MODIFIED_BY="[Empty name]" NAME="McDonald 1976a" TYPE="JOURNAL_ARTICLE">
<AU>McDonald CJ</AU>
<TI>Protocol-based computer reminders, the quality of care and the non-perfectability of man</TI>
<SO>New England Journal of Medicine</SO>
<YR>1976</YR>
<VL>295</VL>
<NO>24</NO>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2013-09-25 23:25:16 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>PLOS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>e1000097</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mollon-2009" MODIFIED="2013-11-05 11:23:44 +0100" MODIFIED_BY="[Empty name]" NAME="Mollon 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mollon B, Chong J Jr, Holbrook AM, Sung M, Thabane L, Foster G</AU>
<TI>Features predicting the success of computerized decision support for prescribing: a systematic review of randomized controlled trials</TI>
<SO>BMC Medical Informatics and Decision Making</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1984a" MODIFIED="2013-11-04 13:13:32 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1984a" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD, Smith CR, Lietman PS</AU>
<TI>Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>4</NO>
<PG>657-62</PG>
<IDENTIFIERS MODIFIED="2012-10-27 21:44:24 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-27 21:43:56 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Moore 1984a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1984b" MODIFIED="2013-11-04 13:13:39 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1984b" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD, Smith CR, Lietman PS</AU>
<TI>The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1984</YR>
<VL>149</VL>
<NO>3</NO>
<PG>443-8</PG>
<IDENTIFIERS MODIFIED="2012-10-27 21:47:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-27 21:47:09 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Moore 1984b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1987" MODIFIED="2013-11-04 13:13:48 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1987" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD, Lietman PS, Smith CR</AU>
<TI>Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1987</YR>
<VL>155</VL>
<NO>1</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-National-Asthma-2002" MODIFIED="2013-11-04 13:14:05 +0100" MODIFIED_BY="[Empty name]" NAME="National Asthma 2002" TYPE="JOURNAL_ARTICLE">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics - 2002</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2002</YR>
<VL>110</VL>
<NO>5 Suppl</NO>
<PG>S141-219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nieuwlaat-2011a" MODIFIED="2013-11-04 13:14:12 +0100" MODIFIED_BY="[Empty name]" NAME="Nieuwlaat 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski N L, et al</AU>
<TI>Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review</TI>
<SO>Implementation Science</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearson-2009" MODIFIED="2013-11-05 11:23:57 +0100" MODIFIED_BY="[Empty name]" NAME="Pearson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pearson SA, Moxey A, Robertson J, Hains I, Williamson M, Reeve J, et al</AU>
<TI>Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990-2007)</TI>
<SO>BMC Health Services Research</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-11-04 13:14:19 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-2010" MODIFIED="2013-11-05 11:24:07 +0100" MODIFIED_BY="[Empty name]" NAME="Robertson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D</AU>
<TI>The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature</TI>
<SO>International Journal of Pharmacy Practice</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>69-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rolfe-1995" MODIFIED="2013-11-04 13:14:31 +0100" MODIFIED_BY="[Empty name]" NAME="Rolfe 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rolfe S, Harper NJ</AU>
<TI>Ability of hospital doctors to calculate drug doses</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6988</NO>
<PG>1173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shojania-2009" MODIFIED="2013-11-05 11:27:08 +0100" MODIFIED_BY="[Empty name]" NAME="Shojania 2009" TYPE="COCHRANE_REVIEW">
<AU>Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J</AU>
<TI>The effects of on-screen, point of care computer reminders on processes and outcomes of care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-09-25 23:37:18 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-25 23:37:18 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001096.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2013-11-04 13:14:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG, Donner A</AU>
<TI>Methods in health service research. Evaluation of health interventions at area and organisation level</TI>
<SO>British Medical Journal</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>376-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yourman-2008" MODIFIED="2013-11-04 13:14:42 +0100" MODIFIED_BY="[Empty name]" NAME="Yourman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yourman L, Concato J, Agostini JV</AU>
<TI>Use of computer decision support interventions to improve medication prescribing in older adults: a systematic review</TI>
<SO>American Journal of Geriatric Pharmacotherapy</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>2</NO>
<PG>119-29</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-11-05 11:26:26 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Durieux-2008" MODIFIED="2013-09-25 23:39:55 +0200" MODIFIED_BY="[Empty name]" NAME="Durieux 2008" TYPE="COCHRANE_REVIEW">
<AU>Durieux P, Trinquart L, Colombet I, Nies J, Walton R, Rajeswaran A, et al</AU>
<TI>Computerized advice on drug dosage to improve prescribing practice</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<PG>CD002894</PG>
<IDENTIFIERS MODIFIED="2013-09-25 23:39:55 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-25 23:39:55 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002894.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walton-2001" MODIFIED="2013-11-05 11:26:26 +0100" MODIFIED_BY="[Empty name]" NAME="Walton 2001" TYPE="COCHRANE_REVIEW">
<AU>Walton R T, Harvey E, Dovey S, Freemantle N</AU>
<TI>Computerised advice on drug dosage to improve prescribing practice</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<PG>CD002894</PG>
<IDENTIFIERS MODIFIED="2013-11-05 11:26:26 +0100" MODIFIED_BY="Elizabeth Paulsen">
<IDENTIFIER MODIFIED="2013-11-05 11:26:26 +0100" MODIFIED_BY="Elizabeth Paulsen" TYPE="DOI" VALUE="10.1002/14651858.CD002894"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-10-27 19:51:44 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-05 11:32:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ageno-1998">
<CHAR_METHODS MODIFIED="2013-11-05 11:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Episode of care<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:32:11 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)</P>
<P>Level of training: Accredited/licensed</P>
<P>Clinical specialty: Other, anticoagulant clinic</P>
<P>Country: Canada (Ontario)</P>
<P>Centre: 1 general hospital (Hamilton General Hospital)</P>
<P>Location of care: Outpatient care</P>
<P>Participants: 101 outpatients on long-term oral anticoagulant therapy after mechanical heart valve replacement</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:32:11 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Long-term warfarin therapy<BR/>Intervention: Prediction rules, computer-assisted group (n = 50) vs. control group (n = 51)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Proportion of doses adjustments (potential unit of analysis error)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (percentage of days in range with an INR of 2.5-3.5 according to the Duxburry method (reported as time spent in days per 100 patient-days of treatment), % of INRs &gt; 5: reported, % of INRs &lt; 2: reported, mean INR values: no dispersion data, % of INRs in range (2.3-3.7): not included, % of days in range (2.5-3.5): not included, % of days in range (2.3-3.7): not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:32:06 +0100" MODIFIED_BY="[Empty name]">
<P>- The author confirm that none of the participants was included in both studies <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK> and <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>
</P>
<P>- Therapeutic INR range: "Warfarin is administered with a therapeutic INR range of 2.5 to 3.5, according to the 1995 American College of Chest Physicians recommendations"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ageno-2000">
<CHAR_METHODS MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Other (dose, INR, participant)<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: General/family practice<BR/>
</P>
<P>Country: Canada (Ontario)</P>
<P>Centre: 1 general hospital (Hamilton General Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 101 participants who required oral anticoagulation (heart valve replacement, treatment of venous thromboembolism, atrial fibrillation, prophylaxis for deep vein thrombosis, acute myocardial infarction and vascular surgery)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin adjustment in hospitalized people<BR/>Intervention: Computer-based control of oral anticoagulation (n = 50 participants) vs. standard manual dosing (n = 51 participants). The computerized induction treatment module (DAWN AC INDUCTION) calculated the daily dosage of warfarin based on algorithms that could be set at every centre according to the local clinical practice<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Proportion of doses adjustments (potential unit of analysis error) (daily dose of warfarin: no dispersion data)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (% of INRs &gt; 5: reported, mean INR values: no dispersion data, % of participants with at least 1 INR &gt; upper limit of therapeutic range: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Minor bleeding (major bleeding: not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>- There were different indications for oral anticoagulation: "heart valve replacement (n:74), treatment of venous thromboembolism (n:16), atrial fibrillation (n:5), prophylaxis for deep vein thrombosis (n:4), acute myocardial infarction (n:1), and vascular surgery (n:1)"</P>
<P>- The author confirm that none of the participants was included in both studies <LINK REF="STD-Ageno-1998" TYPE="STUDY">Ageno 1998</LINK> and <LINK REF="STD-Ageno-2000" TYPE="STUDY">Ageno 2000</LINK>
</P>
<P>- Therapeutic INR range: "Because of a higher risk of bleeding during the early days of treatment due to the presence of pacing wires which are usually removed between the fifth and seventh post operative day, the initial therapeutic INR for participants following heart valve replacement ranges between 1.5 to 2.6. After the wires are removed, the therapeutic INR is 2.5 to 3.5 for mechanical valves, and 2.0 to 3.0 for bioprosthetic valves. For all other indications, the therapeutic INR ranges between 2.0 and 3.0. In the algorithm set in the computer, we defined a low therapeutic regime for the first 5 days of treatment for all the participants following heart valve replacement"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2007">
<CHAR_METHODS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + pharmacists)<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>
</P>
<P>Country: USA (Salt Lake City)</P>
<P>Centre: 1 general urban hospital and surgical centre (LDS Hospital, Intermountain's outstanding heart network in the Salt Lake Valley)</P>
<P>Location of care: Inpatient care<BR/>Participants: 206 participants being initiated on oral anticoagulation. 200 participants analyzed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin initiation<BR/>Intervention: Pharmacogenetic-guided dosing (n = 101) versus standard empirical dosing (n = 99). Pharmacogenetic-arm dosing was determined with a regression equation included CYP2C9 (*1, *2, *3) and VKORC1 (C1173T) genotypes, age, weight and sex. Standard dosing followed the 10-mg warfarin nomogram of Kovacs et al.<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:33:17 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Dose adjustments per participant</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Time (%) within therapeutic range (% of out-of-range INRs: not included, Number of INR measurements: not included, % participants reaching therapeutic INR on days 5 and 8: not included)</P>
<P>Time to achieve therapeutic control: None (time to first supratherapeutic INR: not included)</P>
<P>Clinical events: % participants with adverse events (clinical plus INR &#8805; 4), % participants with serious adverse events (clinical only)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>- Therapeutic INR range: "Although the target INR range was 2 to 3, we prospectively defined an out-of-range INR value, for purposes of end-point analysis and for clinical dose adjustment, as 1.8 or 3.2 to allow for measurement error and to avoid problems inherent in overcorrection"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2008">
<CHAR_METHODS MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_NOTES MODIFIED="2013-11-05 11:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>- Same study as <LINK REF="STD-Anderson-2007" TYPE="STUDY">Anderson 2007</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asberg-2010">
<CHAR_METHODS MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Other (blood sample, participant)<BR/>Power calculation: Not done "In this pilot study, the number of subjects needed to be included was empirically based"<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Nephrology<BR/>Country: Norway (Oslo)<BR/>Centre: 1 university hospital<BR/>Location of care: Mixed (nephrology and standard clinical follow-up)<BR/>Participants: 40 adult kidney transplant recipients on CsA, prednisolone and mycophenolate were included 2 weeks after transplantation (discharge from the surgical department) and followed for at least 8 weeks (standard clinical follow-up)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: CsA in early post-transplant phase<BR/>Intervention: Computer dosing of CsA doses (n = 20 participants) vs. standard practice (n = 20 participants). Individual CsA doses were calculated by a population pharmacokinetic model and suggested to the physician<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Indirect intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Daily CsA dose</P>
<P>Serum concentrations and therapeutic range: None (% participants with a deviation from the targeted blood concentration &gt; 50% on at least 1 occasion: not included)</P>
<P>Physiological parameters: Glomerular filtration rate (renal function) (mL/min) (% of blood concentrations within the therapeutic window for an individual: reported, 2-hour plasma glucose (mmol/L): not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with cytomegalovirus infections</P>
<P>Healthcare costs: None</P>
<P>Improvement: Proportion of participants without biopsy-confirmed rejections<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>"The attending physician specified individual therapeutic C2 windows based on clinical evaluation of patient characteristics and risk factors. The standard protocol at our center is 900-1100 µg/L for the first month of transplant, followed by 700-900 µg/L up to month 3 in a normal risk patient; high-risk patients start with a therapeutic window of 1200-1600 µg/L followed by appropriate tapering"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:33:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Augstein-2007">
<CHAR_METHODS MODIFIED="2013-11-05 11:33:59 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done. "Using a one-sided test at a 5% level of statistical significance, the trial was designed to have an 85% statistical power to detect a difference of 0.5% in change in A1C ( A1C) from baseline to end of trial between the CGMS and CGMS/KADIS group, with an assumed SD of 0.6"<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:33:52 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: General/family practice, diabetes specialty<BR/>Country: Germany<BR/>Centre: 5 outpatient centres (3 general and 2 diabetes specialist practices)<BR/>Location of care: Outpatient care<BR/>Participants: 49 insulin-treated outpatients. 46 subjects completed the study (3 subjects had incomplete first CGMS monitoring and were excluded)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:33:52 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in people with diabetes<BR/>Intervention: CGMS + KADIS (n = 24 participants) vs. CGMS (n = 25 participants). CGMS provides information about glycaemic control by glucose readings every 5 min and was used as the source of glucose data. All participants were educated to use CGMS monitors and the CGMS data were downloaded and transferred to the centre (Institute of Diabetes) for analysis. Depending on the group to which the participant belonged, physicians received either CGMS data alone or CGMS data plus KADIS decision support report. KADIS is based on a mathematical model that describes the glucose/insulin metabolism in type 1 diabetes in the form of a coupled differential equation<BR/>Computer advice: Not reported<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Insulin (IU/day)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Mean sensor glucose (mmol/L), A1C (%) (duration of hypoglycaemic excursions (h/day): not included, duration of hyperglycaemic excursions (h/day): not included, Bread Exchange Unit: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:33:48 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Begg-1989">
<CHAR_METHODS MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: New Zealand</P>
<P>Centre: 1 general hospital (Christchurch Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 50 hospital inpatients (ICU excluded)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Aminoglycoside<BR/>Intervention: Pharmacokinetic model, computer-assisted group (n = 24) vs. control group (n = 26)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Aminoglycoside (mg/day)</P>
<P>Serum concentrations and therapeutic range: Aminoglycoside peak plasma concentration after 2 days (mg/L), % participants within drug therapeutic range (plasma peak concentrations of 6-10 mg/L and trough concentrations of 1-2 mg/L at 2 days), % participants with plasma peak concentrations of 6-10 mg/L at 2 days (peak concentration criterion alone) (peak concentrations after 5 days: not included, through concentrations: not included, number of dose alterations: not included)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Death, nephrotoxicity (increase in creatinine clearance)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>"Patients in the intensive care unit were excluded, since they formed the basis of a similar study with a different control group being conducted concurrently"</P>
<P>Hickling K, Begg E, Moore ML (1989): 32 adult patients in intensive care unit at Christchurch Hospital (New Zealand) who required gentamicin or tobramycin therapy for serious life threatening infections, other than those receiving haemodialysis for renal acute failure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blaha-2009">
<CHAR_METHODS MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: Not reported<BR/>Clinical specialty: Surgical ICU<BR/>Country: Czech Republic (Prague)</P>
<P>Centre: 1 university hospital (Charles University and General University Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 120 adults admitted to the postoperative ICU after elective cardiac surgery were randomly assigned into the Matias protocol based on the absolute glucose value (n = 40), the Bath protocol based on the relative glucose change (n = 40), or the computer-based model predictive control algorithm with variable sampling rate (eMPC) (n = 40)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill people (cardiac surgery patients)<BR/>Intervention: Matias protocol based on the absolute glucose value (n = 40 participants) versus computer-based model predictive control algorithm with variable sampling rate (eMPC) (n = 40 participants). The eMPC is an enhanced version of the model predictive control algorithm (MPC), a model of the glucoregulatory system. Glucose concentration, insulin dosage, and carbohydrate content of enteral and parenteral input are the input variables for the eMPC. The insulin infusion rate and the time of the next glucose sample are the outputs. Group with the Bath protocol based on the relative glucose change (n = 40) was excluded since most of standard protocols use the absolute glucose value and this protocol had not been used in the Charles University and General University Hospital before the study<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: % of time within the target range for blood glucose during the study or the first 48 h (80-110 mg/dL or 4.4-6.1 mmol/L), mean blood glucose (mmol/L)</P>
<P>Time to achieve therapeutic control: Time to target range (hours), mean sampling interval (hours)</P>
<P>Clinical events: Proportion of participants with severe hypoglycaemic episodes (blood glucose level &lt; 2.3 mmol/L)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>- "The target glucose range was 4.4 &#8211; 6.1 mmol/l, which has been demonstrated to reduce mortality and morbidity". "severe hypoglycemic episodes (blood glucose &lt;2.3 mmol/l)"</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burton-1991">
<CHAR_METHODS MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: House staff team (a random number table was used to determine which of the house staff teams would be assigned to the intervention group. At the end of each 4 months, during the study, intervention groups were changed to control and vice versa to ensure equal allocation of participant types and infections to each group)<BR/>Unit of analysis: Participant (cluster was <U>not</U> taken into account in the analysis)<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not reported<BR/>Country: USA (Dallas)</P>
<P>Centre: 1 Veterans Administration Medical Center (680-bed tertiary care - affiliated institution)<BR/>Location of care: Inpatient care<BR/>Participants: 147 participants treated with aminoglycosides</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Aminoglycoside<BR/>Intervention: Dose advice based on Bayesian pharmacokinetic model (n = 72) vs. usual care (n = 75)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Beginning aminoglycoside dose (mg/day), Ending aminoglycoside dose (mg/day)</P>
<P>Serum concentrations and therapeutic range: Aminoglycoside peak serum concentration (mg/L), toxic drug level (% participants within peak concentration &gt; 4 mg/L) (maximum trough concentration: not included, % participants within trough concentrations &#8805; 2 mg/L: not included)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Nephrotoxicity (rise in serum creatinine level of 0.5 mg/dL if the initial value was &#8804; 1.5 mg/dL or a 30% rise in the serum creatinine value), death</P>
<P>Healthcare costs: Length of stay</P>
<P>Improvement: % of participants cured (afebrile for 4 consecutive days and without: recurrence of fever, leukocytosis, recurrence of infection, use of another effective antibiotic within 48 hours of stopping aminoglycoside)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>"All initial and revised dosages in the intervention group were targeted to obtain peak and trough serum concentrations within the recognized therapeutic range of 5 to 10 mg/L for peak concentrations and less than 2 mg/L for through concentrations of gentamicin and tobramycin. The therapeutic range for amikacin was 20 to 30 mg/L for peak concentrations and less than 5 mg/L for through serum concentrations"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:35:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-1987">
<CHAR_METHODS MODIFIED="2013-11-05 11:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + pharmacists)<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: USA</P>
<P>Centre: 1 Veterans Administration Medical Center<BR/>Location of care: Inpatient care<BR/>Participants: 65 adult inpatients receiving warfarin sodium</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Initiation of warfarin therapy<BR/>Intervention: Pharmacokinetic concepts, analogue-computer program (n = 31) vs. empiric dosing (n = 34)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Indirect intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Warfarin stabilization dosage (mg/day) (for the 39 participants who achieved stable prothrombin ratios before discharge)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: Time to stabilization (for the 39 participants who achieved stable prothrombin ratios before discharge)</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>"A prothrombin time (PT) ratio (patient PT divided by control PT) between 1,3 and 2,5 was considered to be in therapeutic range"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casner-1993">
<CHAR_METHODS MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: USA (El Paso, Texas)</P>
<P>Centre: 1 general hospital</P>
<P>Location of care: Inpatient care<BR/>Participants: 35 participants with diagnoses of asthma or obstructive pulmonary disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Theophylline maintenance for asthma<BR/>Intervention: Suggestion based on linear 1 compartment model (n = 17) vs. usual care (n = 18)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: Serum theophylline (mg/L) (at the 3rd level (C3) after adjustment and prior to discontinuation of infusion)</P>
<P>Physiological parameters: None (PH and partial pressure of carbon dioxide (PCO<SUB>2</SUB>) measurements: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with theophylline toxicity (nausea, vomiting, tremor, tachycardia and seizures)</P>
<P>Healthcare costs: Length of stay</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>"Physicians adjusting theophylline infusions were instructed to attain a therapeutic goal of 15mg/L theophylline level and to base this empirically on the C1 and C2 levels that had been obtained"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chertow-2001">
<CHAR_METHODS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Design: NRCT (alternating time series design with 4 consecutive 2-month period)<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Episode of care<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Other mixed<BR/>Country: USA (Boston, Massachusetts)</P>
<P>Centre: 1 urban tertiary care academic medical centre (Brigham and Women's Hospital, 720 beds)<BR/>Location of care: Inpatient care<BR/>Participants: 17,828 inpatients with renal insufficiency<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Renal insufficiency<BR/>Intervention: CDSS periods (n = 7887 participants) vs. control periods (n = 9941 participants)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:36:20 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: Proportion of appropriate orders (potential unit of analysis error)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: Length of stay</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>"The BICS order entry application provides the physician with a range of possible dose amounts for that medication (dose list) along with 1 dose that is highlighted as the default or recommended dose amount." "An expert panel [...] selected those medications that were renally cleared and/or nephrotoxic" "To smooth dose recommendations, renal insufficiency was divided into 3 categories: mild (estimated creatinine clearance, 50-80 mL/min [0,84-1,34 mL/s]), moderate (estimated creatinine clearance, 16-49 mL/min [0,27-0,82 mL/s]), and advanced (estimated creatinine clearance, d15 mL/min [d0,25 mL/s])" "A selection was considered appropriate if the dose amount or frequency interval did not exceed the parameters set forth by the expert panel"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Claes-2005">
<CHAR_METHODS MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: GP practice<BR/>Unit of analysis: Participant (cluster was taken into account in statistical analysis)<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (GP + pathologists)<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: General/family practice + laboratory medicine<BR/>Country: Belgium</P>
<P>Centre: 96 GPs regrouped in 66 GP practices, for whom the clinical laboratory of the Medical Centre for GPs in Tessenderlo determined the INRs on venous blood<BR/>Location of care: Community-based care<BR/>Participants: 834 participants on oral anticoagulation were included (out of 936 participants eligible). 91 participants who underwent a surgical intervention with an interruption of the anticoagulation during the study period were excluded from the analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Oral anticoagulation therapy at steady state (anticoagulation therapy for at least 28 days)<BR/>Intervention: Multifaceted education and DAWN AC computer advice (n = 15 GP practices, n = 201 participants) vs. multifaceted education (n = 17 GP practices, n = 170 participants). The Grol's multifaceted education: summary of the guidelines printed on the cover of a folder containing the anticoagulation files; information booklets on anticoagulation for their patients; website with guidelines, study design, and general information; newsletter sent every 2 months to inform the GPs on the study progress and requested them to send the anticoagulation files for control</P>
<P>Computer advice: Not reported (the pathologist reviewed the computer-generated advice and faxed it the same afternoon to the GP)<BR/>CDSS integration in CPOE: No (advice faxed)</P>
<P>Starter: User-initiated<BR/>Type of intervention: Indirect intervention (the pathologist reviewed the computer-generated advice and faxed it to the GP)</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (% of participants with treatment changes: reported, median number of tests per participant and per month: reported)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (mean % of time in range (0.5 INT-units from target): reported, mean % of time in range (0.75 INT-units from target): not included, % of participants with at least 1 INR &gt; 5: reported, % of participants with at least 1 INR &lt; 2: reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Number of bleeding events (minor + major) per patient-years, number of thromboembolic events per patient-years</P>
<P>Healthcare costs: See <LINK REF="STD-Claes-2006" TYPE="STUDY">Claes 2006</LINK>
</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>- The practices were randomized into 4 groups: multifaceted education (group A), multifaceted education + feedback on the performance<BR/>of the practice (group B), multifaceted education + a CoaguChek device to determine the INR on the spot using capillary blood (group C), multifaceted education + DAWN AC computer advice that generated a recommended dosing scheme and the time to next visit (group D). Only groups A and D were retained for the review</P>
<P>- The target range were defined as within 0.5 INR-units and 0.75 INR-units from the chosen target INR of 2.5 or 3.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:56:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Claes-2006">
<CHAR_METHODS MODIFIED="2013-11-05 11:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: GP practice<BR/>Unit of analysis: Participant (cluster was taken into account in statistical analysis)<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (GP + pathologists)<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: General/family practice + laboratory medicine<BR/>Country: Belgium</P>
<P>Centre: 96 GPs regrouped in 66 GP practices, for whom the clinical laboratory of the Medical Centre for GPs in Tessenderlo determined the INRs on venous blood<BR/>Location of care: Community-based care<BR/>Participants: 834 participants on oral anticoagulation were included (out of 936 participants eligible). 91 participants who underwent a surgical intervention with an interruption of the anticoagulation during the study period were excluded from the analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Oral anticoagulation therapy at steady state (anticoagulation therapy for at least 28 days)<BR/>Intervention: Multifaceted education and DAWN AC computer advice (n = 15 GP practices, n = 201 participants) vs. multifaceted education (n = 17 GP practices, n = 170 participants). The Grol's multifaceted education: summary of the guidelines printed on the cover of a folder containing the anticoagulation files; information booklets on anticoagulation for their participants; website with guidelines, study design, and general information; newsletter sent every 2 months to inform the GPs on the study progress and request them to send the anticoagulation files for checking</P>
<P>Computer advice: Not reported (The pathologist reviewed the computer-generated advice and faxed it the same afternoon to the GP)<BR/>CDSS integration in CPOE: No (advice faxed)</P>
<P>Starter: User-initiated<BR/>Type of intervention: Indirect intervention (the pathologist reviewed the computer-generated advice and faxed it to the GP)</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
<P>Serum concentrations and therapeutic range: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
<P>Physiological parameters: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
<P>Time to achieve therapeutic control: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
<P>Clinical events: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
<P>Healthcare costs: None ((monthly cost per participant (in EUR): reported, incremental cost-effectiveness ratio (ICER): reported)</P>
<P>Improvement: See <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>- This is a cost-effectiveness analysis conducted as a part of the Belgian Improvement Study on Oral Anticoagulation Therapy (BISOAT) study reported by Claes et al. (see <LINK REF="STD-Claes-2005" TYPE="STUDY">Claes 2005</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:57:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cordingley-2009">
<CHAR_METHODS MODIFIED="2013-11-05 11:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Nurses<BR/>Level of training: Not reported<BR/>Clinical specialty: ICU<BR/>Country: UK (London), Belgium (Leuven)<BR/>Centre: 1 large specialist heart and lung hospital affiliated with the university and NHS Foundation Trust (Royal Brompton Hospital (RBH)), 1 university hospital (University Hospital Gasthuisberg (KUL))<BR/>Location of care: Inpatient care<BR/>Participants: 34 critically ill patients admitted to ICU with hyperglycaemia (glucose &gt; 120 mg/dL)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill patients with hyperglycaemia<BR/>Intervention: eMPC algorithm (n = 16 participants) vs. standard care (n = 18 participants). The eMPC algorithm calculates the time of the next glucose sample and the optimum insulin infusion rate expected to achieve the target glucose concentration<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:38:29 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: % of time in target glucose range (hyperglycaemia index (area of the glucose-time concentration curve above 110 mg/dL (6.1 mmol/L) divided by the time of the study): not included (data differed between text, table 3, table 4 and table 5 and the author had not replied by January 2012), blood glucose: not included (sample mean), time-weighted mean glucose concentration (mg/dL) (area under the glucose-time curve for each participant divided by the elapsed time): not included)</P>
<P>Time to achieve therapeutic control: Time to establish glucose control (T<SUB>target</SUB>) (time from study entry until the plasma glucose concentration was in the target range of 80-110 mg/dL (4.4-6.1 mmol/L)) (minutes), mean sampling interval (hours)</P>
<P>Clinical events: Proportion of participants with plasma glucose concentrations &lt; 60 mg/dL, proportion of participants with plasma glucose concentrations &lt; 40 mg/dL</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>- "At KUL nursing staff (each taking care of 2 patients) aimed to maintain plasma glucose in the range 80-110 mg/dL (4.4-6.1 mmol/L) using a paper-based guideline that allows intuitive decisions to be taken. At RBH, nurses (each taking care of 1 patient) used a written dynamic insulin infusion protocol targeting a plasma glucose concentration of 72-108 mg/dL (4-6 mmol/L)"</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Destache-1990">
<CHAR_METHODS MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + clinical pharmacists)<BR/>Level of training: Mixed<BR/>Clinical specialty: Internal medicine, surgery ICU<BR/>Country: USA (Omaha, Nebraska)</P>
<P>Centre: 1 tertiary care facility (Saint Joseph Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 145 participants treated with aminoglycosides for infection<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Aminoglycoside<BR/>Intervention: Participants whose doctors accepted recommendations based on a 1 compartment Bayesian pharmacokinetic model (n = 75) vs. those of doctors who did not (n = 70)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Indirect intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Number of doses adjustments (potential unit of analysis error) (number of serum aminoglycoside concentrations drawn/participant: not included)</P>
<P>Serum concentrations and therapeutic range: proportion of participants with first peak aminoglycoside serum concentrations "adequate" 0.5 h after infusion</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None (time for elevated temperature to decrease to &lt; 99.8 °F (37.7 °C): not included, time for elevated heart rate to decrease to &lt; 90 beats/min: not included, time for respiratory rate to decrease to &lt; 24/min: not included)</P>
<P>Clinical events: Death, nephrotoxicity (&#8805; 0.5 mg/dL rise in serum creatinine)</P>
<P>Healthcare costs: Length of hospital stay (h), direct cost per participant (USD)</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>"First peak concentrations were categorized as "adequate" (&gt;=5.0 mcg/ml and &gt;=20.0 mcg/ml for amikacin [an aminoglycoside]), "low" (&lt;5.0 mcg/ml and &lt;20.0 mcg/ml for amikacin), or not drawn"</P>
<P>"The target trough therapeutic ranges are concentrations of &lt;2.0 mcg/ml for gentamicin and tobramycin and 5-10 mcg/ml for amikacin"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzmaurice-2000">
<CHAR_METHODS MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Primary care practice and participant (2 control populations: participants individually randomized as controls in the intervention practices and all participants in the control practices, which allow an estimate of the Hawthorn effect)<BR/>Unit of analysis: Participant, INR (cluster was taken into account in statistical analysis)<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: Not reported<BR/>Clinical specialty: General/family practice<BR/>Country: UK (Birmingham)</P>
<P>Centre: 12 practices</P>
<P>Location of care: Community-based care<BR/>Participants: 224 outpatients with cardiovascular disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin adjustment for long-term therapy<BR/>Intervention: CDSS group (n = 122) vs. routine care (n = 102)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Proportion of INR measurements within therapeutic range (unit of analysis error)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Death, number of haemorrhagic events (epistaxis) per patient-years, number of thrombotic events per patient-years</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>There were 2 levels of randomization. Practices were randomly tagged as intervention or control practices. Then, in intervention practices, participants were individually randomized to intervention or control. We did not analyze 'control practices' because of a potential unit of analysis error</P>
<P>"Dosing recommendations made by the CDSS were based on the current INR in relation to individual therapeutic range, based on the British Society of Haematology guidelines, with the 2 main ranges being 2.0 to 3.0 and 3.0 to 4.5"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez-1989">
<CHAR_METHODS MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: USA (Virginia, Richmond)</P>
<P>Centre: 1 emergency department (Medical College of Virginia)</P>
<P>Location of care: Inpatient care<BR/>Participants: 82 participants with asthma treated with aminophylline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Theophylline<BR/>Intervention: Bayesian 1 compartment pharmacokinetic model (n = 37) vs. population-based guidelines (n = 30)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Theophylline loading dose (mg/kg), theophylline maintenance dose (mg/kg/h)</P>
<P>Serum concentrations and therapeutic range: Theophylline concentration (4 hours post load) (mg/L) (theophylline concentration at 1 and 2 hours post load: not included)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with adverse reactions (including nausea and vomiting)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>"Patients in group 1 received an IV bolus of aminophylline to achieve a serum theophylline concentration of 10 to 20 mg/L"</P>
<P>"Patients in group 2 received and IV aminophylline bolus followed by a maintenance infusion to achieve a serum theophylline concentration of 15 mg/L"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hickling-1989">
<CHAR_METHODS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Not reported<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (intensive care)<BR/>Country: New Zealand</P>
<P>Centre: 1 general hospital (Christchurch Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 32 ICU patients who required aminoglycoside therapy for serious life threatening infections<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: aminoglycoside (gentamicin or tobramycin)<BR/>Intervention: Pharmacokinetic model, computer-assisted group (n = 15) vs. control group (n = 17)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:42:12 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: Aminoglycoside mean peak concentration at 48-72 h, % participants within drug therapeutic range after 2 days (peak plasma concentrations 6-10 mg/L measured 1 h after the start of the infusion, and peak trough concentrations 1-2 mg/L within 30 min of the next dose), % participants achieving peak plasma concentrations at 48-72 h &gt; 6 mg/L (peak concentration criterion alone) (proportion of participants achieving peak plasma concentrations at 48-72 h &gt; 5 mg/L: not included, proportion of participants achieving peak plasma concentrations at 48-72 h &gt; 7 mg/L: not included)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>"The program was designed to predict the dose and dose interval required to achieve any desired peak and trough concentration. For the purpose of the study the specific target concentrations were a peak of 8 mg/l and a trough of 1.5 mg/l"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:42:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hovorka-2007">
<CHAR_METHODS MODIFIED="2013-11-05 11:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (Department of Cardiovascular Surgery)<BR/>Country: Czech Republic (Prague)</P>
<P>Centre: 1 university hospital (Charles University and General University Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 60 adults admitted for major elective cardiac surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill patients (cardiac surgery patients)<BR/>Intervention: Laptop-based algorithm eMPC (n = 30 participants) vs. standard protocol treatment (n = 30 participants). The eMPC is an enhanced version of the model predictive control algorithm (MPC), a model of the glucoregulatory system. Glucose concentration, insulin dosage, and carbohydrate content of enteral and parenteral input are the input variables for the eMPC. The insulin infusion rate and the time of the next glucose sample are the outputs<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:42:37 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Total Insulin dose (insulin units/24 h)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: % of time within the target range for blood glucose in the first 24 h (80-110 mg/dL or 4.4-6.1 mmol/L), blood glucose levels at ICU (mmol/L) (blood glucose levels at operating theatre: not included, time (h) above the target range for blood glucose in the first 24 h (&gt;110 mg/dL): not included, time (h) under the target range for blood glucose in the first 24 h (&gt;110 mg/dL): not included)</P>
<P>Time to achieve therapeutic control: Mean sampling interval (hours)</P>
<P>Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose level &lt; 2.9 mmol/L)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>- "The target range for blood glucose levels, as defined by the study protocol, was 4.4&#8211;6.1 mmol/liter, which has reduced mortality and morbidity in post-cardiac surgery patients." "Severe hypoglycemia was defined as blood glucose less than 2.9 mmol/liter"</P>
<P>- The authors were contacted and confirmed that none of the participants from <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK> was included in <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>
</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:43:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hurley-1986">
<CHAR_METHODS MODIFIED="2013-11-05 11:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Other (emergency)<BR/>Country: Australia (Victoria)</P>
<P>Centre: 1 community hospital (Preston and Northcote Community Hospital (PANCH))</P>
<P>Location of care: Inpatient care<BR/>Participants: 91 participants admitted to hospital with asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Theophylline<BR/>Intervention: Doctors given estimate of theophylline clearance based on 1 compartment linear pharmacokinetic model (n = 48) vs. usual care based on theophylline levels (n = 43). Computer gave advice on dose each day based on estimates of theophylline clearance</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant:<B> </B>Initial and maintenance daily dose of theophylline (mg/day)</P>
<P>Serum concentrations and therapeutic range: serum concentration at day 2 (&#956;g/mL), proportions of participants with serum trough concentrations in the therapeutic range, proportions of participants with serum concentrations in the toxic range</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: Death, length of stay</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-14 17:42:06 +0100" MODIFIED_BY="[Empty name]">
<P>"Ideally theophylline serum concentrations should be within a relatively narrow therapeutic range of 10 to 20 µg/ml"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jowett-2009">
<CHAR_METHODS MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: INR<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not reported<BR/>Country: Europe, Israel, Australia<BR/>Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)<BR/>Location of care: Outpatient care<BR/>Participants: 13,219 anticoagulation patients randomized at each centre into manual-dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants analyzed (167 participants without INR results): 2631 for the DAWN AC study and 10,421 for the PARMA 5 study<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phenprocoumon)<BR/>Intervention: Computer-assisted dosage program (PARMA5 (n = 5290 participants)) versus manual dosage (n = 5131 participants). Computer-assisted dosage program (DAWN AC (n = 1315 participants)) versus Manual dosage (n = 1316 participants). Recruitment was restricted to new patients initiated oral anticoagulation. 2 subroutines: induction and steady-state monitoring; the aim of the dosage algorithm was to maintain the INR value as close as possible to the mean target INR and to provide the next appointment date</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: No<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
<P>Serum concentrations and therapeutic range: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
<P>Physiological parameters: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
<P>Time to achieve therapeutic control: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
<P>Clinical events: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
<P>Healthcare costs: None (total cost per participant (Euros, base 2006) for all INR visits during the time period of the study (4.5 years) (dosing cost (staff time and the software for computer dosing), clinical event cost): reported)</P>
<P>Improvement: See <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>- This is a cost-effectiveness analysis conducted as a part of the European Action on Anticoagulation's (EEA) randomized multicentre study of computer-assisted oral anticoagulant dosage vs. manual dosing reported by Poller et al (see <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>)</P>
<P>- Costs were available for 28/32 clinics. There was no distinct results for PARMA 5 and DAWN AC systems</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:44:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kremen-2007">
<CHAR_METHODS MODIFIED="2013-11-05 11:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (Department of Cardiovascular Surgery ICU)<BR/>Country: Czech Republic (Prague)</P>
<P>Centre: 1 university hospital (Charles University and General University Hospital)</P>
<P>Location of care: Inpatient care<BR/>Participants: 20 adults who underwent a planned-cardiac surgery (coronary artery bypass or valve replacement) with glycaemia higher than 6.7 mmol/L at the time of admission to ICU<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill patients (cardiac surgery patients) with hyperglycaemia<BR/>Intervention: Laptop-based algorithm MPC (n = 10 participants) vs. routine blood glucose management protocol (n = 10 participants). The MPC is a model representing the glucoregulatory system. Glucose concentration, insulin dosage, and carbohydrate intake are the input variables for the MPC. The insulin infusion rate is the output parameter and was adjusted hourly as suggested by the algorithm<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Total Insulin dose (insulin units/48 h)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Mean blood glucose (mmol/L) (Time (h) within the target range for blood glucose in the first 24 h (80-110 mg/dL or 4.4-6.1 mmol/L): reported, duration of hyperglycaemia (&gt; 8.3 mmol/L) (h): not included)</P>
<P>Time to achieve therapeutic control: Time to establish glucose control (T<SUB>target</SUB>) (time from study entry until the plasma glucose concentration was in the target range of 80-110 mg/dL (4.4-6.1 mmol/L)) (min), time to target range (hours)</P>
<P>Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose level &lt; 2.9 mmol/L)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>- "The target range for blood glucose levels, as defined by the study protocol, was 4.4&#8211;6.1 mmol/liter, which has reduced mortality and morbidity in post-cardiac surgery patients." "Severe hypoglycemia was defined as blood glucose less than 2.9 mmol/liter"</P>
<P>- The authors were contacted and confirmed that none of the participants from <LINK REF="STD-Kremen-2007" TYPE="STUDY">Kremen 2007</LINK> was included in <LINK REF="STD-Hovorka-2007" TYPE="STUDY">Hovorka 2007</LINK>
</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:44:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Meur-2007">
<CHAR_METHODS MODIFIED="2013-11-05 11:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Nephrology<BR/>Country: France<BR/>Centre: 11 centres<BR/>Location of care: Inpatient care<BR/>Participants: 137 renal allograft recipients receiving basiliximab, CsA, MMF and corticosteroids. 130 participants analyzed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: MMF dosing in renal transplant patients<BR/>Intervention: Concentration-controlled (CC) regimen (n = 65 participants) vs. fixed-dose (FD) MMF (n = 65 participants). In the CC group, MMF dose adjustments were calculated by a computer program to reach an MPA AUC target of 40 mg.h/L and were proposed to the physician. In the FD group, MMF dose adjustments were based on clinical experience<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:44:49 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (MMF dose: not included (fixed dose in control group))</P>
<P>Serum concentrations and therapeutic range: None (serum creatinine level (&#956;mol/L): not included)</P>
<P>Physiological parameters: None (% participants within therapeutic range at day 14 (MPA AUC &gt; 30 mg.h/L): reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Death, proportion of participants with cytomegalovirus infections, proportion of participants with adverse events (anaemia, leukopenia, gastrointestinal adverse effects, infections)</P>
<P>Healthcare costs: None</P>
<P>Improvement: Proportion of participants without treatment failure (a composite of death, graft loss, acute rejection and MMF discontinuation), proportion of participants without biopsy-confirmed rejections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:44:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Treatment failure (a composite of death, graft loss, acute rejection and MMF discontinuation)<BR/>"In the CC group, MMF dose adjustments were calculated by a computer program (available at www.chu-limoges.fr/stp/stpacces.htm, June 21, 2007) to reach an MPA AUC target of 40 mg.h /L. The minimum dose change was 250 mg twice a day. Each dose adjustment of at least 250 mg twice a day that was able to result in an AUC closer to 40 mg.h /L was proposed by the program to the physician"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Meur-2007-extract">
<CHAR_METHODS MODIFIED="2013-08-01 02:05:25 +0200" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]">
<P>Text extracted from original article <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:45:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leehey-1993">
<CHAR_METHODS MODIFIED="2013-11-05 11:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + pharmacists)<BR/>Level of training: Not reported<BR/>Clinical specialty: Not applicable<BR/>Country: USA (Hines, Illinois)<BR/>Centre: 1 Veterans Affairs Hospital<BR/>Location of care: Inpatient care<BR/>Participants: 324 participants receiving aminoglycosides for suspected or confirmed infection were enrolled and randomly assigned to 1 of 3 groups: usual physician-directed dosing (group 1), pharmacist-assisted dosing (group 2), or pharmacist-directed dosing (group 3). 81 participants were dropped from the study because they received &lt; 72 h of therapy, leaving 243 study participants (73 in group 1, 90 in group 2, 80 in group 3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Aminoglycoside in participants with suspected or confirmed infection<BR/>Intervention: Pharmacist-directed dosing (group 3, n = 80) vs. usual physician-directed dosing (group 1, n = 73). Participants randomized to group 1 (customary dosing) had no intervention from study personnel other than the placement of an order in the hospital chart for the determination of serum creatinine levels post-therapy. In participants randomized to group 3 (pharmacist-directed dosing), all orders for aminoglycoside dosing were written by a pharmacist (with countersignature by 1 of the 2 study physicians) specially trained in the Bayesian dosing methods used in the study). Group 2 (pharmacist-assisted dosing) was excluded: dosing and monitoring recommendations were written by a pharmacist in the progress note section of the hospital chart, and the physicians caring for the participant were notified of these suggestions (the pharmacist served as a consultant)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Indirect intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Mean total aminoglycoside doses (mg) (duration of therapy: not included)</P>
<P>Serum concentrations and therapeutic range: Mean peak serum aminoglycoside levels (µg/mL) (mean serum trough concentrations (µg/mL): reported)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Need for dialysis, nephrotoxicity</P>
<P>Healthcare costs: None</P>
<P>Improvement: Proportion of participants with response to treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Nephrotoxicity was defined as a &#8805; 100% increase in serum creatinine concentration with at least a 44 µmol/L (0.5 mg/dL) increment in this value</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:45:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lesourd-2002">
<CHAR_METHODS MODIFIED="2013-11-05 11:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Obstetrics and gynaecology<BR/>Country: France (Toulouse, Rouen, Paris)</P>
<P>Centre: 3 centres (private and university teaching hospitals)<BR/>Location of care: Outpatient care<BR/>Participants: 164 women undergoing ovarian stimulation to treat infertility</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Ovarian stimulation by gonadotropins<BR/>Intervention: CDSS group (n = 82) vs. control group (n = 82)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Number of follicle-stimulating hormone units administered</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None (cancelled cycles of ovarian stimulation: not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: Proportion of participants with clinical pregnancies (ongoing pregnancies: not included, mean number of follicles &#8805; 18 mm: not included)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-24 12:02:36 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manotti-2001">
<CHAR_METHODS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Design: NRCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not reported<BR/>Country: Italy</P>
<P>Centre: 5 anticoagulant clinics, all federated with the FCSA (Italian Federation of Anticoagulation Clinics)</P>
<P>Location of care: Outpatient care<BR/>Participants: 335 participants on oral anticoagulants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: initiation of oral anticoagulant therapy (warfarin and acenocoumarol)<BR/>Intervention: Computer-aided dosing (n = 145) vs. manual dosing (n = 190)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (maintenance dose (mg/week): not included (number of appointments, available only for warfarin))</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (% of participants reaching a stable state of anticoagulation (3 INR measurements within therapeutic range): reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>"The use of only two separate therapeutic ranges was suggested:<BR/>Low Intensity = INR 2.0 to 3.0; target value 2.5. People with deep venous thrombosis/pulmonary embolism, atrial fibrillation, heart valve disease, biological valve prosthesis.<BR/>High Intensity = INR 3.0 to 4.5 ; target value 3.5. People with a mechanical heart valve prosthesis, coronary or other arterial disease"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mihajlovic-2003">
<CHAR_METHODS MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Not reported<BR/>Level of training: Not reported<BR/>Clinical specialty: Psychiatry<BR/>Country: Serbia<BR/>Centre: 1 psychiatric clinic of a clinical hospital centre (Clinical Hospital Center Kragujevac)<BR/>Location of care: Not reported<BR/>Participants: 60 participants with major depressive disorder (according to ICD-10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Amitriptyline in the treatment of major depressive episode<BR/>Intervention: Computer-aided dosing of amitriptyline (n = 30 participants) vs. usual dose regimen (n = 30 participants). The individualization of amitriptyline dose was calculated using the modified Bayesian method (on the basis of therapeutic steady-state concentration of 80 ng/mL, participant's sex, weight, age, creatinine plasma concentration, albumin plasma concentration and volume of the liquid on the 'third space')<BR/>Computer advice: Not reported<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: Not reported<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2013-09-25 14:47:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Can this J be changed to 'day'?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-11-05 11:46:33 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Drug daily doses of amitriptyline + nortriptyline at day 14 (mg) (at day 28, day 42, day 56: not included)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Steady-state plasma concentration of amitriptyline + nortriptyline at J14 (during the treatment course) (at day 28, day 42, day 56: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with adverse effects of amitriptyline per days of research at day 14 (at day 28, day 42, day 56: not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: Hamilton Depression Rating scale scores at day 28 (at day 14, day 42, day 56: not included, Clinical Global Impression scale: not included)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Among the 60 participants included in the study, 15 were also included in <LINK REF="STD-Jankovic-1999" TYPE="STUDY">Jankovic 1999</LINK> (excluded study)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:47:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mihajlovic-2010">
<CHAR_METHODS MODIFIED="2013-11-05 11:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Not reported<BR/>Level of training: Not reported<BR/>Clinical specialty: Psychiatry<BR/>Country: Serbia<BR/>Centre: 1 psychiatric clinic of a clinical hospital centre (Clinical Hospital Center Kragujevac)<BR/>Location of care: Not reported<BR/>Participants: 60 participants with major depressive disorder (according to ICD-10).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:46:55 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Amitriptyline in the treatment of major depressive episode<BR/>Intervention: Computer-aided dosing of amitriptyline (n = 30 participants) vs. usual dose regimen (n = 30 participants). The individualization of amitriptyline dose was calculated using the modified Bayesian method (on the basis of therapeutic steady-state concentration of 80 ng/mL, participant's sex, weight, age creatinine plasma concentration, albumin plasma concentration and volume of the liquid on the 'third space')<BR/>Computer advice: Not reported<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: Not reported<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>Serum concentrations and therapeutic range: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>Physiological parameters: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>Time to achieve therapeutic control: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>Clinical events: None</P>
<P>Healthcare costs: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>Improvement: See <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>This is a safety analysis conducted as a part of the randomized multicentre study of computer-aided dosing of amitriptyline vs. usual dose regimen reported by Mihajlovic et al. (see <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mitra-2005">
<CHAR_METHODS MODIFIED="2013-11-05 11:47:29 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant, dose of treatment<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:47:29 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Rehabilitation<BR/>Country: USA<BR/>Centre: 1 free-standing, 288-bed, academic rehabilitation centre<BR/>Location of care: Inpatient care<BR/>Participants: 280 hospitalized rehabilitation patients who were prescribed warfarin for anticoagulation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin (Coumadin) to maintain hospitalized rehabilitation patients within a therapeutic INR (2.0-3.0)<BR/>Intervention: Computer-aided dosing of warfarin (n = 14 participants) vs. physician dosing (n = 16 participants). The computer-generated program (DAWN AC) gave instructions to the physicians for warfarin dosing and for timing and frequency of blood draws<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: Not reported<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (time spent in days per 100 patient-days of treatment: reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with thromboembolism (pulmonary embolism, deep vein thrombosis) (number of blood draws: not included)</P>
<P>Healthcare costs: Length of stay (days)</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>"The goal of both groups was to maintain patients within a target INR of 2.0 - 3.0"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:51:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mungall-1994">
<CHAR_METHODS MODIFIED="2013-11-05 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed physicians + pharmacists)<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (coronary care unit)<BR/>Country: USA (Michigan)</P>
<P>Centre: 2 medical centres (McLaren Regional Medical Center, Midland Regional Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 51 participants needing anticoagulation with heparin after myocardial infarction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Heparin adjustment<BR/>Intervention: Bayesian computer-generated starting doses (n = 25) vs. doctors using nomogram (n = 26)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Indirect intervention (dosage determined by pharmacy using)</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: mean heparin dose (units/h)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (activated partial thromboplastin time ratio (compared with baseline activated partial thromboplastin time before heparin therapy): not included, number of activated partial thromboplastin time measurements per day of therapy: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with clinical adverse events (recurrent chest pain, recurrent chest pain and readministration of thromboplastin, development of congestive heart failure, thrombotic stroke, arterial embolization, pulmonary embolus, transient ischaemic attack), proportion of participants with bleeding events</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:51:42 +0100" MODIFIED_BY="[Empty name]">
<P>- The therapeutic range was 1.2-2.5 times the participant's baseline activated partial thromboplastin time<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pachler-2008">
<CHAR_METHODS MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported (non-inferiority trial but no margin addressed)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Nurses<BR/>Level of training: Not reported<BR/>Clinical specialty: ICU<BR/>Country: Austria (Graz)<BR/>Centre: 1 x 9-bed medical ICU in a tertiary teaching hospital<BR/>Location of care: Inpatient care<BR/>Participants: 50 mechanically ventilated medical ICU patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill patients with hyperglycaemia<BR/>Intervention: Laptop-based algorithm eMPC (n = 25 participants) vs. routine nurse-based protocol (n = 25 participants). The eMPC is an enhanced version of the MPC, a model of the glucoregulatory system. Glucose concentration, insulin dosage and carbohydrate content of enteral and parenteral input are the input variables for the eMPC. The insulin infusion rate and the time of the next glucose sample are the outputs<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Insulin (IU/h) (change of insulin rate (number of times in 72 h): reported, carbohydrate administration (g/h): not included)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Hyperglycaemia index (mmol/L) (blood glucose (mmol/L): not included (unit of analysis error))</P>
<P>Time to achieve therapeutic control: Mean sampling interval (hours)</P>
<P>Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose levels lower than 2.2 mM)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>- Hyperglycaemic index was used as primary endpoint for the assessment of glucose control. The hyperglycaemic index developed by Vogelzang et al. is defined as the AUC above the upper limit of normal (glucose level 6.1 mmol/L, modified from the original 6.0 mmol/L) divided by the total length of stay (time in study)</P>
<P>- Non-inferiority trial analyzed like superiority trial</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plank-2006">
<CHAR_METHODS MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant, time under treatment<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Not reported<BR/>Level of training: Not reported<BR/>Clinical specialty: ICU<BR/>Country: Europe (Austria, Czech Republic, UK)<BR/>Centre: 3 ICUs across Europe (Graz, Prague, London)<BR/>Location of care: Inpatient care<BR/>Participants: 60 participants undergoing cardiac surgery with postsurgery hyperglycaemia (glucose &gt; 120 mg/dL)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in critically ill patients with hyperglycaemia<BR/>Intervention: Laptop-based algorithm MPC (n = 30 participants) vs. routine blood glucose management protocol (n = 30 participants). The MPC is a model representing the glucoregulatory system. Glucose concentration, insulin dosage and carbohydrate intake are the input variables for the MPC. The insulin infusion rate is the output parameter and was adjusted hourly as suggested by the algorithm<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Indirect intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Insulin dosages used for the first 24 h (insulin units/24 h)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: % of time within the target range for blood glucose in the first 24 h (80-110 mg/dL or 4.4-6.1 mmol/L), mean glucose levels (mg/dL) (% of time above the target range for blood glucose in the first 24 h (&gt; 110 mg/dL): not included, % of time between 54 and 79 mg/dL for blood glucose in the first 24 h (2.9 to &lt; 4.4 mmol/L): not included)</P>
<P>Time to achieve therapeutic control: Mean sampling interval (h)</P>
<P>Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose level &lt; 54 mg/dL or &lt; 3 mmol/L)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>- "The target range for blood glucose levels, as defined by the study protocol, was 80-110 mg/dl (4.4-6.1 mmol/l), which has been demonstrated to reduce mortality and morbidity in postcardiac surgery patients. The MPC algorithm and the routine care management protocol in Graz are aiming for exactly the same target range, while in Prague a slightly higher level for the upper limit (81-117 mg/dl [4.5-6.5 mmol/l]) and in London a slightly lower level for the lower limit (72-108 mg/dl [46 mmol/l]) is implemented in the routine glucose protocol. Likewise, small differences in the definition of hypoglycemia can be found among the routine management protocols (London: 54 mg/dl [3.0 mmol/l], Graz: 60 mg/dl [3.3 mmol/l], and Prague: 63 mg/dl [3.5 mmol/l]). For the study protocol, blood glucose levels 54 mg/dl (3.0 mmol/l) were defined as hypoglycemic events"</P>
<P>- The author was contacted and confirmed that the algorithm gave advice to the ICU personnel (nurses and physicians), who input the glucose values and changed the infusion rate</P>
<P>- The study is part of CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients; <A HREF="http://www.clinicip.org">www.clinicip.org</A>), an integrated project funded by the European Community<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-1998-pop1">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Episode of care<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not applicable<BR/>Country: Europe (Manchester (UK), London (UK), Oslo (Norway), Esbjerg (Denmark), Gaia (Portugal))</P>
<P>Centre: 5 centres</P>
<P>Location of care: Outpatient care<BR/>Participants: 79 inpatients needing anticoagulant therapy (stabilized patients)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin therapy maintenance<BR/>Intervention: Computer-generated-dose group (n = 39) or traditional-dose group (n = 40)</P>
<P>Computer advice: Not reported<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (proportion of doses adjustments: unknown denominator)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Proportion of time spent within target (INR)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>The proportion of time within target INR range was determined according to the Rosendaal method</P>
<P>"The program has two main modules - the induction module for starting warfarin therapy over the first 4 days to reach a dose within 1 mg of eventual maintenance dose, and the maintenance module (version 4 only was used) for finely tuning the dose to the therapeutic range and sustaining it"</P>
<P>"The INR target ranges were decided by the individual centre, based on one of: the guidelines on oral anticoagulation of the British Society of Haematology, the Leuven Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-4.5, and 2.5-3.5"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-1998-pop2">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Episode of care<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not applicable<BR/>
</P>
<P>Country: Europe (Manchester (UK), London (UK), Oslo (Norway), Esbjerg (Denmark), Gaia (Portugal))</P>
<P>Centre: 5 centres</P>
<P>Location of care: Outpatient care<BR/>Participants: 175 outpatients needing anticoagulant therapy (in the stabilization period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin therapy stabilization<BR/>Intervention: Computer-generated-dose group (n = 83) or traditional-dose group (n = 92)</P>
<P>Computer advice: Not reported<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (proportion of doses adjustments: unknown denominator)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Proportion of time spent within target (INR)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>The proportion of time within target INR range was determined according to the Rosendaal method</P>
<P>"The program has two main modules - the induction module for starting warfarin therapy over the first 4 days to reach a dose within 1 mg of eventual maintenance dose, and the maintenance module (version 4 only was used) for finely tuning the dose to the therapeutic range and sustaining it"</P>
<P>"The INR target ranges were decided by the individual centre, based on one of: the guidelines on oral anticoagulation of the British Society of Haematology, the Leuven Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-4.5, and 2.5-3.5"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>- Same data as <LINK REF="STD-Poller-1998-pop1" TYPE="STUDY">Poller 1998 pop1</LINK>; <LINK REF="STD-Poller-1998-pop2" TYPE="STUDY">Poller 1998 pop2</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]">
<P>- Abstract corresponding to the Protocol of the study published in 2008 (<LINK REF="STD-Poller-2008" TYPE="STUDY">Poller 2008</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>- Clinical endpoint report from the European Action on Anticoagulation (EAA), which gave the combined results using 2 currently marked computer-assisted dosage programs (DAWN AC and PARMA 5). The subgroup analyses were included (<LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>, <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2008-PARMA-5">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: INR<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not reported<BR/>Country: Europe, Israel, Australia<BR/>Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)<BR/>Location of care: Outpatient care<BR/>Participants: 13,219 anticoagulation patients randomized at each centre into manual-dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants analyzed (167 participants without INR results): 2631 for the DAWN AC study and 10,421 for the PARMA 5 study<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phenprocoumon)<BR/>Intervention: Computer-assisted dosage program (PARMA5 (n = 5290 participants)) versus manual dosage (n = 5131 participants). Recruitment was restricted to new patients initiated oral anticoagulation. 2 subroutines: induction and steady state monitoring; the aim of the dosage algorithm was to maintain the INR value as close as possible to the mean target INR and to provide the next appointment date<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Time in target INR range (INR: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Death, number of bleeding events (major + minor) (events per 100 patient-years), number of thrombotic events (events per 100 patient-years)<B> </B>(number of events (minor bleeding events, major bleeding events, thrombotic events, deaths): not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]">
<P>- Time in target INR range = proportion of time for which participants were maintained within the locally decided target INR ranges</P>
<P>- This report is a subgroup analysis of the previous clinical endpoint report from the European Action on Anticoagulation (EAA) (Poller 2008b), which gave the combined results using 2 currently marked computer-assisted dosage programs (DAWN AC and PARMA 5 ) (<LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>, <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>)</P>
<P>- There were some incoherences between the number of events adjudicated in Poller 2008b (table 2) and the sum of number of events in <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> (table II) and in <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK> (table 2). The author confirmed the numbers in Poller 2008b and <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and corrected those in <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2009-DAWN-AC">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: INR<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Not reported<BR/>Country: Europe, Israel, Australia<BR/>Centre: 32 centres in 13 countries (Europe: 29, Israel: 2, Australia: 1)<BR/>Location of care: Outpatient care<BR/>Participants: 13,219 anticoagulation patients randomized at each centre into manual-dosed or computer-assistant dosed arm (DAWN AC or PARMA 5). 13,052 participants analyzed (167 participants without INR results): 2631 for the DAWN AC study and 10,421 for the PARMA 5 study<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Oral anticoagulation (warfarin, nicoumalone (acenocoumarol), phenprocoumon)<BR/>Intervention: Computer-assisted dosage program (DAWN AC (n = 1315 participants)) versus manual dosage (n = 1316 participants). Recruitment was restricted to new patients initiated oral anticoagulation. 2 modules: induction and maintenance; the time to the next test was set by the program using a table of variables<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Not reported<BR/>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Time in target INR range (INR: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Death, number of bleeding events (major + minor) (events per 100 patient-years), number of thrombotic events (events per 100 patient-years) (number of events (minor bleeding events, major bleeding events, thrombotic events, deaths): not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>- Time in target INR range = proportion of time for which participants were maintained within the locally decided target INR ranges</P>
<P>- This report is a subgroup analysis of the previous clinical endpoint report from the European Action on Anticoagulation (EAA) (Poller 2008b), which gave the combined results using 2 currently marked computer-assisted dosage programs (DAWN AC and PARMA 5 ) (<LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>, <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK>)</P>
<P>- There were some incoherences between the number of events adjudicated in Poller 2008b (table 2) and the sum of number of events in <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> (table II) and in <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK> (table 2). The author confirmed the numbers in Poller 2008b and <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and corrected those in <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-2009-erratum">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-08-06 13:13:45 +0200" MODIFIED_BY="[Empty name]">
<P>- Erratum from original article <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodman-1984">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Not reported<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: USA</P>
<P>Centre: 1 medical centre (University of Southern California Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 20 participants admitted to medical ICU or coronary care unit needing lignocaine therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Lidocaine therapy<BR/>Intervention: Advice on initial therapy using individualized linear 2 compartment pharmacokinetic model (n = 9) vs. usual care (n = 11)<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: mean first hour infusion rate (&#956;g/kg/min), mean final infusion rate (&#956;g/kg/min), mean overall infusion rate</P>
<P>Serum concentrations and therapeutic range: serum concentrations (lidocaine)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: proportion of participants with adverse reactions (monitoring of rhythm, intermittent hard-copy rhythm strips, serial electrocardiographs, daily measurements of electrolyte and cardiac enzyme levels, liver function tests)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Objective: "To achieve and maintain plasma concentrations in the approximate middle of the usual therapeutic range of 1.5 to 5.0 µg/mL"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:56:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rousseau-2010">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Nephrology<BR/>Country: France<BR/>Centre: 11 centres<BR/>Location of care: Inpatient care<BR/>Participants: 137 renal allograft recipients receiving basiliximab, CsA, MMF and corticosteroids. 130 participants analyzed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: MMF dosing in renal transplant patients<BR/>Intervention: Concentration-controlled (CC) regimen (n = 65 participants) vs. fixed-dose (FD) MMF (n = 65 participants). In the CC group, MMF dose adjustments were calculated by a computer program to reach an MPA AUC target of 40 mg.h/L and were proposed to the physician. In the FD group, MMF dose adjustments were based on clinical experience<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
<P>Serum concentrations and therapeutic range: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
<P>Physiological parameters: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
<P>Time to achieve therapeutic control: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
<P>Clinical events: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
<P>Healthcare costs: Cost per participant during the first year of transplantation based on diagnosis-related groups reimbursements (EUR, base 2007) (hospital stays, drugs, biological tests and medical transportation)</P>
<P>Improvement: See <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>This is a cost-effectiveness analysis conducted as a part of the APOMYGRE randomized multicentre study of concentration-controlled dosing regimen of MMF vs. fixed-dose reported by Le Meur et al. (see <LINK REF="STD-Le-Meur-2007" TYPE="STUDY">Le Meur 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saager-2008">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (trained healthcare professionals)<BR/>Level of training: Not reported<BR/>Clinical specialty: Not reported<BR/>Country: USA<BR/>Centre: 1 large academic medical centre<BR/>Location of care: Inpatient care<BR/>Participants: 40 participants with diabetes mellitus scheduled for cardiac surgery (cardiothoracic ICU)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in people with diabetes undergoing cardiac surgery<BR/>Intervention: Computer-guided glucose management system (n = 20 participants) vs. standard paper-based insulin protocol (n = 20 participants). The computer system (EndoTool Glucose Management System (MD Scienti&#64257;c)) used the previous 4 dose responses to recommend the insulin dose, glucose determination frequency, and a 50% dextrose dose (when appropriate) for hypoglycaemia<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Mean blood glucose (mg/dL) in ICU (available in operating room: not included, time in blood glucose range in operating room: reported, time in blood glucose range in ICU: reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with side effects (hypoglycaemia: &lt; 60 mg/dL at any time) in ICU (available in operating room: not included)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>"The standard paper-based ICU insulin protocol was developed at this institution with the goal of targeting blood sugar concentrations between 90 and 150 mg/dL"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sato-2011">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant, blood glucose measurements<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Anaesthesiologists<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (anaesthesiology/cardiology)<BR/>Country: Canada (Montreal)<BR/>Centre: 1 university hospital (Royal Victoria Hospital, McGill University Health Centre)<BR/>Location of care: Inpatient care<BR/>Participants: 42 participants without diabetes undergoing elective cardiac surgery were randomized. 36 participants were analyzed. All studies were conducted by 6 anaesthesiologists, each anaesthesiologist was assigned to 3 manual and 3 GINCS studies in random order</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Glucose and insulin administration in cardiac surgical patients<BR/>Intervention: GIN Computer Software (GINCS) (n = 18) versus manual control group (n = 18). The computer program uses an algorithm based on the original clamp equation (DeFronzo et al.) and modified for its use during cardiac surgery requiring extracorporeal circulation. It takes account of the characteristic of glucose dynamics during cardiac surgery and CPB, including plasma glucose fluctuation, alterations in glucose utilization, transfusion of blood products, and rewarming of the patients<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: Not reported<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: mean amount of insulin infused (IU) (mean amount of glucose administered (g): reported)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Mean blood glucose (mmol/L), % of participants with all measurements within the target range for blood glucose (4-6 mmol/L) (% of time within the target range for blood glucose (4-6 mmol/L) (unit of analysis error): reported, % of time below the target range for blood glucose (4-6 mmol/L) (unit of analysis error): not included, % of time above the target range for blood glucose (4-6 mmol/L) (unit of analysis error): not included, time (min) within the target range for blood glucose (4-6 mmol/L): not included, time (min) below the target range for blood glucose (4-6 mmol/L): not included, time (min) above the target range for blood glucose (4-6 mmol/L): not included)</P>
<P>Time to achieve therapeutic control: Mean sampling interval (min)</P>
<P>Clinical events: Proportion of participants with hypoglycaemic episodes (blood glucose level &lt; 2.9 mmol/L)</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>"Target glycemia was defined as BG [blood glucose] between 4.0 to 6.0 mmol/L. Hyperglycemia was defined as BG 7.0 mmol/L. Hypoglycemia was defined as a BG 2.9 mmol/L. Time within, above and below target range was calculated by assuming the linearity of BG level over time"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terrell-2010">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Provider<BR/>Unit of analysis: Medication, participant visit (cluster was taken into account in statistical analysis)<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Mixed<BR/>Clinical specialty: Emergency<BR/>Country: USA<BR/>Centre: 1 urban public hospital<BR/>Location of care: Inpatient care<BR/>Participants: 42 emergency medicine faculty and resident physicians randomized (intern physicians excluded). Subjects were adults with renal insufficiency who were being discharged home from the emergency department. 6015 participant visits with prescription initially written for a targeted medication. Among the 2783 visits in which creatinine level was estimated, 113 (4%) participant visits (corresponded to 119 prescriptions) resulted in prescription of at least 1 medication that required dosage adjustment (3232 participant visits excluded because of insufficient information in the electronic medical record to estimate the creatinine clearance)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: 10 high-use medications that require adjustments for renal impairment (amoxicillin, amoxicillin/clavulanate, cephalexin, ciprofloxacin, colchicine, hydrochlorothiazide, levofloxacin, lisinopril, ranitinide, trimethoprim/sulfamethoxazole)<BR/>Intervention: Computerized decision support (21 physicians) vs. control group (21 physicians). Decision support was provided when an intervention physician prescribed a targeted medication to a person whose creatinine level was below the threshold for dosage adjustment for that particular medication. The physician could either accept or reject the decision support's recommendation.<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None (% excessively dosed prescriptions: reported,<B> </B>% visits with excessively dosed prescriptions: not included)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-02 14:33:34 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Theil-1993-fentanyl">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (anaesthesia)<BR/>Country: USA (Durham, North Carolina)</P>
<P>Centre: 1 University Medical Center (Duke University Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 24 participants undergoing cardiac surgery with continuous infusion of IV anaesthetics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Fentanyl<BR/>Intervention: Computer-controlled pump using pharmacokinetic model to achieve target serum level (n = 12) vs. infusion controlled by doctor (n = 12)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (fentanyl loading dose (&#956;g/kg): reported, fentanyl maintenance infusion dose during cardiopulmonary bypass (&#956;g/kg): reported, fentanyl total dose (&#956;g/kg): reported, mean number of infusion changes during cardiopulmonary bypass (potential unit of error analysis): reported)</P>
<P>Serum concentrations and therapeutic range: None (mean plasma fentanyl concentration during cardiopulmonary bypass (ng/mL): reported)</P>
<P>Physiological parameters: None (haemodynamic values: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>"The primary objective for all patients was to maintain heart rate (HR) and mean arterial pressure (MAP) within 20% of baseline values. If possible, hemodynamic control was achieved by altering only the anesthetic infusions. Hypertension (MAP&gt;20% baseline) and tachycardia (HR&gt;20%) were initially treated by incremental increases in fentanyl or midazolam.[...] Hypotension (MAP&gt;20%) prior to and during cardiopulmonary bypass (CPB) was treated by intravenous volume expansion, and a decrease in anesthetic delivery"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Theil-1993-midazolam">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Not reported<BR/>Clinical specialty: Other (anaesthesia)<BR/>Country: USA (Durham, North Carolina)</P>
<P>Centre: 1 University Medical Center (Duke University Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 24 participants undergoing cardiac surgery with continuous infusion of IV anaesthetics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Midazolam<BR/>Intervention: Computer-controlled pump using pharmacokinetic model to achieve target serum level (n = 12) vs. infusion controlled by doctor (n = 12)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None (midazolam loading dose (&#956;g/kg): reported, midazolam maintenance infusion dose during cardiopulmonary bypass (&#956;g/kg): reported, midazolam total dose (&#956;g/kg): reported, mean number of infusion changes during cardiopulmonary bypass (potential unit of error analysis): reported)</P>
<P>Serum concentrations and therapeutic range: None (mean plasma midazolam concentration during cardiopulmonary bypass (ng/mL): reported)</P>
<P>Physiological parameters: None (haemodynamic values: not included)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>"The primary objective for all patients was to maintain heart rate (HR) and mean arterial pressure (MAP) within 20% of baseline values. If possible, hemodynamic control was achieved by altering only the anesthetic infusions. Hypertension (MAP&gt;20% baseline) and tachycardia (HR&gt;20%) were initially treated by incremental increases in fentanyl or midazolam.[...] Hypotension (MAP&gt;20%) prior to and during cardiopulmonary bypass (CPB) was treated by intravenous volume expansion, and a decrease in anesthetic delivery"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadher-1997">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: In training<BR/>Clinical specialty: Not reported<BR/>Country: UK (London)</P>
<P>Centre: 1 district general hospital (Whittington Hospital)</P>
<P>Location of care: Mixed<BR/>Participants: 148 inpatients requiring start of warfarin therapy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin therapy initiation<BR/>Intervention: CDSS group (n = 72 ) vs. control group (n = 76)</P>
<P>Computer advice: Not reported<BR/>CDSS integration in CPOE: No<BR/>Starter: Not reported<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (time spent in days per 100 patient-days of treatment: reported)</P>
<P>Time to achieve therapeutic control: Median time to reach therapeutic prothrombin ratio (days), median to reach stable dose (days)</P>
<P>Clinical events: Thromboembolism, haemorrhage, death</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>"We developed an initiation regimen aiming for a therapeutic range of international normalised ratio of 2 to 3"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadher-1997-pop1">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant, participant time<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: Mixed<BR/>Clinical specialty: Other (cardiology)<BR/>Country: UK (London)</P>
<P>Centre: 1 district general hospital (Whittington Hospital)</P>
<P>Location of care: Outpatient care<BR/>Participants: Participants who had been initiated on warfarin therapy as inpatients and followed in the outpatient clinic. Most of these participants required anticoagulation for deep vein thrombosis, pulmonary embolus or atrial fibrillation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin long-term therapy (therapeutic range 2-3)<BR/>Intervention: CDSS group (n = 37) vs. control group (n = 44)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Maintenance dose (mg/day)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (time spent in days per 100 patient-days of treatment: reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Thromboembolism, haemorrhage</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic range of INR was 2-3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadher-1997-pop2">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant, participant time<BR/>Power calculation: Not reported<BR/>Concealment of allocation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + nurses)<BR/>Level of training: Mixed<BR/>Clinical specialty: Other (cardiology)</P>
<P>Location of care: Outpatient care<BR/>Country: UK (London)</P>
<P>Centre: 1 district general hospital (Whittington Hospital)</P>
<P>Participants: Participants who had been on warfarin for more than 1 year. Most of the participants required anticoagulation for heart valve disease, valve replacement or recurrent thromboembolism</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin long term (therapeutic range 3-4.5)<BR/>Intervention: CDSS group (n = 50) vs. control group (n = 46)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Not reported<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Maintenance dose (mg/day)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (time spent in days per 100 patient-days of treatment: reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Thromboembolism, haemorrhage</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic range of INR was 3-4.5<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verner-1992">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Internal medicine<BR/>Country: Israel (Tel Hashomer)</P>
<P>Centre: A 1400 bed regional teaching hospital (Sheba Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 25 participants needing aminophylline therapy for acute asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Theophylline<BR/>Intervention: Computer suggested dose based on individualized pharmacokinetic model to doctor (n = 10) vs. usual care (n = 15)</P>
<P>Computer advice: Not reported<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Loading dose of theophylline (mg)</P>
<P>Serum concentrations and therapeutic range: Serum theophylline concentration 20 minutes after completion of loading dose infusion (&#956;g/mL) (% of time spent in therapeutic range (serum theophylline concentrations in 10-20 µg/mL): reported)</P>
<P>Physiological parameters: None</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: Mean hospitalization time (days)</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>"The computer program was used to estimate the predicted admission serum theophylline concentration, and the partial loading dose needed to achieve the target concentration which was set at 16 g/ml"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wexler-2010">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Provider (physicians team)<BR/>Unit of analysis: Participant (cluster was <U>not</U> taken into account in statistical analysis)<BR/>Power calculation: Done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Physicians<BR/>Level of training: In training<BR/>Clinical specialty: Internal medicine<BR/>Country: USA (Boston)<BR/>Centre: 1 tertiary care medical centre (Massachusetts General Hospital Diabetes Center)<BR/>Location of care: Inpatient care<BR/>Participants: 144 insulin-treated people with type 2 diabetes enrolled. 128 participants analyzed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Insulin in general medical inpatients with type 2 diabetes<BR/>Intervention: Electronic basal-bolus insulin order template (n = 65 participants) vs. usual insulin ordering (n = 63 participants). The total daily dose of insulin required for the participant (basal (long-acting) and prandial (short-acting)) was calculated by multiplying the weight of the participant by 0.5 units/kg. A button to use insulin-dose calculator was available<BR/>Computer advice: Given in real time<BR/>CDSS integration in CPOE: Yes<BR/>Starter: System-initiated<BR/>Type of intervention: Direct intervention<BR/>Calculated dose given as a recommendation: Yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: Basal insulin dose (units)</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: Mean blood glucose (mg/dL)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: Proportion of participants with hypoglycaemia (&lt; 60 mg/dL at any time) (severe hypoglycaemia (&lt; 40 mg/dL at any time): not included, prolonged hyperglycaemia (3 consecutive glucose values &gt; 240 mg/dL): not included)</P>
<P>Healthcare costs: Length of stay (days)</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-30 17:27:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1987">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not done<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Mixed (physicians + pharmacists)<BR/>Level of training: Accredited/licensed<BR/>Clinical specialty: Other (anticoagulant clinic)<BR/>Country: USA (California)</P>
<P>Centre: 2 university hospitals (Veterans Administration Medical Center, Davis Medical Center)</P>
<P>Location of care: Inpatient care<BR/>Participants: 75 participants requiring anticoagulation with warfarin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Warfarin initiation<BR/>Intervention: Initial dose suggested by Bayesian computer pharmacokinetic and pharmacodynamic model (n = 39) vs. usual care (n = 36)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Not reported</P>
<P>Calculated dose given as a recommendation: Yes<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None (participant with supratherapeutic prothrombin ratio (PR) at any time: not included)</P>
<P>Physiological parameters: Days on warfarin PR therapeutic</P>
<P>Time to achieve therapeutic control: Time to reach a therapeutic PR, time to reach a therapeutic dose</P>
<P>Clinical events: Proportion of participants with a bleeding complication, death</P>
<P>Healthcare costs: Length of stay</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic range was defined as PR = 1.8 ± 0.4, or, using a generalized formula, PR±(0.22)*(PR)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1991">
<CHAR_METHODS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Unit of allocation: Participant<BR/>Unit of analysis: Participant<BR/>Power calculation: Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Profession: Nurses<BR/>Level of training: Mixed<BR/>Clinical specialty: Not reported<BR/>Country: USA (California)</P>
<P>Centre: 1 university hospital (Davis Medical Center)</P>
<P>Location of care: Outpatient care</P>
<P>Participants: 50 participants needing anticoagulation with warfarin (long-term oral therapy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical problem: Long-term warfarin adjustment<BR/>Intervention: Maintenance dose suggested by Bayesian computer pharmacokinetic model (n = 24) vs. usual care (n = 26)</P>
<P>Computer advice: Given in real time<BR/>CDSS integration in CPOE: No<BR/>Starter: User-initiated<BR/>Type of intervention: Direct intervention</P>
<P>Calculated dose given as a recommendation: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of drug administered to the participant: None</P>
<P>Serum concentrations and therapeutic range: None</P>
<P>Physiological parameters: None (proportion of participants within target (final prothrombin time): reported)</P>
<P>Time to achieve therapeutic control: None</P>
<P>Clinical events: None</P>
<P>Healthcare costs: None</P>
<P>Improvement: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-31 10:41:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CDSS: clinical decision support system; CGMS: continuous glucose monitoring system; CPOE: computer physician order entry; CsA: cyclosporine A; eMPC: Enhanced software Model Predictive Control; GP: general practitioner; ICU: intensive care unit; INR: international normalized ratio; IU: international unit; IV: intravenous; KADIS: KArlsburg Diabetes Management System; MMF: mycophenolate mofetil; MPA: mycophenolic acid (MPA); NRCT: non-randomized controlled trial; RCT: randomized controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-10-31 16:13:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:18:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abbrecht-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:18:50 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (computer controlled pump not under physician control)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:36:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Absalom-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:36:42 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (automatic control of the propofol infusion using closed-loop system)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albisser-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (prediction of future glycaemia and future risks of hypoglycaemia and hyperglycaemia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:02:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvis-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:02:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:36:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barletta-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:36:45 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barras-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (trial comparing individualized dosing of enoxaparin based on participa
nt weight and renal function to conventional dosing)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barras-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose calculated from an equation including the weight of the participa
nt)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-27 12:10:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bartal-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-27 12:10:10 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (utility of pharmacokinetic monitoring of aminoglycoside levels in the context of once-daily treatment (primary endpoint: renal toxicity))</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berg-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (individually tailored treatment duration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burger-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (t
able with therapeutic drug monitoring rules depending on the concentration ratio method (standardized pharmacokinetic curve))</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:02:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bury-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:02:20 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:37:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caraballo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:02:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-1987a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:02:55 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavalcanti-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (
the target range for blood glucose was different according to the interventions or the conventional treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:37:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:37:36 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiarelli-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (trial comparing growth hormone
 dosing using a prespecified algorithm to conventional 
growth hormone dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:37:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:37:46 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:37:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cupissol-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:37:55 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (control of the cisplatin infusion using automatic pump)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 15:58:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demakis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 15:58:16 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (reminder to standard of care)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dillon-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (some participa
nts in the standardized dosing arm crossed-over to 
pharmacokinetic dosing arm)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:37:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donovan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:37:59 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doran-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (cohort with 4 participa
nts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:38:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dortch-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:38:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (retrospective study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:38:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:38:11 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (no recommendation to the healthcare professional: chemotherapy protocol)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:38:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:38:39 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faber-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (individualize
d dosing concerned the day of administration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 16:36:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldstein-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 16:36:51 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alert for prescribing laboratory monitoring test)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fety-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (no recommendation to the healthcare professional: chemotherapy protocol)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Field-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:12 +0200" MODIFIED_BY="[Empty name]">
<P>- The dose advice was not individualized (maximal suggested dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Field-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:15 +0200" MODIFIED_BY="[Empty name]">
<P>- The dose advice was not individualized (maximal suggested dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:26:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fihn-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:26:58 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzmaurice-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:23 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:03:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzmaurice-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:03:27 +0200" MODIFIED_BY="[Empty name]">
<P>- Design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flanders-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:27 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fritsch-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:31 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (target-controlled inhalation induction)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukudo-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:34 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (control group without random or quasi-random allocation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gamelin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (table with dose-adjustment algorithm according to plasma concentration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:10:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghazal_x002d_Aswad-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>- Conference publication (contact author failed due to erroneous email)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gopakumaran-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:44 +0200" MODIFIED_BY="[Empty name]">
<P>- Discussion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:10:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffey-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:10:50 +0100" MODIFIED_BY="[Empty name]">
<P>- The dose advice was not individualized (most commonly used dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guarracino-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:48 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (evaluation of automated protamine dose assay)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guarracino-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
ot a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:39:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hermayer-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:39:57 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:27:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hobbs-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:27:58 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose adjustment based on the occurrence of adverse events)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:28:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horn-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:28:15 +0200" MODIFIED_BY="[Empty name]">
<P>- Design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:03:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:03:59 +0200" MODIFIED_BY="[Empty name]">
<P>- Design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jankovic-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- The 15 participa
nts from the Jankovic study were included in the Mihajlovic study (60 participa
nts)
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jannuzzi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:10 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dosage based on serum drug level monitoring)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jellinek-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:14 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (decision support algorithm)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:11:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Judge-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jung-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (no individualized dose recomme
nded to the healthcare professional: protocol for adjustment of growth hormone dosage)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kazemi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:21 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirk-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:24 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 16:26:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koide-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 16:26:26 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before after study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kristrom-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:34 +0200" MODIFIED_BY="[Empty name]">
<P>- The dose advice was not individualized (dose selection within an interval using a predicted response)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kroese-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
ot a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-la-Cour-Freiesleben-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:47 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (paper nomogram)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 17:37:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lester-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 17:37:25 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (email with low-density lipopr
o
tein
 therapeutic goal)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ligtenberg-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not a study but a comment on <LINK REF="STD-Plank-2006" TYPE="STUDY">Plank 2006</LINK>

</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lillis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:51 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (case history)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 17:24:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 17:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (closed-loop system)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:04:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manotti-2001--maintenance">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:04:16 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mar-Fernandez-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (no recommendation to the healthcare professional: pharmacokinetic model used for drug monitoring)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:40:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mar-Fernandez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:40:59 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (predictive performance of population models)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:12:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matheny-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (reminders for annual intervals for laboratory monitoring)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurizi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control (advice delivered directly to the participa
nt: self monitor glucose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCluggage-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:03 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (historical control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 16:31:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCowan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 16:31:09 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (software that implements guidelines during consultations)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCoy-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:13 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCoy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:20 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-27 14:13:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McDonald-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-27 14:13:03 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (reminders)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:33:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McDonald-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:33:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose prescribing rather than drug dosage)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMichael-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome (n
o professional behaviour change or participa
nt outcomes)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMullin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
ot a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMullin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:27 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (list of prescriptions most appreciate)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMullin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:32 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (list of prescriptions most appreciate)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motykie-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:35 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (historical control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mullett-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:41 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:04:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murchie-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:04:49 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nash-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:44 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (thresholds)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:41:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newby-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:41:46 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (automated adjustment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nieuwenhuyze-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:34:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nightingale-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:34:35 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose prescribing rather than drug dosage)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oppenheim-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (
not a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Overhage-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- The dose advice was not individualized ('
response orders'
)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 16:38:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 16:38:39 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alert for prescribing laboratory monitoring test)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 17:25:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pea-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 17:25:06 +0100" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:35:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peck-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:35:09 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (screen showing the most commo
nly used dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:01 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (screen showing a default dose and minimum/maximum dose)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phillips-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
ot a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piazza-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:12 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alerts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:54:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poller-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:54:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Popovic_x002d_Todorovic-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:16 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (rules without calculation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Proost-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Discussion (p
resentation of the project PharmDIS-e+)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roberts-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:26 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rochon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:33 +0200" MODIFIED_BY="[Empty name]">
<P>- Discussion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rood-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:36 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothschild-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:39 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome (survey)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothschild-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:42 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (feedback)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:42:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothschild-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:42:48 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (smart infusion pumps providing decision support feedback)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:54:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rotman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:54:49 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 15:52:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roumie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 15:52:34 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (alert with guidelines or goal blood pressure)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 18:17:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruiz-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 18:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (closed-loop system)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:55:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryff_x002d_de-Leche-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 17:55:03 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (infusion not under physician control)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santana-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (treatment plan in 
2 cohorts)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santana-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
ot a comparative study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneider-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:00 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (organizational computer program)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schrezenmeir-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control (advice delivered directly to the participa
nt)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiach-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (comparison of 
2 systems of prothrombin time measurement)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shieh-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (comparison of 
2 protocols for drug controller)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soper-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:13 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (historical control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sparano-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (trial comparing 
2 therapies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:06:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strack-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:06:14 +0200" MODIFIED_BY="[Empty name]">
<P>- Design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-03 10:06:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tamblyn-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-03 10:06:32 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computer drug dosage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tamblyn-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:21 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (adherence calculation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tamblyn-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:30 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (adherence calculation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terrell-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:33 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (recommendation on substitute therapies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:19:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomson-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 17:21:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tierney-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 17:21:12 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (reminders)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-31 16:13:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2013-09-25 16:58:43 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;I am not sure what you mean by this. Do you mean that you did not make contact with the author because an email was sent to someone else?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-10-31 16:13:34 +0100" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomek-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-31 16:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>- Conference publication (the author was contacted by January 201
2 but 
the message could not be delivered because the recipient ad
d
ress was rejected
)
)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 17:58:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Traugott-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:37 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (before and after study without control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trivedi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:44 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (discussion)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trivedi-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:48 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (decision support tool without calculation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Bol-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:50 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose calculated from an equation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Leeuwen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Abstract corresponding to the study published in 2007 (excluded study: <LINK REF="STD-van-Leeuwen-2007" TYPE="STUDY">van Leeuwen 2007</LINK>
)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Leeuwen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (n
o control group: comparison of 
2 computer algorithms)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:43:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Lent_x002d_Evers-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:43:55 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (historical control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Wyk-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (screening and treatment of dyslipidaemia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verstappen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (CAMERA study: comparison of 
2 strategies of management in early rheumatoid arthritis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verstappen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (CAMERA study: comparison of 
2 strategies of management in early rheumatoid arthritis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:44:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasmuth-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:44:06 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasmuth-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:08 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (trial comparing 
2 doses of treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-27 12:13:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whipple-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-27 12:13:24 +0100" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (the clinical pharmacist calculated the dose and interval of aminoglycoside concentration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-25 18:00:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-25 18:00:23 +0200" MODIFIED_BY="[Empty name]">
<P>- Absence of relevant data for primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-26 16:18:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Willcourt-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-26 16:18:09 +0200" MODIFIED_BY="[Empty name]">
<P>- Participa
nt aid not under physician control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:44:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:44:13 +0200" MODIFIED_BY="[Empty name]">
<P>- Design (cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-04 16:44:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamamoto-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-04 16:44:25 +0200" MODIFIED_BY="[Empty name]">
<P>- Not computerized drug dosage (dose calculated from an equation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-11-07 09:28:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2011">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:31 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS MODIFIED="2013-11-06 14:59:47 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_INTERVENTIONS MODIFIED="2013-11-06 14:58:25 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_OUTCOMES MODIFIED="2013-11-06 14:58:21 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:33 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:38 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Anderson-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:36 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:38 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:41 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Caduff-2013">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:40 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:41 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:46 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Dumont-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:44 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:46 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:28:08 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Horibe-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:28:05 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:28:08 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:51 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Jeanne-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:48 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:51 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:26:57 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Joerger-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:56 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:26:57 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:02 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Kelly-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:26:59 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:02 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:28:15 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Kim-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:28:14 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:28:15 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:28:22 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Magee-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:28:20 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:28:22 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:08 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Nieuwlaat-2011">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:06 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:08 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:12 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Nieuwlaat-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:10 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:12 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:28:00 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Overgaard-2010">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:58 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:28:00 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:55 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Pielmeier-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:54 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:55 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:50 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Radhakrishnan-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:49 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:50 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:17 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Rasmussen-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:15 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:17 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:25 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Spaniel-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:23 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:25 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:30 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Tamblyn-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:28 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:30 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:41 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Whitehead-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:39 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:41 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-11-07 09:27:36 +0100" MODIFIED_BY="Elizabeth Paulsen" STUDY_ID="STD-Wiltshire-2012">
<CHAR_METHODS MODIFIED="2013-11-07 09:27:34 +0100" MODIFIED_BY="Elizabeth Paulsen"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-11-07 09:27:36 +0100" MODIFIED_BY="Elizabeth Paulsen">
<P>Not yet assessed</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-07-28 21:46:06 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-07 09:35:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>"Randomization (in permuted blocks of 5) to the pharmacogenetic or standard arm"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 09:35:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>"Patients with even random numbers, derived from a random number table, were assigned for the CGMS and patients with uneven random numbers for the CGMS/KADIS group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>"Computer generated randomisation procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-18 13:12:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>"Random number table to determine which 9 of the 17 house staff teams would be assigned as control groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>"The patients were randomly assigned to one of the three groups for warfarin dosage prediction". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>"Each patient was randomized to one of two groups as determined by a computer-derived randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-23 16:14:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>"The study periods consisted of 4 alternating 8-week blocks of intervention and control subperiods"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>"The 66 GP-practices were divided into four different groups using a stratified block randomization. Six different strata of GP-practices were defined depending on the number of anticoagulated patients (5 patients, 6-14 patients, 15 patients) and the type of practice (single-handed GP or group practice). These six strata (numbered containers with cards) were divided blindly over the four intervention groups by a university staff member as follows: out of the first container a card was drawn and placed in box A, the next card in box B, C, D, A, B, etc. The same procedure was followed for the other five boxes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>"The 66 GP-practices were divided into four different groups using a stratified block randomization. Six different strata of GP-practices were defined depending on the number of anticoagulated patients (5 patients, 6-14 patients, 15 patients) and the type of practice (single-handed GP or group practice). These six strata (numbered containers with cards) were divided blindly over the four intervention groups by a university staff member as follows: out of the first container a card was drawn and placed in box A, the next card in box B, C, D, A, B, etc. The same procedure was followed for the other five boxes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:38:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>"Patients entered into the trial were randomized [...]". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>"Randomization assignments were determined by a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>Practices were randomly selected by means of random numbers from a list of 21 practices that had expressed interest in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:58:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>"A random-numbers table was used to pre-assign 82 patients to either group 1 or group 2"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>"Randomisation was carried out by computer using a random number generator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>"Within the first 3 days posttransplant, patients were randomized by an interactive voice response system administered by a private company; randomization was balanced within centers in blocks of 4 patients, and patients were enrolled and assigned to one of the two groups by physicians at each center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>"Patients were randomized into two arms." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>"Random table, in blocks of 10"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>"Random table, in blocks of 10"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>"Subjects were randomized using a random number table into one of two groups: group P (physician dosing) or group C (computer dosing)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>Participants fulfilling the inclusion criterion were randomly assigned using serially numbered, sealed envelopes to either the intervention group (BG control by the eMPC) or the control group (routine BG management protocol)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>"60 patients were randomized by individual centers in blocks of 10"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>"Randomisation was done according to computer-generated order at each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>"Randomisation was done according to computer-generated order at each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>"Within the first 3 days posttransplant, patients were randomized by an interactive voice response system administered by a private company; randomization was balanced within centers in blocks of 4 patients, and patients were enrolled and assigned to one of the two groups by physicians at each center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>"Consenting patients were allocated according to a computer-generated randomization schedule into the computer-assisted or manual group (Plan procedure, SAS software, SAS Institute, Cary, NC)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>"A biostatistician randomly assigned physicians in blocks of 2, stratified by stage of training (i.e., faculty status and by year of residency training) into the intervention or control group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>"We used simple randomization with a table of random numbers to assign the patients to management by doctors aided by the decision support system (intervention group) or to management by doctors alone (control group)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>"Simple randomization using random number tables was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>"Simple randomization using random number tables was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>"Randomization was based on the final digit in the patient's identification card number (odds versus even)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>"Using a computerized coin toss, we randomly assigned seven teams of providers (42 internal medicine residents) working in general medical acute care units to have the option to use the order template (intervention group) or to use usual insulin ordering (control group)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>Random sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-11-05 13:59:36 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>"Consecutive patients who were discharged from the Hamilton General Hospital (Ontario, Canada) after mechanical heart valve replacement were randomized to be controlled by the computerized system or standard manual monitoring by trained personnel". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>"Consecutive patients who were hospitalized at the Hamilton General Hospital (Ontario, Canada) and who required oral anticoagulation were randomized to control by the computerized system or standard manual dosing until the seventh day of treatment or until discharge, whichever happened first". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>"The randomization arm assignment was blinded to patients and clinicians/investigators and known only to a designated research assistant and pharmacist"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-16 11:46:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>"A single center randomized prospective trial in adult kidney transplant recipients on CsA-based immunosuppression was performed." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>Random number table. No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>"Computer generated randomisation procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-18 13:12:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>"Random number table to determine which 9 of the 17 house staff teams would be assigned as control groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>"The patients were randomly assigned to one of the three groups for warfarin dosage prediction". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>"Each patient was randomized to one of two groups as determined by a computer-derived randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-23 16:14:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>"The study periods consisted of 4 alternating 8-week blocks of intervention and control subperiods"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>Unit of allocation: GP practice</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>Unit of allocation: GP practice</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>"Patients entered into the trial were randomized [...]". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>"Assignments were individually placed in sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>Practices were randomly selected by means of random numbers from a list of 21 practices that had expressed interest in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:58:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>"A random-numbers table was used to pre-assign 82 patients to either group 1 or group 2"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>"Randomisation was carried out by computer using a random number generator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>"Within the first 3 days posttransplant, patients were randomized by an interactive voice response system administered by a private company; randomization was balanced within centers in blocks of 4 patients, and patients were enrolled and assigned to one of the two groups by physicians at each center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>"Patients were randomized into two arms." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>"Random table, in blocks of 10". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>"Random table, in blocks of 10". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>"Subjects were randomized using a random number table into one of two groups: group P (physician dosing) or group C (computer dosing)." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>Participants fulfilling the inclusion criterion were randomly assigned using serially numbered, sealed envelopes to either the intervention group (BG control by the eMPC) or the control group (routine BG management protocol)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>"60 patients were randomized by individual centers in blocks of 10". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>"Randomisation was done according to computer-generated order at each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>"Randomisation was done according to computer-generated order at each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Sealed envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>"Within the first 3 days posttransplant, patients were randomized by an interactive voice response system administered by a private company; randomization was balanced within centers in blocks of 4 patients, and patients were enrolled and assigned to one of the two groups by physicians at each center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>"Consenting patients were allocated according to a computer-generated randomization schedule into the computer-assisted or manual group (Plan procedure, SAS software, SAS Institute, Cary, NC)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>"A biostatistician randomly assigned physicians in blocks of 2, stratified by stage of training (i.e., faculty status and by year of residency training) into the intervention or control group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>"We used simple randomization with a table of random numbers to assign the patients to management by doctors aided by the decision support system (intervention group) or to management by doctors alone (control group)." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>"Simple randomization using random number tables was used." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>"Simple randomization using random number tables was used." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>Odd versus even identification card number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>"Using a computerized coin toss, we randomly assigned seven teams of providers (42 internal medicine residents) working in general medical acute care units to have the option to use the order template (intervention group) or to use usual insulin ordering (control group)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Baseline outcome measurements similar</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>No baseline measure of outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>No baseline measure of outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:22:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>Not applicable (initiation of warfarin therapy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>"There was no significant differences between the number of samples collected in the 2 groups (P=0.12) or in the percentage of C2 values obtained in each group (MAP-BE: 82%, CONTR: 78%, P=0.39)." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>"Both study groups included type 1 and type 2 diabetic subjects in equal proportions. There were no significant differences in age, sex, diabetes duration, BMI [body mass index], or insulin application between groups (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>No significant differences on blood glucose at study start or number of participants with history of diabetes (Table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:23:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>Not applicable (initiation of warfarin therapy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>Not appropriate (theophylline maintenance for asthma)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:23:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>"The 6 months retrospective analysis showed that the patients of the practices assigned to groups A, B, C, and D were 55, 49, 46, and 44% of time within 0.5 INR-units from target, respectively. There was no significant difference among the four groups in the per cent within 0.5 INR-units from target (P = 0.50) or within 0.75 INR-units from target (P = 0.70)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>"The 6 months retrospective analysis showed that the patients of the practices assigned to groups A, B, C, and D were 55, 49, 46, and 44% of time within 0.5 INR-units from target, respectively. There was no significant difference among the four groups in the per cent within 0.5 INR-units from target (P = 0.50) or within 0.75 INR-units from target (P = 0.70)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>"Glucose concentration at study entry was similar in both groups (Table 3)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:23:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:24:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:24:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>No significant differences on blood glucose at study start or number of participants treated with diabetes before study start (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>No significant differences on blood glucose at study start (table 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:24:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 14:23:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:25:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>Not applicable (initiation of oral anticoagulant therapy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:25:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-03 15:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>No significant differences on blood glucose at study start or number of participants treated with insulin before study start (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>Blood glucose at entry was reported by ICU (Graz, Prague, London) but not across study groups (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>Not appropriate (warfarin therapy maintenance)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>Not appropriate (Warfarin therapy maintenance)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:26:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Not appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-03 16:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>No significant differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>No significant differences on preoperative blood glucose (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>Not applicable (people undergoing cardiac surgery)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>Not applicable (people undergoing cardiac surgery)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>Not appropriate (warfarin therapy initiation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:27:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-27 17:27:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>It is unclear if the mean blood glucose values given at the beginning of the results were baseline data or results with all randomized participants (186 ± 56 mg/dL in intervention participants versus 206 ± 61 mg/dL in control participants (P value = 0.004))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>"There were no significant differences between the groups with respect to age, gender, target prothrombin times, percentage of patients initially below the target, percentage of patients initially above the target, or the mean of the absolute value of the differences between initial prothrombin times and the corresponding target prothrombin times (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2013-11-07 09:35:04 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Baseline characteristics similar</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>Participant randomization. "The two groups were similar with respect to age and gender." No further information provided.</P>
<P>Providers were 2 physicians and 3 registered nurses, all with several years of experience in the management of people on oral anticoagulants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>Participant randomization. "The two groups were similar with respect to age (64.6 manual group; 63.3 computer group), whereas the proportion of males was higher in the computer group (64%) than in the manual group (53%) [...] The proportion of participants following heart valve replacement was 78% in the computer group and 69% in the manual group.[...] The mean INR was 2.09 in the computer group, and 2.07 in the manual group"</P>
<P>Providers were trained nurses or physicians (supposed to be the same providers at baseline and during intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>"Clinical characteristics were balanced except for older age and greater prevalence of hypertension in pharmacogenetic patients." The results on primary endpoint were unchanged by further adjustment for differences in age and hypertension</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 09:35:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>Participant randomization. "There was no relevant demographic differences between groups"</P>
<P>Providers were physicians (supposed to be the same providers at baseline and during intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>Participant randomization. "The two groups were similar with respect to age (64.6 manual group; 63.3 computer group), whereas the proportion of males was higher in the computer group (64%) than in the manual group (53%) [...] The proportion of participants following heart valve replacement was 78% in the computer group and 69% in the manual group.[...] The mean INR was 2.09 in the computer group, and 2.07 in the manual group"</P>
<P>Providers were trained nurses or physicians (supposed to be the same providers at baseline and during intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>"There were no major differences between the groups in their demographic features (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 19:19:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>No significant differences on baseline characteristics (Table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>"As shown in Table II, there were no significant differences in any of the patient characteristics between subjects in the control versus the intervention group." "In a similar manner, there were no significant differences in the clinical diagnosis between patients in each group (Table I)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>Demographic data only available for the subgroup of participants who achieved stable prothrombin ratios before discharge (54/101 participants)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>"There were no significant differences between the kinetic group in age or height, although there was a significant difference in actual body weight (85.5 versus 69.0 kg; p&lt;0.05), but the ideal weights of both groups was not significantly different (55.7 versus 54.1 kg). Theophilline infusion doses were based on ideal body weight"</P>
<P>Table 1: 54.7 versus 54.1 kg</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>Mean age of participants and sex "were not significantly different across periods". The mean Diagnosis Related Group (DRG) weight "was higher during control periods"</P>
<P>"The number of admissions and the hospital census were higher during the control periods"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>Baseline characteristics were not reported for GP practices, GPs or participants. Number of participants per group were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>Baseline characteristics were not reported for GP practices, GPs or participants. Number of participants per group were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>No significant differences on main characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>No significant differences except for weight (table 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>No apparent differences (table 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>No apparent differences on patient demographics (table 2). No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>No significant differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>No apparent differences (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics of the 13,052 participants (see table 1 of <LINK REF="STD-Poller-2008-PARMA-5" TYPE="STUDY">Poller 2008 PARMA 5</LINK> and <LINK REF="STD-Poller-2009-DAWN-AC" TYPE="STUDY">Poller 2009 DAWN AC</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>5 men/5 women in MPC group, 9 men/1 women in standard group (table 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>"The sex ratio differed between groups in that there were a larger percentage of males in the CC-treated group (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>Sex gender not reported. There were differences on use of contrast media and the presence of lung disease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>Participants in the group with the decision by software were younger than in the group with the decision by clinicians (31.7 ± 4.5 years versus 33.1 ± 4.2 years, P value &lt; 0.05 (table 2))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>No apparent differences (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>"In general, the demographic characteristics of the patients were similar in the experimental and control groups (table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>"In general, the demographic characteristics of the patients were similar in the experimental and control groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>"A larger percentage of patients in group C had a history of atrial fibrillation (28% vs. 6%), and group P had a larger proportion of patients with a history of DVT [deep vein thrombosis] (50% vs. 7%)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>No significant differences on main characteristics (table II)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>No significant differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>Baseline characteristics of participants were reported by ICU (Graz, Prague, London) but not across study groups (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics of the 10,421 participants (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics of the 2631 participants (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>There were 6/9 men in the computer-assisted therapy group and 11//11 in the conventional lidocaine therapy group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>"The sex ratio differed between groups in that there were a larger percentage of males in the CC-treated group (table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>No significant differences on blood glucose (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>No significant differences on participants demographic (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>"There were no important differences in the characteristics of intervention and control physicians or the 2 groups of patients who received their care" (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>No significant differences on participants demographic (table 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>No significant differences on participants demographic (table 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>No apparent differences on baseline characteristics (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>There were significant differences between the groups (age, asthma/chronic obstructive lung disease and associated medical conditions)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>There was no significant differences on participants demographic or primary diagnosis (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>There was no significant differences on demographic and clinical characteristics of participants (table 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>"There were no significant differences between the groups with respect to age, gender, target prothrombin times, percentage of patients initially below the target, percentage of patients initially above the target, or the mean of the absolute value of the differences between initial prothrombin times and the corresponding target prothrombin times (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="GROUP" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-05.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>Not clearly specified in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>Not clearly specified in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>No apparent missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>"There was no significant differences between the number of samples collected in the 2 groups (P=0.12)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>"Of the 49 subjects found eligible, 46 (24 in the CGMS and 22 in the CGMS/KADIS group) completed the study. Three subjects had incomplete first CGMS monitoring (one in the CGMS and two in the CGMS/KADIS group) and were excluded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>Number of participants randomized: 50 (24 in the computer-assisted group, 26 in the control group)</P>
<P>Number of participants analyzed: 45 ("for the remaining patients aminoglycoside therapy was discontinued before analysis of plasma concentration"). Peak concentrations were available for 33 participants at 2 days, and 26 participants at 5 days. Trough concentrations were available for 32 participants at 2 days, and 26 participants at 5 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>"Because the duration of the ICU stay and the total monitoring time differed among patients, only data for up to 48 h were used for the comparison of the protocols. Forty-eight hours of ICU stay were accomplished in 109 of 120 patients included in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>Number of participants randomized: 147 (72 in intervention group and 75 in the control group)</P>
<P>Number of participants analyzed: 136 for number of participants cured (68 in each groups), 143 for toxic drug levels (70 in intervention group and 73 in the control group)</P>
<P>"Intervention patients were excluded from the study if recommended dosing was not implemented within 48 hours of the first dose of aminoglycoside"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>Number of participants randomized: 101</P>
<P>Number of participants analyzed: 87 (31 in the analogue-computer group, 22 in the linear-regression group, 34 in the empiric-dosing group)</P>
<P>"Fourteen randomized patients (3 analog computer, 7 linear regression, 4 empiric dosing) were removed from the study because they did not receive an initial warfarin dosage of 10 mg for three days or because the drug was discontinued before day 5"</P>
<P>"33 patients were discharged before they met the stated criteria for a stable PT [prothrombin]"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>"Twelve patients were withdrawn from study because of incomplete data collection (i.e., either C1, C2, or C3 was missing or inadequate time interval between levels), which left 35 patients for analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>A log was kept of all instances</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>Number of participants per group were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>Number of participants per group were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>18 participants vs 16 participants. No apparent missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>Many participants excluded from analysis: 20 of the 90 participants from the control group (monitored by other clinical pharmacists), 35 of the 110 participants from the computer advice group (recommendations were not always followed)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>224 participants were recruited. 40 participants discontinued the study before 12 months, including 11 participants randomized to intervention who returned to hospital care</P>
<P>Only participants with 3 or more INR results (n = 202) were included in the analysis of proportion of time spent in the target INR range</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>"Fifteen patients were excluded because of protocol violations (three left the ED against medical advice; 12 had insufficient blood level data)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>4 participants (out of 32) were excluded because a dose change was made on clinical grounds before the 4th dose of aminoglycoside</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>The number of glucose values used for calculation varied in each hour (figure 2) but the blood glucose was measured in 1- to 4-h intervals as requested by each algorithm during surgery and postoperatively over 24 h</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>96 participants enrolled, 91 participants analyzed (1 participant because of intolerance to aminophylline, 1 because of lack of cooperation, 3 because of previous enrolment in the trial)</P>
<P>Loading doses were available for 72 participants, infusion rate at day 1 for 91 participants, infusion rate at day 2 for 74 participants. Missing values were equally distributed and unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>Both cost and outcome data were available for 6218/6447 in manual-dosed group and 6366/6605 in computer-assisted dosage group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>The blood glucose was measured in 1- to 2-h intervals as requested by each algorithm during surgery and postoperatively over 48 h</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>"There were seven withdrawals (CC, n = 5; FD, n = 2) due to death, primary non functioning graft or because MMF was not administered." In most of tables, only percentages are reported and according to the first decimal of percentages, there were missing data in the denominator. However, missing values were unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>81 participants were dropped from the study because they received &lt; 72 h of therapy, leaving 243 study participants (73 in group 1, 90 in group 2, 80 in group 3). Incomplete data were unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2012-01-18 13:58:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>Data were provided with patient-years. No details for follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>Not stated. Denominator not reported in tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>Not stated. Denominator not reported in tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>"The total number of data points (INR values) was 1014, excluding 36 days during which the INR score could not be imputed." The original group of 32 patients was reduced to 30 through loss of data sheets. It is unclear if missing values could overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>Mean length of stay was 8 days. According to denominator in tables, there were no missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>Not stated. Denominator not reported in tables. The treatment was discontinued ahead of schedule in 2 participants of the control group and in 5 participants assigned to the eMPC group. It is not clear if these participants were excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>Not stated. Denominator not reported in tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>285 randomized, 254 analyzed (16 excluded vs. 15)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>285 randomized, 254 analyzed (16 excluded versus 15)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>44/5175 in manual-dosed group and 87/5377 in computer-assisted dosage group did not receive allocated intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>12/1328 in manual-dosed group and 24/1339 in computer-assisted dosage group were excluded because no INR results were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>"There were seven withdrawals (CC, n = 5; FD, n = 2) due to death, primary non functioning graft or because MMF was not administered." In most of tables, only percentages were reported and according to the first decimal of percentages, there were missing data in the denominator. However, missing values were unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>The blood glucose was measured in short intervals as requested by each algorithm before, during and after cardiopulmonary bypass (over maximum 320 min)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>46% of participant visits excluded because of insufficient data to estimate creatinine clearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>Data were reported for all participants included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>Data were reported for all participants included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>64/76 participants in the control group were followed up as outpatients and 53/72 in the intervention group. There was no description of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>Data were reported for all participants included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>144 insulin-treated people with type 2 diabetes were admitted, 16 participants whose point-of-care glucose values were between 60 and 180 mg/dL were excluded (non-target population)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>There were 4/36 participants in the physician-dosed group and 3/39 in the computer-dosed group which data could not be analyzed. Incomplete data were unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>2/26 participants in the nurse-specialist group and 1/24 participant in the computer group did not return for follow-up. Incomplete data were unlikely to overturn the study results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>Outcomes included bleeding events. Minor and major bleeding events were not clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>Outcomes were objective. "An independent Data and Safety Monitoring Committee tracked unblinded safety data. A separate independent Clinical Events Committee adjudicated key clinical adverse events blinded to study arm"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>Outcomes were objective. Nephrotoxicity and % of participants cured were clearly defined in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>Outcomes were objective. Theophylline toxicity was defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>Outcomes were objective. Nephrotoxicity was clearly defined in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>Main outcomes were objective. Monitoring for haemorrhagic and thrombotic events is not clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>Main outcomes were objective. Adverse events are not clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>Main outcomes were objective. Events were adjudicated by a committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>"Acute rejection was diagnosed by renal biopsy except in patients with contraindications and were graded according to the Banff classification, in which case diagnosis was based on clinical and laboratory criteria (in particular, any unexplained increase in serum creatinine)." No committee reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>"Study data were reviewed by one of the authors who was blinded as to group assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>Main outcomes (pregnancies) are objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>Main outcomes were objective. Hamilton scale is an hetero-questionnaire</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:47:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>Main outcomes were objective. Clinical Global Impression Scale is an hetero-questionnaire</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>Pulmonary embolism, deep vein thrombosis: No committee reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>Main outcomes were objective. Bleeding and clinical events are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes are clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>Main outcomes were objective. Events were adjudicated by a committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>Main outcomes were objective. Events were adjudicated by a committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Main outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>"Acute rejection was diagnosed by renal biopsy except in patients with contraindications and were graded according to the Banff classification, in which case diagnosis was based on clinical and laboratory criteria (in particular, any unexplained increase in serum creatinine)." No committee reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>Main outcomes were objective. Hypoglycaemic episodes were clearly defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>Outcomes were objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:33:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>Participants were randomized. "The randomization arm assignment was blinded to patients and clinicians/investigators and known only to a designated research assistant and pharmacist"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:35:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>Teams were randomized in 1 site. At the end of each 4 months during the study, intervention groups were changed to control and vice versa</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>Alternating 8-week blocks of intervention and control subperiods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>GP practices were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>GP practices were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>Practices were randomized and participants individually randomized as controls in the intervention practices (intrapractice controls) and all participants in the control practices (interpractice controls)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:47:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>Physicians were randomized but the study was carried out in a single site and included a small sample of residents and academic emergency physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>Participants were randomized but blinded ("Both systems were attached to each patient by an independent operator")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>Participants were randomized but blinded ("both systems were attached to each patient by an independent operator")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>Team of providers were randomized but the study was carried out in a single site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>Participants were randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>Pilot study. Outcomes were not defined in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Outcomes were not defined in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>All relevant outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>Outcomes were not described in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-07" LEVEL="STUDY" MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-1998">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ageno-2000">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:33:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2007">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 09:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asberg-2010">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Augstein-2007">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Begg-1989">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:34:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaha-2009">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1991">
<DESCRIPTION>
<P>No evidence of other risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1987">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casner-1993">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-2001">
<DESCRIPTION>
<P>"The Cockcroft-Gault formula may overestimate renal function when the serum creatinine is increasing, and underestimate renal function when the serum creatinine is decreasing"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2005">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claes-2006">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cordingley-2009">
<DESCRIPTION>
<P>An erratum had been published because there were some inconsistencies in the text and tables; we found other inconsistencies in tables, full text, and abstract; the author was contacted (had not replied by January 2012)<I>.</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Destache-1990">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2000">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1989">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hickling-1989">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovorka-2007">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurley-1986">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:43:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowett-2009">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremen-2007">
<DESCRIPTION>
<P>Pilot study with 10 participants in each groups. Article in Czech language. Authors were contacted but had not replied by February 2012</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Meur-2007">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Le-Meur-2007-extract">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:45:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leehey-1993">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesourd-2002">
<DESCRIPTION>
<P>Few results reported (1 sentence in the results). Not enough information to evaluate the bias of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manotti-2001">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mihajlovic-2003">
<DESCRIPTION>
<P>Selection bias/opportunistic series:</P>
<P>- <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>: 60 participants admitted during 1997</P>
<P>- <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>: Safety analysis of the study reported by <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>All 15 participants from the Jankovic study were included in the Mihajlovic study (confirmed by the author S. Jankovic)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mihajlovic-2010">
<DESCRIPTION>
<P>Selection bias/Opportunistic series:</P>
<P>- <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>: 60 participants admitted during 1997</P>
<P>- <LINK REF="STD-Mihajlovic-2010" TYPE="STUDY">Mihajlovic 2010</LINK>: Safety analysis of the study reported by <LINK REF="STD-Mihajlovic-2003" TYPE="STUDY">Mihajlovic 2003</LINK>
</P>
<P>All 15 participants from the Jankovic study were included in the Mihajlovic study (confirmed by the author S. Jankovic)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mitra-2005">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mungall-1994">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pachler-2008">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plank-2006">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop1">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-1998-pop2">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2008-PARMA-5">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poller-2009-DAWN-AC">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poller-2009-erratum">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodman-1984">
<DESCRIPTION>
<P>Only 20 participants were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseau-2010">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saager-2008">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sato-2011">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terrell-2010">
<DESCRIPTION>
<P>46% participant visits were excluded, only prescription that required dosage adjustment were analyzed and there was no adjustment for within-patient correlation</P>
<P>"Providers in the intervention group initially prescribed targeted medications more often than control physicians did and consequently had substantially more opportunities to adjust dosing"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-fentanyl">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Theil-1993-midazolam">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadher-1997">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997-pop1">
<DESCRIPTION>
<P>- The nurse-practitioners used the computer-decision support system and were compared to the clinician group of 3 junior doctors undergoing general professional training in general medicine</P>
<P>- The was a risk of contamination due to logistical problems ("it was difficult to shield the clinicians from the CDSS suggestions")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadher-1997-pop2">
<DESCRIPTION>
<P>- The nurse-practitioners used the computer-decision support system and were compared to the clinician group of 3 junior doctors undergoing general professional training in general medicine</P>
<P>- The was a risk of contamination due to logistical problems ("it was difficult to shield the clinicians from the CDSS suggestions")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verner-1992">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wexler-2010">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1987">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-05 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1991">
<DESCRIPTION>
<P>No evidence of other risk of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-11-04 12:58:14 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-11-04 12:57:15 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-11-04 12:57:15 +0100" MODIFIED_BY="Grade Profiler">Computerized advice on drug dosage for leading serum concentrations within therapeutic range</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Computerized advice on drug dosage for leading serum concentrations within therapeutic range</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with leading serum concentrations within therapeutic range<BR/>
<B>Settings:</B> outpatient/inpatient<BR/>
<B>Intervention:</B> computerized advice on drug dosage<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Computerized advice on drug dosage</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serum concentrations - aminoglycoside antibiotics: peak concentration</B>
<BR/>Follow-up: 2 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean serum concentrations - aminoglycoside antibiotics: peak concentration in the intervention groups was<BR/>
<B>0.79 standard deviations higher</B>
<BR/>(0.46 to 1.13 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>372<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 0.79 (95% CI 0.46 to 1.13)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serum concentrations - theophylline</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean serum concentrations - theophylline in the intervention groups was<BR/>
<B>0.41 standard deviations higher</B>
<BR/>(0.2 lower to 1.02 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>201<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 0.41 (95% CI -0.2 to 1.02)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Proportion of participants within therapeutic range - aminoglycoside antibiotics: % of participants with peak concentrations adequate after 2 days</B>
<BR/>Follow-up: 2 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 4.44 </B>
<BR/>(1.94 to 10.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>72<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>135 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
<BR/>(262 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>670 per 1000</B>
<BR/>(293 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Proportion of participants with toxic drug levels - theophylline</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.53 </B>
<BR/>(0.25 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>109<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>273 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>145 per 1000</B>
<BR/>(68 to 308)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>217 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(54 to 245)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>SMD:</B> standardized mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Lack of blinding of participants and personnel in all studies. Incomplete outcome data in three studies. Random sequence generation and allocation concealment unclear in one study.<BR/>
<SUP>2</SUP> I<SUP>2</SUP> = 51%.<BR/>
<SUP>3</SUP> No funnel plot was performed since the validity conditions were not met.<BR/>
<SUP>4</SUP> No blinding of participants and personnel in the two studies. Random sequence generation and allocation concealment unclear in one study.<BR/>
<SUP>5</SUP> I<SUP>2</SUP> = 76% <BR/>
<SUP>6</SUP> Lack of blinding of participants and personnel, incomplete outcome data in all studies. Participants were not similar at baseline in one study.<BR/>
<SUP>7</SUP> No blinding of participants and personnel in the two studies. Random sequence generation and allocation concealment unclear in one study.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-11-04 12:57:24 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-11-04 12:57:24 +0100" MODIFIED_BY="Grade Profiler">Computerized advice on drug dosage for leading physiological parameters within therapeutic range</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Computerized advice on drug dosage for leading physiological parameters within therapeutic range</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with leading physiological parameters within therapeutic range<BR/>
<B>Settings:</B> outpatient/inpatient<BR/>
<B>Intervention:</B> computerized advice on drug dosage<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Computerized advice on drug dosage</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Oral anticoagulants: time in target INR range (%)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean oral anticoagulants: time in target INR range (%) in the intervention groups was<BR/>
<B>0.19 standard deviations higher</B>
<BR/>(0.06 to 0.33 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>13,581<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 0.19 (95% CI 0.06 to 0.33)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Insulin: time in target glucose range (%)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean insulin: time in target glucose range (%) in the intervention groups was<BR/>
<B>1.27 standard deviations higher</B>
<BR/>(0.56 to 1.98 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>234<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 1.27 (95% CI 0.56 to 1.98)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>INR:</B> international normalized ratio; <B>SMD:</B> standardized mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> No information given on random sequence generation and allocation concealment in half of the studies.<BR/>
<SUP>2</SUP> I<SUP>2</SUP> = 79%.<BR/>
<SUP>3</SUP> No funnel plot was performed since the validity conditions were not met.<BR/>
<SUP>4</SUP> No blinding of participants and personnel in all studies.<BR/>
<SUP>5</SUP> I<SUP>2</SUP> = 83%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-11-04 12:57:32 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-11-04 12:57:32 +0100" MODIFIED_BY="Grade Profiler">Computerized advice on drug dosage for reducing time to achieve therapeutic control</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Computerized advice on drug dosage for reducing time to achieve therapeutic control</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with reducing time to achieve therapeutic control<BR/>
<B>Settings:</B> outpatient/inpatient<BR/>
<B>Intervention:</B> computerized advice on drug dosage<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Computerized advice on drug dosage</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Time to achieve therapeutic range - oral anticoagulants: time to achieve therapeutic prothrombin ratio (days)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean time to achieve therapeutic range - oral anticoagulants: time to achieve therapeutic prothrombin ratio (days) in the intervention groups was<BR/>
<B>0.22 standard deviations lower</B>
<BR/>(0.69 lower to 0.26 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>223<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.22 (95% CI -0.69 to 0.26)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Time to achieve therapeutic range - insulin: time to achieve therapeutic control (hours)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean time to achieve therapeutic range - insulin: time to achieve therapeutic control (hours) in the intervention groups was<BR/>
<B>0.14 standard deviations lower</B>
<BR/>(0.98 lower to 0.7 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>194<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.14 (95% CI -0.98 to 0.7)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Time to stabilization - oral anticoagulants: time to stabilization (days)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean time to stabilization - oral anticoagulants: time to stabilization (days) in the intervention groups was<BR/>
<B>0.56 standard deviations lower</B>
<BR/>(1.07 to 0.04 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>255<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.56 (95% CI -1.07 to -0.04)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>SMD:</B> standardized mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment was unclear, and there was no blinding of participants and personnel in both studies.<BR/>
<SUP>2</SUP> I<SUP>2</SUP> = 66%.<BR/>
<SUP>3</SUP> No funnel plot performed but very small studies in favour of the intervention.<BR/>
<SUP>4</SUP> In all studies: the random sequence generation and the allocation concealment were unclear, and there was no blinding of participants and personnel.<BR/>
<SUP>5</SUP> I<SUP>2</SUP> = 86%. Meta-analysis should be interpreted with caution.<BR/>
<SUP>6</SUP> Sequence generation and/or allocation concealment were unclear in all studies. There was no blinding of participants and personnel in all studies. Data were incomplete in two studies.<BR/>
<SUP>7</SUP> I<SUP>2</SUP> = 71%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-11-04 12:58:06 +0100" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-11-04 12:57:40 +0100" MODIFIED_BY="Grade Profiler">Computerized advice on drug dosage for leading to fewer clinical adverse events</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Computerized advice on drug dosage for leading to fewer clinical adverse events</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with leading to fewer clinical adverse events<BR/>
<B>Settings:</B> outpatient/inpatient<BR/>
<B>Intervention:</B> computerized advice on drug dosage<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Computerized advice on drug dosage</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.08 </B>
<BR/>(0.8 to 1.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>14,046<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(10 to 18)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
<BR/>(22 to 41)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anticoagulants: events - bleeding</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.65 </B>
<BR/>(0.3 to 1.41)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>552<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(18 to 86)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<BR/>(20 to 92)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anticoagulants: events - thromboembolism</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.25 </B>
<BR/>(0.66 to 16.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>355<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(7 to 176)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(5 to 112)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Insulin - hypoglycaemia (&lt; 60 mg/dL)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.71 </B>
<BR/>(0.35 to 1.48)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>378<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
<BR/>(31 to 133)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
<BR/>(23 to 99)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Insulin - severe hypoglycaemia (&lt; 40 mg/dL)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.69 </B>
<BR/>(0.11 to 4.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>292<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(2 to 59)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
<BR/>(1 to 34)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Aminoglycoside antibiotics - nephrotoxicity</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.42 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>493<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>162 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
<BR/>(68 to 172)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
<BR/>(65 to 163)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> No (or unclear) blinding of participants and personnel in all studies. In half of the studies: sequence generation and/or allocation concealment were unclear, and the data were incomplete.<BR/>
<SUP>2</SUP> No funnel plot was performed since the validity criteria were not met.<BR/>
<SUP>3</SUP> In all studies: sequence generation or allocation concealment, or both were unclear, and there was no blinding of participants or personnel. Data were incomplete or unclear in four studies.<BR/>
<SUP>4</SUP> Allocation concealment was unclear in all studies. There was no blinding of participants and personnel in all studies and the blinding of outcome assessment was unclear in one study. Data were incomplete or unclear in all studies.<BR/>
<SUP>5</SUP> Large confidence intervaI due to very small studies (n = 335 for four studies) and a few events (n = 8).<BR/>
<SUP>6</SUP> No (or unclear) sequence generation or allocation concealment, or both in all studies. No (or unclear) blinding of participants or personnel in all studies. Selective reporting in one study.<BR/>
<SUP>7</SUP> Random sequence generation and allocation concealment were unclear in half of the studies. No (or unclear) blinding of participants or personnel in all studies.<BR/>
<SUP>8</SUP> Large confidence interval due to only three events for 292 participants.<BR/>
<SUP>9</SUP> No blinding of participants and personnel in all studies. Incomplete outcome data in three studies. Baseline characteristics not comparable in one study.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-11-04 12:58:14 +0100" MODIFIED_BY="Grade Profiler" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-11-04 12:58:14 +0100" MODIFIED_BY="Grade Profiler">Saving healthcare resources for saving healthcare resources</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Saving healthcare resources for saving healthcare resources</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> saving healthcare resources<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> saving healthcare resources<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Saving healthcare resources</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) in the intervention groups was<BR/>
<B>0.15 standard deviations lower</B>
<BR/>(0.33 lower to 0.02 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>18,507<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.15 (95% CI -0.33 to 0.02)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days) - oral anticoagulants</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) - oral anticoagulants in the intervention groups was<BR/>
<B>0.12 standard deviations lower</B>
<BR/>(1.1 lower to 0.86 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.12 (95% CI -1.1 to 0.86)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days) - insulin</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) - insulin in the intervention groups was<BR/>
<B>0.18 standard deviations higher</B>
<BR/>(0.17 lower to 0.53 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>128<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 0.18 (95% CI -0.17 to 0.53)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days) - theophylline</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) - theophylline in the intervention groups was<BR/>
<B>0.2 standard deviations lower</B>
<BR/>(0.56 lower to 0.16 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>151<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.2 (95% CI -0.56 to 0.16)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days) - aminoglycoside antibiotics</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) - aminoglycoside antibiotics in the intervention groups was<BR/>
<B>0.35 standard deviations lower</B>
<BR/>(0.58 to 0.12 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>295<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.35 (95% CI -0.58 to -0.12)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (days) - anti-rejection drugs</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (days) - anti-rejection drugs in the intervention groups was<BR/>
<B>0.04 standard deviations lower</B>
<BR/>(0.07 to 0.01 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>17,828<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.04 (95% CI -0.07 to -0.01)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>SMD:</B> standardized mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> I<SUP>2</SUP> = 57%.<BR/>
<SUP>2</SUP> No funnel plot was performed since the validity criteria were not met.<BR/>
<SUP>3</SUP> No blinding of participants and personnel in all studies, and blinding of outcome assessment unclear in half of the studies. Random sequence generation or allocation concealment, or both unclear in all studies.<BR/>
<SUP>4</SUP> I<SUP>2</SUP> = 81%. Meta-analysis should be interpreted with caution.<BR/>
<SUP>5</SUP> Although small studies (n = 105 for all the studies).<BR/>
<SUP>6</SUP> To be interpreted with caution since based on only one monocentric study of 128 participants.<BR/>
<SUP>7</SUP> No blinding of participants and personnel in the three studies. No or unclear random sequence generation and allocation concealment in two studies.<BR/>
<SUP>8</SUP> Although small studies (n = 151 for all studies).<BR/>
<SUP>9</SUP> No blinding of participants and personnel in all studies.<BR/>
<SUP>10</SUP> Alternating time series design with four consecutive two-month period.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-11-05 11:55:40 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-05 11:55:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Serum concentrations and therapeutic range</NAME>
<CONT_OUTCOME CHI2="25.175487412500846" CI_END="1.0378749307849884" CI_START="0.47181012336539685" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7548425270751926" ESTIMABLE="YES" I2="68.22305813222265" I2_Q="21.047793213962255" ID="CMP-001.01" MODIFIED="2013-11-05 11:55:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0014515915429936799" P_Q="0.2817912681478755" P_Z="1.7210556349301677E-7" Q="2.533178085091459" RANDOM="YES" SCALE="2.5" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15179206091088193" TOTALS="SUB" TOTAL_1="297" TOTAL_2="296" UNITS="" WEIGHT="300.0" Z="5.227190059070166">
<NAME>Serum concentrations (mg/L) - part A (SMD &gt; 0 in favour of the intervention)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.138070959180528" CI_END="1.131952664248437" CI_START="0.4571255717814855" DF="3" EFFECT_SIZE="0.7945391180149612" ESTIMABLE="YES" I2="51.12470970194649" ID="CMP-001.01.01" MODIFIED="2012-12-06 15:17:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10508269814635407" P_Z="3.925093161090808E-6" STUDIES="4" TAU2="0.05682791594339701" TOTAL_1="187" TOTAL_2="185" WEIGHT="100.0" Z="4.615309826772577">
<NAME>Aminoglycoside antibiotics: peak concentration</NAME>
<CONT_DATA CI_END="2.492962816164292" CI_START="0.7209825097038668" EFFECT_SIZE="1.6069726629340795" ESTIMABLE="YES" MEAN_1="7.45" MEAN_2="5.14" MODIFIED="2011-11-21 16:35:24 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.44" SD_2="1.35" SE="0.4520440988807906" STUDY_ID="STD-Hickling-1989" TOTAL_1="13" TOTAL_2="14" WEIGHT="11.347562729895863"/>
<CONT_DATA CI_END="1.6175471850379628" CI_START="0.3718869358394855" EFFECT_SIZE="0.9947170604387242" ESTIMABLE="YES" MEAN_1="6.49" MEAN_2="4.27" MODIFIED="2011-11-21 16:28:16 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="1.83" SD_2="2.49" SE="0.3177763109485905" STUDY_ID="STD-Begg-1989" TOTAL_1="22" TOTAL_2="23" WEIGHT="18.779981197760844"/>
<CONT_DATA CI_END="0.8404830872872374" CI_START="0.18294622937379346" EFFECT_SIZE="0.5117146583305154" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.4" MODIFIED="2012-12-06 15:10:37 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="1.8" SD_2="1.7" SE="0.1677420766656966" STUDY_ID="STD-Burton-1991" TOTAL_1="72" TOTAL_2="75" WEIGHT="34.88085710818327"/>
<CONT_DATA CI_END="1.0327594843130192" CI_START="0.37837209383467285" EFFECT_SIZE="0.705565789073846" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.0" MODIFIED="2012-12-06 15:17:02 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="1.7" SD_2="1.0" SE="0.1669386263319302" STUDY_ID="STD-Leehey-1993" TOTAL_1="80" TOTAL_2="73" WEIGHT="34.991598964160026"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.679310706246538" CI_END="1.0206814701342177" CI_START="-0.1999680820800514" DF="3" EFFECT_SIZE="0.41035669402708314" ESTIMABLE="YES" I2="76.33940779981019" ID="CMP-001.01.02" MODIFIED="2013-09-26 10:36:09 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005384034860871689" P_Z="0.18757151255495544" STUDIES="4" TAU2="0.2895801403082948" TOTAL_1="101" TOTAL_2="100" WEIGHT="100.00000000000001" Z="1.3177972984121886">
<NAME>Theophylline</NAME>
<CONT_DATA CI_END="0.1693154019719767" CI_START="-0.7470560015713092" EFFECT_SIZE="-0.2888702997996663" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="17.9" MODIFIED="2013-09-26 10:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="5.2" SD_2="7.0" SE="0.2337725108143585" STUDY_ID="STD-Hurley-1986" TOTAL_1="37" TOTAL_2="37" WEIGHT="28.169390244853417">
<FOOTNOTE>Mean serum concentration at day 2.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.4159503226463759" CI_START="0.40197354644856464" EFFECT_SIZE="0.9089619345474703" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="11.4" MODIFIED="2013-09-26 10:23:24 +0200" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="3.1" SD_2="3.9" SE="0.25867229811260073" STUDY_ID="STD-Gonzalez-1989" TOTAL_1="37" TOTAL_2="30" WEIGHT="27.200484635127918">
<FOOTNOTE>Theophylline concentration (4 h post load).</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.4154987977020483" CI_START="-0.22471317430944826" EFFECT_SIZE="0.5953928116963" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="13.6" MODIFIED="2013-09-26 10:23:31 +0200" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="5.06" SD_2="5.8" SE="0.41842911016459466" STUDY_ID="STD-Verner-1992" TOTAL_1="10" TOTAL_2="15" WEIGHT="20.86832877536019">
<FOOTNOTE>Serum theophylline concentration 20 minutes after completion of loading dose infusion.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.180716190231995" CI_START="-0.16867893900989162" EFFECT_SIZE="0.5060186256110517" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="12.6" MODIFIED="2012-12-11 14:23:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Casner: theophylline maintenance for asthma&lt;/p&gt;" NOTES_MODIFIED="2012-12-11 14:23:42 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="138" SD_1="4.4" SD_2="4.1" SE="0.34423977682389656" STUDY_ID="STD-Casner-1993" TOTAL_1="17" TOTAL_2="18" WEIGHT="23.761796344658478">
<FOOTNOTE>Serum theophylline level at C3 (just before discontinuation of the infusion). Theophylline maintenance for asthma.</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.315022370887085" CI_START="0.3298666510774031" DF="0" EFFECT_SIZE="1.322444510982244" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2012-10-26 15:57:58 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.00901920734208989" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="2.6113252348046267">
<NAME>Lidocaine</NAME>
<CONT_DATA CI_END="2.315022370887085" CI_START="0.3298666510774031" EFFECT_SIZE="1.322444510982244" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="3.7" MODIFIED="2011-11-23 14:55:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Walton Data in Revman 2008. Non retrouv&amp;#233; dans le papier&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 14:55:27 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="166" SD_1="0.9" SD_2="1.33" SE="0.5064265811689237" STUDY_ID="STD-Rodman-1984" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.767732104367424" CI_END="-0.19552196768631552" CI_START="-0.9849463895210226" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5902341786036691" ESTIMABLE="YES" I2="74.25245910739513" I2_Q="74.25245910739513" ID="CMP-001.02" MODIFIED="2013-11-04 13:32:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02057117501322503" P_Q="0.020571175013224918" P_Z="0.00338048506997172" Q="7.767732104367425" RANDOM="YES" SCALE="2.35" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4039370529586537" TOTALS="SUB" TOTAL_1="54" TOTAL_2="54" UNITS="" WEIGHT="300.0" Z="2.930838470436874">
<NAME>Serum concentrations (ng/L) - part B (SMD &lt; 0 in favour of the intervention)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5144745373388692" CI_START="-2.3427668455453006" DF="0" EFFECT_SIZE="-1.428620691442085" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2012-12-12 17:59:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0021911769788189265" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001" Z="3.0630168821768566">
<NAME>Midazolam</NAME>
<CONT_DATA CI_END="-0.5144745373388692" CI_START="-2.3427668455453006" EFFECT_SIZE="-1.428620691442085" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="96.0" MODIFIED="2012-10-26 15:58:50 +0200" MODIFIED_BY="[Empty name]" ORDER="459" SD_1="13.0" SD_2="42.0" SE="0.4664096694193791" STUDY_ID="STD-Theil-1993-midazolam" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0776912251395105" CI_START="-0.5315121941540388" DF="0" EFFECT_SIZE="0.2730895154927358" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2012-12-12 17:59:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5059030658311751" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6652305215163309">
<NAME>Fentanyl</NAME>
<CONT_DATA CI_END="1.0776912251395105" CI_START="-0.5315121941540388" EFFECT_SIZE="0.2730895154927358" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.5" MODIFIED="2012-10-26 15:58:52 +0200" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="0.6" SD_2="0.8" SE="0.41051861972636755" STUDY_ID="STD-Theil-1993-fentanyl" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1585752650350558" CI_START="-1.2015376784366" DF="0" EFFECT_SIZE="-0.680056471735828" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" MODIFIED="2012-12-12 17:59:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.010589465675750673" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.555962084402438">
<NAME>Antidepressants: steady-state plasma concentration</NAME>
<CONT_DATA CI_END="-0.1585752650350558" CI_START="-1.2015376784366" EFFECT_SIZE="-0.680056471735828" ESTIMABLE="YES" MEAN_1="150.91" MEAN_2="178.95" MODIFIED="2012-12-11 14:34:02 +0100" MODIFIED_BY="[Empty name]" ORDER="170" SD_1="38.82" SD_2="42.49" SE="0.26606672919204094" STUDY_ID="STD-Mihajlovic-2003" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>Amitriptyline+nortriptyline concentration.</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.206304349513122" CI_END="2.2650732929771094" CI_START="0.8394305544649774" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3789023642838485" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" I2="83.61502431258177" I2_Q="91.72290961879371" ID="CMP-001.03" LOG_CI_END="0.35508225942634636" LOG_CI_START="-0.07601522693530635" LOG_EFFECT_SIZE="0.13953351624552002" METHOD="MH" MODIFIED="2013-11-04 13:15:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0022358171127822013" P_Q="5.092383561844382E-4" P_Z="0.2045249742956592" Q="12.081540178304316" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.2574130603678422" TOTALS="SUB" TOTAL_1="98" TOTAL_2="99" WEIGHT="200.0" Z="1.268764839180842">
<NAME>Proportion of participants within therapeutic range</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.010070531670510235" CI_END="10.129593201984669" CI_START="1.9448187965365784" DF="1" EFFECT_SIZE="4.438493354787065" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.0055920047205233" LOG_CI_START="0.2888791432811176" LOG_EFFECT_SIZE="0.6472355740008204" MODIFIED="2013-11-04 13:15:42 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;pas les memes chiffres que V2???&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:15:42 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.9200648458322708" P_Z="4.002258334202891E-4" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="37" WEIGHT="100.0" Z="3.539934840870627">
<NAME>Aminoglycoside antibiotics: % of participants with peak concentrations adequate after 2 days</NAME>
<DICH_DATA CI_END="11.889393320567734" CI_START="1.5607367438715865" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.0751596944629447" LOG_CI_START="0.1933296549357824" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2013-09-26 10:37:56 +0200" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.5179913303473508" STUDY_ID="STD-Hickling-1989" TOTAL_1="13" TOTAL_2="14" VAR="0.26831501831501825" WEIGHT="66.05726949569816">
<FOOTNOTE>Peak plasma concentrations 6-10 mg/L after 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="19.39153227305414" CI_START="1.14136147789823" EFFECT_SIZE="4.704545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.287612127358233" LOG_CI_START="0.05742321058322759" LOG_EFFECT_SIZE="0.6725176689707303" MODIFIED="2013-09-26 10:38:01 +0200" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.722619059246987" STUDY_ID="STD-Begg-1989" TOTAL_1="22" TOTAL_2="23" VAR="0.5221783047870006" WEIGHT="33.94273050430184">
<FOOTNOTE>Peak plasma concentrations 6-10 mg/L after 2 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3229279949470454" CI_START="0.38186316489591166" DF="0" EFFECT_SIZE="0.7107583774250441" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.12153620681170331" LOG_CI_START="-0.41809223231529763" LOG_EFFECT_SIZE="-0.1482780127517971" MODIFIED="2013-08-06 13:40:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2814311910484245" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="1.0771098912535124">
<NAME>Anti-rejection drugs</NAME>
<DICH_DATA CI_END="1.3229279949470454" CI_START="0.38186316489591166" EFFECT_SIZE="0.7107583774250441" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.12153620681170331" LOG_CI_START="-0.41809223231529763" LOG_EFFECT_SIZE="-0.1482780127517971" MODIFIED="2013-07-24 22:59:20 +0200" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.3169804163470546" STUDY_ID="STD-Le-Meur-2007" TOTAL_1="63" TOTAL_2="62" VAR="0.10047658434755209" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27602699267187036" CI_END="1.1261675860117168" CI_START="0.24967717698046604" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5302625233620717" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.05160302307705967" LOG_CI_START="-0.602621154742984" LOG_EFFECT_SIZE="-0.2755090658329622" METHOD="MH" MODIFIED="2013-11-04 13:15:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.599317227525955" P_Q="1.0" P_Z="0.09878490899908805" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="55" WEIGHT="100.0" Z="1.6507731287039475">
<NAME>Proportion of participants with toxic drug levels</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.27602699267187036" CI_END="1.1261675860117168" CI_START="0.24967717698046604" DF="1" EFFECT_SIZE="0.5302625233620717" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.05160302307705967" LOG_CI_START="-0.602621154742984" LOG_EFFECT_SIZE="-0.2755090658329622" MODIFIED="2013-09-26 10:24:56 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.599317227525955" P_Z="0.09878490899908805" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="55" WEIGHT="100.0" Z="1.6507731287039475">
<NAME>Theophylline</NAME>
<DICH_DATA CI_END="1.0957135173789252" CI_START="0.22816182883097874" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.03969701939919998" LOG_CI_START="-0.6417570107271624" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-02-14 17:39:11 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.4002894705480775" STUDY_ID="STD-Hurley-1986" TOTAL_1="37" TOTAL_2="37" VAR="0.16023166023166022" WEIGHT="92.16797621837648"/>
<DICH_DATA CI_END="15.619811043133367" CI_START="0.07177470094485151" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1936757758011496" LOG_CI_START="-1.144028608351085" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-09-26 10:24:56 +0200" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.373179127074352" STUDY_ID="STD-Casner-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.8856209150326797" WEIGHT="7.832023781623514">
<FOOTNOTE>Theophylline toxicity (nausea, vomiting, tremor, tachycardia and seizures)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-11-04 13:16:23 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Physiological parameters</NAME>
<CONT_OUTCOME CHI2="26.67143786651703" CI_END="6.450247205887423" CI_START="0.9009892195023657" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="3.675618212694894" ESTIMABLE="YES" I2="81.25335414977033" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-11-04 13:16:09 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Poller 1998: data = all INR ranges (2.5-4.5)&lt;/p&gt;&lt;p&gt;Manotti=cutoff 2.8. Unit of error analysis: % of time spent in/out range (table 4): absolute time spent by patients and % (of patient time) reported&lt;/p&gt;&lt;p&gt;Poller 2008: local target INR ranges&lt;/p&gt;&lt;p&gt;Vadher 1997: therapeutic range 2-3. Unit of error analysis: % of time spent in/out range (table 2): absolute time spent by patients and % (of patient time) reported&lt;/p&gt;&lt;p&gt;Vadher pop1: therapeutic range 2-3. Unit of error analysis: % of time spent in/out range (table 3): absolute time spent by patients and % (of patient time) reported&lt;/p&gt;&lt;p&gt;Vadher pop2: therapeutic range 3-4.5. Unit of error analysis: % of time spent in/out range (table 3): absolute time spent by patients and % (of patient time) reported&lt;/p&gt;&lt;p&gt;White 1987: therapeutic range 1.8+/-0.4&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:16:09 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="6.609067089113907E-5" P_Q="1.0" P_Z="0.009420310161279049" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="5.45805832155645" TOTALS="YES" TOTAL_1="6868" TOTAL_2="6713" UNITS="" WEIGHT="99.99999999999999" Z="2.5964117492740386">
<NAME>Oral anticoagulants: % time in target INR range</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.713515506170822" CI_START="-5.513515506170805" EFFECT_SIZE="1.1000000000000085" ESTIMABLE="YES" MEAN_1="69.7" MEAN_2="68.6" MODIFIED="2012-02-28 17:52:54 +0100" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="23.4" SD_2="24.3" SE="3.3743046088282127" STUDY_ID="STD-Anderson-2007" TOTAL_1="101" TOTAL_2="99" WEIGHT="11.897855371388031"/>
<CONT_DATA CI_END="28.06538832268663" CI_START="2.3346116773133776" EFFECT_SIZE="15.200000000000003" ESTIMABLE="YES" MEAN_1="66.4" MEAN_2="51.2" MODIFIED="2013-09-26 10:27:57 +0200" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="29.9" SD_2="28.4" SE="6.564094250796018" STUDY_ID="STD-Poller-1998-pop1" TOTAL_1="39" TOTAL_2="40" WEIGHT="4.128246761445597">
<FOOTNOTE>The INR target ranges were decided by the individual centre, based on one of: the guidelines on oral anticoagulation of the British Society of Haematology, the Leuven Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-4.5, and 2.5-3.5.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="15.897384766084995" CI_START="-0.29738476608500086" EFFECT_SIZE="7.799999999999997" ESTIMABLE="YES" MEAN_1="61.8" MEAN_2="54.0" MODIFIED="2013-09-26 10:28:22 +0200" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="27.1" SD_2="27.5" SE="4.131394673553257" STUDY_ID="STD-Poller-1998-pop2" TOTAL_1="83" TOTAL_2="92" WEIGHT="8.896523268543612">
<FOOTNOTE>The INR target ranges were decided by the individual centre, based on one of: the guidelines on oral anticoagulation of the British Society of Haematology, the Leuven Group, and the ACCP Consensus. Three different ranges of INR resulted; 2.0-3.0, 3.0-4.5, and 2.5-3.5.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.3415062474786497" CI_START="0.058493752521356024" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" MEAN_1="65.7" MEAN_2="65.0" MODIFIED="2012-02-01 15:46:44 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="16.5" SD_2="16.9" SE="0.3273051201648429" STUDY_ID="STD-Poller-2008-PARMA-5" TOTAL_1="5290" TOTAL_2="5131" WEIGHT="36.01089365120608">
<FOOTNOTE>The INR target ranges were locally decided.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="4.70395837628204" CI_START="2.0960416237179564" EFFECT_SIZE="3.3999999999999986" ESTIMABLE="YES" MEAN_1="66.8" MEAN_2="63.4" MODIFIED="2012-02-01 15:46:51 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="16.4" SD_2="17.7" SE="0.6652971108487193" STUDY_ID="STD-Poller-2009-DAWN-AC" TOTAL_1="1316" TOTAL_2="1315" WEIGHT="33.96344227160015">
<FOOTNOTE>The INR target ranges were locally decided.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="27.397169936380156" CI_START="4.6028300636198445" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="58.0" MEAN_2="42.0" MODIFIED="2013-09-26 10:28:56 +0200" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="23.0" SD_2="27.0" SE="5.814989472398257" STUDY_ID="STD-White-1987" TOTAL_1="39" TOTAL_2="36" WEIGHT="5.103038675816523">
<FOOTNOTE>The therapeutic range was defined as PR=1.8 ± 0.4, or, using a generalized formula, PR±(0.22)*PR.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.461759556886882" CI_END="34.42874482047255" CI_START="9.940345523609787" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="22.18454517204117" ESTIMABLE="YES" I2="87.2132352531957" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-11-04 13:16:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.235314890348562E-5" P_Q="1.0" P_Z="3.835612795870287E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="135.78700819023018" TOTALS="YES" TOTAL_1="116" TOTAL_2="118" UNITS="" WEIGHT="99.99999999999999" Z="3.551143463768416">
<NAME>Insulin: % time in target glucose range</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.975011894078248" CI_START="-0.37501189407825386" EFFECT_SIZE="7.799999999999997" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="38.2" MODIFIED="2012-02-28 19:42:44 +0100" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="19.0" SD_2="18.3" SE="4.171001078877827" STUDY_ID="STD-Blaha-2009" TOTAL_1="40" TOTAL_2="40" WEIGHT="25.477128933761872"/>
<CONT_DATA CI_END="23.838784009574795" CI_START="8.161215990425205" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="64.2" MEAN_2="48.2" MODIFIED="2013-09-26 10:26:53 +0200" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="8.9" SD_2="14.1" SE="3.999453087610855" STUDY_ID="STD-Cordingley-2009" TOTAL_1="16" TOTAL_2="18" WEIGHT="25.71239551262686">
<FOOTNOTE>Means and standard deviation were estimated from medians and ranges.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="42.90849040607124" CI_START="22.89150959392876" EFFECT_SIZE="32.9" ESTIMABLE="YES" MEAN_1="60.4" MEAN_2="27.5" MODIFIED="2012-02-27 16:14:10 +0100" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="22.8" SD_2="16.2" SE="5.10646648867884" STUDY_ID="STD-Hovorka-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="24.111099504270328"/>
<CONT_DATA CI_END="42.2390700945229" CI_START="23.7609299054771" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="52.0" MEAN_2="19.0" MODIFIED="2013-09-26 10:27:23 +0200" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="18.75" SD_2="17.75" SE="4.7138978916957175" STUDY_ID="STD-Plank-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="24.699376049340934">
<FOOTNOTE>% of time within the target range for blood glucose in the first 24 h (80-110 mg/dL ou 4.4-6.1 mmol/L). Means were estimated from medians. SDs were estimated from ranges.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="21.187459880019475" CI_END="-0.4154093160296198" CI_START="-1.0252081989353983" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.720308757482509" ESTIMABLE="YES" I2="62.24181640790133" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-11-04 13:16:23 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;Pachler: median (IQR)&lt;/p&gt;&lt;p&gt;Plank: median (range)&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:16:23 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0066657909851309816" P_Q="1.0" P_Z="3.65117008174777E-6" Q="0.0" RANDOM="YES" SCALE="2.33" SORT_BY="EFFECT_SIZE" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.1290722903300893" TOTALS="YES" TOTAL_1="260" TOTAL_2="260" UNITS="" WEIGHT="99.99999999999999" Z="4.630310950020719">
<NAME>Insulin: mean blood glucose (mg/dL)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8671226545974968" CI_START="-2.1339452199596853" EFFECT_SIZE="-1.500533937278591" ESTIMABLE="YES" MEAN_1="106.31" MEAN_2="133.33" MODIFIED="2012-12-11 14:41:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Unit of analysis error&lt;/p&gt;" NOTES_MODIFIED="2012-12-11 14:41:00 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="120" SD_1="10.63" SD_2="22.7" SE="0.32317496019180025" STUDY_ID="STD-Pachler-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="10.363429808437195">
<FOOTNOTE>Mean blood glucose (original data in mmol/L)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.3385793993389731" CI_START="-2.317731399486068" EFFECT_SIZE="-1.3281553994125206" ESTIMABLE="YES" MEAN_1="116.58" MEAN_2="121.08" MODIFIED="2012-12-11 14:41:04 +0100" MODIFIED_BY="[Empty name]" ORDER="169" SD_1="1.98" SD_2="4.14" SE="0.5048949918871962" STUDY_ID="STD-Kremen-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.30225185884434">
<FOOTNOTE>Mean blood glucose (original data in mmol/L)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.5603564595928364" CI_START="-1.6521966797807597" EFFECT_SIZE="-1.106276569686798" ESTIMABLE="YES" MEAN_1="108.11" MEAN_2="131.53" MODIFIED="2013-09-26 10:26:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Unit of analysis error?&lt;/p&gt;" NOTES_MODIFIED="2013-09-26 10:26:11 +0200" NOTES_MODIFIED_BY="[Empty name]" ORDER="167" SD_1="18.02" SD_2="23.42" SE="0.2785357865757278" STUDY_ID="STD-Hovorka-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="11.710414348029564">
<FOOTNOTE>Blood glucose levels in intensive care unit (original data in mmol/L).</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.24356895430529069" CI_START="-1.550482401130989" EFFECT_SIZE="-0.8970256777181398" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="147.0" MODIFIED="2013-09-26 10:26:05 +0200" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="18.0" SD_2="27.0" SE="0.3334024138031272" STUDY_ID="STD-Saager-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.073741694357622">
<FOOTNOTE>Mean blood glucose (mg/dL) in intensive care unit</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.32686891028006976" CI_START="-1.237983579696715" EFFECT_SIZE="-0.7824262449883923" ESTIMABLE="YES" MEAN_1="106.31" MEAN_2="120.72" MODIFIED="2012-03-20 12:15:57 +0100" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="23.42" SD_2="10.81" SE="0.23243148256891485" STUDY_ID="STD-Blaha-2009" TOTAL_1="40" TOTAL_2="40" WEIGHT="13.217112771204045"/>
<CONT_DATA CI_END="-0.019140333306577606" CI_START="-1.0504429409245561" EFFECT_SIZE="-0.5347916371155669" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="131.0" MODIFIED="2013-09-26 10:26:23 +0200" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="10.5" SD_2="35.0" SE="0.26309223428408934" STUDY_ID="STD-Plank-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="12.204406652680815">
<FOOTNOTE>Mean glucose levels in 24 h (mg/dL)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.1313527029498328" CI_START="-0.83473714000832" EFFECT_SIZE="-0.4830449214790764" ESTIMABLE="YES" MEAN_1="194.0" MEAN_2="224.0" MODIFIED="2012-12-11 14:41:25 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="66.0" SD_2="57.0" SE="0.1794381025893062" STUDY_ID="STD-Wexler-2010" TOTAL_1="65" TOTAL_2="63" WEIGHT="15.005919757096592">
<FOOTNOTE>Mean blood glucose (mg/dL)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.17261321151818287" CI_START="-0.9977641961571917" EFFECT_SIZE="-0.4125754923195044" ESTIMABLE="YES" MEAN_1="136.76" MEAN_2="152.25" MODIFIED="2012-03-20 12:16:15 +0100" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="26.49" SD_2="44.32" SE="0.2985711515382839" STUDY_ID="STD-Augstein-2007" TOTAL_1="22" TOTAL_2="24" WEIGHT="11.089920915769909">
<FOOTNOTE>Mean sensor glucose (original data in mmol/L)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.9128630339109531" CI_START="-0.3998004622599461" EFFECT_SIZE="0.2565312858255035" ESTIMABLE="YES" MEAN_1="91.89" MEAN_2="90.09" MODIFIED="2012-12-11 14:41:31 +0100" MODIFIED_BY="[Empty name]" ORDER="178" SD_1="3.6" SD_2="9.01" SE="0.3348692900800783" STUDY_ID="STD-Sato-2011" TOTAL_1="18" TOTAL_2="18" WEIGHT="10.032802193579919">
<FOOTNOTE>Mean blood glucose (original data in mmol/L)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-11-04 13:30:27 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Time to achieve therapeutic control</NAME>
<CONT_OUTCOME CHI2="13.493425791713532" CI_END="0.828679259287556" CI_START="-1.220555127258375" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19593793398540943" ESTIMABLE="YES" I2="70.35593435096041" I2_Q="1.3133315687319673" ID="CMP-003.01" MODIFIED="2013-11-04 13:16:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00910034681892935" P_Q="0.31411190249542464" P_Z="0.7078057527086952" Q="1.0133080951014843" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.097703885659696" TOTALS="SUB" TOTAL_1="177" TOTAL_2="180" UNITS="" WEIGHT="200.0" Z="0.37480465518040595">
<NAME>Time to achieve therapeutic range</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.883100484727969" CI_END="0.6881757381480264" CI_START="-1.8440759163548845" DF="1" EFFECT_SIZE="-0.5779500891034292" ESTIMABLE="YES" I2="65.31511803708939" ID="CMP-003.01.01" MODIFIED="2013-11-04 13:16:34 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Vadher: median used from survival analysis. Some patients were censored or below the therapeutic range&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Unit&amp;#233; en jours, &amp;#224; transformer en heures? Non, pas de MA, car pas la m&amp;#234;me chose que Insuline!!! pas le m&amp;#234;me param&amp;#232;tre biologique.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-11-04 13:16:34 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.08951364597308986" P_Z="0.37096498044120796" STUDIES="2" TAU2="0.5519127474134052" TOTAL_1="111" TOTAL_2="112" WEIGHT="100.0" Z="0.894667287502909">
<NAME>Oral anticoagulants: time to achieve therapeutic prothrombin ratio (days)</NAME>
<CONT_DATA CI_END="-0.0811101743189433" CI_START="-2.5188898256810566" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.5" MODIFIED="2012-12-11 14:43:06 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.6" SD_2="3.4" SE="0.6218939915710207" STUDY_ID="STD-White-1987" TOTAL_1="39" TOTAL_2="36" WEIGHT="44.457699161802246"/>
<CONT_DATA CI_END="0.8752558575723822" CI_START="-0.8752558575723822" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2012-12-11 14:43:02 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="2.88" SD_2="2.53" SE="0.44656731678555767" STUDY_ID="STD-Vadher-1997" TOTAL_1="72" TOTAL_2="76" WEIGHT="55.54230083819776"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.272416601959108" CI_END="2.2731349452993506" CI_START="-1.2151663237354504" DF="2" EFFECT_SIZE="0.52898431078195" ESTIMABLE="YES" I2="38.88308723276084" ID="CMP-003.01.02" MODIFIED="2013-11-04 13:16:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19471712338985214" P_Z="0.5522189018942902" STUDIES="3" TAU2="1.0480730490681824" TOTAL_1="66" TOTAL_2="68" WEIGHT="100.0" Z="0.5944384487216271">
<NAME>Insulin: time to achieve therapeutic control (h)</NAME>
<CONT_DATA CI_END="2.6293650719194384" CI_START="-6.829365071919438" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="10.9" MODIFIED="2012-02-28 19:47:38 +0100" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="13.9" SD_2="6.3" SE="2.412985702402731" STUDY_ID="STD-Blaha-2009" TOTAL_1="40" TOTAL_2="40" WEIGHT="11.52600588753032"/>
<CONT_DATA CI_END="2.368429727399051" CI_START="-3.128429727399051" EFFECT_SIZE="-0.3799999999999999" ESTIMABLE="YES" MEAN_1="6.45" MEAN_2="6.83" MODIFIED="2012-10-12 16:43:47 +0200" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="1.92" SD_2="5.59" SE="1.4022858323307539" STUDY_ID="STD-Cordingley-2009" TOTAL_1="16" TOTAL_2="18" WEIGHT="26.269970963735346"/>
<CONT_DATA CI_END="2.3296925484568427" CI_START="0.4703074515431579" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="8.9" MODIFIED="2012-02-27 18:13:45 +0100" MODIFIED_BY="[Empty name]" ORDER="172" SD_1="0.9" SD_2="1.2" SE="0.4743416490252569" STUDY_ID="STD-Kremen-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="62.204023148734336"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.979670700830917" CI_END="-0.03942122306187479" CI_START="-1.0743868843665152" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5569040537141949" ESTIMABLE="YES" I2="71.34535301555267" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-11-04 13:30:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.030505928866291887" P_Q="1.0" P_Z="0.034921136397928744" Q="0.0" RANDOM="YES" SCALE="4.868907114293411" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.14706942246038593" TOTALS="SUB" TOTAL_1="132" TOTAL_2="123" UNITS="" WEIGHT="100.0" Z="2.109271696508774">
<NAME>Time to stabilization</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.979670700830917" CI_END="-0.03942122306187479" CI_START="-1.0743868843665152" DF="2" EFFECT_SIZE="-0.5569040537141949" ESTIMABLE="YES" I2="71.34535301555267" ID="CMP-003.02.01" MODIFIED="2013-11-04 13:30:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.030505928866291887" P_Z="0.034921136397928744" STUDIES="3" TAU2="0.14706942246038593" TOTAL_1="132" TOTAL_2="123" WEIGHT="100.0" Z="2.109271696508774">
<NAME>Oral anticoagulants: time to stabilization (days)</NAME>
<CONT_DATA CI_END="0.029823405504687206" CI_START="-1.2584784184500535" EFFECT_SIZE="-0.6143275064726832" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.42" MODIFIED="2013-09-26 10:29:54 +0200" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="1.26" SD_2="3.47" SE="0.3286544635811426" STUDY_ID="STD-Carter-1987" TOTAL_1="20" TOTAL_2="19" WEIGHT="27.328379977432633">
<FOOTNOTE>For the 39 patients who achieved stable prothrombin ratios before discharge</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.14217333374495303" CI_START="-0.5038455893259854" EFFECT_SIZE="-0.1808361277905162" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="9.0" MODIFIED="2011-11-09 16:02:47 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="3.75" SD_2="15.3" SE="0.16480377398938278" STUDY_ID="STD-Vadher-1997" TOTAL_1="76" TOTAL_2="72" WEIGHT="40.01045621549832"/>
<CONT_DATA CI_END="-0.4646322936946319" CI_START="-1.4744592866212431" EFFECT_SIZE="-0.9695457901579375" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="9.4" MODIFIED="2012-01-31 14:16:55 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="1.7" SD_2="5.2" SE="0.2576136604784572" STUDY_ID="STD-White-1987" TOTAL_1="36" TOTAL_2="32" WEIGHT="32.661163807069045"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-11-04 13:30:47 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Clinical improvement</NAME>
<DICH_OUTCOME CHI2="0.9080862789387925" CI_END="1.2213305411608957" CI_START="1.0227529675745015" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1176401188941267" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.0868332174051337" LOG_CI_START="0.009770748301783533" LOG_EFFECT_SIZE="0.04830198285345858" METHOD="MH" MODIFIED="2013-11-04 13:30:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3406228237009611" P_Q="1.0" P_Z="0.014011378539166704" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="139" TOTAL_2="132" WEIGHT="99.99999999999999" Z="2.4569715420793448">
<NAME>Aminoglycoside antibiotics</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9080862789387925" CI_END="1.2213305411608957" CI_START="1.0227529675745015" DF="1" EFFECT_SIZE="1.1176401188941267" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="76" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.0868332174051337" LOG_CI_START="0.009770748301783533" LOG_EFFECT_SIZE="0.04830198285345858" MODIFIED="2013-11-04 13:30:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3406228237009611" P_Z="0.014011378539166704" STUDIES="2" TAU2="0.0" TOTAL_1="139" TOTAL_2="132" WEIGHT="99.99999999999999" Z="2.4569715420793448">
<NAME>Number of participants cured</NAME>
<DICH_DATA CI_END="1.6421968625250918" CI_START="0.5465282181989571" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.21542521805966583" LOG_CI_START="-0.26238740975871166" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2012-03-19 09:09:31 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.28066950279116826" STUDY_ID="STD-Burton-1991" TOTAL_1="68" TOTAL_2="68" VAR="0.07877536979704161" WEIGHT="2.6011811197868573"/>
<DICH_DATA CI_END="1.2281782973776962" CI_START="1.0260693048589502" EFFECT_SIZE="1.122584541062802" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="57" LOG_CI_END="0.08926141887876257" LOG_CI_START="0.011176695767311968" LOG_EFFECT_SIZE="0.05021905732303723" MODIFIED="2012-02-28 16:08:03 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.04586735288127931" STUDY_ID="STD-Leehey-1993" TOTAL_1="71" TOTAL_2="64" VAR="0.0021038140603358013" WEIGHT="97.39881888021313">
<FOOTNOTE>Clinical cure of infection or improvement</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5067128195142017" CI_END="1.3199643945279742" CI_START="1.0045628121985382" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="66" I2="60.1071174880815" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.12056221645692419" LOG_CI_START="0.0019770970209212002" LOG_EFFECT_SIZE="0.06126965673892271" METHOD="MH" MODIFIED="2013-11-04 13:30:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11336246143198014" P_Q="1.0" P_Z="0.0428346658503603" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="2.0253185412226626">
<NAME>Anti-rejection drugs</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5067128195142017" CI_END="1.3199643945279742" CI_START="1.0045628121985382" DF="1" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="66" I2="60.1071174880815" ID="CMP-004.02.01" LOG_CI_END="0.12056221645692419" LOG_CI_START="0.0019770970209212002" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2013-11-04 13:30:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11336246143198014" P_Z="0.0428346658503603" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="2.0253185412226626">
<NAME>No biopsy-confirmed rejections</NAME>
<DICH_DATA CI_END="1.2530500940728997" CI_START="0.7069255674445468" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.09796843343992931" LOG_CI_START="-0.15062631088462758" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2011-11-23 16:32:57 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.14602578338007538" STUDY_ID="STD-Asberg-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.0213235294117647" WEIGHT="25.757575757575758"/>
<DICH_DATA CI_END="1.430695511777063" CI_START="1.0480044481623034" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="49" LOG_CI_END="0.15554721473407576" LOG_CI_START="0.020363125976184258" LOG_EFFECT_SIZE="0.08795517035512998" MODIFIED="2011-11-23 16:33:32 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.0794078029084171" STUDY_ID="STD-Le-Meur-2007" TOTAL_1="65" TOTAL_2="65" VAR="0.006305599162742016" WEIGHT="74.24242424242424"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-11-04 13:31:13 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Clinical adverse events</NAME>
<DICH_OUTCOME CHI2="6.861566128245864" CI_END="1.4540073729193135" CI_START="0.8035872726705946" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0809356221566422" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.16256660873075976" LOG_CI_START="-0.09496695028703117" LOG_EFFECT_SIZE="0.033799829221864267" METHOD="MH" MODIFIED="2012-12-11 14:46:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5516399357504809" P_Q="0.6319179618285046" P_Z="0.6069245015801741" Q="1.722614365685596" RANDOM="YES" SCALE="961.3" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7116" TOTAL_2="6930" WEIGHT="100.0" Z="0.5144684693607801">
<NAME>Death</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3626765255565874" CI_END="1.511052275431204" CI_START="0.7843697892454234" DF="3" EFFECT_SIZE="1.0886798219948741" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="67" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.17927948918257147" LOG_CI_START="-0.10547914195055035" LOG_EFFECT_SIZE="0.036900173616010536" MODIFIED="2012-04-02 09:44:07 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9478400007690574" P_Z="0.6114813275195087" STUDIES="5" TAU2="0.0" TOTAL_1="6838" TOTAL_2="6661" WEIGHT="81.79257223468744" Z="0.5079600995612708">
<NAME>Oral anticoagulants</NAME>
<DICH_DATA CI_END="4.053184812972962" CI_START="0.17245836938076103" EFFECT_SIZE="0.8360655737704918" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6077964067084911" LOG_CI_START="-0.7633157245341523" LOG_EFFECT_SIZE="-0.07775965891283065" MODIFIED="2011-11-09 20:07:54 +0100" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.8053980530064396" STUDY_ID="STD-Fitzmaurice-2000" TOTAL_1="122" TOTAL_2="102" VAR="0.6486660237865638" WEIGHT="3.5279442416389264"/>
<DICH_DATA CI_END="1.5526257987941914" CI_START="0.7111317998636313" EFFECT_SIZE="1.0507718966603654" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" LOG_CI_END="0.19106679822625816" LOG_CI_START="-0.14804990046743632" LOG_EFFECT_SIZE="0.021508448879410932" MODIFIED="2012-02-01 15:09:58 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.19919882746740764" STUDY_ID="STD-Poller-2008-PARMA-5" TOTAL_1="5290" TOTAL_2="5131" VAR="0.03968017286439004" WEIGHT="57.67257040904539"/>
<DICH_DATA CI_END="2.57618818950474" CI_START="0.6426457309088112" EFFECT_SIZE="1.2866920152091255" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.410977584882739" LOG_CI_START="-0.19202837312828283" LOG_EFFECT_SIZE="0.10947460587722806" MODIFIED="2012-02-01 15:09:58 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.3542086846633067" STUDY_ID="STD-Poller-2009-DAWN-AC" TOTAL_1="1315" TOTAL_2="1316" VAR="0.12546379229090984" WEIGHT="18.239983995210633">
<FOOTNOTE>The authors corrected the number of events from original article.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.2961306397367744" CI_START="0.15271074297874618" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8630926015825384" LOG_CI_START="-0.8161304098834926" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2011-11-09 20:08:24 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.9863839092231123" STUDY_ID="STD-Vadher-1997" TOTAL_1="72" TOTAL_2="76" VAR="0.972953216374269" WEIGHT="2.3520735887924937"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 16:01:32 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.0" STUDY_ID="STD-White-1987" TOTAL_1="39" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.163644200073064" CI_END="3.098226156758144" CI_START="0.1388198827677215" DF="2" EFFECT_SIZE="0.6558165840149621" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="61.26766441476156" ID="CMP-005.01.02" LOG_CI_END="0.49111311614986825" LOG_CI_START="-0.8575483266917141" LOG_EFFECT_SIZE="-0.18321760527092298" MODIFIED="2012-04-02 09:44:18 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.075636165825123" P_Z="0.5943604415446833" STUDIES="3" TAU2="1.1549331566723424" TOTAL_1="165" TOTAL_2="161" WEIGHT="16.07434498745502" Z="0.53252787728264">
<NAME>Aminoglycoside antibiotics</NAME>
<DICH_DATA CI_END="1.6502989627353144" CI_START="0.02649156865008266" EFFECT_SIZE="0.20909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21756262670180385" LOG_CI_START="-1.5768923249830684" LOG_EFFECT_SIZE="-0.6796648491406322" MODIFIED="2011-11-21 17:29:42 +0100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.054071721314963" STUDY_ID="STD-Begg-1989" TOTAL_1="22" TOTAL_2="23" VAR="1.1110671936758894" WEIGHT="2.0596932178272875"/>
<DICH_DATA CI_END="3.125075787511147" CI_START="0.035554693283007234" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49486055406370305" LOG_CI_START="-1.449103063503028" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-11-21 17:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.1418938517337989" STUDY_ID="STD-Burton-1991" TOTAL_1="68" TOTAL_2="68" VAR="1.303921568627451" WEIGHT="1.7550576801743754"/>
<DICH_DATA CI_END="4.353392965822095" CI_START="0.8003974076772649" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.638827871197211" LOG_CI_START="-0.09669432662413499" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2011-11-21 17:37:40 +0100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.43204937989385733" STUDY_ID="STD-Destache-1990" TOTAL_1="75" TOTAL_2="70" VAR="0.18666666666666665" WEIGHT="12.259594089453358"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.639638725295671" CI_START="0.008861656404955636" DF="0" EFFECT_SIZE="0.17959183673469387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.561058277221226" LOG_CI_START="-2.052485092977916" LOG_EFFECT_SIZE="-0.7457134078783451" MODIFIED="2011-11-22 12:43:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2633707418457666" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="43" WEIGHT="0.9709754214614349" Z="1.1184596658281725">
<NAME>Theophylline</NAME>
<DICH_DATA CI_END="3.639638725295671" CI_START="0.008861656404955636" EFFECT_SIZE="0.17959183673469387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.561058277221226" LOG_CI_START="-2.052485092977916" LOG_EFFECT_SIZE="-0.7457134078783451" MODIFIED="2011-11-22 12:43:44 +0100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.5352083129033078" STUDY_ID="STD-Hurley-1986" TOTAL_1="48" TOTAL_2="43" VAR="2.356864564007421" WEIGHT="0.9709754214614349"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.64894352488065" CI_START="0.06390207737730504" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="1.194485023236973" LOG_CI_START="-1.194485023236973" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 17:37:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="1.1621073563960995" Z="0.0">
<NAME>Cyclosporine</NAME>
<DICH_DATA CI_END="15.64894352488065" CI_START="0.06390207737730504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194485023236973" LOG_CI_START="-1.194485023236973" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 17:37:27 +0100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.4032928308912467" STUDY_ID="STD-Le-Meur-2007" TOTAL_1="65" TOTAL_2="65" VAR="1.9692307692307693" WEIGHT="1.1621073563960995"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.993631771425648" CI_END="1.768063188930658" CI_START="0.44044335235260645" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8824577486224815" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" I2_Q="68.31855882608761" ID="CMP-005.02" LOG_CI_END="0.24749778223446928" LOG_CI_START="-0.3561099404702907" LOG_EFFECT_SIZE="-0.05430607911791071" METHOD="MH" MODIFIED="2013-11-04 13:30:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6607405866219138" P_Q="0.07562909740386603" P_Z="0.7243338870580744" Q="3.1564220658731745" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="446" TOTAL_2="461" WEIGHT="200.0" Z="0.3526726223307427">
<NAME>Anticoagulants: events</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.752420934550348" CI_END="1.4081533939157973" CI_START="0.3007389424479517" DF="5" EFFECT_SIZE="0.6507584517243943" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.14864996624260685" LOG_CI_START="-0.5218103318089689" LOG_EFFECT_SIZE="-0.18658018278318098" MODIFIED="2013-11-04 13:30:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8822305636508858" P_Z="0.27533282934053305" STUDIES="6" TAU2="0.0" TOTAL_1="273" TOTAL_2="279" WEIGHT="99.99999999999999" Z="1.090863812657268">
<NAME>Bleeding</NAME>
<DICH_DATA CI_END="6.96264540555288" CI_START="0.1494259637536985" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8427742779368819" LOG_CI_START="-0.8255739344130467" LOG_EFFECT_SIZE="0.00860017176191757" MODIFIED="2013-09-26 10:31:56 +0200" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.9799959983911899" STUDY_ID="STD-Ageno-2000" TOTAL_1="50" TOTAL_2="51" VAR="0.960392156862745" WEIGHT="16.150007595164915">
<FOOTNOTE>Minor bleedings (until discharge or until the 7th day of treatment)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.381165751618111" CI_START="0.050249334898983755" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7308763694678753" LOG_CI_START="-1.2988696821982768" LOG_EFFECT_SIZE="-0.28399665636520083" MODIFIED="2012-04-02 10:01:30 +0200" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-Mungall-1994" TOTAL_1="25" TOTAL_2="26" VAR="1.4215384615384614" WEIGHT="10.910953904746316"/>
<DICH_DATA CI_END="2.7938256794948026" CI_START="0.09970177622764873" EFFECT_SIZE="0.5277777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4461993048578736" LOG_CI_START="-1.0012971044867902" LOG_EFFECT_SIZE="-0.2775488998144583" MODIFIED="2013-09-26 10:32:02 +0200" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.850266556071841" STUDY_ID="STD-Vadher-1997" TOTAL_1="72" TOTAL_2="76" VAR="0.722953216374269" WEIGHT="21.45414153554374">
<FOOTNOTE>Haemorrhagic events (maximum length of follow-up: 13 months).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.2992694083576595" CI_START="0.056124402530242916" EFFECT_SIZE="0.5945945945945946" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7992901827364547" LOG_CI_START="-1.250848269226032" LOG_EFFECT_SIZE="-0.22577904324478873" MODIFIED="2013-09-26 10:32:11 +0200" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="1.2042614750317724" STUDY_ID="STD-Vadher-1997-pop1" TOTAL_1="37" TOTAL_2="44" VAR="1.4502457002457003" WEIGHT="10.694974392988987">
<FOOTNOTE>Haemorrhagic events (maximum length of follow-up: 3 months).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.467435888089495" CI_START="0.24409968268118537" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5400084398372147" LOG_CI_START="-0.6124327851461042" LOG_EFFECT_SIZE="-0.036212172654444715" MODIFIED="2013-09-26 10:32:15 +0200" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.676949680231269" STUDY_ID="STD-Vadher-1997-pop2" TOTAL_1="50" TOTAL_2="46" VAR="0.4582608695652174" WEIGHT="33.84609434880582">
<FOOTNOTE>Haemorrhagic events (maximum length of follow-up: 6 months).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4729145559774848" CI_START="0.007061196130561548" EFFECT_SIZE="0.13214285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3932091108988803" LOG_CI_START="-2.151121725449329" LOG_EFFECT_SIZE="-0.8789563072752242" MODIFIED="2012-12-11 14:50:46 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.4945525279117018" STUDY_ID="STD-White-1987" TOTAL_1="39" TOTAL_2="36" VAR="2.2336872586872585" WEIGHT="6.9438282227502155">
<FOOTNOTE>Bleeding complications (length of follow-up: In-hospital).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12416740743904937" CI_END="16.02661610398087" CI_START="0.6579212196943361" DF="1" EFFECT_SIZE="3.247191219300764" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="1.2048418341129945" LOG_CI_START="-0.18182610623460882" LOG_EFFECT_SIZE="0.5115078639391929" MODIFIED="2012-04-02 10:03:22 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7245578956094386" P_Z="0.14818688258244847" STUDIES="4" TAU2="0.0" TOTAL_1="173" TOTAL_2="182" WEIGHT="100.0" Z="1.4459654859814832">
<NAME>Thromboembolism</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 10:03:17 +0200" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitra-2005" TOTAL_1="14" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.885966669187155" CI_START="0.4833046847791888" EFFECT_SIZE="4.222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.566861169483233" LOG_CI_START="-0.31577899512826246" LOG_EFFECT_SIZE="0.6255410871774852" MODIFIED="2012-04-02 10:03:18 +0200" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="1.1058721519119057" STUDY_ID="STD-Vadher-1997" TOTAL_1="72" TOTAL_2="76" VAR="1.2229532163742691" WEIGHT="54.25132006560183"/>
<DICH_DATA CI_END="25.197077633430638" CI_START="0.2244976101209716" EFFECT_SIZE="2.3783783783783785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4013501740644172" LOG_CI_START="-0.6487882778980698" LOG_EFFECT_SIZE="0.37628094808317364" MODIFIED="2012-04-02 10:03:20 +0200" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.2042614750317724" STUDY_ID="STD-Vadher-1997-pop1" TOTAL_1="37" TOTAL_2="44" VAR="1.4502457002457003" WEIGHT="45.74867993439817"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 10:03:22 +0200" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.0" STUDY_ID="STD-Vadher-1997-pop2" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="17.39730964072089" CI_END="0.9258913614316695" CI_START="0.6015465995226877" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7463020836073371" ESTIMABLE="YES" I2="65.51190888758948" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.033439967852207944" LOG_CI_START="-0.22073072388246517" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12708534586733652" MODIFIED="2013-11-04 13:31:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.007928820662024716" P_Q="0.4383962765591679" P_Z="0.007817535437809936" Q="0.6004769363244415" RANDOM="YES" SCALE="2.16" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.04615392580715029" TOTALS="SUB" TOTAL_1="19020" TOTAL_2="18784" WEIGHT="200.0" Z="2.6598504500943556">
<NAME>Anticoagulants: event rates</NAME>
<GROUP_LABEL_1>Favours intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.387356635635247" CI_END="1.080303381301797" CI_START="0.602430747517078" DF="2" EFFECT_SIZE="0.806726703129919" ESTIMABLE="YES" I2="68.68814262159808" ID="CMP-005.03.01" LOG_CI_END="0.03354573541559273" LOG_CI_START="-0.2200928702465677" LOG_EFFECT_SIZE="-0.09327356741548752" MODIFIED="2013-11-04 13:31:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0410207582228137" P_Z="0.14943722703233042" STUDIES="4" TAU2="0.045276019413773336" TOTAL_1="9510" TOTAL_2="9392" WEIGHT="100.0" Z="1.4415221402646081">
<NAME>Bleeding</NAME>
<IV_DATA CI_END="0.8055551225287338" CI_START="0.4034123036788043" EFFECT_SIZE="0.5700621437348545" ESTIMABLE="YES" ESTIMATE="-0.5620099" LOG_CI_END="-0.09390473632362602" LOG_CI_START="-0.3942508603663707" LOG_EFFECT_SIZE="-0.2440777983449984" MODIFIED="2012-02-21 17:07:03 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SE="0.1764248" STUDY_ID="STD-Claes-2005" TOTAL_1="70" TOTAL_2="60" WEIGHT="29.053785678823065"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-29 16:26:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fitzmaurice: 0 bleeding dans groupe controle --&amp;gt; rate not estimable&lt;/p&gt;" NOTES_MODIFIED="2011-11-29 16:26:44 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="129" SE="0.0" STUDY_ID="STD-Fitzmaurice-2000" TOTAL_1="87" TOTAL_2="68" WEIGHT="0.0"/>
<IV_DATA CI_END="1.003453598853491" CI_START="0.7306396841608032" EFFECT_SIZE="0.8562493915538485" ESTIMABLE="YES" ESTIMATE="-0.1551936" LOG_CI_END="0.0014972948824988719" LOG_CI_START="-0.1362967430958998" LOG_EFFECT_SIZE="-0.06739972410670052" MODIFIED="2011-11-14 18:02:40 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SE="0.0809409" STUDY_ID="STD-Poller-2008-PARMA-5" TOTAL_1="7704" TOTAL_2="7665" WEIGHT="42.82980406859889"/>
<IV_DATA CI_END="1.5112683015825734" CI_START="0.7361184666365991" EFFECT_SIZE="1.0547381214488558" ESTIMABLE="YES" ESTIMATE="0.05329251" LOG_CI_END="0.17934157324232336" LOG_CI_START="-0.13305228720277565" LOG_EFFECT_SIZE="0.023144643019773852" MODIFIED="2012-02-01 15:03:43 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SE="0.1835017" STUDY_ID="STD-Poller-2009-DAWN-AC" TOTAL_1="1649" TOTAL_2="1599" WEIGHT="28.116410252578046">
<FOOTNOTE>The authors corrected the number of events from original article.</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="8.583307782441446" CI_END="0.9359253135366721" CI_START="0.49374666845077053" DF="3" EFFECT_SIZE="0.6797867352909107" ESTIMABLE="YES" I2="65.04843964541283" ID="CMP-005.03.02" LOG_CI_END="-0.028758806404040497" LOG_CI_START="-0.30649582175197027" LOG_EFFECT_SIZE="-0.16762731407800538" MODIFIED="2012-04-02 10:06:05 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03537614069902295" P_Z="0.017988227411758085" STUDIES="4" TAU2="0.06594618058318838" TOTAL_1="9510" TOTAL_2="9392" WEIGHT="100.0" Z="2.365860366192082">
<NAME>Thromboembolism</NAME>
<IV_DATA CI_END="0.9062495711561985" CI_START="0.45383887084028823" EFFECT_SIZE="0.6413199529665552" ESTIMABLE="YES" ESTIMATE="-0.4442268" LOG_CI_END="-0.04275218593216715" LOG_CI_START="-0.34309830997491175" LOG_EFFECT_SIZE="-0.19292524795353946" MODIFIED="2012-04-02 10:06:05 +0200" MODIFIED_BY="[Empty name]" ORDER="465" SE="0.1764248" STUDY_ID="STD-Claes-2005" TOTAL_1="70" TOTAL_2="60" WEIGHT="27.41885052242793"/>
<IV_DATA CI_END="0.7168026132243167" CI_START="0.38062881089930156" EFFECT_SIZE="0.5223367939568144" ESTIMABLE="YES" ESTIMATE="-0.6494427" LOG_CI_END="-0.14460042004956966" LOG_CI_START="-0.4194983417951284" LOG_EFFECT_SIZE="-0.28204938092234905" MODIFIED="2012-04-02 10:06:05 +0200" MODIFIED_BY="[Empty name]" ORDER="466" SE="0.1614764" STUDY_ID="STD-Fitzmaurice-2000" TOTAL_1="87" TOTAL_2="68" WEIGHT="28.923889143645003"/>
<IV_DATA CI_END="1.329662078478926" CI_START="0.727061599741579" EFFECT_SIZE="0.9832325451766744" ESTIMABLE="YES" ESTIMATE="-0.01690962" LOG_CI_END="0.12374128299800692" LOG_CI_START="-0.13842879231216867" LOG_EFFECT_SIZE="-0.007343754657080855" MODIFIED="2012-04-02 10:06:05 +0200" MODIFIED_BY="[Empty name]" ORDER="467" SE="0.154" STUDY_ID="STD-Poller-2008-PARMA-5" TOTAL_1="7704" TOTAL_2="7665" WEIGHT="29.68475272436218"/>
<IV_DATA CI_END="1.1987963094914076" CI_START="0.3005787855158425" EFFECT_SIZE="0.6002772182815215" ESTIMABLE="YES" ESTIMATE="-0.5103637" LOG_CI_END="0.07874539729497503" LOG_CI_START="-0.5220416746424283" LOG_EFFECT_SIZE="-0.22164813867372662" MODIFIED="2012-04-02 10:06:05 +0200" MODIFIED_BY="[Empty name]" ORDER="468" SE="0.3529053" STUDY_ID="STD-Poller-2009-DAWN-AC" TOTAL_1="1649" TOTAL_2="1599" WEIGHT="13.972507609564891"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="3.978255874899091" CI_END="1.3960450462380327" CI_START="0.3623163447326316" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7112031624191935" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.14489943190962032" LOG_CI_START="-0.44091207372953617" LOG_EFFECT_SIZE="-0.1480063209099579" METHOD="MH" MODIFIED="2013-11-04 13:31:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7822785550221889" P_Q="0.9736934880344184" P_Z="0.32199000004509903" Q="0.001087436465849516" RANDOM="YES" SCALE="616.89" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="335" TOTAL_2="335" WEIGHT="200.0" Z="0.9903767873295428">
<NAME>Insulin</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7333104463313957" CI_END="1.4758486769950359" CI_START="0.34582302614079163" DF="4" EFFECT_SIZE="0.7144105651544544" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.16904183030877634" LOG_CI_START="-0.46114609321086497" LOG_EFFECT_SIZE="-0.14605213145104434" MODIFIED="2013-11-04 13:31:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6033986482676048" P_Z="0.3636240908618821" STUDIES="7" TAU2="0.0" TOTAL_1="189" TOTAL_2="189" WEIGHT="99.99999999999999" Z="0.9084811270599817">
<NAME>Hypoglycaemia (&lt; 60 mg/dL)</NAME>
<DICH_DATA CI_END="3.2538143285262993" CI_START="0.04321850781931099" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5123927672864305" LOG_CI_START="-1.3643302318309927" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-11-29 12:39:14 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Cordingley-2009" TOTAL_1="16" TOTAL_2="18" VAR="1.2152777777777777" WEIGHT="11.275603616504569"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-26 10:33:48 +0200" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Hovorka-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Blood glucose &lt; 2.9 mmol/L (&lt; 52 mg/dL).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.704864004538551" CI_START="0.010796617622400985" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5687722708409982" LOG_CI_START="-1.9667122795130358" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-09-26 10:33:45 +0200" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Kremen-2007" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="6.177577687207221">
<FOOTNOTE>Blood glucose &lt; 2.9 mmol/L (&lt; 52 mg/dL).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254143" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-09-26 10:33:42 +0200" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Plank-2006" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="5.86730256479601">
<FOOTNOTE>Blood glucose level &lt; 54 mg/dL.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-21 13:02:13 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Saager-2008" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="9.787850361549104"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-26 10:33:39 +0200" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.0" STUDY_ID="STD-Sato-2011" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Blood glucose &lt; 2.9 mmol/L (&lt; 52 mg/dL).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.0918705592709994" CI_START="0.3548252626915534" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3205348077604612" LOG_CI_START="-0.44998546703377157" LOG_EFFECT_SIZE="-0.06472532963665513" MODIFIED="2011-11-21 13:02:29 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.45260742355100614" STUDY_ID="STD-Wexler-2010" TOTAL_1="65" TOTAL_2="63" VAR="0.20485347985347985" WEIGHT="66.89166576994309"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2550160865001971" CI_END="4.307030028654871" CI_START="0.11090565987777581" DF="2" EFFECT_SIZE="0.6911396439514694" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.6341778996784689" LOG_CI_START="-0.9550462898205067" LOG_EFFECT_SIZE="-0.16043419507101891" MODIFIED="2013-11-04 13:31:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5339209937995282" P_Z="0.6923103506281665" STUDIES="4" TAU2="0.0" TOTAL_1="146" TOTAL_2="146" WEIGHT="100.0" Z="0.3957216940260689">
<NAME>Severe hypoglycaemia (&lt; 40 mg/dL)</NAME>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-26 10:34:03 +0200" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Blaha-2009" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="33.288542261882014">
<FOOTNOTE>Blood glucose level &lt; 2.3 mmol/L (&lt; 41 mg/dL).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 10:08:10 +0200" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.0" STUDY_ID="STD-Cordingley-2009" TOTAL_1="16" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-04-02 10:08:10 +0200" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Pachler-2008" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="33.650286865065944"/>
<DICH_DATA CI_END="7.788909173546039" CI_START="0.013413834011187871" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891476639561981" LOG_CI_START="-1.8724470721172688" LOG_EFFECT_SIZE="-0.4904852162776439" MODIFIED="2012-04-02 10:08:10 +0200" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="1.6235424698834187" STUDY_ID="STD-Wexler-2010" TOTAL_1="65" TOTAL_2="63" VAR="2.6358901515151514" WEIGHT="33.06117087305204"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.183521434278024" CI_END="1.0554939756302477" CI_START="0.42116282541209804" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6667344486239505" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.023455758858258863" LOG_CI_START="-0.3755499694687238" LOG_EFFECT_SIZE="-0.1760471053052325" METHOD="MH" MODIFIED="2012-12-11 14:48:42 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5352015022135772" P_Q="1.0" P_Z="0.08371446369274968" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="252" TOTAL_2="241" WEIGHT="100.0" Z="1.729528984095301">
<NAME>Aminoglycoside antibiotics</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.183521434278024" CI_END="1.0554939756302477" CI_START="0.42116282541209804" DF="3" EFFECT_SIZE="0.6667344486239505" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.023455758858258863" LOG_CI_START="-0.3755499694687238" LOG_EFFECT_SIZE="-0.1760471053052325" MODIFIED="2012-04-02 10:09:15 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5352015022135772" P_Z="0.08371446369274968" STUDIES="4" TAU2="0.0" TOTAL_1="252" TOTAL_2="241" WEIGHT="100.0" Z="1.729528984095301">
<NAME>Nephrotoxicity</NAME>
<DICH_DATA CI_END="1.138372297796997" CI_START="0.15361936810679175" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.05628431868173981" LOG_CI_START="-0.8135540256350418" LOG_EFFECT_SIZE="-0.378634853476651" MODIFIED="2012-02-07 14:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.5109473492209244" STUDY_ID="STD-Begg-1989" TOTAL_1="22" TOTAL_2="23" VAR="0.26106719367588926" WEIGHT="21.04171648383555"/>
<DICH_DATA CI_END="1.8709202676934027" CI_START="0.1745294109446294" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.27205527972950033" LOG_CI_START="-0.7581313771020892" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-11-21 17:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.6051367417290708" STUDY_ID="STD-Burton-1991" TOTAL_1="75" TOTAL_2="75" VAR="0.36619047619047623" WEIGHT="15.001214476428034"/>
<DICH_DATA CI_END="1.4600297651099496" CI_START="0.21479014160809523" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.16436170968254407" LOG_CI_START="-0.6679856556701431" LOG_EFFECT_SIZE="-0.25181197299379954" MODIFIED="2011-11-21 17:38:48 +0100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.4889249625940765" STUDY_ID="STD-Destache-1990" TOTAL_1="75" TOTAL_2="70" VAR="0.23904761904761906" WEIGHT="22.97994807245649"/>
<DICH_DATA CI_END="2.0260636091171094" CI_START="0.48232179006558856" EFFECT_SIZE="0.9885416666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3066530760957839" LOG_CI_START="-0.3166631173203354" LOG_EFFECT_SIZE="-0.00500502061227575" MODIFIED="2012-02-28 16:04:52 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.3661390174775476" STUDY_ID="STD-Leehey-1993" TOTAL_1="80" TOTAL_2="73" VAR="0.13405778011942393" WEIGHT="40.97712096727992"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7635417833524982" CI_END="1.3966405146849477" CI_START="0.5807570266451862" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9006157852273258" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.1450846361933968" LOG_CI_START="-0.23600552691770615" LOG_EFFECT_SIZE="-0.045460445362154725" METHOD="MH" MODIFIED="2013-08-06 13:41:18 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3822224355606514" P_Q="1.0" P_Z="0.6400633260705588" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="0.4676102626401181">
<NAME>Anti-rejection drugs</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7635417833524982" CI_END="1.3966405146849477" CI_START="0.5807570266451862" DF="1" EFFECT_SIZE="0.9006157852273258" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.1450846361933968" LOG_CI_START="-0.23600552691770615" LOG_EFFECT_SIZE="-0.045460445362154725" MODIFIED="2012-11-27 13:39:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3822224355606514" P_Z="0.6400633260705588" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="0.4676102626401181">
<NAME>Cytomegalovirus infections</NAME>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2011-11-22 17:39:47 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Asberg-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="22.271433090794048"/>
<DICH_DATA CI_END="1.6448496151690464" CI_START="0.6079583147163438" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.216126197551777" LOG_CI_START="-0.216126197551777" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-31 11:21:25 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.2539071965676918" STUDY_ID="STD-Le-Meur-2007" TOTAL_1="65" TOTAL_2="65" VAR="0.06446886446886446" WEIGHT="77.72856690920595"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-11-04 13:31:20 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Healthcare resources</NAME>
<CONT_OUTCOME CHI2="18.688748347956203" CI_END="0.024104534199862054" CI_START="-0.3325444820090324" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1542199739045852" ESTIMABLE="YES" I2="57.19349497862505" I2_Q="55.47207129812133" ID="CMP-006.01" MODIFIED="2013-10-27 18:45:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.016615851880130594" P_Q="0.061522699154063054" P_Z="0.09006951332814526" Q="8.983126133669083" RANDOM="YES" SCALE="1.06" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03279131021437131" TOTALS="YES" TOTAL_1="8227" TOTAL_2="10280" UNITS="" WEIGHT="100.00000000000001" Z="1.695031141612081">
<NAME>Length of stay (days)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.242732419088964" CI_END="0.8626526957254064" CI_START="-1.1033889468992322" DF="1" EFFECT_SIZE="-0.1203681255869129" ESTIMABLE="YES" I2="80.9259767605349" ID="CMP-006.01.01" MODIFIED="2012-12-11 14:14:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.022038684280659582" P_Z="0.8103364128736231" STUDIES="2" TAU2="0.4098006270623421" TOTAL_1="53" TOTAL_2="52" WEIGHT="14.207805075886577" Z="0.2399920590918891">
<NAME>Oral anticoagulants</NAME>
<CONT_DATA CI_END="1.1497592688220366" CI_START="-0.30308606837869073" EFFECT_SIZE="0.4233366002216729" ESTIMABLE="YES" MEAN_1="38.7" MEAN_2="31.7" MODIFIED="2011-11-22 16:21:59 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="15.6" SD_2="16.5" SE="0.37063062093502375" STUDY_ID="STD-Mitra-2005" TOTAL_1="14" TOTAL_2="16" WEIGHT="4.864884987334836"/>
<CONT_DATA CI_END="-0.12000531870167991" CI_START="-1.0460598598465765" EFFECT_SIZE="-0.5830325892741282" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="20.0" MODIFIED="2012-12-11 14:09:24 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="8.0" SD_2="15.0" SE="0.23624274436915588" STUDY_ID="STD-White-1987" TOTAL_1="39" TOTAL_2="36" WEIGHT="9.342920088551741"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5258066877724704" CI_START="-0.16865318098219007" DF="0" EFFECT_SIZE="0.17857675339514018" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" MODIFIED="2012-12-06 17:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3134596864772722" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="12.898622066697907" Z="1.0079891463223352">
<NAME>Insulin</NAME>
<CONT_DATA CI_END="0.5258066877724704" CI_START="-0.16865318098219007" EFFECT_SIZE="0.17857675339514018" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.0" MODIFIED="2012-12-06 17:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SD_1="5.19" SD_2="5.93" SE="0.1771613851663784" STUDY_ID="STD-Wexler-2010" TOTAL_1="65" TOTAL_2="63" WEIGHT="12.898622066697907"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2961155637731556" CI_END="0.1570366000354154" CI_START="-0.5578653216788092" DF="2" EFFECT_SIZE="-0.20041436082169692" ESTIMABLE="YES" I2="12.896370219561401" ID="CMP-006.01.03" MODIFIED="2012-10-27 21:14:20 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31725273250644104" P_Z="0.2718091798023784" STUDIES="3" TAU2="0.014424268315248531" TOTAL_1="75" TOTAL_2="76" WEIGHT="20.39001289793256" Z="1.0989057862741662">
<NAME>Theophylline</NAME>
<CONT_DATA CI_END="0.7998306609408408" CI_START="-0.5276152138889707" EFFECT_SIZE="0.13610772352593498" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="8.8" MODIFIED="2011-11-22 14:16:24 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="21.6" SD_2="15.4" SE="0.33864037433864475" STUDY_ID="STD-Casner-1993" TOTAL_1="17" TOTAL_2="18" WEIGHT="5.613403884356496"/>
<CONT_DATA CI_END="-0.005207556450618767" CI_START="-0.8377601416534728" EFFECT_SIZE="-0.4214838490520458" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="8.7" MODIFIED="2011-11-22 14:16:36 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="4.5" SD_2="6.7" SE="0.2123897662839528" STUDY_ID="STD-Hurley-1986" TOTAL_1="48" TOTAL_2="43" WEIGHT="10.626356915741292"/>
<CONT_DATA CI_END="0.8001519460592184" CI_START="-0.8001519460592184" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.4" MODIFIED="2011-11-22 14:16:36 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="0.5" SD_2="0.5" SE="0.408248290463863" STUDY_ID="STD-Verner-1992" TOTAL_1="10" TOTAL_2="15" WEIGHT="4.150252097834773"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2784344193997986" CI_END="-0.11750159899485257" CI_START="-0.5776208145100653" DF="1" EFFECT_SIZE="-0.34756120675245894" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.04" MODIFIED="2013-10-27 18:45:02 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5977292546446824" P_Z="0.003066378317714222" STUDIES="2" TAU2="0.0" TOTAL_1="147" TOTAL_2="148" WEIGHT="27.432926305248998" Z="2.9610041253996555">
<NAME>Aminoglycoside antibiotics</NAME>
<CONT_DATA CI_END="-0.08254093652411126" CI_START="-0.7384168934669535" EFFECT_SIZE="-0.4104789149955324" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="17.6" MODIFIED="2013-10-27 18:45:02 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="7.5" SD_2="13.8" SE="0.1673183696527865" STUDY_ID="STD-Burton-1991" TOTAL_1="72" TOTAL_2="74" WEIGHT="13.618114594417287">
<FOOTNOTE>
In the original article, the author indicated the mean 
and standard errors (SEM). The SEM given for intervention group (6.9 days) was not coherent with the bar chart and pvalue of the 
test presented by the author

. We calculated the
 standard deviation (SD) from bar chart. Our calculation was in coherence with the result of the test given 
by the author.

</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.03624039368834242" CI_START="-0.609417641220316" EFFECT_SIZE="-0.2865886237659868" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="18.5" MODIFIED="2011-11-21 18:25:49 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="11.3" SD_2="22.4" SE="0.16471170899096274" STUDY_ID="STD-Destache-1990" TOTAL_1="75" TOTAL_2="74" WEIGHT="13.81481171083171"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.013269682225026405" CI_START="-0.07238602703993802" DF="0" EFFECT_SIZE="-0.04282785463248221" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.05" MODIFIED="2013-08-06 13:41:26 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.004513342721964134" STUDIES="1" TAU2="0.0" TOTAL_1="7887" TOTAL_2="9941" WEIGHT="25.070633654233955" Z="2.8398593613185845">
<NAME>Anti-rejection drugs</NAME>
<CONT_DATA CI_END="-0.013269682225026405" CI_START="-0.07238602703993802" EFFECT_SIZE="-0.04282785463248221" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.5" MODIFIED="2012-12-06 17:43:08 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SD_1="4.5" SD_2="4.8" SE="0.015080977324382946" STUDY_ID="STD-Chertow-2001" TOTAL_1="7887" TOTAL_2="9941" WEIGHT="25.070633654233955"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-07 09:35:06 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-11-04 13:30:09 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAANLCAYAAABrLBs0AABUh0lEQVR42u2dD4RVXd/+H5IkSSRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-11-07 09:35:06 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEyCAMAAAAcIS4IAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-07 09:35:06 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaEAAAflCAIAAACw0+HVAACAAElEQVR42uydz07jSPewLSEhFlmw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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-11-05 11:55:41 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.1 Serum concentrations (mg/L) - part A (SMD &gt; 0 in favour of the intervention).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyMAAAIgCAMAAACh7kbtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-11-04 13:32:44 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.2 Serum concentrations (ng/L) - part B (SMD &lt; 0 in favour of the intervention).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyoAAAGQCAMAAAB22WTPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAABAmElEQVR42u19D3QkR3nnN5Kme3pmdqQeSXhle7F2pdg5gk2sXUur
lRYfowWfWThzxJC8cDjGec8vuRAcXvY54ONh4JIDc+FxJPyz370zjmMIOQewz4sJWDobaWTvsJZz
hiPPRlppvfaOjaRuSavRaKYlzVVV/+/pmenRzEgj6fvZ2q6urvq+r6vrV396uurziYBAIEqjAYsA
gUCqIBBIFQQCqVIQsZgeahNKp6ZpzBxVx2jQz4cTLjrdLa4plBzHcx9rJzY51MZiMQVGY0XMINf8
N4ssS8vNXJD+wQ6wmdt6m3dor3Jdv7c0IyO1sqDthO+Nhd4bN2FXDSAONWciv1iGe4/mX1uDf188
88gbP70+TUtqJfP6q2nyt/02/31Jm1/XbKb2rmyNzTuNKrGYGOLTHAmAFOG5UxKJCQqxMLkUjrXl
eC4iaWn8NA1tmk7xfIRmfFAIVPF13+rAQlQYSQNQnTa7YrFQACDCUa1bhAxkYW5EVa+EbLc53g7K
ODlKatkoIY4XRomNaSEQ1ZJEg9BOYvhBuLVjAG6NStR2Sb0PI8zSS6d4Tkjosmpn8596tpnY2zG4
NTbvvF5lQxi4K0vaFTh45CfhiYMkZv7VZ3sVUHqfzQ4FF4/QmI3gwF0KTUPQPBE8faSZBP4sfCxd
PTN+Hy6xY2TodIiJN+wCePIitBwJCSx6S+CHwx9tA2Dqm/qC1hpx3zqs3UeOnWrZND+ZXe5/mJxf
Fj62oqd5idwNrbswklELNhQ60qnehxFm6Q9OhM7336jL2mM27zyqTM/BQ1qzFJiEVRJItwaglfzH
3wBTaVp6MD2rpWHJpiJ65Eb1zJgEtYG7AXqmmBWGXQBvjUIaps7Bka0qk0UefnndxxQW5mHyZ5ZL
kf72YxFmJyublYZIhNn5lKU0ovAtW4cJU5MwoN6HEWbpV2Gyg/SkRjlXbHPIk82/Uxc2+3bST5Ax
GCH/6wf/cRI1lqVB6RMPLYf/4Av7B40YMyk/QA6jinZWNVv4gUcZV7hBItepk142orcCUtfKADy3
oqs31Mbg59fe8tjPr4URTi0b8frErz5ksZP9K93KLNUj+QGjGIHLK1IwImto85m+Mm222Gm1v5o2
7+CXxY3w6MiIeu/RfxxoGfjHaIMZY3smEpyowZhnn1aARLzPrSZIW1i4UTk5QSbwFHGq2cRs/O74
LLOTlU0KXuHzcl8DnD3CLEafrUi7QQJTVuU2P6/ZPOaweWytXJvtdlrD8WrZvEOpQp8ZBxPtsZB6
PhXvi0+RmENKLOh4rgHomoDxqlvwq3iL9FOijFjRRXTYdTKth5wVsHYQYqPRJsJeWi1WobvT+u7V
P+BnrapaNg1wzUQeqT8FT1rPie3JmPbWm7eEAb4L3fTMXs4V2OzXbM44bObKttlqZ8Bmc6BaNu9Q
qjw6dgBmhk8unllQz1tXwd8KM2cPhxKL1jR0DnE2dfLsYtUt6Hhq47LPDr9KdH4+9bxTJ9Hakzp8
dmmrimMpMcQvDS9AaOwKWHtu+SvWa03kPwKtbILji+93Dmsv+9ELx22zwZ7UVc89o4ZnLGFalsud
Z5Yc5VxzmwUPNlvtnK6NzT78XBKB2OVzFQQCqYJAIFUQCKQKAoFUQSCQKggEojyqSGGeGwolnGsu
iqwbSOSGOF77jAdqsziDLV5oi5UtWolwHBduZ0sbAg86JFrEjYaK3mjptRPu0MuSqRcLq7eUtUMH
0SvxMU4CJcbnpdBCbcGCpRaItZNjeyxgaOU4QXFNWrgMc9xQLgGSanEL1wwQjup281xOqcITj8WE
WBsVqP9mSNfP8EJ7mZaGOT4nQUK1tJlvAcildUs57lQ1LLVS5eHefdkn+t5expqLdwz9fXah709q
zOZntK8fyoJ4JJUd7qXfK4683vRwm+UKXcJiLmO5t6+UpJLrPdxwQCtLqr7h+nRB9UXKeg2uHoDB
q8nRb8lqw3VHC+YW6Ce79ItSQ292sX9feTfRNBT55NAJ6IIzI0T16vlVSKypHyMoS43J4aGWqjxe
HiiDFTC+XRlRnupfLk9Ga+9wcEiEfwe3UEszkVVQBJV67UuNry9OVMVSC1XuJk9FGFk11nnE9HUE
AmmhFLV90td+hJkhCryF5HhATw3QfDNpuRLBQEuMigiSRi/C08ZISxCLPcgHlTItHH8/rLHFC6dY
y6GQ9kyIautDCufKQhscH2HfPkQD4JaQrTPh1dUSbD1EAfWl13u41nNWlkx9CNpcUrD1LGyxRiLI
+YP5FhK9MEr+2sEv6etw9LKlazD5UZa7AH7NvnbOwKyVPRu6rlgsGuQfBEm4WTRsoZEC39xyp3Ff
PMz1kILcUD/QWe/IwQmt6W8ZDESPj6SqQpVZZumq0SAQHCc67c85IQRarPWPWBoRecPSVTg+Be+G
dfgMPduYXYdWrY1IE0uF6ljaYA320Aqjr/Ng7QpbR8CRuIcZ6421H7Ov0cuNcL29iuWe6/863HD0
CbUbmL8AzUdOhw5bOH1X6GhTmRY23Qa/T/McnAgHhzohImVS/XTVAl0fUiQXHA7oNfRlt25JXWfC
1joY6yHc4GXthFux9hgl8xK4tA7qeha2WOPG+ezK0fyPJoheUuZr5Phrc62FUbYnpwbemYXC3y37
nxsYhfTAc5YKOEqel6FrfWrgj+Dh/uc2dFvoR+9rSwOHN75m3JePftB2GzEhxYckaGhvULJTekvw
ctUGDczS0YFnLaROk/KzP+dY/xMb1vpHLD2yvmy3dBg+Bx/gSYVtSDZI2XPa0Kx6llqosjQO/feG
EvbOka4jeJ00LR9lTcuqvvYjzfj8jDPHzBQ8Tvr8iKzecStJG5mytukzk8CXW5S/bJv0M92TU8SQ
9IHIPrZqwbI+xAWLPBy7LqzW0Sjk8hMY60zAXA/hBi/rPfJhLcuo24fHlvUs6bOnIoQQDvj6E9n4
K2NKot/nN9daGGU701Fi8c3X4CRcBl+2jPTvfe4ZU9d0BymUu2FqWrflBnpPfva3bjQ33QK91/hY
sO8ACIuBdv4Qdz+9MgDR6g2weXgMBuHrFktPnllyPOc+6Jmx1r8ZP/vTi8AP3Y+Rw3+Ofy149AAE
OoVD3P/iWqpsqYUq/osT49BnWy0+CNFe0nPH15Jr45T1OXq+zh4/Re/F5+05olHSdm1Ar1+rIyRt
r83UqGu9KYp/JgX0a6b71luJvJbr1vfBoCp9oAjBHnkhDr1qf+b6kfwotUWlkHjtxrmCsu6GT5E/
mp6o3wDx01raXmBWFFJvKcsCq1RZWVE8de83wnDcefk5ePZ4U7RpMEZCmm7axFrKdrBosd0S/z0p
M3aHOUd6cRS6TV0s/wA1wmJLr/qn23LhzHI0DpDK9E6RfmQhe251+oOpj9ErcZCqR5Vfx/9W4uO3
mJZ+dox2dbbnnFMttdU/SxG8ckvqT4ilyxk/szRzLj3zsdQHq2yp9WVxdOHiC1qTEmcDMX0dgX/w
NwbZePV2x9qP6OLFCfL4xvT6wJZuNIJkjDga1ahRPUGifMN7x7NxP2grEhRYgQsvecnGVnCo6xOu
Jma43LixzsR1PYQxlPaw3sNNvVmW+8B1zGmsZznpekd+QlCOzXk5y1oLa9mWMKBp8s0DTZbx11z4
aKdDl7G0xX1tTTSVTecstndx0Ul/Tu1vrq4eVfxNAw8PNlla1OPBvk86nvO4auntBdYeRe/KrOS0
e6UGTvDRAf9DajFeXQOqBGLR6OO012XNcLKNTQvZOoIfkraG2f1d+9qPQCwd/d8kx+3Q1skiDnYR
29IwYZSvtpqjEdrVBCe6yx6AwX2DX1THHl3JWJDouqbLQyaBmNakzkelWdIz5UGzjLY6bushLE+y
5NoJF+hlSdWLMOeSQF3Poq5vybjc0b+StnSSSBgghWeutSBl22qmGSvWZM6RhxawvmKVn00rdl1+
6OrUbeHz38sG71RE0kQKfFJ9apmXIK7czq6MrUrpWKhKdXCOjMDmrJYuPPs3iv05k/s+mF//TEs5
5aeDPLG0TQD65uG9PHSrTYrQXTVLLVS5dCbFfSbxNFtzIcfvoBVEW0cQGIPxDprEsfbjp4n3+E8k
FqA/vqyuYmpcGR8hj+RLIu1o2JD67MnU2QWQxy/9UFW3fGa+XBPvVd9rEN2dZ54muq7z0jMtvbWZ
W+qhq1li+4UPH89PoK0zCcavdFsPYXtBUGK9hxv0sqTqj7/gsmmZtp6FlnWou3M9P0EHKfNWmB2H
sZctay1I2TboZQtw/9iVhU1I+yA+yfhktA7HWxbiVl0jz6406LbYl3KwTP98IZSekCHc2Ll8lswU
2qADhNBh1tUOr3W0DC9UiSrpOIyl2RjXmL4Mttif88+e/XwDuK49ijNLG4Off0GCZxqXmnvI7Kut
YRYOh1ipz35vfX/z2apY6mW9igSXH3txzrNILnhu8hNn3N7PbdVK890LUrb7bnpupYwcbalNbFPT
fml16+8teai+LfVCFT7XECxjjjH6rnXwB2fdHjRksbZXhMJlWwihOaF8NaGyVFQJ4SePb8JSYa6e
qIJAIBCInYff2RatTdirIHYctqXS4kf4CARSBYGoFVVC6q9AY0GOCyv2OHPlRkyPcBW4RR5FEIht
pIoS1BZvvHP9fLP2/ZQRR3CZunJjBH8cQexxqtykB9KZjpe0n0BuMi/zWcjyYFnHYq4piJl+TGi0
vqbDsf4BgdglVElcMMNd2ieGlrjRNVjXvj3Q/GFoawpGRk5DwlxLYK7pcKx/QCB2CVWWzS/xRlMQ
dMb5jynHtK83NX8Y6QORj9KPwxNiXDb9mFj8YdjXPyAQu2Zar6N9aHAi71OWX0IL+WNQ17FAy3X/
5Xt0zcCJY6f95loCc/2HY/0DArHbqCItNZzO/xizI67EO9Sgto5lBT5Mv81XVsfZGgJ9LYHXNR0I
xI6mCpmhfxf2CZD/3tc/qK8U0tax3A5X0zUF4iD1Wmr6MfG4pgOB2PG9yscHrnXb+qrRWM6nrWPp
j79NYmOs60hqcy2B4G1NBwKxk4BfFiN2HGLb8sseftiCQCBVEIjqoQmLALFFyPfE2Iy9CgKBAzAE
AqmCQCCQKggEUgWB2AJY3oCpW6yDKNt+lSRneoR6lNVdAOwHcGSxHNwvVgBqp+iu2VVXqYTeUlnV
ix7Ty2IF6t1K2xohei9LSzq7SbJxdIjPk21LoVogmvn3GlXcy150UEkWDfqYh0JZagPRYkcpTpVO
6C2Vra4VunE3yZtVL7trMyNk0TNTCpskOrQbIdn1rq151GZ1b/Yq1gI12x7jechu5WJtrmguo7HT
2hsmQy3VvKbLkqOsTkX0nFD2QFxvqQpTtsJEhdTL1auFeaLEwjaKXovfxb6Smyp8H8rOMlLnVNFb
LXu19DDaYVVfNE70xqhAy2jPUdYATKxaTd58Fyh7ZMHm1IvVazPETRCwSEK1+MWqVOsdtUtD0yYe
k2wbIoClX7bmFAtWaRHcc3hvzMtjl8eOy3t35ZjDVUdwWfdEO2R581OF/Izm4KGUTLEa881dMwDL
G+LmPST9ACV6BRkKzBErnKmUmaOKz1a/cbGqVX9TpVCarY7WShbzSiSvPROdYh0p9u6X6E1l10mx
jCJTZy15TBErZEtNsInxTMnORxZr06l4HUyJBUzKS+HULjtn8YgSv6vIJUZfxWp80RQVMEWuTfpN
vE4qUU3JHK2GTNlUV6SaJBfWLtttr+6T27W9SoG5hhZtPxQfpsmsEzeTGoO3zY6Aimn2eh95NcCj
vHLVexNcKJVdG6nRhl41XAbBTDLm2a5pt4p3z5KXYi8BV0HuZZSa6lR3Qla1j/BxFSRi67myrdl3
zbQeseshVnS5/JHY27OQfdl/BXDAPYdUQSBcoKxdthFQnqbB1hdZTNu7RpuS6R20nzUOwBC1hZRu
+UqgcXn1/IWk6uFU88Y+9+0L06u+Rn8wkp7faVSRwjw3FEoYcyf1A522oJFgNASOi1EBEmGOO6WA
om6H38LdD/AVbRPw0Zu5oXCCpq3rzfCpA5m2IM99TNk+9SGOD+WpD5IryimOI2VIn02OJUiEh2h5
N/MtAKfSXhWoLfsQFRjkuFC7+gz1J6zfu3FN4W1fZ2k6aR3RvB4AhGOmhEI9yVhLjn+zb3X6tmRB
N8Bzv37t/GpDIx9qTkt1TpVG01Xz5csLl375js+taacHYZoejl45rSc4bwbVi9KZ1zLf6ZX8sJDJ
Xj08Mz0Nt8WH15PvfYClSfa8+to9h/9SIWlDH/zJfXVaAO2+PnIvGxsRKSJtg6twZd9Roj63lmo9
PGfnihLuJ1dEn/SDc5/0feH4HH9sgW6e/sDxe35AytsXWVlTXvR8f2rD1kFCkfXzf3XjmyfZM1Rf
JJn33rxGrk2RChA18jAQnY/lVO0dZ14mjxmS36Qppg/aklmQ/J9Njav8XzfKy2+wMZfG6UJHYXZp
Ye2z+/xCZvWSh4pycHqbe5W7YQ2EkVXWY7DmoiUgJDj2+WeO5yLA06DmO0VFV+Y0ZEGaIv/sV6d4
D/lz8JvahsX7B4SoNMI8RjROHqrXtuJatiP5amb2EmwDUzT/Nems/2Wnw4CbfPTfLEz2gADvhnOT
qn0C9NDy3phdh1be8/2xvoG5KUhlOi6Dp60pzHtfznSsAVGrZOwyiM5J1cnBBpmRU3xooyD3n4oI
nHzFuQsXuXmYp34UyJ+34+zrFxpXfQOBcCSaqO8BWAP0GCRQm5sf98ey9PPP5qHToSPNGRbUfadQ
ZOAtcDuQjjNHWJbmQmTMqdwuZc6pVwPwki5pEpR6pcotF3Xeb8u8zfBfMwE+xxX2M0QOolG4DYbp
IUcjblNDDckGKXuunPuDmDaUDvx292uORF0wpF07Sa99PWi/zHQyrEGKo651bnnNhSTpSIhvWD58
/uIbbD6yyb8nkhfOT/1G451kSJasV6osjUP/vSELn2cCoHq3O0JbslUWXGnQfKdQkIaNEELopg/R
txzuuwqE0OFD/EGeOccbAMsMpW6pcpdmZFsKhG1Qr/uvSZ8ER/1c9quFSPtq6pkDVKpMqqFAp3CI
6+JaPN8ftK9rk4GLE5Nvtqch9/6c5VrbjxzThklDO8THQkcPWKRacYVvI1etGXru73Jw+YV6pYr/
4sQ49N1oRkR74afq/NxoVUD8tOY7RS+9LyUimbgPUsN+OkJYyH5gdS4TYbQaA6PEo84ms+7Qdmnw
nm38QS3ZMvCC67Q2rpbzGD341FJloYXMufTMSuqD3lUY0+boOUfDZbl3dm31HkdWU3sq0zsFa+4K
/NJiOiteHThwxWVt6rhqU3/X/cWVLb9YnVtdWZR765UqEF24+ALpKeJ6HyBJ2uUG1Z0KKyur7xQf
IYN/WUnlGvRzgO4m/7FZNj7m4Brj5Vq9vwhMXILTJ7ZPvXIQPisXeD5SgvwzRJ8Aq6yN+rM4xEcH
/A8Vk2p/QdV7Mpa/7JAmIff+L7Z7773XkpKmaDS0l8assLySXb36YAv3Nm1M1er12LZf+Kuu3IUH
Ur7jHXX4ytRClUAsGn0cmkiZJNtYROcvyKiL9g0cTHSRkVYcJLvvlCbS3gl8e3RQgOCdbd104g9p
GcaTTKrAfUqKqgPkfeCvb6rc4JsRtlF9a265gGszP3TdBPeRoidPgKNvW0hENxsMZ3joLj6sHTF9
QZOM7GwEPsqTBxWwJjnhm5HUJNo1LaVKNHrCdDLtAp8UzNwF4Z9d8K2+klvtvLLjPfrvKMWObfuv
vCowt55J/bVUvz8rWKhy6UyK+0ziaZDjd6gVu/Fdz/4M7h+7EmbOfj71/CIE41dC0Oo75atkfB1q
WEx9WILQI0vXD8+QsVqjH/hOVu1mv/+j/anE0+pssM6/Cggc+1CJHwlqiszATQXUz/ekUol+mEmc
TA2zuvVUIrXcQ4ZAbQ2zcDhUPr9va1xa7rF9uJgx7t1xzXjHw3Qy7UuNnc1nvb6qjXYsplbjucBV
9+5vK5ho/xVXHfwVIcmSUO8/3Ff0ZbF0ObfkKWFLOokeuesNsRJL25OH0pWKsAwxL1vPbqzps/5W
cmy/49uN/p/zm6kX2/NlcWUf4UdXvTnaDnzjI1g16w18rvgvSeEnS/m75cCXKUtl+/cGw9nchr/R
3zhZQdu5E6mCQGxHf4jrVRCI+gVSBYFAqiAQSBUEAqmCQCBVEIhdQRXZ8q895BGyM08ZEuX8q/Im
zUAg6r1XEd0IUEl2BKLOqSLLsrbnIAtZg+Sg+oPQL8hgPQMzPav9cp5EZ15dBGhizQRgXDEiEIjt
grsrItUtisUpis1Pl+k5Jc8Xi6hvOi0WkpiX17bzul2cLDqdSSEQdUEV2dvYyLrhsItHPJvnNbGI
zzz3rdbFvAQIRL1RRTSGQaXZI3uck7hxpeRgSq5ozoNAbNUAzItzQHHzM/KS/lXyE2D/gqjPaX3x
jkUu3rE4+hFX/xCyJYfsJl3Ou4IdC6L+ehXdh4ZscYpicfWheU6x9j2y0/+T7Lgom87OTR9xqn8Q
q5sQNexIAHvYqQeibrCp9SoVu+UoQCoEwgu2Z71K2WveS7sMxbqP2DvT+iIQq5DClg6JhdjZ03oE
AoFUQSCQKggEUgWBqI9pvew6zdZf6ZY1/bZ+Aalnd0gwv5B01Wr+TqP9IGMm0b7IzLOnUB7dJzsC
USWqFPt6t8KaJhepq6KLePNLYvsXyHpMOXlsHzUjENUcgMmWRSPa4hTH0hXzKrgvarHLkrVFLuaK
F3VpS0EiioU4tQkgRRDV7lUczbO1NXYsXQH7CpL89ScOWaJtGQr7n0blD7qK1Gx9/OYc2HllA3Yr
iKpTpUSLLNrrn2z7CtljdRTdRneiGzPch3DGJwNlfUKDQFSZKlpT7f0TRdk1mH8ue6/IzslNBd/8
IxC1oopYeppfqJPIW2kieq/h8iZY4CkPdiqI2g3AZI+vV0VZdFZHuWhNNWc6eZfFTVRuL+mQKYga
UcVcmGJ7KVtwhQrYF7XYlnLZMllWvDC5svqrh8uvJFpKOvW3G1Nkel4oj4w/rCCqgZ3nX2WTdR6p
snuA/lU8jrlkZAoCqVKt+Ul1MiEQO5oqCARSBYFAqiAQSBUEAqmCQCCQKggEUgWBQKogEEgVBAKp
gkAgVRAIpAoCgUCqIBBIFQQCqYJAIFUQCKQKAoFUQSD2IFVCMXYYC3JcWKGhtiDPfYyFYhSOzG1B
d6F5CRGIXUUVJdinBt65fr65t4WGltcjqV9o69JHRpwbZVx3FAsQsRepcpMeSGc6XoIsDa1mZi+p
IRVShOdOSaTbiAb5BznSf4Ai8JwQJTFiiE8HYu3QHhOwWBG7myqJC2a4CxqNkCVN55HT4YmDJLA+
NfBHhEIjEJEyqf4VErMhDNzFw32gAIfFitjdVFluNYKjKdDmIW0pEPQZSIx0MJFJWCUn0x2QU3ug
A5F9sEFj5uChJ+BPSBI/Fiti98F9z+L2ocGJBZUplwbvOaHNVWhnAp9QT6IAg2zq0nLdmX0sSGIG
jnOgrMUzWKyI3d2rmDOSpYbTKlMSl+D0CcuVRnh0ZMRGhRW48JJ5lhlsGfxTLFXEnqAKGWZ9F/YJ
augG34xtks7BRHsspJ+NgQS3wzVd5vUo9MG3sFQRe6VX+fjAtdqPKIFjH7L9nDIzfHLxzIJ+dv/Y
ldAfv04yr0+NwvgclipiF6K6O+FL+yL9LyJVELXF9uyEX12qcD5fUMJHidiNVGmqqrQssDfJCMTu
QxMWAWInYjEvpnk7pvUIBAKpgkAgVRAIpAoCgVRBIHYCLG/ANM+9DsfwsunyXT3q7uxtBxay/0Tj
7tO3Uk+/hj4Xb/fuCS2hAilFL6lcpNZWvVtpWyPEsgrTKcAsPtksUPut2U0ydFktkveSO1oLVdzL
XnRQSRYN+pgH2Cpv16Y+0SR38YRyiTolg5dUkJdK9JZws+rdStsWIYvlMMUpwFJ8ovut2U2SHZLU
w+Yco+98qlgfk9mSma2JW7lYipKWn5ZDZg2OM0KsAp/EzfVQxaqqKJes+G7thlgt7rurl2tVC0vf
ghYvbok5pbpCV/yT68xB3lwFqIgqeqtlL83i2kRLDhbMi6hJD+OxxMXqF6JcnfIXN29WhUVaOLvL
rW3POKuQVvphy2JN6FAuVURvZJcL1UPRGRA1MlWFL2UL8UpUb4ItgxRPGUSvnCrrvmg/LW92qlBK
k35rxcSLMuyleUrBAVixDk19SPoBQHQb0HrpE7e9bdoaoVUZd7rrr1Zn7aj1lpauSM8jbtX0dCdQ
RSwaLXrIIYvVZ4tl7rQd47maVY9NdJZyJZos+vZY77BZNJQ7r5LdDoVzyPbpzNbXqBoxRd5uptRO
k1xHI4Kd0asUGI1q0faDaw72LrHKb05k7X1+yYolGu/vvI2qZU/zdFN9CanVUm8vZqs4NeyVYKaA
EppMFaKcPyHLu7qX4NvC+5Wxp69DlHgqslh/j9T9Ddgu+ggfmVKnXNmWrLtqWl9tIFPqEmIFl7f5
kfZAFl5TruaA++nuogoCUSUol2dDyvrcWXYyPQ+wv6mp4Z97a6u0EffiRuwkSO/5XlN78tWFpdSK
FpMmf8tLC/Lf7uOCwsX7tmKuIoV5biiUMOZO6vZfFh8qoyFwXIwKkAhz3CkFFNX/Sgt3P8BXRrX0
N3ND4QRNG4jWceFTpzKmH5ntUR/i+FCe+iC5opziOFKG9NnkWIJEeIiWdzPfAnAq7a0NVmWAoSdm
OMvRN3mzyFevkZScoNhtMdMphpwt7UsejAS5trfOvPrEvOv12eT5ad9+Ptxcmwdp6VUuX1649Mt3
fG5NOz0I0/Rw9MppPcF5M6helM68lvlOr+SHhUz26uGZ6Wm4LT68nnzvAyxNsufV1+45/JcKSRv6
4E/uq1OitPv6yL1sbESkiJTdhqHEvqNEfW4t1Xp4zv6ElXA/uSL6pB+c+6TvC8fn+GMLdAfcB47f
8wNS3r7IypryosfZiCqDhDQ909PTf/f0GYU9R3WfIFP+P+2/5RvkQTYozS8n3li3WWmmi/Qt/PBX
s2vTWh3ZgmLKNoXS/INNb6RY69CqtREuxznSwWSvTvPBBcOXQ/V7lbthDYSRVdZjsOaiJSAkmA8V
yPFcBHjmToW0J4LWa0BX5jSZWElT5J/96hTvIX8OfpNXr+4fEKLSCOsmGycP1Wufci2rDk4/MlsG
1adNOut/GdYdV2jdJjZN9oAA74Zzk6p9AvTQ8t6YXYdW3psOTYZVj/TOMZvHNVP+OnyGHpazs5Nm
XbvJkS4Lc8eZ+4MtQPLBXLCRX114jZuHeeqrgfyVOr64fvH8Kt8k5B5srwlVGqDHIAHDxo/7Y8yH
SvPQ6dCR5gwLPpld7n9YS5CBt8DtIBEqEZaluRDpF5Xbpcw59WoAjH2/J0GpV6rcclHn/basCDV8
2kyAz3GF/XKQg2gUboNhemBeOm5TQw3JBil7zpsOTYZVz6FjgVlrElP+5+ADPNv2MHDvuPHbReJV
ezoe2tJb4BskGQ0LA4H3Lbw2R0dcZf/NXlx438uNQkRMVpsqS+PQf685VwGYCYDq8e4IbcnUvfBW
GiIReEhLQBo2QgihmxaybzncdxUIocOH+IM8c443AJYZSt1S5S7NSNOPzJZC92mTPgkOx5rLfrUQ
aV8Ng2qVZ60OCwU6hUNcF9fiRYcmw6JHWu1+ypbElP+f418LHj1AAhd/99ifG7ZE7eleGb/uZPyV
mhfOhRzkLlQow5fb2GirNlX8FyfGoe9GMyLaC+r76lHalmjj3k9vnFPLXivbLyUimbgPUsN+2jMv
ZD+wOpeJMFrRffJ1Sc4ms+5A/chs4w9qyZaBF1x3sI2r5TzGnrpaqiy0kDmXnllJfdCL8LjBA13P
/zv2D/Y3q6b85Yx/Cuh8NfoB+GaeKC2deOzFzw4cqHmp9MrLq6/86lBLx5vUcVWZf2/quOr58Nrq
8qK/2lSB6MLFF0hPEdf7AEnSLjfQoIoUvGKOkH2EDP5lJZVr0M8Bupv8x2bZsJuDa4yXa/X+CtLp
R2arJ/cH4bNygecjJcg/Q/QJsKrcqD+LQ3x0wP+Qt2esP0ldz4T19zT6HsuUDyavXNo3LR1H5ypr
W1M2vbJvVflV11Xc27RxVauH4/7Lr2r+lbK6dKKKo0QLVQKxaPRxUoY+SKo9VucvyKiL9g0cTHSR
kVYcaIlfM2HkaCJlKvDt0UEBgne2ddOJP6RlGE8yqQL3KSkaY8OKffXu9M7pR2aL0ZpbPu5+xQ9d
N8F9pOjJE+Do2xYS0c0Gwxkeur0Nazno6oIv08y6nk+o4zgV1HO0KV/g2wQyFBXubO8iz9P2Npic
aOn8MJqu9gum4nyRllZfyR3qvHz/e0B/U+x+fM/+4MGuXCa9JFf7F0kLVS6dSXGfSTwNcvwOtWI3
vuvZnzEfKjNnP596fhGC8SshOL74fiPHV8m4N9SwmPqwBKFHlq4fniFjtUY/8J2s2s1+/0f7U0Qe
wVq9fxXg9COzxcgM3FRA/XxPKpXoh5nEydQwqwtPJVLLPaRBb2uYhcMhT/yeozIOW/Wsg+OHLlP+
M41LzT3TEH5ksefsEh17u6VbTAy1nFnc6lKKyovpzJcDnZcXmHu0/X7LoXA8s7wg1eRnvIq+LJYu
55Y8JWxJJ6OAqD/EoLj/heShdCXZa2X1o5l/k10/8gS0aj1K29EXmpreqPHIpbKP8KOrK94a7W98
BKtlPYLPFf81Kfzk8aIjO9+2uMjV/Ku0K8q6An/47Ubupa1oiH34vS9ix/WF29KX4UasCARSBYFA
qiAQSBUEAqmCQCBVEIi9QxXZ8q895BGyM08ZEuWC2+3h3m2IXderiG4EqCQ7AlHnVJFlWdvxkIWs
QXJgBDAuyGA9AzM9q/1ynkRnXl0EaGLNBGBcMSIQiO2CuysizSVTnocUzfMKgOOCsS+6qG86LRaS
mJfXtqG7XZxxZQ/uu46oa6rI3sZG1n2IXTzi2fyoiEV85rnvqS/mJUAg6o0qojEMKs0e2eOcxI0r
JQdT9emoBYFUKdKJiN7m4GW1/yXdruQnwP4FUZ/T+uIdi1y8Y3H0I65uI2RLDtlNupx3BTsWRP31
KrrzDNXbsmiLNB3cWfsei9Nz0XowLhoSwXSOp/kHsboJUcOOBHvSmwei3rCp9SoVueRwJsM3W4gy
sT3rVcpe8y6XnDlg3UfsnWl9EYhVSGFLh8RC7OxpPQKBQKogEEgVBAKpgkDUx7Redp1m6690y5p+
y07X8nKek3XzC0lXrebvNKr3dEsa7YvMPHtseYxfcfB9HKLqVClWryqscHnUAZvavItmHddCokll
WSyVR6eMyijkCqJmAzDZsmhEW5ziWLpiXgX3RS12WbK2yMVc8aIubfFIxHJ/qsTfNhG17VUczbN1
iYlj6YqjDc9ff+KQJdqWobD/Ra2rAOcA0GVcJVorvnNg55ZHtn7Kj90KolZUyWvPC8c51qZ4/j1R
dOsFRO9jN+OTAbGQeOQHYguoojXV3j9RlF2D+efyJuZBoudIj1cRiKpRRSy3bRbtA66C1Vb0QDix
rPcKMnIDsb0DsGKvrMA+AnNWZbloLZdFZ5RcyfJgsfxuCoGoFlXMhSm2l7IFV6iAfVGLbSmXLZNl
xQuTK6uvgF1+JdFS0qm/nLewXyzEWvc8SBxEVbDz/KuUW/WRKrsO6F/F45hLRqYgkCqbnp9UKTUC
sYuogkAgVRAIpAoCgVRBIJAqCAQCqYJAIFUQCKQKAoFUQSCQKggEUgWBQKogEAikCgKBVEEgkCoI
BFIFgUCqIBBIFQRiD1IlFGOHsSDHhRUaag/yXLCNRSqxWKzdSDkaAoipqbVD+aAyvMe7qRkNGsG2
oMc8lWA0mH9ebR2IOkWjYIaVfUdhmga+s3H+wZ55yhXf+j7p306tMdbsB0im9bTnr5yGaZYYDqqZ
ygeV4T3eTY0l5VG3TJs2zaPFllJAbB0ObkuRW3uVm/RAOtPxEmRpKJWZuwx8LDILZyBDG9EHhYDI
kwBtTxNCoIVck05xfE6i1/igQg7BIEg5notIpLH306h2geNC5BDiuMCoVYZ2XW2a2wWeCyVZvBTh
eJI9EeT8wTQooYAIIJBeTYkF1JRUHkdTMpltLKjpZN1JlOqj/CcyhaipJyrwzS38zVEtH01CdZFr
EOG5ZpY1yD/IZIXadTtisbQQiHLqXZO7U+3SzgGoXppTDPFprMl7YACWuGCGu6BRDdz52+OvscA6
/Ag2aODPwsfShDNsL6ZY/xM07uBE+CdDnSRwV+go3YRvfhE6h4KLRw7CDUff2Hc0Apf6k819zbA8
lz1/7IRVhnZdxRJNdYjFHzwSCh3phBvnsytHRWjqCxIGcKDAw8DTlKq8LE25zBOZl1hQ08nwV6E+
th1gRMqk+ldMPWtLA4c3ljMrWj6apPNIKHJ0HzQfOR06TIm/PjXwx1RWqm9ZtwPgsvCxlax61/MX
NLu0c2geOh06QlgGG8GBu7BO7QGqLLeag/AUaMPyL0wcO8B41O877uunTfb0rEoZij7omSGHVZh8
K+uGZiZZVU774QaYSpNeaBiuWH80DQPwH9ceXYH0gcgdkLPK0K6PaJugXaF8QW2WV2FqkuRKnz0V
ISTlYfJnAK8TFR8lhCHQ5LEusEGTCbpOhsNTKqmIyn1El6YH4Ck/+1u35MvA1OzIKjlEpoAmme4g
GYgs/0hat4PkMe863arbpeEI9EyRlOy2HsI6tUth310ypraS0L44OLGgxUm3xmnti/72mVSo7wWZ
JiF/9gM3SOmlsLN4hklhUWPZaGoA4kH5qZMD0P2oJF6fCFxny6xdV1WJK+RkQaDxWvan/uuZ4LVG
Bj53/qoGWiVBk0fjLTK1TNqNqJa09DAJmh5NEP3T8pl37T9uWK8ZB8Zt2G+X6LfZxQ1ac2KlqjXq
aHdJaanh9IIjbg36Yn3wh47YcZBoR+ODR0dG6NQgIZmCSVQWpOS/9AyswInk6TOTy7AMr7zsUKVe
VyEnP5sYaFYprGY/CRdeonVVVeMf/I1BjkwJYro8Np0yZWo6VcGaJSuqBJseR744sLQnaB6f5c4s
djih2WXolSSswHtpAGa8YP0u7BPUUIBPdgObSCvwLyOfga/rqbTqlYYJOjcIQFcyRkdsJ7rVYQ+d
WBxSSFTw1obPwx+AcOvCBTL7aYRrJkxNVIZ2XZ3WC7f+h1dIGhrPU4nUiEwXGyJ10/nCD6EXXiKD
tRFdHk3ZAPsmVDbpOtUeSrPkdriGStD02O58n2ZLQNUVh4ku9V5V+7sUEmnYYb1r0O3SzjlbTsRe
oQrBxweujamV91Jj5/LZRdoqb8AbpDas6VUlGL+SHn727OephOmzqc4zNFnD8pl5NcHM2cOhxCIs
JpZCz34NnjnTuf+5EMm1+CNTDZWhXVfxzJml/WfCLH6mJ3XVc8/AQryTzgjWnlv+Cq3TYzDeoaVk
8kJjV5DUISrz/rErdZ0MD2iW9Mevozbb9GjaQ5ot06qumbMnU88bnenM2VQosaTboYHqY9Ds0s5n
zn4+9fwiVqa9NFepdAxZ24G6BJcfe3GuHixB7MG5SlWpwkG2lrbyuYag5DVpFmsUUqWqaKqmsBpX
zwywN7IekyIQ9UsVBKIS5E/3mut9Wo9AIJAqCARSBYFAqiAQSBUEYifA+gZMdcZL/lX/t19xeOq1
neoe7t0OemL9rwxo9oDqj94Qp4ec0vL05hviqqVQKlmLdlevmeWWQSwYUbb6IjflvTwLl4hsXBBL
mON4mlqEvJe80jY5n45LFXB71qIzm+h+sIoFsSyuyFZVpjiDdy7EsunNN6QQH11TyYZy2U19fpnI
djtdIspXX+SmZK+lWaxERHtRFzTH+jQtEWU6Rt9FVHG0hmbzYpaSXoxqZRULECkvUi6/ULUshepD
nsRC9aZEfRKhlHxXCwqZVW4rW1p9lSEWVSZ6fSybudcizWGh2YBcYfHWjCoipYBsHXPZmhdHW5M/
KivcqomGgrKfaYEBTK0LTSxBCrlka1BRbRe9lWv5VbPSshSLi6roNhe3/ClX3KuYRrqYKlp6/qL1
qUoDWdF1VlKwHohGHTZDxSuVFztF2xSkgFmFykKGStW72UP+Lzur2rqJRadP3od18h6aqEDpD1sq
ahjlqrc7Ri0pqNBlVlEFO01ZmnqxNEHEEuZWVEyip9rqNFQEl/mUCGXJqMP2vi6o4jZ/rtJYoJZj
kypal5dZLFylZNHxMsky9qw6vIzvxPJTeL7fPYcG5+CqdL9iSSQXG35VqUZ4FSxvjiny5uzJLxVR
BBtTtAi5Zr12jQiInNhcr2IbPjgGHqJsvJ1nF7TL9oODWuU/CLu4IiPtQgnl4oOMPHOLpZLFUull
8zWha6GVqb7w3ath0XsJerBddDzKvLvwfFu7Ed6WdlXW1lREFcT29SHe5nDVg9eP8Otox5YqF0jx
XygQ28mVbc2+qwZg1ZnZiThDrE+IFT73mjzQo9npK2be+lzdFZZ1e28EYlsRCLz4RNA/N5V+I3Mh
2tzatlFgw6jt394bgdhOSBHh6LlX59TdseaTM796RzhaR1sRWqgihXluKJQw5k6q3xCL3xKL3xPt
YlSARJjjTinM+wqJbOHuB/jKqJb+Zm4onGA770Xr9fG0hThOUNi955StV6/5r1FyHB/OqxVBUsjK
KY4jZWjalwgP0fJu5lsATpXedl/Lz0ZLPC+0QSKk+86JmZ5h7H51LHlUaDotaVVZsSr6llFyQ77z
F+dtcd+7MOW7uUWpk6piGYBdvrxw6Zfv+Nya3supvkksfkss3kXUi9KZ1zLf6ZX8sJDJXj08Mz0N
t8WH15PvfYClSfa8+to9h/9SIWlDH/zJffVJlQal+eXEG+tfOD7HH1vY+n1eNP81fyHM+4+csm94
o4T7SSGLPukH5z7pM+174Pg9PyDl7YusrCkvepiNqPlJKP12SVhdW/v7oz9/k+o756C+V5rTr46Z
RwPR+VhOLR01bfrtP38TkTVdJf810nu+m1tY/SVAq8Z9y/HnC9kWoXmlvgZgd8MaCCOrrMdgzUVL
QEgwFyKq/xDm90QJcbyg9RrQlTkNWZCmyD/71SneQ/4c/Ka2Fev+ASEqjbCbbJw8VKe9ynJ2dhIa
4d1wbhK2YeswzX/NV2FqCo7bL93E6moWJntAsNgn0F33s7Axuw6tfGkFWn5a7eLSbCYN6yDMOe7U
6VfHzKOB6JzU9otS07bGBSqrOt2JKLS/dXWWCCWjLuqLIe/4+oWX3xzc/s6lwRrsMUjAsPHj/hhz
IaL6D2F+T5qfzC73P6wlyMBb4Ha6bW+OsCzNhUj3qdwuZc5pkzQwdsCeBAXqFYF7xxdhGKJRzfPE
FoP5r8lR9QfsF9QdZdmV2yz23aaGGpINUvZcafFafoL1PwjdGVLgv8Fom4MqTr86Zh4NTKc1LZM1
X43xb8ud/LmLc0BlFfv7v69NL/PNyXqhytI49N8bsoxRZwLQxwKG/xCAlYZIxPAhQho2Qgihmz5E
33K47yoQQocP8QfpOJr6QLHMUOqXKhd/99ifw6BarbYBzH8NdeAC33L0d361EGlfbbFvUg0FOoVD
XBfXUkq8lp+GJvn+vhboH7/3Ot+aXZPDr46Zx2jpjNJR0zJZV1Xj9temvDMuN1UvVPFfnBiHvhvN
iGgv/FQtQLNVET+9cU4tS630vpSIZOI+SA376QhhIfuB1blMhNFqzNw2Pgq+uqVK9APwTWIrnThs
i/pzpEeOF7wcV8vZtE8LLWTOpWdWUh8sJT5uaQMmbyFP6B3HTr+YK/R7SPvQ4IRkywMWnVYwWZVj
bnk413k5aOOtwn/vuaIzl1karBeqQHTh4gukp4jrfYAkaZct/kNS8Io5QvYRMviXlVSuQT8H6G7y
H5tl/qw4uMaYt9X3W0ofDNl8q2yDAUT9kPvzkRLkH9O+Rv1ZHOKjA/6iPsLoCyotv17fG8ijJXOV
jDWJZXqt+tVpMJ+8mqLRWTrVbFmii+lc5EAbm5ew8Vbe8bIDLfGVxW1/iWqhSiAWjT4OTaQIkqr7
7c5fkFGX6reE+Q9RvZlYPKQ0kbZH4NujgwIE72xTHZqkZRhPMqkC9ykpqro72Qf+OmWJcGd7F7Gb
+VbhtmGipPqv4aF7An7olsAPXTfBfbp9pNqSiG42GM6QTMWHtdQRjZafZBTUjI2QbjOfxsjIiMka
3a8OB11d8GXtBwFNSLeq3Zjndwme94/2wJaF5fVftGjOR2Heemz7i0OZ7HJdNLUWqlw6k+I+k3ga
5PgdalE2vuvZn2l+S5j/EOr3JDi++H4jx1fJwDbUsJj6sAShR5auH54hY7VGP/Cd7PXJ7Pd/tD9F
5NERad3ujRx+ZLHn7BLMJE6mhue3Xr3mv2ZuePlkwvWDqvmeVCrRb7HvqURquYfMNdoaZuFwqOS3
Flp+gsWzJCTDM4nmpUQBXzCaX505mucwHXdrYDqtpbP4fKolUd0PwI77lKs797fa4t52IDD7gFwv
rWxFTiOky7klTwlb0sm6/RFyz6KUD5rkoXSlIsqG8qa0MkfmJoSXHek3zRZSuwP9q0RXV7yNM77x
Eaya9QY+V3xmHn7yeAkJHPhq8Kvtgx9V1gX/VJG2dRe4IkIgtqQ/rN/1KggEAqmCQCBVEAikCgKB
VEEgkCoIxK6gimz51x7yCNmZpwyJsosbiE2agUDUe6/iYWvK8rIjEHVOFVmWtY0SWcgaJAdGAOOC
DNYzMNOz2i/nSXTm1UWAJtZMAMYVIwKB2C4UdEVEXTKJVtd0Fn9RAI4LpisrfdNpsZDEvLy2Dd3t
4owrm/COh0DUkCqyt7GRdQt2F9d3Ns9rbhuGO3bQE/Ou4hZ7iDqniuGm1MNEXPY4J/G0uX7JBDj8
QtTlAMzSnIve5uBltf8lnbbkJ8D+BVGf0/riHYtcvGNx9COuHnNkSw7ZTbqcdwU7FkT99Sq68wzV
27Joi9QdvNn8a1jO5Dz3i9bk2txf5Y/mH8TqJkSULTrMK3vQmwei3rCp9SoVu+UoQCoEwgu2Z71K
2Wve5ZIzB6z7iL0zrS8CsQopbOmQWIidPa1HIBBIFQQCqYJAIFUQiPqY1suu02z9lW5Z02/rF5B6
docE8wtJV63m7zSgeZ8H85NK2fV1gC0PfmWJqB1VitWrCitcHnXApjbvorWOOyu9LJbKY3yYzLIj
VxA1G4DJlkUj2uIUx9IV8yq4L2qxy5K1RS7mihd1aUtBIopuHBXL5ycCUYtexdE8W5eYOJauONr9
/PUnDlmibRkK+59G5Q+6XAhhDKbA7cd9uQiJjA9ykDKI2lDFtXV3j3OsTfHc8otuzb9rJDhXeVkn
MPj7JWJ7qaI11d4/UZRdg/nncvkDJfdVXsgQRF1QRSw9zS82tZALVmrRA+HEsiYaMjIHsb0DsGKv
rMA+AnNWbblor2HOdPIui255SliBJEFsI1XMhSm2l7IFV6iAfVGLbSmXLZNlxQuTyyRrL8IcExV1
Nk+n/nZjiszStSRmHm9kQyC8Yef5Vym36iNVdh3Qv4o3iDIyBYFUKe8lQvVTIxC7iCoIBFIFgUCq
IBBIFQQCqYJAIJAqCARSBYFAqiAQSBUEAqmCQCBVEAikCgKBQKogEEgVBAKpgkAgVRAIpAoCgVRB
IJAqCMSmIdcu9T9tix1IFQQCexUEAqmCQGwxfLj5D2I7Jic7BSJSBVFr5og1S127xMVS4wAMgcC5
CgKBVEEgcFqPQNQjmrAIEDWa15e3t7r36Xd5gst7B1BENFIFUSOmiGVVU7lGguWq2YxzFURtIJZN
rFoRtko2I1UQO49Y2yIXqYKo6Rhs99iMcxXENk/o5R3iWg2pgqjVqMdjp1JXPMEPWxA4/KrUZuxV
ELUahdVoZCXWbsRW1Gb8tR6B8AQcgCEQSBUEAqmCQCBVEHsFUsUJam4BTusRVUSM/jPiPbmR9OYn
SyQV0pbUleotoMDVMjfgy2JExRjZZOpMqaT9I0Vlj1RseX8ZInAAhqgS2gWOj0IgCYoAiSAnJNR2
n/zFmm+GtJ8X2vTOICYGuCgJxEAJ+cMKTREIJEAJWM79oywBSU3iQkbc5vUmBJ4MoSSBD5JhV6yF
59OqApFoDXNUA1IFsSX43VA2lIL0W+BNfrghkA3cYF5qfATuCmd+/H4jYv1ieBlol9H6isK10hQX
uSV4hjfO4eLSEGh9SutjalyOxm1e7zv4GTLcejiQCbyZnG0kF1o0BRehyZ99rAmpgqj9ZCVGm/Gv
zoE0AN9SIMtDYBKmAmaCySh8Wxn9rQeMiJmoNMgCv9cKUoalOP0+eNxvnE9HhUE98WoPTK2yTGbc
JvQePddBpDw+BZN9qrABNdEU6ZKmIMLjtB5Rc6aoA36lXdnoH5EuX9Um436FHcgfPShipmHfnJbc
jKd1PZ6hIekTDwRWLed6AjU1b8RVolf7l8vaFVg1YK+CqDmac3NhgGij2EhquwSSWrX017H+5TeC
y/mZ4iMjI+rsPhppSVvPLWmkoi91veqNS7own1PEGInM4QAMsUVYm0vTSs5dP0sqqABdZLQzlpb0
UUsgHX183ZFjVAJ+HsSgevY/eqJgPVerMB2A/QK6+Mr1frE7ScZmXxSg+4sOBZDphokMUgWxRVjc
9wFam349RjqHkVY+I5Oo5v3f0q7uE7m88Q2/H+av4tIaNX48OgXWc9ol7GdcuJnLzleu9z+tHCSX
+lu51X4j7x/tV9mW4W5Zw7kKAlEVYK+CQCBVEAikCgKBVEEgkCoIBFIFgUCqIBAIpAoCgVRBIJAq
CARSBYFAqiAQSBUEAqlSCFLJiK2TUkquhE8aUSEaBZfIB4ezkHh4DSAc1vZJivZ/+jFbktg0/M2a
HtLwlTXjmhlZCi9OOqT8zWakFJRrCq1EGALh2qtIfzwC0o3HSGhkRWuO7x3+qD3NCEC/EdJwzHbZ
IzLODP2bkVJQril0BB82otpU6eJ6oYPte9H70S6VPHfLa2zzpACfjt7MjYK2RRPdQ4nutxSleyuR
U3UvJ7Ds9QRSkO27pO0FqO3lpO27FGu+mUlp4TUpQoKeCgokBF0K268JEiEumGCmKAGeSNX3e1J1
KIFA1Ehj7jFF5Y4K/oCobyil2aLJRCAqpUr2DYCk6u/7liw7CE3RL3aT48bFp6Lrjww/rDb56h5K
FPPJwHdpBM/2ctKwcTGcAvjuYmbeutKS7eWk77vU+AiT8niSXVpLBm6gUrhnYIkzpND9muCGhez8
CXb+dWFmBYz9nth+UiRuX5+ZhunV5b5LUoIr+oZSb+YzgYcNmQhEpVRRfk4mJ2rwt9Q999o5iFDS
zEeP909Hj5vTgCk13Vp08lF69N8Cjz+hX5uOSgMAH/eDcIJu2QRs0yZ1fyd936VJNftb1cN8VN3D
6Yn3weOv61LU/ZoCRIo6pHp8iu7mpO/3pO4ndffU7JNmGlWvJjctgH4G0DcFk4+DdQ8oBKISqvh6
jWCU7QMjKdfHHlbI0MUPBom06+rBD1G2Rebch6T7f8t+7VgsFiPXRkbo/3rkQBR6fWZ2U8oGPR5X
pG+m7VIGiBR2DXJRTQBLa4izpIlarZOac+YWaiQvszOKzx1RFarkzFerakhoGBkZaXissBRF333p
H0S/ox7SjZ2yzvTu+y6RyEYWWBUzLlLUDs7czck0XYsz0lhwha/1p9Z0+XtAIRCbpoq/2wgKbCfX
B+gkW/jT/PquoxW6STfAKfBG4AeOVP9dgajgfJ1l2Xep25RyELo4Vp9bA859ZFZ1KdDUlbzZ2O9J
A4kLWNNY5G786+QJw1a6B5QfnzmielS5wwheRmuW9CM6OZlcc/yOp+2hxKRwmZ8BjIYhPRBxCDvc
wq0849Rg2Xfp26YUH5+dIfV+P0wO/NiRQW7m02EW+j/pzjPGfk8aSFyQpVlZMuI0uaE7OhoMW+ke
UCZjY/j0EWXAbR8w6fKL2vhH6kh6Gdebe6Elu1Y2bYopZfSmFXwyiB1AFYhmUmog9NWPeBHCGZMR
PrT5T0j4TDWkIBBbSBUEAuFlroJAIJAqCARSBYFAqiAQSBUEAqmCQCBVEAikCgKBQKogEEgVBAKp
gkAgVRAIpAoCgVRBIJAqCAQCqYJAbBb/HyR91XZ1emvQAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-11-04 13:15:55 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.3 Proportion of participants within therapeutic range.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAykAAAFwCAMAAACLqsROAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-11-04 13:15:32 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Serum concentrations and therapeutic range, outcome: 1.4 Proportion of participants with toxic drug levels.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsoAAADwCAMAAAAuNrKQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2013-11-04 13:16:10 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Physiological parameters, outcome: 2.1 Oral anticoagulants: % time in target INR range.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxIAAAEwCAMAAAAU4bftAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2013-11-04 13:16:17 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Physiological parameters, outcome: 2.2 Insulin: % time in target glucose range.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwIAAADgCAMAAACHBiGeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2013-11-04 13:16:24 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-002.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Physiological parameters, outcome: 2.3 Insulin: mean blood glucose (mg/dL).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxcAAAGQCAMAAADr1G1HAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2013-11-04 13:16:51 +0100" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Time to achieve therapeutic control, outcome: 3.1 Time to achieve therapeutic range.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAAFACAMAAADtWrigAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2013-11-04 13:30:28 +0100" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Time to achieve therapeutic control, outcome: 3.2 Time to stabilization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvsAAADwCAMAAACpB1uWAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2013-11-04 13:30:36 +0100" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Clinical improvement, outcome: 4.1 Aminoglycoside antibiotics.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsoAAADwCAMAAAAuNrKQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2013-11-04 13:30:48 +0100" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-004.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Clinical improvement, outcome: 4.2 Anti-rejection drugs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADQCAMAAAA05Ik9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2013-08-01 15:05:26 +0200" MODIFIED_BY="[Empty name]" NO="15" REF_ID="CMP-005.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.1 Death.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuwAAAKwCAMAAAD0stpCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2013-11-04 13:30:55 +0100" MODIFIED_BY="[Empty name]" NO="16" REF_ID="CMP-005.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.2 Anticoagulants: events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtgAAAIQCAMAAACMtunuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2013-11-04 13:31:02 +0100" MODIFIED_BY="[Empty name]" NO="17" REF_ID="CMP-005.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.3 Anticoagulants: event rates.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4IAAAGQCAMAAADMVi7qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-18" MODIFIED="2013-11-04 13:31:14 +0100" MODIFIED_BY="[Empty name]" NO="18" REF_ID="CMP-005.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.4 Insulin.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsoAAAIgCAMAAACrl7+WAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-19" MODIFIED="2013-08-01 15:05:52 +0200" MODIFIED_BY="[Empty name]" NO="19" REF_ID="CMP-005.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.5 Aminoglycoside antibiotics.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsoAAADwCAMAAAAuNrKQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-20" MODIFIED="2013-08-06 13:41:19 +0200" MODIFIED_BY="[Empty name]" NO="20" REF_ID="CMP-005.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Clinical adverse events, outcome: 5.6 Anti-rejection drugs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsoAAADQCAMAAAApmremAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAgNElEQVR42u1da3Ab13U+fGAXC4CPBclYku1EEhm746ZuTckiIZLN
GFTiqmrqNpXdTtO4Tn7YmSStOxPVjdOH8ujUcTruNBmnHns647hK2iajpLYaxYlrYiyToEREljOu
244dUqQlW3REEktSBEEAfPTeu+8HgAWIBx/nsyksdu8999y73549e/fDbo0ICMRWQC0OAQKpjEAg
lRGIrUvlcFhdGvTnL03L6DUKQKvAcccyVmu+bL5UqOthDy+0GZo1Lsnb1tvvre9znbBRqLwHxpWl
t24Yz1ualhkfL7yVtnnPO3/dMJOxW3P2pUJdj6y+NHpxWe+Q7oC6bZ393gY+b6gEIxx+WvCKPFmA
eCPHN8bJGv/9YRqk/WHxGMevxY1l6JHeyHNNtGLQxz/tpolkrzcoRBKkIrFPKyYFb5CTrfl8qr0q
oA9WaYdafR7exw60tsN8xrAtI/CcELT0u8qw+Zypps8bLFf+s8DBZAogAnv2+/37d5M1z391uGsS
Ml23rF4I+Pp3G8sQNO0/7d/XTBZWxno+5aaBDLzJPpv3+4X9dGCvCxxcTMvWZi7r9iqOpLwrbu/+
RUN3I3XmWmTBY9jWGE8lQou2flcVis8L3b9o7G6gPjdU0+cNRuXxKXIwUyzB2Cj0kIUPBAV4DFpg
3xKMjkHaWIYgBY1jZNTIyp2w5qaBHggqIz12EfaThRd1a8kW3V7Fz0dHRubpwgBcv3KSOnDPQZ/H
uC15Y2ODQ7+reg5VfF6F65dPLjn7/NnK+bzBqEx41ssW1uDoUbJf6Zqx4W/ElqJ3sTUrxjI0GMOB
oLliHkQhrjYVhEHycUCvGDTYqzAiXxqSFwLR0G076W2roeEl07bmW1caHPpdRbjx+Ss/qJzPG3Uy
rgZORiJpmWF87wdJhsvWWKce6iAeJ2XdwwM3KUukor3zBdsrWdrp63qYeTX5s86eRXq24EKDxm2L
cPmNDeCns8+vDmTx+eMGnw+V2eeNSGUaOXlonwwrsyvjg6GhcfDSNT5LdOXgQjvZ4h5Cx1I8SS4k
ibW9pLY1Vhdsr2SYPfsNepz6jtY+An9MuTAz9BvGbffBze3r6Hd5fa6LZ/H5JoPP0TL7vBGp7Ive
ABOdifedO6Oc+B8ELgjj5xO7R14yliGYOH8kcX62ANtTP1jZ0URqjHcm9p2fV9f6h66XFwq2Vzrw
vfSSaC427z/7TXb+8HS1GraForfG19HvMvu8M4vPv2rx+ZUy+lyDciLE1gDeuEYglREIpDICgVRG
IJDKCKQyArGpqBwP8Fy/PwatZt1nDqVpbK2f4/0ZFyXzIszguKlVcFfJUM5kKYdpq07Zyaovi9UM
xPkwF4dMmLdtV5ZafRa7GRhUTbMPrQZZy3FCxtGbrGOWWeP612IQl/1tprKzQFAdC55by6x3jxAu
ZHWX53ythbkb9/NcY4aMF3NX5JqJu0l1P3B8ILNOUbOByicONKR/2PXrcGvIbeU7+r+dnu36TGkO
qgiB44bs/tAKeqVc5bKYPt6d32p3FqPLcFMP9N5EPj2GimbPrXW/Db+d1cf0XKihsBGr7298uP8Q
tMMI7d/SW0sQW5bvWmbm6yYH+tetQrsT/j2ru6nG7kRh1k50zQb2t5LxilF3FxP3QGZFjj6th2re
9R9oLF1Ufoi0IkSWPKq8lPxl/F4RQAi3kWOJ3XI8xssq3wDzIQO3kBpPqaUBmg6TyBLzeZvDZv2v
UiAcfloRtjqjNRwg/wbCrWvk+KXSZNHPJ5k/bQLH+bPWZNpjVi7m4zw+J/XVILvn7QsnVR20plMe
9JN4GHOowvrKisi6W8tmMiYwSP7awBNX/VX7TuMMP8jqGjH8J5AZztp7AVZV/xX9dVw4LGr9oysF
vqn5fq/qCQ/TnZAmtdgN+JWda3BIOTE193qDfZHEOrkxHIf+7O5Owwq0kbHzDioacsj4eNldZZ+L
Pq65mb9/UOOXMAopuE4+9Nc8z0CLcj5b6pkNxiPJ0lG5FjqFQcpP0KJLfZcvTm/4Z+AE0GabLvhO
M5Xv1Dt0cx3cJgwara2dC/0T3N79Q/n3Aw763wf93fXZnZk+e4CcgA6cTff75vbvIStWfT0PMn+u
hSaburLptpn2uJGV++BMerHb6QZm3y3dGZjsPrtD1UFrOuUPdb37VuiD9hpyX1kRWXdr2b5Cjnye
/K3A1d2qv3rfj4z1fChtGEmGR0mdR7P2fpCMp+Y/01+fCJ1b1fpHTwTzPftWv3lQ9aSGahvuJS4k
eH8cattqM+kx9YzxZgnOk8kHwJvM4W49LEyn3zp4CGQNOdR3+6hy0aAh7+1cnRg9pJKDurtGxmvx
fhKV7iMJWuqivOUP4Vppc+X5YQgd95viEw+jPwV4lxz6n2WH/hKMNZIDi/SSRYYz1hoTY3AKvNAo
yUNh1/9OjAKfI/H1Qgv5j78dxpKsmfEpeIZt7IE/Wj65mG3Iqfb4dnnx/LFGpgS1md5HDD8G/6jp
oDWd8irs+vFJhz2WUvsKFt2twqNQLB29NJSJhWo8mr963yd2WivQcBVqO9ho9Mrk4/FzZ3T/mf76
IRgbN/bvRQ/7U/tXDx0CHZ/okK/rRhDmvG38Xu5JebhKIacMjrb1iNndHZmjA/NJphNnGnIexibA
oEsmYwAzuo6cg+foiQeiC6Guz8E+v7DHu5djYW60JO4aqOy5cmEYukzxqReCB8iZL7o8uTw8xQ4s
8l3RDBMcuPKKuQbTAK/CATl7dND/kgI1ORLasY5UJtVxcZBKk1dlCz1s48PR1G2fz95fRXtMdvTx
JwLQ52T6ruGl+DeG79Z00JpO+cmhgyd2OQRyra9W3a2Mc3C2rz5Y3xsmS5q/pr7b9dMPwSL5M3hl
9PG1QejQ/Wf1e2jHDP07IP+p/bs8shCMAiRSB8ZIHJ5NX1wavyfxp3SLrspeD66S/6ayuXt6aPUa
iLeu/pT1k7nbK7tr1JDTZEIdByn2QOtQLXHXcxc8AQ+kL6anaX5fMneNk3HB2SuvKjsvyhINGKIS
U+JP7/t7WT52H/1+yFBj7soFsvuGQPGFCVLrIK5ltYqudlAtEMvtc/B7Pc093wvW6mJlBYcmT4+M
LmS/OFa1x0dMql6Taa73hl4uWGMz/Yl3fzZwcDGLVbmvZt2tcuATUnIkEGXIv7q/xr7bMTW0HJ2y
BTg1uwp077b4H5WHP4u2GoKJdHLNkK+1c8FRz5ocr28qATc8UW7Yk81dwRfaDQtw6U2bu9l0yZ6F
dKKmTqfdc4uegztX5bFsKC2VveFg8BQ9awH1ZLKVnSs6aF75IxIL2Ah/F9ovwLChRjL4n6TGfdC6
m63Y007cSsIFbXwVXW0dtMkFDnVkTTAYxqJd0TFSa29GlyZTf4Sjs5ehLkslpj3mWTnicnuWUhND
3YMTJh20HA58R593HHmv3FdyNIOiuzXh/0jMHCV97yFu6f6SvrfoZYas0Ybr8VgDnE4T6WwyY/bf
A+279f7Zprx892dEEmIEflIe1dQbEM3cx7YMyarsdaK+ry67u7PDS5N1cPMFYzrK3LXrkuVKxM9g
zwwI3Eg7c/fTyxBtY/z7+VBz/OWwr3RUvjaS4L4YewlODt0IUvSTdNCXzy18nY7lEAzvpEXGzyeO
nJ/Tarwc+y3PodgshKILsoq9bnE4QnbJYyIov5VRdLXS8LUfyc0tjMzkyJWhZQk8LaTWPn9Ma4b6
c2Zk945z2XYN0x7PsXKz0d0rWUwHU5AOmnTQsk557gN9u845RAWlr08O3QCK7taEnWRMWmCKcP1N
g7+k77Vq34HVNXMD7Be9QzrR+5rN/kfOLtbq/bNV+sllf/KCBIG63QvnSZLaCjtB8O9j4X9geWfz
wLq1wf+gzTMaQ692rPe+3xed+7G+aYZP1IGjLpm566/ZvfiqAAFP3yJ1d7DWQ/N7NpYDq9d9aeDt
dXrrRq8ch10HX5t2bZLzXRz9/IjTTFAYIlv8jhPpe8Od5xYLqNGaKGISqu3aUpU6WFTLRfWxLFTm
12p9BeTlgx9eAY9vymlHQ3qLUzl737PBP13EQ3X8BTVRSviF6SIqTQsbhMoIBAKxHfF7VWm1HqMy
ouSoCqlQ5InYIkAqI7YeleO6Tlf0codVnZBfmRQf9Hn4gKq3aHV/SWq9VZRVlKpvCHo5i33a3oZ4
rDBiw8IwgyHepk4GB3/t1at+D/uSaeqWJ4Nbr9VfFo6cVSYIC5ghLmIymes9aRGYbP0Z6a2EcFV2
liEqr2oPnkoNSZ60TOs71a1UUypEklS73BZm2mC7LlXR7Wb8vBg2aYfp+qTynGSmWw4Iqoa5TeA5
f5sSlWWdLtcLR4OKLfqcZV+GUzXUql6a6WP15/oiEEYqK7pXgo/V+PivK/qfy8pWRVNKtcsZ8FEl
rl2Xquh2W7oYwXTtcFP/af/+Hcpzkpk1We9M8buhhaYuXShEdbpM56vY2rPf39jdqCp/Nb0008dq
z/VFIMyXfbLulWC0Z8b/HFuCBVUdo2hKqXY5LYdvuy5V0e0uwdglMGqH90PnGCwpz0lm1pJa/jAG
jZmv6vc1teck67am9N8XaHpppo/VnuuLQFjv9sWPRlMsMz0J8pKepvI9Jxn9+LVEoGaJrvT0RSAc
TdFF5Y+j0tShNN/Dvr34dyO+X4EIW09LTu5aHeqtmTzKVoFaR0wehOisIDekrKMfii2lda0B8jGY
Ub4FEz0Q9Um4EzFXtkZlPTyz/Na8TtWUenrFHjmntutSNd1unM506NrbWiZkVZ6TrBZWNMzSlY/H
epqcHGO2zKpss15ae64vAmGisqJ7JVdXPOz9H3IeN81+/Twqa0qpdvk00wbbdamKbpeHdvnnSar2
VlEty89JVqFomIWjf37JSYms25oMexUtskUvrT3XF4EwUVnVvQLMn9/X37lsLrjzRVlTSrXLfUwb
bNelKrrdmZGkSIju71C1txPnH0m8Mqc8J1kjoqxhPjMyf91IwO6YYovpi19m7YFVL60/1xeBKFgZ
F29oyKtd5r3jqY+dwzM/5sobmsputMvB5EpN3ZwHdylSuZKoL7B8is6I5Yvc8mUiAlH1GQwEAqmM
QCCVEQikMgKBVEYglRGIDQXzZJwkOi/bIMk/RVQ+lLJSOX+fSFVDYv4yYhF+5Cmf06pto7ZCzDOE
ufywWqXWnLYaPNLaUlazQlLFfjDKXkzbuHGoLIkuB1+S95PyAZJxZbkgFuqVawblLp/Tqm2jvsL1
YNr9sDfp0IR5RCTLQMmFxO0kG6zPER0kQ2hgO4askEdTtOyD8o+YG1qIlT+ERGsZsYTNijnbNI2I
vgukCsRhhx9ZPmtabygQqSaVtVgrmiKv/K1yFCosC9iAWA+p3GQGxhERKzpQkTzrq3/jmoy9qJ3Q
rAOirJeggke/pX1JLAt9xLw7P/dlg2jNVUVmk/xfdKqqhJCsBtT8wskxUdmRm+7QL22u7LRrN0a6
VcbdUuIcX2ahaCBk8b3NZSB/+iGJ25fKon79my/725jDVB6vCgrKlbiC2ICD31h9F2qtZy1JC8OS
Q2CWqjWY0iZhslSBPmtTn0UP1HaZwVATDFHN+rTrdEnNlSX54sKcipQ1PXNj3NGrdZvOaVVS528l
JRsQDVPtolSMH7oRU5P6VrNDlokMx7rbA4VK7yV88ufGSpxy75Dq7K6NL713c8MNsZGy422VbRRC
ZaRxtSAWuVO21R7DFzggSof5as5qoDIOsUWAVEYglRGIjXrZZ7tMlsScV89mVa2k3S0s7dWGWRPt
pqjrmRZ3pnNZVbqr91pdKkavbLrRkl+vbJtSNm+Vp6DF7Ull57GVcm4ULR/qTi8dk8U8btiLut1/
7kzntGo+lPUVxeiVQXIeWeVosemVpVx1lUMP9cq23abfWdJ3kpgvtpQEmjxGclvcdfvuTeeyahNh
SEXL4aRCRsVU3Fy3GqGYtV/ncGiKVaSyMRhQ1ko2nZUbVUKJ4fLXLcX8IEpcl9XsTC50IMQCaGMV
5ot2dysckZkH80V2qAIJRr5Br8x9UdetSJrAUhJLZ7pwq+vWK7tyqKit2y/BcLFqA0IsSzAoyqpY
RlKJLrZuQzbXuxsq96Ll0o9hGffK+k3nyi+qevxL247Otbkvpg1X4ZItPG+w9KLwM0hBv8veXPtV
FEX8QZToIHXVRbCiUYZv1M2WSyArub+KK9QTd6YLsGp5jIhYVK6cV69s9iSLXnkbAuVEmwGbRa9c
VTlRPfJkk3N5I2VFCnk30MvOEBsu8y1uOkOs/Dk34xfi1RkkTDAQpUTTwnRLbU1VXjyOURlROrR5
J6ZhZupqIF5dKscDPNfvj6lflRdQtvq0AoN+sGwMChALcNyxDGTCFNDMPQnw9UGl/GGuPxCjZfV3
qJbz1ObjOb/mSakQ83NcwNmqj3zPHCObY2zs1lgsigX66Xg08c0Ax5LunZft0KUAxzfGVTtsrMNG
+7IjpBSn7yvZF9lfnnq1xvGETqUcBzc4NjMpL1ze0Vp5KtcJ2uKuhdlr/3vHl9VXT+4B9ubT7hu0
F6C+pS/KG+Mj76T+7UDcA7Op9E0DE+PjcG90YGXyI0+xMpOdb7/zhX1/myFl/ff816Nl70og9PSz
+6Yz6Ztib4yPl8zqt7v/+z2dMxmlf0byBUJkEMSa+LMXH675at80f3CWvhX8qb4vPEvGo6ZxcTnz
WgHZsGyHLt3+9Ml9D9QodthYR0C3//0ddz1BHGnomr16x1fUfZVp6AbFue/Spb8QZjz7j6XH98B4
5ag0+fgpn3LstkzVNKSqGJUfgmUQIkss4rLDudkrxDj2WMY1nmsEni5m/BwvKFEX2lOnIQ3xMfLP
Dvn64xnPGvwSL2/d0SME4xH2Jsq60b3l78oq9E2TLlxX2vesrYAwrffPgDvZ673TMNoJAvwmXBwF
+nZvstxJx2N1agVaePfNKHYIktA3RuwpdhTo9lfgi/RjGaYFWNF80Q8wVuhxGBuDvooSKe6//l2Y
aaE8BvI58xYfqx6Va6FTI6nMjRdC4TR9PmNT/2n//qYUW3w+vRA6oRRIwS30Der01e7LkOT8M2Qo
74unLspbvfCGamkUKnAh4IHkIHFpBRbv95euub+HwVZCIrV/hsyDvaB4DYJBuBcG6Ad7wf298lLt
ZG08fdF9M4odthvIgA6odhTo9r8Md/O+OOnn4CDxTfXlbXWp/gXN2o2V5FHyI2/T0TH8vdstVo3K
88MQOm7Mvya80MUW9tMIIb95crG2sRGe0SJWCyGs0EEHuWYh0PU+EPz79vJ7aJ4I0AOGDLkCVL40
fOR4lJxyowuhrs+VzGpo+PitNctq/wxY8MidpOci6JUJxI5atuTdLezl2rlmt80odtgR2fGcbkeB
bv8vo9/0dd8IEn/8+FBI80Ud6bZP/bpm7VuV5NHOEacTWrWo7LlyYRi6PqivCB6Al+XrN3qQKznd
36xelEdKGdvHYo2paA0kBjz0DDibvntpOtXIaD8E2nVsEGrK35UTB7/0Wo8IiZTnLniiZFbvOHj6
tTVR7Z8NUXkchuhHjdxrtjSbupicWEzc47aZqMbVSyOJz0TBYNFglbI25Rkj54j3pl473XuHzUzi
+7q1imI2eYOcW2h/O96Zr95kXHD2yqvkUIqqMTQeVzbX0kVlrOCSngHWELJ6FjKJtVr1O0BHvefg
FDseObhZS6Qq0ZWHaK6cLvUcY4bmyim9f7bxi8fIP/10hNjmOnWs9vLBHs8z7vcDs0P3QiK1uMrp
dhh0+0oMSdNc2X6q676VXujQHRMndSoJT+L1Njm3aGH5RfPCzurlyt5wMHgK6sk4TMpTKbtfJ1kF
ja0cXGgnmUQUKLdvvqDVqCdjKvBtwV4BfPe3dtALQ0hKMDzJrArcX8WDYTaX11CJV17X0lzZQ5od
aQe+ZFbrINlKrGr9syXo7XfCo2RoyAhx9GqZrOhgyViKhw73aZVihxjwcZmX+zjdjhJmVfsC3yqQ
a8J6mivXgWm2jXyJRCL0ioY0fQF+VGEq9V39F/ZJ+dz2ek3FX3JuoPK1kQT3xdhLIEU/KbtR9+Gz
P4Unh26AifOPJF6ZA1/0BvANz31Uq/E4+MBfO5f4eBz835m/bWCC5CJ1HuB3s0vxqf/48Y4Esceu
tyug9Zgfae4fmYWAp2/x/ETJrJ6JNc2TKzy1f1bMdCYSsRBMxI4kBthV4YuxxEInya1ba6dgn19w
24xih+Andb5HXo1rdpTLFs3+mbr5ps5xmPtAf//IGZr7OWF6YOFIrOKy1OCD779OXrr+ah9UHOu6
cR3fxbnLh5qTk0FAFIdwjlfTTO5NFlu1PGi6NgOtNcvVGKf1aTCCS4uuynmf+ARSsljwa07XmzIC
z+cKfxzUVPxGRSYQPnVnZPNRGYFwOhmgyBOBQCojkMo4BAikMgKBVEYgkMoIhCMMd+GUu0P2p/fl
+7lveX+hbn3W8OYwjagmlTfmW5HtzxreDKYRGyPBkCRJeXQPW7KsBn0DKeNYspQQHRdLbRqxpaKy
OViJ1nhl/CIZnxsuViaySUg9RNGXfU6P9JSMlBUrEuTk9xGI5XgypvogTiTClozKYLsStH+R7Awv
c9Asn3XzQx0RW5LK5pe3iLmIVcYEo+zPV8bEZesnGLbwKxmeuCxBjii9mZiMEXnLRmU1WWDZqX7q
NeYQlnxCEsuXYJif4rxZTCMqD9QrI0oO1CsjEEhlBAKpjEAqIxBIZQQCqYxAOMM4r6zcMSj+DdbW
N+FaFND6SothfWLXUUGszXMrjeSyICkNWueK5RuXos1fbUmye5rVM9Ob67N7IwHKR6tE5XVDtH+X
HG9x2xmlH0Y2nZ1FdSfmtKDQzUmpZ3NFMm0SwbmKg2eiJLroD/sfmVzlBMOqWDZKkiVJFi0bFMvG
Ynp5qz1d6+xy90o6A0W1aRcW1I2G0OnkU2HxUsziHRTQH0Tlo7Jdsawv0v/BoljWo5eovqRcdA5u
hpiZhSFZ6CMa8pfcFjTdpjGsa+IRQ6UsL9d15Zmkv0E6pzfI8ipRWXIXlIySSNFpN1t3oJOsuYh9
LBZgwZK2ay6LOc8BuYRyUpY3XYvZB4Kpu1HfUQ0qa0IxKT+7JXB3ELjZXAaIJa8hFvw7QNHhShhR
4cs+Mf8OFgvggWS/NHJzGs9zpi7qlO6iWamoY8GxloSa/g0wg5FjTk5yTjFFQyKZLS5LhYdNMVsk
FAsmmrtKostDab2nAUQFqGxSLGvJoLyoaJjNSaPhmzb7a8sas/7ySKktiYY2DBN5LvTE5grWFXl/
8ZR1yiyXZ9nJrTks10OSVwZF6ZUlcT2bS9VMCS0U2hI+OiMnqqNXLvgWieQqM95kKPBOBrJ4U+XK
xeeEJdvPYuUsiIWbRTpvMKCcCIFURiCQyggEUhmByHvZ56gudlDnuLvEt0p0rBOsRnkR5FAwG+4V
ajPXLrXFeNt4u1I511zpOgmRi1K5dcIGFkv6NlfaYmXiELm8jRMMyaBBVsTJFukyZHnasv05y6oR
i+JZljYXdKAURknk73aOypbwZvzBhEW6DDmetmzmnEn5bNQ3GxW/uTINTZEjiU6MzqZZVuI2huXt
TeU8sc0srhDNT1t2yRrRKd4WwLg82mJMkZHKplDn/qmAkuOi/btUeObgvFF0c6Qgm5HKYv7LwGzM
simTC3gufpYEI6d4J6e2WEI6Y4Lh+hQt2lNYKWdgtT6gwKhzznKU5HJEzH2AIZO3N5XN0lz9B8zZ
FMpgFjWbpMGmSgbFs3xRJuozIqKTC46Ce9fa4qJmPhCbFpvv+crFaIsRFQU+X9nl7IeETEZsCSoX
oy1GIJURCKQyAoFURiCQygikMgKBVEYgkMoIBFIZgUAqI5DKCARSGYFAKiMQSGUEUhmBQCojEEhl
BAKpjEAqIxBIZcRmglSxSt+vWEvGWkhlBEZlBAKpjECUHDX443rMlTczdP7W4y7eNijDi3OrXQkv
+xCYKyMQSGUEAi/7EIj8wMu+bQT7mw1zXGsZHlJd/ucAK0+Qz/tiBGMxa2mk8jZisu39XpKbwgXP
4knFHGOQ80UdDsVspTFX3ubcLn2MLTYmr7cYUnkbQyxhqeLLF/mKPKQyYqsCqYxAKiMQSGUEouTA
ybhtdJWX5c2GeQpX2j+XxWyl8W4fAhMMBAKpjEAglREIpDKiQMTXXaDsHuBl37ZCmP7j/g3q+svW
Dz+fp6iQzPVq9gLbzdKAo2dOwMm4bYBIkaVT+YqGIjltR9bteagAE5hgbBu0CRwfBO8kZASI+Tgh
JsdN8hduOgxJDy+0qsE0LHq5IFkIQ8bvCWRoCa83Bhmv4btnkBUgpck6v7au+HZjAk9ShLjA+0ha
EW7m+aTcgEhaDXC0BaQyguH3/Wl/ApK3wHs8cLs37b1d31T3HXgwkHrho9qKlSuBBaAht+VShmuh
Ja5w83CG177Dlfl+UGJyy3PyujW6rvh27+AnSDpxwpvyvpd8W52cbVYauAL1nvRz9UhlBITDNAw+
Pg3xHvhWBtI8eEdhzKsXGA3Cv2YGf/kpbcVEMN7LFv6gBeIpVuL078Apj/Z9PCj0qoWXOmFsiVXS
1xXRbvfFncTKqTEY7ZKN9ciFxkhIH4NGHi/7EMrVUqYtsxqKxHctKRdrngz7IH/0IyOmahumleL6
esrFaIouxT//lHfJ8F0tIJfmtXXraVf5l0ubGzC2gFEZAU1r0wGAYJ1YR9gYh7i869XpLs/CL3wL
9krRSCQiX/0FG5uTxu+GMvGck2Zu243GVWM1VhNDZOUaJhgIBcvTSUpC7rYpQiAB2snZfCgZV8/K
3mTw1IqlxmAc+BkQffK3f+4MgvG7TDGaYLwO7fz62/1axyTJPb4mQMfXLA1AqgMupJDKCAVzDXfT
vX11iATXSAufksiqph3fUrY2iJzt/M3vgJn3cUmFui8MjoHxOw2pOxhXD3PpmfW3++nFPWRTqIVb
Cml1P7VDPhpS3F3LmCsjtgkwKiOQyggEUhmBQCojEEhlBFIZgUAqIxBIZQQCqYxAKiMQmxX/D3Ky
3JB3jipjAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-21" MODIFIED="2013-11-04 13:29:13 +0100" MODIFIED_BY="[Empty name]" NO="21" REF_ID="CMP-006.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Healthcare resources, outcome: 6.1 Length of stay (days).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwIAAAKgCAMAAAAfwTrbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-10 20:36:50 +0100" MODIFIED_BY="[Empty name]">EPOC Methodological Filter</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 17:54:44 +0200" MODIFIED_BY="[Empty name]">
<P>The version below is from the MEDLINE search January 2012; ML = MEDLINE; EM=EMBASE. Different lines are combined, as relevant, for each database. Note, an updated version of this filter is available from M. Fiander; the updated version searches MEDLINE and EMBASE separately; and some terms have been changed and update. </P>
<P>38 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$ or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or tailor$ or target$ or team$ or usual care)).ab. (110,691)<BR/>39 (collaborativ$ or collaboration? or tailored or personali?ed).ti,ab. [added v2.0] (74,907)<BR/>40 (exp hospitals/ or exp Hospitalization/ or exp Patients/ or exp Nurses/ or exp Nursing/) and (study.ti. or evaluation studies as topic/) [changed for v2.0 based on analysis of MeSH found on CBA &amp; ITS not found by Filter 1.6] (30,850)<BR/>41 demonstration project?.ti,ab. (1678)<BR/>42 (pre-post or "pre test$" or pretest$ or posttest$ or "post test$" or (pre adj5 post)).ti,ab. (46,471)<BR/>43 (preimplement$ or pre-implement$ or post-implement$ or postimplement$).ti,ab. (538)<BR/>44 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (424)<BR/>45 trial.ti. or ((study adj3 aim?) or "our study").ab. (431,900)<BR/>46 (before adj10 (after or during)).ti,ab. (293,674)<BR/>47 ("quasi-experiment$" or quasiexperiment$ or "quasi random$" or quasirandom$ or "quasi control$" or quasicontrol$ or ((quasi$ or experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw. [ML] (80,309)<BR/>48 ("time series" adj2 interrupt$).ti,ab,hw. [ML] (566)<BR/>49 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or hour? or day? or "more than")).ab. (5903)<BR/>50 pilot.ti. (28,429)<BR/>51 Pilot projects/ [ML] (64,176)<BR/>52 (clinical trial or multicenter study).pt. [ML removed RCT--redundant v2.0] (542,215)<BR/>53 (multicentre or multicenter or multi-centre or multi-center).ti. (21,517)<BR/>54 random$.ti,ab. or controlled.ti. (575,112)<BR/>55 (control adj3 (area or cohort? or compar? or condition or group? or intervention? or participant? or study)).ab. not (controlled clinical trial or randomized controlled trial).pt. [ML remove DESIGN changed truncation on Compare] (253,384)<BR/>56 "comment on".cm. or systematic review.ti. or literature review.ti. or editorial.pt. or letter.pt. or meta-analysis.pt. or news.pt. or review.pt. [to exclude irrelevant publication types] (2,799,405)<BR/>57 exp animals/ not humans.sh. [ML] (3,548,210)<BR/>58 *experimental design/ or *pilot study/ or quasi experimental study/ [EM] (16,229)<BR/>59 ("quasi-experiment$" or quasiexperiment$ or "quasi random$" or quasirandom$ or "quasi control$" or quasicontrol$ or ((quasi$ or experimental) adj3 (method$ or study or trial or design$))).ti,ab. [EM] (80,309)<BR/>60 ("time series" adj2 interrupt$).ti,ab. [EM] (566)<BR/>61 (animal model? or animal experiment? or animal study? or animal trial? or canine or feline or bovine or cow or cows or mice or dog? or cat or cats or rabbit? or rat or rats or veterinar$).ti. or (animal or veterinary).hw. [EM] (1,520,705)<BR/>62 (editorial or letter or note or "review" or trade or survey).pt. [EM] (2,568,506)<BR/>63 meta-analysis/ or systematic review/ or "literature review".ti. or "systematic review".ti. or (meta-analy$ or metaanalyt$).ti. [EM] (54,052)<BR/>64 (or/38-46,49-50,53-54,58-60) not (or/61-63) [EPOC Methods Filter EM 2.2] (1,238,652)<BR/>65 (or/38-55) not (or/56-57) [EPOC Methods Filter ML 2.2] (1,536,696)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-11-04 13:29:10 +0100" MODIFIED_BY="[Empty name]">MEDLINE strategies pre-2012</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 17:04:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid MEDLINE(R) &lt;1966 to February week 2 2006&gt;</B>
<BR/>
<BR/>1 Drug Therapy, Computer-Assisted/ (741)<BR/>2 Hospital Information Systems/ (7328)<BR/>3 exp Computer Systems/ (92,088)<BR/>4 computer$.tw. (143,023)<BR/>5 Decision Support Systems, Clinical/ (1664)<BR/>6 or/1-4 (208,784)<BR/>7 (advice or decision).tw. (78,007)<BR/>8 decision making/ (38,305)<BR/>9 7 or 8 (103,525)<BR/>10 ad.fs. (723,104)<BR/>11 Prescriptions, Drug/ (14,228)<BR/>12 prescrib$.tw. (40,147)<BR/>13 Drug Therapy/ (15,882)<BR/>14 dt.fs. (1,079,478)<BR/>15 or/10-14 (1,570,045)<BR/>16 6 and 15 (12,313)<BR/>17 16 and 9 (488)<BR/>18 randomized controlled trial.pt. (211,387)<BR/>19 controlled clinical trial.pt. (70,364)<BR/>20 intervention studies/ (3146)<BR/>21 experiment$.tw. (761,730)<BR/>22 (time adj series).tw. (5395)<BR/>23 (pre test or pretest or (posttest or post test)).tw. (6701)<BR/>24 random allocation/ (54,389)<BR/>25 impact.tw. (168,252)<BR/>26 intervention?.tw. (208,619)<BR/>27 chang$.tw. (1,242,619)<BR/>28 evaluation studies/ (115,439)<BR/>29 evaluat$.tw. (1,066,921)<BR/>30 effect?.tw. (2,186,420)<BR/>31 comparative studies/ (1,240,136)<BR/>32 or/18-31 (5,027,583)<BR/>33 17 and 32 (316)<BR/>34 limit 33 to yr=1996-2005 (238)<BR/>35 from 34 keep 1-238 (238)</P>
<P>
<B>Search strategy - used for original review</B>
</P>
<OL>
<LI>Computer systems/</LI>
<LI>Artificial intelligence/</LI>
<LI>1 or 2</LI>
<LI>(prescr* Or drug therapy)</LI>
<LI>3 and 4</LI>
<LI>comparative study/</LI>
<LI>clinical trials/</LI>
<LI>6 or 7</LI>
<LI>5 and 8</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-01-10 21:47:18 +0100" MODIFIED_BY="[Empty name]">MEDLINE strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Medline search strategy version 1.1</B>
<BR/>Search date:  30 January 2011 [scroll down for January 2012 search]</P>
<P>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1948 to 30 January 2011</P>
<P>1     Drug Therapy, Computer-Assisted/ (1152)</P>
<P>2     ((drug administration or drug drug or drug therapy or dosing or dose calculation? or calculat$ dose or dosage) adj3 computer$).ti,ab. (231)</P>
<P>3     ((individuali$ or guided) adj3 (dose or dosage or dosages or dosing)).ti. (334)</P>
<P>4     ((individual$ or guided) adj3 (drug therapy or pharmacokinetic?)).ti,ab. (1175)</P>
<P>5     or/1-4 [Drug Therapy Computer assisted combine with filters only] (2796)</P>
<P>6     exp drug therapy/ (896,284)</P>
<P>7     (dosing or dosage? or dose).ti. (104,326)</P>
<P>8     or/6-7 [Drug Therapy or dosing] (967,277)</P>
<P>9     exp computer systems/ (115,366)</P>
<P>10     Decision Support Systems, Clinical/ (3340)</P>
<P>11     Decision Making, Computer-Assisted/ (2071)</P>
<P>12     Software/ (60,470)</P>
<P>13     computer$.ti. (54,422)</P>
<P>14     automated.ti. (18,978)</P>
<P>15     decision support.ti. (1899)</P>
<P>16     or/9-15 [computers software decision support] (208,642)</P>
<P>17     Drug monitoring/ and dt.fs. (4856)</P>
<P>18     (individual$ and (dose or dosage or dosing)).ti. and ad.fs. (426)</P>
<P>19     exp Drug Therapy/ and individuali$.ti. (441)</P>
<P>20     or/17-19 (5609)</P>
<P>21     8 and 16 [Drug Therapy &amp; Computer/Decision Terms] (6013)</P>
<P>22     5 or 20 or 21 [Results before filters] (13,339)</P>
<P>23     computer-assisted.ti. and ad.fs. (117)</P>
<P>24     pharmacokinetic$ service.ti,ab. (52)</P>
<P>25     (computer-assisted or computeri$).ti. and ad.fs. (445)</P>
<P>26     (or/23-25) or 5 or 20 or 21 [Results before filters] (13,568)</P>
<P>27     (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti. (706,828)</P>
<P>28     exp animals/ not humans.sh. (3,479,051)</P>
<P>29     "comment on".cm. or systematic review.ti. or literature review.ti. or editorial.pt. or letter.pt. or meta-analysis.pt. or news.pt. or review.pt. [This line is not found in Cochrane Handbook; added by TSC to exclude irrelevant publication types] (2,742,935)</P>
<P>56     (or/31-47) not (or/48-49) [EPOC Methods Filter ML 2.1] (1,501,919) [Details of EPOC Filter see Appendix 2]</P>
<P>57     26 and (or/30,56) [Results with filters] (3181)</P>
<P>58     limit 57 to ed="20060101-20110131" (1247)</P>
<P>59     limit 57 to yr="1996-current" (2497)</P>
<P>60     58 or 59 (2499)</P>
<P>
<B>MEDLINE strategy  version 1.5 </B>
</P>
<P>
<B>Search date: 11 January 2012</B>
</P>
<P>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1948 to Present&gt;</P>
<P>1     Decision Making, Computer-Assisted/ and (dt or ad or tu).fs. (187)</P>
<P>2     (computer$ and (dosage or dosing or drug therapy)).ti. (186)</P>
<P>3     Decision Support Systems, Clinical/ and (dt.fs. or Drug Therapy/) (241)</P>
<P>4     or/1-3 [Screen All--No Filters] (596)</P>
<P>5     Drug Therapy, Computer-Assisted/ (1168)</P>
<P>6     (computer-assisted or computeri$).ti. and ad.fs. (449)</P>
<P>7     pharmacokinetic$ service.ti,ab. (52)</P>
<P>8     Electronic Prescribing/ (209)</P>
<P>9     Clinical Pharmacy Information Systems/ (1002)</P>
<P>10     ((drug administration or drug drug or drug therapy or dosing or dose calculation? or calculat$ dose or dosage) adj3 computer$).ti,ab. (238)</P>
<P>11     ((individuali$ or guided or computer$) adj3 (dose or dosage or dosages or dosing)).ti. (504)</P>
<P>12     ((individual$ or guided or computer$) adj3 drug therapy).ti,ab. [Removed pharmacokinetic] (387)</P>
<P>13     (model-based and (drug therapy or pharmacokinetic$ or dosing or prescribing or dosages or dosage)).ti. (25)</P>
<P>14     exp *Drug Therapy/ and individuali$.ti. (163)</P>
<P>15     (computer-assisted or computeri$ or computer guided).ti. and ad.fs. [Corrected truncation on computeri$ changed dt.fs to AD.fs] (453)</P>
<P>16     or/5-15 [Drug Ther Comp-Assist; removed computer$.hw. and dt.fs; combine with filters only] (3756)</P>
<P>17     exp Drug Therapy/ [includes drug dose calculation, medication errors and more Focussed MeSH] (914,787)</P>
<P>18     exp *Drug Therapy/ [includes drug dose calculation, medication errors and more Focussed MeSH] (222,951)</P>
<P>19     exp Prescriptions/ (21,054)</P>
<P>20     *Drug interactions/ (2709)</P>
<P>21     Drug Information Services/ (3411)</P>
<P>22     Drug monitoring/ (10,882)</P>
<P>23     (dosing or dosage? or dose or prescrib$).ti. [added prescrib] (115,984)</P>
<P>24     (prescrib$ adj3 (drug? or medication? or medicine?)).ab. (13,275)</P>
<P>25     ((dose or dosage? or dosing or doses) adj3 (calculat$ or decision-making or decision support or individuali$)).ab. [added making/support; truncated calculat] (9976)</P>
<P>26     or/18-25 [Drug/Prescribing Terms DT Focussed] (363,417)</P>
<P>27     exp Computer Systems/ (117,863)</P>
<P>28     Medical Order Entry Systems/ (956)</P>
<P>29     Hospital Information Systems/ (9377)</P>
<P>30     Decision Support Systems, Clinical/ (3430)</P>
<P>31     Decision Making, Computer-Assisted/ (2100)</P>
<P>32     Software/ or Software design/ or User-computer interface/ or Software validation/ (79,722)</P>
<P>33     (computer$ or handheld? or blackberry or iphone).ti. (55,888)</P>
<P>34     computer$.hw. and (dt or ad).fs. [changed from computer?.hw.] (11,624)</P>
<P>35     automated.ti. (19,394)</P>
<P>36     (decision making or decision support).ti. [changed from decision.ti] (12,758)</P>
<P>37     or/27-36 [Computer Terms 7 Synonyms] (248,157)</P>
<P>38-65     (or/38-55) not (or/56-57) [EPOC Methods Filter ML 2.2] (1,536,696) [<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>]</P>
<P>66     (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti. (697,453)</P>
<P>67     exp animals/ not humans.sh. (3,548,210)</P>
<P>68     "comment on".cm. or systematic review.ti. or literature review.ti. or editorial.pt. or meta-analysis.pt. or news.pt. or review.pt. [This line is not found in Cochrane Handbook; added by TSC to exclude irrelevant publication types] (2,360,104)</P>
<P>69     66 not (or/67-68) [Cochrane RCT Filter 6.4.d Sens/Precision Maximizing] (548,915)</P>
<P>70     16 and 69 [Comp Dosing &amp; RCT] (335)</P>
<P>71     (16 and 65) not 70 [Comp Dosing &amp; EPOC Unique] (595)</P>
<P>72     26 and 37 and 69 [DT &amp; Computer Terms &amp; RCT] (538)</P>
<P>73     26 and 37 and 65 [DT &amp; Computer Terms &amp; EPOC] (1467)</P>
<P>74     4 not (or/67-68) [Keyword results not animal not review] (515)</P>
<P>75     or/70-74 [Final Results ML1.5 before date limits] (2495)</P>
<P>76 Limit 75 to yr="1996 -Current" (959)</P>
<P>77  75 and (1996$ or 1997$ or 1998$ or 1999$ or 2000$ or 2001$ or 2002$ or 2003$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$ or 2011$).ep,ed. (992)</P>
<P>78  76 or 77 (1955) After removing results found by MEDLINE strategy version 1.1 there were 995 results]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-01-10 21:47:24 +0100" MODIFIED_BY="[Empty name]">EMBASE strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-05 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>EMBASE Classic + EMBASE &lt;1947 to 22 March 2011&gt; </B>
</P>
<P>Search date: 22 March 2011 [scroll down for January 2012 search]</P>
<P>1     "computerized provider order entry"/ and (dt or ad).fs. (7)</P>
<P>2     (computer$ and (dosage or dosing or drug therapy)).ti. (225)</P>
<P>3     computer$.ti. and (order entry.ti. and (drug? or medication? or medicine? or prescription?).ti,hw.) (232)</P>
<P>4     or/1-3 [Screen all no filters] (458)</P>
<P>5     computer assisted drug therapy/ (655)</P>
<P>6     decision support system/ and (dt or ad).fs. (704)</P>
<P>7     computer assisted therapy/ and (dt or ad).fs. (270)</P>
<P>8     ((drug administration or drug drug or drug therapy or dosing or dose calculation? or calculat$ dose or dosage) adj3 computer$).ti. (130)</P>
<P>9     ((individuali$ or guided or computer$) adj3 (dose or dosage or dosages or dosing)).ti. (632)</P>
<P>10     ((individual$ or guided or computer$) adj3 drug therapy).ti,ab. (518)</P>
<P>11     (model-based and (drug therapy or pharmacokinetic$ or dosing or prescribing or dosages or dosage)).ti. (29)</P>
<P>12     drug therapy/ and individuali$.ti. (109)</P>
<P>13     (computer-assisted or computeri$ or computer guided).ti. and ad.fs. (205)</P>
<P>14     exp drug therapy/ and "clinical decision making"/ and computer$.ti. (8)</P>
<P>15     electronic prescribing/ and (dose or dosing or dosage or error? or interaction? or optimal or optimi$).ti. (25)</P>
<P>16     electronic prescribing/ and (decision support system/ or "clinical decision making"/) (22)</P>
<P>17     ("computerized provider order entry"/ or decision support system/ or "clinical decision making"/) and (dose or dosing or dosage?).ti. (48)</P>
<P>18     dose calculation/ and (computeri$ or computer-guided or computer supported or decision support?).ti. (26)</P>
<P>19     (exp drug therapy/ or medication error/ or drug interaction/ or prescription/ or exp pharmacological procedures/) and computeri$.ti. (889)</P>
<P>20     or/5-18,19 [Drug Therapy &amp; computerization] (3739)</P>
<P>21     exp *drug therapy/ (526,418)</P>
<P>22     *dose calculation/ (1111)</P>
<P>23     medication error/ and (reduce? or reducing or prevent$).ti. (785)</P>
<P>24     *drug interaction/ (51,265)</P>
<P>25     *prescription/ (21,361)</P>
<P>26     exp *pharmacological procedures/ (141,085)</P>
<P>27     (dosing or dosage? or dose or (prescrib$ adj2 support$) or (prescrib$ adj2 decision$)).ti. (136,746)</P>
<P>28     or/21-27 [Drug Therapy/Dosing] (751,233)</P>
<P>29     "computerized provider order entry"/ (116)</P>
<P>30     *computer assisted therapy/ (1604)</P>
<P>31     (computeri$ or computer guided or computer supported or handheld? or blackberry or iphone).ti. (18,639)</P>
<P>32     automated.ti. (23,147)</P>
<P>33     *decision support system/ (4622)</P>
<P>34     (((physician? or doctor? or prescrib$ or clinical) adj3 decision$) or decision support).ti. (4938)</P>
<P>35     *"clinical decision making"/ (692)</P>
<P>36     *computer/ or *analog computer/ or *analog digital converter/ or *computer system/ or *computer terminal/ or *digital computer/ or *hybrid computer/ or *microcomputer/ or *microprocessor/ or *minicomputer/ or *personal digital assistant/ (43,577)</P>
<P>37     *"automation, computers and data processing"/ or *automation/ (8009)</P>
<P>38     or/29-37 [Computer Terms/Decision Making Terms] (95,370)</P>
<P>39     controlled clinical trial/ or controlled study/ or randomized controlled trial/ [EM] (3,540,729)</P>
<P>40     (book or conference paper or editorial or letter or review).pt. not randomized controlled trial/ [Per BMJ Clinical Evidence filter] (3,465,909)</P>
<P>41     (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not randomized controlled trial/ [Per BMJ Clinical Evidence filter] (37,685)</P>
<P>42     (animal$ not human$).sh,hw. (3,535,914)</P>
<P>43     39 not (or/40-42) [Trial filter per BMJ CLinical Evidence] (2,298,627)</P>
<P>44- 69 [EPOC Filter <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>]</P>
<P>70     (or/44-52,55-56,59-60,64-66) not (or/67-69) [EPOC Methods Filter EM 2.2] (1,439,626)</P>
<P>72     28 and 38 and 70 [Dosing &amp; Computer Terms &amp; EPOC Filter] (363)</P>
<P>73     28 and 38 and 43 [Dosing &amp; Computer Terms &amp; RCT] (219)</P>
<P>74     4 not (or/40-42) [Computerized Dosing No Filter set] (367)</P>
<P>75     20 and 43 [Computer Dosing &amp; RCT] (590)</P>
<P>76     20 and 70 [Computer Dosing &amp; EPOC Filter] (740)</P>
<P>77     or/72-76 [Results EM before date limits] (1579)</P>
<P>78     limit 77 to yr="1996 -Current" (1176)</P>
<P>79     limit 77 to em="199601-201112" (1156)</P>
<P>80     (1996$ or 1997$ or 1998$ or 1999$ or 2000$ or 2001$ or 2002$ or 2003$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$ or 2011$).dp. (3,127,690)</P>
<P>81     77 and 80 (325)</P>
<P>82     78 or 79 or 81 (1178)</P>
<P>83     dose calculation/ and 38 and (or/43,70) (24)</P>
<P>84     83 not 82 (11)</P>
<P>85     82 or 84 [ move line 83 to line 22 for subsequent searches] (1189)</P>
<P>86     85 not ("in-vivo" or in-vitro).ti,ab,hw. (1167) [Final results]</P>
<P>
<B>Search Date: 10 January 2012</B>
</P>
<P>77 or/72-76 [Results EM before date limits] (1789)<BR/>78 limit 77 to yr="1996 -Current" (1382)<BR/>79 limit 77 to em="199601-201112" (1166)<BR/>80 (1996$ or 1997$ or 1998$ or 1999$ or 2000$ or 2001$ or 2002$ or 2003$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$ or 2011$).dp. (3,270,662)<BR/>81 77 and 80 (357)<BR/>82 78 or 79 or 81 [Results restricted by dates] (1384)<BR/>83 82 not ("in-vivo" or in-vitro).ti,ab,hw. (1354)<BR/>84 ("201112" or "201113" or "201114" or "201115" or "201117" or "201118" or "201119" or 20112? or 20113? or 20114? or 20115? or 2012$).em. [Entry week March 14 to Jan 11, 2012] (1,000,478)<BR/>85 77 and 84 [Results for March 21-2011 to Jan 11-2012] (197)<BR/>86 limit 77 to yr="2012" (3)<BR/>87 or/85-86 (197)<BR/>88 87 not ("in-vivo" or in-vitro).ti,ab,hw. (191)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-11-05 11:21:33 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-01-10 21:47:32 +0100" MODIFIED_BY="[Empty name]">CINAHL strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 17:04:07 +0200" MODIFIED_BY="[Empty name]">
<P>Search date: 23 March 2011 and January 2012</P>
<TABLE COLS="3" ROWS="72">
<TR>
<TD>
<P>#</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>In January 2012, this strategy yielded an additional 39 citations after duplicates were removed</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>S70</P>
</TD>
<TD>
<P>S68 and S69</P>
</TD>
<TD>
<P>643</P>
</TD>
</TR>
<TR>
<TD>
<P>S69</P>
</TD>
<TD>
<P>Date from: 19960101-20111231</P>
</TD>
<TD>
<P>2,096,912</P>
</TD>
</TR>
<TR>
<TD>
<P>S68</P>
</TD>
<TD>
<P>S65 NOT (S66 OR S67)</P>
</TD>
<TD>
<P>668</P>
</TD>
</TR>
<TR>
<TD>
<P>S67</P>
</TD>
<TD>
<P>TI systematic review OR TI ( meta-analy* or metaanaly* )</P>
</TD>
<TD>
<P>10,388</P>
</TD>
</TR>
<TR>
<TD>
<P>S66</P>
</TD>
<TD>
<P>PT systematic review OR PT meta-analysis</P>
</TD>
<TD>
<P>20,143</P>
</TD>
</TR>
<TR>
<TD>
<P>S65</P>
</TD>
<TD>
<P>S62 or S63 or S64 or S6</P>
</TD>
<TD>
<P>691</P>
</TD>
</TR>
<TR>
<TD>
<P>S64</P>
</TD>
<TD>
<P>( S18 and S54 ) or ( S18 and S61 )</P>
</TD>
<TD>
<P>451</P>
</TD>
</TR>
<TR>
<TD>
<P>S63</P>
</TD>
<TD>
<P>S24 and S28 and S54</P>
</TD>
<TD>
<P>186</P>
</TD>
</TR>
<TR>
<TD>
<P>S62</P>
</TD>
<TD>
<P>S24 and S28 and S61</P>
</TD>
<TD>
<P>98</P>
</TD>
</TR>
<TR>
<TD>
<P>S61</P>
</TD>
<TD>
<P>S55 or S56 or S57 or S58 or S59 or S60</P>
</TD>
<TD>
<P>133,520</P>
</TD>
</TR>
<TR>
<TD>
<P>S60</P>
</TD>
<TD>
<P>TI ( &#8220;control* N1 clinical&#8221; or &#8220;control* N1 group*&#8221; or &#8220;control* N1 trial*&#8221; or &#8220;control* N1 study&#8221; or &#8220;control* N1 studies&#8221; or &#8220;control* N1 design*&#8221; or &#8220;control* N1 method*&#8221; ) or AB ( &#8220;control* N1 clinical&#8221; or &#8220;control* N1 group*&#8221; or &#8220;control* N1 trial*&#8221; or &#8220;control* N1 study&#8221; or &#8220;control* N1 studies&#8221; or &#8220;control* N1 design*&#8221; or &#8220;control* N1 method*&#8221; )</P>
</TD>
<TD>
<P>61,173</P>
</TD>
</TR>
<TR>
<TD>
<P>S59</P>
</TD>
<TD>
<P>TI controlled or AB controlled</P>
</TD>
<TD>
<P>46,994</P>
</TD>
</TR>
<TR>
<TD>
<P>S58</P>
</TD>
<TD>
<P>TI random* or AB random*</P>
</TD>
<TD>
<P>82,074</P>
</TD>
</TR>
<TR>
<TD>
<P>S57</P>
</TD>
<TD>
<P>TI ( &#8220;clinical study&#8221; or &#8220;clinical studies&#8221; ) or AB ( &#8220;clinical study&#8221; or &#8220;clinical studies&#8221; )</P>
</TD>
<TD>
<P>11,917</P>
</TD>
</TR>
<TR>
<TD>
<P>S56</P>
</TD>
<TD>
<P>(MM "Clinical Trials+")</P>
</TD>
<TD>
<P>6418</P>
</TD>
</TR>
<TR>
<TD>
<P>S55</P>
</TD>
<TD>
<P>TI ( (multicent* n2 design*) or (multicent* n2 study) or (multicent* n2 studies) or (multicent* n2 trial*) ) or AB ( (multicent* n2 design*) or (multicent* n2 study) or (multicent* n2 studies) or (multicent* n2 trial*) )</P>
</TD>
<TD>
<P>5655</P>
</TD>
</TR>
<TR>
<TD>
<P>S54</P>
</TD>
<TD>
<P>S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53</P>
</TD>
<TD>
<P>292,909</P>
</TD>
</TR>
<TR>
<TD>
<P>S53</P>
</TD>
<TD>
<P>TI ( (time points n3 over) or (time points n3 multiple) or (time points n3 three) or (time points n3 four) or (time points n3 five) or (time points n3 six) or (time points n3 seven) or (time points n3 eight) or (time points n3 nine) or (time points n3 ten) or (time points n3 eleven) or (time points n3 twelve) or (time points n3 month*) or (time points n3 hour*) or (time points n3 day*) or (time points n3 "more than") ) or AB ( (time points n3 over) or (time points n3 multiple) or (time points n3 three) or (time points n3 four) or (time points n3 five) or (time points n3 six) or (time points n3 seven) or (time points n3 eight) or (time points n3 nine) or (time points n3 ten) or (time points n3 eleven) or (time points n3 twelve) or (time points n3 month*) or (time points n3 hour*) or (time points n3 day*) or (time points n3 "more than") )</P>
</TD>
<TD>
<P>877</P>
</TD>
</TR>
<TR>
<TD>
<P>S52</P>
</TD>
<TD>
<P>TI ( (control w3 area) or (control w3 cohort*) or (control w3 compar*) or (control w3 condition) or (control w3 group*) or (control w3 intervention*) or (control w3 participant*) or (control w3 study) ) or AB ( (control w3 area) or (control w3 cohort*) or (control w3 compar*) or (control w3 condition) or (control w3 group*) or (control w3 intervention*) or (control w3 participant*) or (control w3 study) )</P>
</TD>
<TD>
<P>34,337</P>
</TD>
</TR>
<TR>
<TD>
<P>S51</P>
</TD>
<TD>
<P>TI ( multicentre or multicenter or multi-centre or multi-center ) or AB random*</P>
</TD>
<TD>
<P>74,381</P>
</TD>
</TR>
<TR>
<TD>
<P>S50</P>
</TD>
<TD>
<P>TI random* OR controlled</P>
</TD>
<TD>
<P>24,452</P>
</TD>
</TR>
<TR>
<TD>
<P>S49</P>
</TD>
<TD>
<P>TI ( trial or (study n3 aim) or "our study" ) or AB ( (study n3 aim) or "our study" )</P>
</TD>
<TD>
<P>58,996</P>
</TD>
</TR>
<TR>
<TD>
<P>S48</P>
</TD>
<TD>
<P>TI ( pre-workshop or preworkshop or post-workshop or postworkshop or (before n3 workshop) or (after n3 workshop) ) or AB ( pre-workshop or preworkshop or post-workshop or postworkshop or (before n3 workshop) or (after n3 workshop) )</P>
</TD>
<TD>
<P>231</P>
</TD>
</TR>
<TR>
<TD>
<P>S47</P>
</TD>
<TD>
<P>TI ( demonstration project OR demonstration projects OR preimplement* or pre-implement* or post-implement* or postimplement* ) or AB ( demonstration project OR demonstration projects OR preimplement* or pre-implement* or post-implement* or postimplement* )</P>
</TD>
<TD>
<P>1024</P>
</TD>
</TR>
<TR>
<TD>
<P>S46</P>
</TD>
<TD>
<P>(intervention n6 clinician*) or (intervention n6 community) or (intervention n6 complex) or (intervention n6 design*) or (intervention n6 doctor*) or (intervention n6 educational) or (intervention n6 family doctor*) or (intervention n6 family physician*) or (intervention n6 family practitioner*) or (intervention n6 financial) or (intervention n6 GP) or (intervention n6 general practice*) Or (intervention n6 hospital*) or (intervention n6 impact*) Or (intervention n6 improv*) or (intervention n6 individualize*) Or (intervention n6 individualise*) or (intervention n6 individualizing) or (intervention n6 individualising) or (intervention n6 interdisciplin*) or (intervention n6 multicomponent) or (intervention n6 multi-component) or (intervention n6 multidisciplin*) or (intervention n6 multi-disciplin*) or (intervention n6 multifacet*) or (intervention n6 multi-facet*) or (intervention n6 multimodal*) or (intervention n6 multi-modal*) or (intervention n6 personalize*) or(intervention n6 personalise*) or (intervention n6 personalizing) or (intervention n6 personalising) or (intervention n6 pharmaci*) or (intervention n6 pharmacist*) or (intervention n6 pharmacy) or (intervention n6 physician*) or (intervention n6 practitioner*) Or (intervention n6 prescrib*) or (intervention n6 prescription*) or (intervention n6 primary care) or (intervention n6 professional*) or (intervention* n6 provider*) or (intervention* n6 regulatory) or (intervention n6 regulatory) or (intervention n6 tailor*) or (intervention n6 target*) or (intervention n6 team*) or (intervention n6 usual care)</P>
</TD>
<TD>
<P>30,362</P>
</TD>
</TR>
<TR>
<TD>
<P>S45</P>
</TD>
<TD>
<P>TI ( collaborativ* or collaboration* or tailored or personalised or personalized ) or AB ( collaborativ* or collaboration* or tailored or personalised or personalized )</P>
</TD>
<TD>
<P>28,509</P>
</TD>
</TR>
<TR>
<TD>
<P>S44</P>
</TD>
<TD>
<P>TI pilot</P>
</TD>
<TD>
<P>8414</P>
</TD>
</TR>
<TR>
<TD>
<P>S43</P>
</TD>
<TD>
<P>(MH "Pilot Studies")</P>
</TD>
<TD>
<P>22,090</P>
</TD>
</TR>
<TR>
<TD>
<P>S42</P>
</TD>
<TD>
<P>AB "before-and-after"</P>
</TD>
<TD>
<P>12,879</P>
</TD>
</TR>
<TR>
<TD>
<P>S41</P>
</TD>
<TD>
<P>AB time series</P>
</TD>
<TD>
<P>1154</P>
</TD>
</TR>
<TR>
<TD>
<P>S40</P>
</TD>
<TD>
<P>TI time series</P>
</TD>
<TD>
<P>154</P>
</TD>
</TR>
<TR>
<TD>
<P>S39</P>
</TD>
<TD>
<P>AB ( before* n10 during or before n10 after ) or AU ( before* n10 during or before n10 after )</P>
</TD>
<TD>
<P>24,522</P>
</TD>
</TR>
<TR>
<TD>
<P>S38</P>
</TD>
<TD>
<P>TI ( (time point*) or (period* n4 interrupted) or (period* n4 multiple) or (period* n4 time) or (period* n4 various) or (period* n4 varying) or (period* n4 week*) or (period* n4 month*) or (period* n4 year*) ) or AB ( (time point*) or (period* n4 interrupted) or (period* n4 multiple) or (period* n4 time) or (period* n4 various) or (period* n4 varying) or (period* n4 week*) or (period* n4 month*) or (period* n4 year*) )</P>
</TD>
<TD>
<P>36,491</P>
</TD>
</TR>
<TR>
<TD>
<P>S37</P>
</TD>
<TD>
<P>TI ( ( quasi-experiment* or quasiexperiment* or quasi-random* or quasirandom* or quasi control* or quasicontrol* or quasi* W3 method* or quasi* W3 study or quasi* W3 studies or quasi* W3 trial or quasi* W3 design* or experimental W3 method* or experimental W3 study or experimental W3 studies or experimental W3 trial or experimental W3 design* ) ) or AB ( ( quasi-experiment* or quasiexperiment* or quasi-random* or quasirandom* or quasi control* or quasicontrol* or quasi* W3 method* or quasi* W3 study or quasi* W3 studies or quasi* W3 trial or quasi* W3 design* or experimental W3 method* or experimental W3 study or experimental W3 studies or experimental W3 trial or experimental W3 design* ) )</P>
</TD>
<TD>
<P>9072</P>
</TD>
</TR>
<TR>
<TD>
<P>S36</P>
</TD>
<TD>
<P>TI pre w7 post or AB pre w7 post</P>
</TD>
<TD>
<P>6548</P>
</TD>
</TR>
<TR>
<TD>
<P>S35</P>
</TD>
<TD>
<P>MH "Multiple Time Series" or MH "Time Series"</P>
</TD>
<TD>
<P>971</P>
</TD>
</TR>
<TR>
<TD>
<P>S34</P>
</TD>
<TD>
<P>TI ( (comparative N2 study) or (comparative N2 studies) or evaluation study or evaluation studies ) or AB ( (comparative N2 study) or (comparative N2 studies) or evaluation study or evaluation studies )</P>
</TD>
<TD>
<P>6067</P>
</TD>
</TR>
<TR>
<TD>
<P>S33</P>
</TD>
<TD>
<P>MH Experimental Studies or Community Trials or Community Trials or Pretest-Posttest Design + or Quasi-Experimental Studies + Pilot Studies or Policy Studies + Multicenter Studies</P>
</TD>
<TD>
<P>26,135</P>
</TD>
</TR>
<TR>
<TD>
<P>S32</P>
</TD>
<TD>
<P>TI ( pre-test* or pretest* or posttest* or post-test* ) or AB ( pre-test* or pretest* or posttest* or "post test* ) OR TI ( preimplement*" or pre-implement* ) or AB ( pre-implement* or preimplement* )</P>
</TD>
<TD>
<P>5364</P>
</TD>
</TR>
<TR>
<TD>
<P>S31</P>
</TD>
<TD>
<P>TI ( intervention* or multiintervention* or multi-intervention* or postintervention* or post-intervention* or preintervention* or pre-intervention* ) or AB ( intervention* or multiintervention* or multi-intervention* or postintervention* or post-intervention* or preintervention* or pre-intervention* )</P>
</TD>
<TD>
<P>111,273</P>
</TD>
</TR>
<TR>
<TD>
<P>S30</P>
</TD>
<TD>
<P>(MH "Quasi-Experimental Studies")</P>
</TD>
<TD>
<P>4469</P>
</TD>
</TR>
<TR>
<TD>
<P>S29</P>
</TD>
<TD>
<P>S24 and S28</P>
</TD>
<TD>
<P>702</P>
</TD>
</TR>
<TR>
<TD>
<P>S28</P>
</TD>
<TD>
<P>S25 or S26 or S27</P>
</TD>
<TD>
<P>18,028</P>
</TD>
</TR>
<TR>
<TD>
<P>S27</P>
</TD>
<TD>
<P>MH "Decision Support Systems, Clinical"</P>
</TD>
<TD>
<P>1046</P>
</TD>
</TR>
<TR>
<TD>
<P>S26</P>
</TD>
<TD>
<P>TI ( decision support or clinical decision ) or TI ( handheld* or iphone or blackberry or computer* ) or TI automated</P>
</TD>
<TD>
<P>12,428</P>
</TD>
</TR>
<TR>
<TD>
<P>S25</P>
</TD>
<TD>
<P>(MH "Computers and Computerization") OR (MH "Decision Making, Computer Assisted") OR (MH "Therapy, Computer Assisted")</P>
</TD>
<TD>
<P>7736</P>
</TD>
</TR>
<TR>
<TD>
<P>S24</P>
</TD>
<TD>
<P>S19 or S20 or S21 or S22 or S23</P>
</TD>
<TD>
<P>81,798</P>
</TD>
</TR>
<TR>
<TD>
<P>S23</P>
</TD>
<TD>
<P>TI drug therapy</P>
</TD>
<TD>
<P>1129</P>
</TD>
</TR>
<TR>
<TD>
<P>S22</P>
</TD>
<TD>
<P>TI ( dose or dosage or dosing ) or TI ( (prescrib* N2 drug*) or (prescrib N2 medication*) or (prescrib* n2 medicine*) ) or AB ( (dose n2 calculat*) or (dosing n2 calculat*) or (dosage* n2 calculat*) )</P>
</TD>
<TD>
<P>8360</P>
</TD>
</TR>
<TR>
<TD>
<P>S21</P>
</TD>
<TD>
<P>(MH "Drug Monitoring") OR (MH "Dose-Response Relationship") OR (MH "Dose-Response Relationship, Drug")</P>
</TD>
<TD>
<P>10,992</P>
</TD>
</TR>
<TR>
<TD>
<P>S20</P>
</TD>
<TD>
<P>(MH "Drug Interactions+")</P>
</TD>
<TD>
<P>9089</P>
</TD>
</TR>
<TR>
<TD>
<P>S19</P>
</TD>
<TD>
<P>(MH "Drug Therapy, Computer Assisted") OR (MH "Drug Therapy+")</P>
</TD>
<TD>
<P>58,703</P>
</TD>
</TR>
<TR>
<TD>
<P>S18</P>
</TD>
<TD>
<P>S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17</P>
</TD>
<TD>
<P>1463</P>
</TD>
</TR>
<TR>
<TD>
<P>S17</P>
</TD>
<TD>
<P>(MH "Drug Therapy, Computer Assisted") and MW ( dose or dosage or dosing or decision support or clinical decision* )</P>
</TD>
<TD>
<P>105</P>
</TD>
</TR>
<TR>
<TD>
<P>S16</P>
</TD>
<TD>
<P>(MH "Drug Therapy, Computer Assisted") and TI ( dose or dosage or dosing or decision support or clinical decision* )</P>
</TD>
<TD>
<P>39</P>
</TD>
</TR>
<TR>
<TD>
<P>S15</P>
</TD>
<TD>
<P>(MH "Drug Therapy, Computer Assisted") and AB ( dose or dosage or dosing or decision support or clinical decision* )</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>S14</P>
</TD>
<TD>
<P>MW drug therapy and TI ( computer support or computer guided or decision support )</P>
</TD>
<TD>
<P>49</P>
</TD>
</TR>
<TR>
<TD>
<P>S13</P>
</TD>
<TD>
<P>(MH "Drug Therapy+") and TI ( computer support or computer guided or decision support )</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>TI ( dose or dosage or dosing ) and MW computeri*</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>TI ( dose or dosage or dosing ) and TI ( computeri* or automated )</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>(MH "Drug Therapy+") and TI ( computeri* or automated )</P>
</TD>
<TD>
<P>249</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>(MH "Drug Therapy+") and TI ( dose or dosage or dosing or clinical decision* or decision support )</P>
</TD>
<TD>
<P>1098</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>(MH "Drug Therapy+") and TI individuali*</P>
</TD>
<TD>
<P>48</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TI Drug therapy and TI individuali*</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>S1 or S2 or S3 or S4 or S5</P>
</TD>
<TD>
<P>246</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>TI computeri* and TI ( dosage or dosing or drug therapy )</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>(MH "Decision Support Systems, Clinical") and MW ( dose or dosage or dosing or drug therapy )</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>(MH "Decision Support Systems, Clinical") and TI ( dose or dosage or dosing or drug therapy )</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>( (MH "Decision Making, Computer Assisted") OR (MH "Therapy, Computer Assisted") ) and MW ( dose or dosage or dosing or drug therapy )</P>
</TD>
<TD>
<P>125</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>( (MH "Decision Making, Computer Assisted") OR (MH "Therapy, Computer Assisted") ) and TI ( dose or dosage or dosing or drug therapy )</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-11-05 11:21:30 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2013-11-04 13:28:59 +0100" MODIFIED_BY="[Empty name]">
<I>The Cochrane Library</I> strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 17:04:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>The Cochrane Library </I>(CENTRAL, CDSR, NHS EED, Methods, HTA, DARE)</B>
</P>
<P>
<B>Search date: 19 April 2011 [Scroll down for 2012]</B>
</P>
<P>ID           Search  </P>
<P>#1           (computer* and dosing):ti or (computer* and drug therapy):ti or (computer* and dosage):ti</P>
<P>#2           MeSH descriptor: [Drug Therapy, Computer-Assisted] this term only</P>
<P>#3           (dosing near/3 (computer* or automated or automate or automating)):ab or (dosing near/3 (computer* or automate or automated or automating)):kw</P>
<P>#4           MeSH descriptor: [Decision Making, Computer-Assisted] this term only</P>
<P>#5           (computer* near/2 dosing):ti,ab,kw</P>
<P>#6           (dos* near/2 calculat* near/5 computer*):ti,ab,kw</P>
<P>#7           (dos* near/2 calculat* near/5 automate*):ti,ab,kw</P>
<P>#8           (automati* near/3 dosing):ti,ab,kw</P>
<P>#9           (dose* near/2 calculat*):ti,ab,kw or (dosing near/3 calculat*):ti,ab,kw</P>
<P>#10        #2 and #9</P>
<P>#11        #1 or #10</P>
<P>#12        #4 and #9</P>
<P>#13        #4 and #9</P>
<P>#14        prescrib*:ti,ab,kw</P>
<P>#15        #4 and #14</P>
<P>#16        #2 and #14</P>
<P>#17        computeri*:ti,kw</P>
<P>#18        #9 and #17</P>
<P>#19        #1 or #3 or #5 or #6 or #7 or #8 or #10 or #12 or #13 or #15 or #6 or #18</P>
<P>#20        MeSH descriptor: [Decision Support Systems, Clinical] this term only and with qualifiers: [Drug therapy - DT, Adverse effects - AE, Therapeutic use - TU]</P>
<P>#21        MeSH descriptor: [Decision Support Systems, Clinical] this term only</P>
<P>#22        (dosing or (dos* next calculat*)):ti,ab,kw and computer*:ti,kw</P>
<P>#23        #21 and #22</P>
<P>#24        MeSH descriptor: [Drug Therapy] explode all trees</P>
<P>#25        #24 and #22</P>
<P>#26        dosing:ti and computer*:ti,kw</P>
<P>#27        #19 or #21 or #23 or #25 or #26  [15 HTA; 20 DARE; 3 CDSR; 523 Central; 0 NHS EED]</P>
<P>
<B>EBM Reviews - Cochrane Central Register of Controlled Trials &lt;4th Quarter 2011&gt;, Ovid </B>
</P>
<P>
<B>Search Date: 11 January 2012</B>
</P>
<P>1     Decision Making, Computer-Assisted/ and (dt or ad or tu).fs. (27)</P>
<P>2     (computer$ and (dosage or dosing or drug therapy)).ti. (32)</P>
<P>3     Decision Support Systems, Clinical/ and (dt.fs. or Drug Therapy/) (30)</P>
<P>4     or/1-3 [Screen All--No Filters] (85)</P>
<P>5     Drug Therapy, Computer-Assisted/ (107)</P>
<P>6     (computer-assisted or computeri$).ti. and ad.fs. (68)</P>
<P>7     pharmacokinetic$ service.ti,ab. (2)</P>
<P>8     Electronic Prescribing/ (9)</P>
<P>9     Clinical Pharmacy Information Systems/ (19)</P>
<P>10     ((drug administration or drug drug or drug therapy or dosing or dose calculation? or calculat$ dose or dosage) adj3 computer$).ti,ab. (50)</P>
<P>11     ((individuali$ or guided or computer$) adj3 (dose or dosage or dosages or dosing)).ti. (80)</P>
<P>12     ((individual$ or guided or computer$) adj3 drug therapy).ti,ab. [Removed pharmacokinetic] (39)</P>
<P>13     (model-based and (drug therapy or pharmacokinetic$ or dosing or prescribing or dosages or dosage)).ti. (2)</P>
<P>14     exp *Drug Therapy/ and individuali$.ti. (19)</P>
<P>15     (computer-assisted or computeri$ or computer guided).ti. and ad.fs. [Corrected truncation on computeri$ changed dt.fs to AD.fs] (72)</P>
<P>16     or/5-15 [Drug Ther Comp-Assist; removed computer$.hw. and dt.fs; combine with filters only] (321)</P>
<P>17     exp Drug Therapy/ [includes drug dose calculation, medication errors and more Focussed MeSH] (98,611)</P>
<P>18     exp *Drug Therapy/ [includes drug dose calculation, medication errors and more Focussed MeSH] (11,674)</P>
<P>19     exp Prescriptions/ (374)</P>
<P>20     *Drug interactions/ (10)</P>
<P>21     Drug Information Services/ (32)</P>
<P>22     Drug monitoring/ (788)</P>
<P>23     (dosing or dosage? or dose or prescrib$).ti. [added prescrib] (29,884)</P>
<P>24     (prescrib$ adj3 (drug? or medication? or medicine?)).ab. (1077)</P>
<P>25     ((dose or dosage? or dosing or doses) adj3 (calculat$ or decision-making or decision support or individuali$)).ab. [added making/support; truncated caluculat] (924)</P>
<P>26     or/18-25 [Drug/Prescribing Terms DT Focussed] (42,757)</P>
<P>27     exp Computer Systems/ (1934)</P>
<P>28     Medical Order Entry Systems/ (25)</P>
<P>29     Hospital Information Systems/ (36)</P>
<P>30     Decision Support Systems, Clinical/ (146)</P>
<P>31     Decision Making, Computer-Assisted/ (98)</P>
<P>32     Software/ or Software design/ or User-computer interface/ or Software validation/ (1251)</P>
<P>33     (computer$ or handheld? or blackberry or iphone).ti. (2190)</P>
<P>34     computer$.hw. and (dt or ad).fs. [changed from computer?.hw.] (1063)</P>
<P>35     automated.ti. (559)</P>
<P>36     (decision making or decision support).ti. [changed from decision.ti] (514)</P>
<P>37     or/27-36 [Computer Terms 7 Synonyms] (6347)</P>
<P>38     ((individuali$ or guided or computer$) and (dose or dosage or dosages or dosing)).ti. [Added Jan 2012 will provide retro results to au] (116)</P>
<P>39     ((drug administration or drug drug or drug therapy or dosing or dose calculation? or calculat$ dose or dosage) adj3 software?).ti,ab. (5)</P>
<P>40     38 or 39 [these lines added for Jan 2012 pre-publication search and will be incorporated into main strategy for subsequent updates] (120)</P>
<P>41     26 and 37 (324)</P>
<P>42     or/4,16,41 [Results all years] (589)</P>
<P>43     limit 42 to yr="2011 -Current" (19)</P>
<P>44     40 not 42 [citations from additional lines] (19)</P>
<P>45     43 or 44 (38)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2013-11-05 11:21:28 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2013-01-10 20:45:06 +0100" MODIFIED_BY="[Empty name]">EPOC Register strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 17:03:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>EPOC Register (Reference Manager)</B>
</P>
<P>Search date: January 2012  <BR/>Note: no date limits applied since this strategy differed from that used in 2007</P>
<P>
<B>Strategy A: All non-indexed fields, e.g. ti, ab</B>
</P>
<P>{computer\*} OR {automated} OR {decision support*} And {dosing} OR {prescrib\*} OR {prescription\*} OR {drug} OR {drugs} OR {pharmaceutical\*} OR {pharmacotherapy} OR {pharmacotherapeutic\*}  [236]</P>
<P> Ran for all years due to differences from 2007 strategy</P>
<P>
<B>Strategy B: Keyword field</B>
</P>
<P>{prescrib*} OR {prescription*} OR {drug} OR {drugs} AND</P>
<P>{computer*} OR {decision support*} OR {automat*}  [103 all years]</P>
<P>Search date: 6 July 2007</P>
<P>("computer-assisted" or "information system*" or "computer-aided" or "computer system*" or "decision support") and (drug* or pharmaceutical* or prescription* or prescrib* or "drug therap*")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;42 trials (46 comparisons) of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;42 trials (53 full-text articles) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;199 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5328 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5328 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;5986 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;64 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;5129 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;143 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;3 conference publications listed as studies awaiting classification&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>